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Morphine (7, 8, Didehydro 4, 5, epoxy 17, methyl
morphinan, 3, 6 Diol) is a major component of the juice
obtained from the poppy, Papaver Somniferum. Morphine
and its congeners have long been known for their
psychological and analgesic properties. Since its
description on tablets of stone by the Sumerian tribe in
4,600 BC, other ancient civilisations including the
Egyptians, the Assyrians and the Greeks in the 4th
Century BC have used it. Many of the early physicians
also used the drug. Hippocrates prescribed poppy wine
and thought it particularly useful for uterine
infections. In the 6th Century AD the Arabs took it to
Persia where it rapidly became popular as a recreational
drug and the great physician Avicenna died in 1037 from
opium intoxication. During the 16th Century it was in
widespread use in Europe and Parcelsus had such a high
opinion of this drug that he named it Laudanum. Thomas
Sydenham was attributed with its introduction to the
United Kingdom in 1680. A century later; the British
introduced it into China,where they bartered tea for
opium. This eventually led to the "Opium War" between
the two countries, part of the settlement of which was
Britain being given Hong Kong for the next 150 years.
Friedrich Serteuner isolated the active constituent of
poppy juice in 1806 and named it morphine after the
Page 345
Greek god of dreams, Morpheus. It was freely used in the American
civil war and produced many addicts. In 1925 Gulland
and Robinson identified its structure.
Metabolism of Morphine
In man morphine is principally metabolised by the
microsomal enzyme UDP-glucuronyl transferase (UDP GT),
mostly to glucuronides. The principal metabolites are
morphine-3-glucuronide (M3G) and morphine-6-glucuronide
(M6G). Choonara and his colleagues (1989) have
demonstrated that in premature infants the clearance of
morphine is reduced compared with children. However, they
also noted the M3G/morphine ratio in plasma and urine
and M6G/morphine ratio in urine were higher in children
than in neonates, suggesting the enhancement of
glucuronidation pathways with growth. Since there was
no difference in the M3G/M6G ratio between children and
neonates, they also suggested that both glucuronidation
pathways develop in a similar fashion. In addition to
M3G and M6G other metabolic pathways may generate small
amounts of normorphine. The principal metabolic pathways
are shown in Figure 11.1.
In common with many acidic drugs morphine is bound to
albumin and decreases in the concentration of this





Figure 11.1: The principal metabolic pathways
morphine.
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Morphine is metabolised by the liver, so a
decrease in hepatic blood flow leads to a reduction in
clearance and a prolonged effect of the drug can be
expected. In addition, changes in the pH of blood will
also give rise to alterations in the amount of free drug
available (Finck et al 1977).
Methods Used to Measure Morphine and Its Metabolites
Three methods have been used in the studies described in
this chapter to assay morphine, M3G and M6G. In the
first studies (1983-1985) the radioimmunoassay (RIA)
method described by the Oxford group (Moore et al 1984a)
was used exclusively, but was found to cross-react with
metabolites which limited its usefulness. High
performance liquid chromatography (HPLC) became
available in 1985, enabling the accurate quantification
of measurement of morphine and its metabolites M3G and
M6G. In 1988 Quinn and his colleagues developed the
extracted radioimmunoassay method which removes the
cross - reacting metabolites from the plasma before
measurement of morphine concentration. The latter
method is more sensitive than HPLC and takes less time
to perform. Newer radioimmunoassays developed to
measure M3G and M6G have not been utilised for studies
in this thesis. Details of the assays used for this




(Moore et al 1984)
LSE-RIA







Table 11.1: Sensitivity of morphine, M3G and M6G
assays (ng/ml). LSE = liquid/solid extraction
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MORPHINE AND LIVER DISEASE
Since morphine has long been thought to be metabolised
in the liver, diseases of this organ could be expected to
decrease elimination and alter the disposition of
morphine, However, studies in patients with liver
disease have given conflicting results. Patwardhan and
his colleagues (1981) studied six patients with moderate
to severe cirrhosis and demonstrated normal elimination
of morphine. When this study was repeated using two RIA
methods, one specific for morphine and the other cross
reacting with morphine and its metabolites, an increase
in elimination half life due to a decrease in clearance
was demonstrated (Mazoit et al 1984). Anaesthesia and
surgeryj by changing hepatic blood floWj could also be
expected to produce further changes. With the
widespread use of this drug it is therefore surprising
that so little information is available on the
disposition of morphine in patients following liver
surgery. One of the aims of part of this thesis was
therefore to try and improve our knowledge in this area
and resolve some of the controversies.
Two of the studies in this chapter have been submitted
by Mr K Quinn as part of a PhD thesis to the University
of Cambridge entitled "The Pharmacokinetics and Drug
Metabolism of Morphine in Man". This work is identified
in the text with his name. I acted as his supervisor.
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STUDIES IN PATIENTS DURING AND AFTER
LIVER TRANSPLANTATION
The first study, performed on patients immediately on
arrival in the intensive care unit, after liver
transplantation, attempted to define the
pharmacokinetics of morphine. The analyses was performed
by Napp Laboratories Ltd., Cambridge.
MORPHINE PHARMACOKINETICS IN PATIENTS
FOLLOWING LIVER TRANSPLANTATION
Advances in the management of chronic pain. (1986) 109-112
Patients and Methods
Five patients were studied on return to the Intensive
Care Unit when cardiorespiratory stability had been
achieved and the blood loss was minimal, usually within
one hour of return to the intensive care unit. A slow
intravenous injection of morphine sulphate (2.5 mg) was
administered, following which blood, urine and bile were
sampled at intervals of 30 mins for 6hrs and then at 12,
and 24hrs from the start of the study. Analysis of the
plasma and urine was performed using radioimmunoassay
(Moore et al 1984a).
Results
Five female patients, age 35 (22-49) years, weight 51
(36-65) kg [mean (range)] completed the study. Three
patients had primary biliary cirrhosis, one fulminant
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hepatitis A and the final patient underwent
retransplantation for rejection. Their biochemical
parameters and the and ischaemic time of the donor liver are
shown in Table 11.2. Individual plasma morphine levels
are shown in Figure 11.2.
After the initial increase,a second peak or plateau of
morphine levels is seen approximately 3 hours after
administration of the morphine. Plasma concentrations
of morphine then decreased to undetectable levels by 12
hours. Urine concentrations of morphine, shown for an
individual patient in Figure 11.3, follow the same
pattern as plasma levels but at far greater values.
Discussion
A previous study in patients following renal
transplantation also demonstrated a plateau of plasma
morphine levels occurring at approximately the same
time but not in normal subjects (Moore et al 1984b).
Second peaks have been described with other opiates





Prothronbin Time Alkaline Creatinine





AM 98 297 4 91 <100 260
AB 180 1000 5 452 <100 174
JT 268 384 5 150 <100 297
BG 138 99 2 159 <100 279
DM 470 110 4.5 145 <100 359
Mean 230.8 378 4.1 199.4 <100 273.
Table 11.2: Biochemical parameters and hepatic ischaemia
time in five patients undergoing liver transplantation.
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TIME (HOURS)
Figure 11.2: Plasma morphine concentrations in 5
patients following a single IV dose of 2.5mg morphine
administered following liver transplantation.
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Figure 11.3: Simultaneous plasma and urinary





Several mechanisms for the appearance of second peaks
following the administration of opiates have been
suggested. These include enterohepatic recirculation
(Hanks and Wand 1989) and gastric secretion of opiates
(Stoeckel, Hengstmann and Schuttler 1979). Both of
these mechanisms were felt to be unlikely in this group
of patients since bile is drained from the T tube and
most gastric contents will be aspirated by the
nasogastric tube.
In an attempt to establish the mechanism of second peaks,
a study was undertaken in children with biliary atresia,
to see if second peaks occurred when biliary drainage is
grossly impaired. Initially this was a pilot study and
it was planned to investigate 6 children but only 2 were
studied before the trial was discontinued.
I was assisted with the sample collection by Dr Maire P
Shelly and with the sample analysis by Mr E Cory (Napp
Laboratories Ltd).
MORPHINE PHARMACOKINETICS IN PAEDIATRIC PATIENTS
BEFORE AND AFTER LIVER TRANSPLANTATION
British Journal of Anaesthesia (1986) 58; 1218-1223
Patients and Methods
Informed consent was obtained from the parents of two
children about to undergo orthotopic liver
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transplantation. The preoperative details of the two
patients are summarised in Table 11.3. Both children
had end stage liver failure unresponsive to other
medical and surgical treatment. One had congenital
biliary atresia, the other cholestatic jaundice
following neonatal hepatitis; both had secondary biliary
cirrhosis. Renal function in both patients was thought
to be normal preoperatively but in retrospect, patient 2
had unrecognised renal impairment at this time. Her
plasma urea was raised although her plasma creatinine
was normal, reflecting loss of muscle bulk due to her
severe liver disease.
Anaesthesia was induced and maintained as described
previously. Following induction of anaesthesia, a
baseline blood sample was taken and lmg/Kg morphine was
administered intravenously as part of the anaesthetic
technique. Blood samples were then taken at 5, 10, 15,
20, 30, 40, 50, 60 minutes after morphine administration
while infusion and monitoring lines were being placed
but before major surgery commenced. Blood removed for
sampling was replaced by blood transfusion to maintain























Table 11.3: details of two paediatric patients before
liver transplantation. CNH = Congenital Neonatal
hepatitis. BA = Biliary Atresia.
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High performance liquid chromatography had recently
become available, allowing the estimation of plasma
morphine, M3G and M6G concentrations. Recovery from
plasma for all three compounds was greater than 90%.
Pharmacokinetic parameters were determined using ESTRIP
(Brown and Manno, 1978) to estimate terminal slopes.
Clearance was calculated as dose divided by the area
under the curve, where AUC was estimated from the data
points by the linear or logarithmic trapezoidal method
and extrapolated to infinity. Volume of distribution at
steady state was calculated as D.AUMC/AUC, where AUMC is
the area under the first moment curve again extrapolated
to infinity.
Clinical and biochemical parameters of the patients'
conscious level and liver and renal function as well as
their opiate requirement, were recorded before and
after surgery.
Results
The plasma concentrations of morphine, M3G and M6G for
both patients are shown in Figure 11.4. During the hour
after induction of anaesthesia but before major
surgery, the plasma concentration of morphine increased










Time after dose (min)
Patient 2
Time after dose (min)
Figure 11.4: Plasma morphine, morphine-3-glucuronide and
morphine-6- glucuronide concentrations in Patient 1 and
Patient 2 for 60 minutes preoperatively and at 24 hours
postoperatively.
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The pharmacokinetic parameters of morphine in Patient 1
were; half life 0.47hr, volume of distribution at steady
state 4.4 1/kg and clearance 93ml/min/kg„and in Patient
2 half life 0.52hr, volume of distribution at steady
state 3 . 4 1/kg and clearance 68ml/min/kg.
The plasma concentration of M3G increased in both
patients but more steeply and to higher values in
Patient 2. While the concentration of M3G then
decreased in Patient 1, it was maintained in Patient 2.
Plasma M6G concentration rose to a peak at approximately
15 minutes in Patient 1 and was maintained at this
level subsequently. In Patient 2, however, the
concentration of M6G again increased gradually for the
first 15 minutes but thereafter it continued to increase,
and at the end of the hour the value was greater than
that of the morphine base.
Patient 1, 24 hours after his original dose of morphine
had no detectable morphine, M3G or M6G present in his
plasma. Patient 2, 24 hours after her original dose of
morphine, had no detectable morphine base but levels of
M3G and M6G were unchanged from concentrations measured
at 60 minutes.
Intraoperative details for both patients are shown in
Table 11.4.
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Patient 1 Patient 2
Duration of 5 5.5
Surgery(hours)




Urine output 6.0 0
(ml/kg)
Table 11.4: operative details regarding the two
paediatric patients undergoing liver transplantation.
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The duration of surgery and the blood loss were
comparable for both patients and both received a large
blood transfusion. Patient 2, however, was anuric
throughout the operation, whereas patient 1 had an
adequate urine output. The patients' postoperative urine
output, conscious level and opiate requirement are shown
in Figure 11.5.
Patient 1 maintained a urine output of approximately
lml/kg/hr. He required regular administration of
fentanyl for analgesia, but in spite of this, remained
difficult to sedate to allow satisfactory control of
his ventilation and further morphine was required 26
hours after his initial dose. Patient 2 continued to
have an inadequate urine output. In addition, although
she received no further opiate, there was no response to
painful stimuli and pinpoint pupils were observed
throughout her oliguric period.
Both patients started to produce bile promptly
postoperatively and continued to do so, indicating
recovery of liver function.
Patient 2 eventually responded to diuretic therapy
with a large diuresis. One hour after the start of her
diuresis, she became responsive to stimuli and her
pupils enlarged slightly. Six hours later she required
further sedation.
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Figure 11.5: Postoperative urine output, conscious level
and opiate requirement for Patient 1 and Patient 2.
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Discussion
Both the patients described here had liver failure
during the initial study period before surgery, yet both
metabolised morphine rapidly; plasma morphine levels
decreased and the concentrations of M3G and M6G
increased. Neither patient was capable of producing bile
at this time but plasma levels of morphine decreased
nevertheless. No second peaks were observed which may
refute the importance of the biliary excretion of
morphine.
The clearance of morphine in these children was greater
than that previously reported in paediatric patients
(Dahlstrom et al 1979). This may reflect the different
methods used to estimate plasma morphine concentrations
or it may result from the relatively short sampling
period available in our study, before surgery was
undertaken, with its consequent haemodynamic
instability.
The main differences between the two children were their
renal function and plasma concentrations of M3G and M6G.
Patient 1 had normal renal function and had eliminated
all detectable morphine, M3G and M6G from his blood by
24 hours after administration of the initial dose.
Patient 2 had impaired renal function and a poor urine
output. Morphine base was no longer detectable at 24
hours after administration but high concentrations of
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M3G and M6G were present in spite of a large
intraoperative blood transfusion to replace an operative
blood loss approximating to her circulating blood
volume. This accumulation of morphine metabolites would
appear to indicate that an adequate urine output is
important for their elimination. The clinical evidence
of recovery in Patient 2 when her diuresis started adds
support to this hypothesis.
Morphine 3 glucuronide is thought to be inactive
parenterally, but M6G is known to be a powerful analgesic
(Shimomura et al 1971), Its other actions, however, are
unknown. Patient 2 was unresponsive to pain and had pin¬
point pupils in association with increased plasma
concentrations of M6G and this may indicate other
opiate-like properties, particularly sedation. The assay
method used was calibrated for only M3G and M6G. Other
metabolites (such as normorphine), possibly active, were
not measured but may have been present.
The two patients described here illustrate that morphine
can be rapidly metabolised, even in the presence of
severe liver failure. Impairment of renal function with
a low urine output in one of the patients was associated
with accumulation of M3G and M6G and with prolonged
narcosis. Morphine has active metabolic products and it
may be these that produce the clinically observed
prolonged action of morphine in patients with renal
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failure. Two further patients are described
demonstrate the importance of renal function and




British Medical Journal (1984) 289; 1071-1072
This 30 - year — old male patient received a morphine
infusion for analgesia and sedation following liver
transplantation. Postoperatively he developed renal
failure which was managed by a regimen of continuous
arterio-venous haemofiltration and intermittent
haemodialysis. His conscious level deteriorated on the
ninth day and morphine toxicity was suspected despite
the presence of midsized pupils. During this period; he
had received 225mg morphine sulphate. The administration
of naloxone produced a prompt improvement, and samples
were taken for subsequent plasma morphine assay by
radioimmunoassay. The results are shown in Figure 11.6,




Figure 11.6: Cumulative morphine dose (O-O) and plasma
morphine concentration (x-x) in a patient receiving an
IV morphine infusion following liver transplantation.
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Patient 2
Lancet (1985) 1: 1100
This patient, a 49-year-old woman with primary biliary
cirrhosis, had participated in the initial (2.5mg)
study of morphine pharmacokinetics following liver
transplantation. Her postoperative course was
complicated by renal failure due to sepsis and she
required continuous arterio-venous haemofiltration.
Informed assent was obtained from her husband for a
second study on the 30th day after the first. During
the first investigation her renal function was normal
(creatinine <100 n.mol/1, urea 6.8 |imol/l, urine output
2.6 1 in this 24 hour period),* on the second occasion
her renal failure was controlled with continuous
arterio-venous haemofiltration and dialysis (creatinine
390 n.mol/1, urea 73.4 n.mol/1, urine output 0.1 1 in
this 24 hour period). Thus, she was studied initially
with normal renal function but poor hepatic function and
subsequently with reasonable liver function but no renal
function. Plasma concentrations of morphine measured
during the two studies are shown on Figure 11.7. During
the first study peak plasma morphine concentrations of
16.8ng/ml were seen after 4 hours, following which





Figure 11.7: Plasma morphine levels for 24 hour period
in a patient following liver transplantation. Day 1:
immediate postoperative study. Day 30: patient in
renal failure.
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However, on the second occasion a peak plasma morphine
concentration (Cmax) of 32.2ng/ml occurred after 6 hours
and the concentration did not decrease below 20ng/ml
during the entire period of study.
The first study was performed when the patient had good
renal function but impaired liver function following an
ischaemic period of 297 minutes. The second was
undertaken when she was in renal failure but her liver
function, apart from an increased bilirubin, was
essentially unchanged. Although the pattern of results
was similar on both occasions, during the second study
the peak plasma level was almost double that of the
earlier study, with little elimination of the morphine during
this period of study. The difference in Cmax may
represent a different volume of distribution, though the
sustained high plasma concentrations of morphine on the
second occasion cannot be explained in this way.
Discussion of the Two Patients
The first patient illustrates the problems of depressed
conscious level which may occur when opiates are
administered to patients with impaired renal function;
the second patient offers some explanation of the
mechanism behind these difficulties, since she was
studied before and after she developed renal failure. As
can be seen from the first patient, plasma
concentrations of morphine decreased during periods of
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haemodialysis but subsequently increased again due to
redistribution from body compartments. During continuous
arterio-venous haemofiltration, however, concentrations
remain constant.
The high plasma concentrations of morphine obtained in
both patients when in renal failure demonstrate the
importance of the kidney in the elimination of morphine.
Increased clinical effects after morphine therapy in
patients with renal failure have led some authors to suggest that
the kidney may be important in morphine metabolism (McQuay and
Moore 1984a,b; McQuay 1986). This appeared to be
supported by pharmacokinetic studies that used
nonspecific assays that did not differentiate between
unchanged morphine and its metabolites (Moore et al
1984b). More recent work using HPLC (Aitkenhead et al
1984) and a specific radioimmunoassay (Chauvin et al
1987) has shown increased volumes of distribution and
accumulation of metabolites, but no decrease in
clearance of unchanged morphine in patients with end
stage renal disease. Thus it is thought that the
accumulation of these metabolites which are
pharmacologically active is the cause for the apparent
sensitivity of renal failure patients to morphine.
The analytical method used for these two patients
employed the radioimmunoassay method described by Moore
et al (1984a) which has difficulty in distinguishing
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morphine from M6G. More recent studies in patients with
renal failure, using high performance liquid
chromatography (Aitkenhead et al 1984) and a specific
radioimmunoassay (Chauvin et al 1987) to measure plasma
morphine concentrations, showed a variable volume of
distribution but a normal morphine clearance. This has
led to speculation regarding the possible role of
morphine metabolites. Morphine has a number of active
metabolites, including M6G (Shimomura et al 1971) and
normorphine (Lasagna and De Kornfield 1958; Johannesson
and Milthers 1962); the 3-glucuronide is thought to be
inactive when administered parenterally (Shimomura et al
1971; Sasajima 1970). Morphine-6-glucuronide
administered parenterally to rats has an analgesic
potency 4 times that of morphine and a duration of
action twice that of morphine. Intracisternal
administration of M6G reveals an analgesic potency 44
times that of morphine (Shimomura et al 1971).
Ball and her colleagues (1985) from Oxford studied
morphine clearance in critically ill patients with
varying degrees of renal dysfunction using their
radioimmunoassay to measure morphine. They concluded
that morphine clearance was dependent upon renal
function. As already discussed^ this radioimmunoassay
method cross reacts with M3G to a small extent (5%)^ but
with M6G to a much greater degree (150%)^ and they were
measuring clearance of morphine and its metabolites.
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Osbourne and his colleagues (1986) demonstrated
increased plasma concentrations of M6G associated with
intoxication after papaveretum administration in three
critically ill patients. They attributed the coma to
M6G, in a similar way to the child with renal failure
discussed in an earlier part of this thesis. It is of
note that all of Osbourne's patients developed renal
failure after receiving papaveretum, which contains
codeine, a substance implicated as a causative agent in
renal failure (Shelly et al 1989).
In patients with renal failure, morphine is metabolised
normally but the metabolites are not eliminated in
oliguric or anuric states. This leads to accumulation of
morphine metabolites and in particular of M6G, which
results in the clinical signs of opioid intoxication.
To examine further the question of second peaks and the
disposition of morphine the original study was continued
using lOmg (rather than 2.5mg) of morphine sulphate and
HPLC as the analytical method. I was assisted in this
study with the sample collection by Dr Maire P Shelly
and with the sample analysis by Mr K Quinn (Ph D
student).
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THE PHARMACOKINETICS OF MORPHINE IN PATIENTS
FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION
British Journal of Anaesthesia (1989) 63; 375-379
Patients and Methods
Seven subjects were studied in a similar way to the
first study in this chapter. After a 10 ml baseline
arterial blood sample had been collected, morphine
sulphate (lOmg) diluted to 10ml with 0.9% saline was
injected over a 2 minute period through a centrally
placed venous catheter. The frequency of sampling was
increased compared with the original study and blood
collected at: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5,
5.5, 6, 12, 18 and 24 hours after drug administration.
Urine and bile specimens were collected at: 1, 2, 3, 4,
5, 6, 12, 18 and 24 hours after drug administration.
Blood samples were placed in a tube containing lithium
heparin anticoagulant and mixed. The tubes were
centrifuged at 3000rpm and the supernatant plasma
removed and stored at -20°C in siliconised tubes prior
to analysis.
Prior to and during the study period analgesia was
provided with bolus doses of fentanyl, which does not
crossreact with the assay method. Laboratory
investigations, including liver function tests and
creatinine clearance, were measured during the 24 hours
of the study period. Additionally^ during surgery
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hepatic arterial blood flow following revascularisation
of the donor liver was measured using a Stratham SP12
electromagnetic flowmeter.
In order to obtain the required degree of sensitivity
and specificity, plasma and urine morphine were measured
using the radioimmunoassay procedure which excludes
metabolites from the measurement (Quinn et al 1988).
Plasma and urine M3G and M6G concentrations were
measured by HPLC (Svensson 1986).
The curve-fitting procedure gave calculations for the
area under the plasma concentration versus time profile
(AUC), distribution half life (t^a), elimination half
life (t^B), volume of distribution of the central
compartment (V1), apparent volume of distribution (Vd)
and total body clearance of morphine normalised for body
weight (CI).
Results
Demographic details of the patients and their diagnoses
are presented in Table 11.5. Postoperative liver
function tests, creatinine clearance, ischaemic time and
intraoperative hepatic arterial blood flow for each
patient are shown in Table 11.6.
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Patient Sex Age Weight Diagnosis
(M/F) (yrs) (kgs)
1 F 52 96.0 Hepatoma
2 M 36 71.8 Budd-Chiari Syndrome
3 M 35 41.0 Hepatoma
4 F 19 82.0 Budd-Chiari Syndrome
5 F 37 55.0 Wilsons Disease
6 F 26 50.8 Hepatocellular
Carcinoma
7 F 44 37.0 Primary Biliary
Cirrhosis
Table 11.5: Demographic details and presenting diagnosis












1 76 84 223 54.8 391 130 420
2 328 136 387 101 267 47 140
3 228 2120 385 63.3 284 71 60
4 37 412 181 88 259 42 400
5 40 181 301 63.7 254 59 100
6 47 148 258 54.3 231 34 213
7 79 104 484 54.6 236 31 600
Table 11.6: Postoperative liver function tests, plasma
creatinine and hepatic ischaemic times in seven patients.
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No patient had major renal impairment during the period
of studyj the creatinine clearance in all cases was in
excess of 50ml /minute (Sharpstone and Trafford 1984).
The plasma concentrations of morphine, M3G and M6G are
shown in the Figure 11.8. Following the injection of
morphine an exponential decline is observed with no
detectable plasma morphine after 24 hours. Four hours
after morphine administration (the peak concentration
for M3G), levels of M3G exceeded the parent drug nearly
ten-fold. No secondary peaks were seen in the plasma
concentrations of morphine. Results of the
pharmacokinetic analysis are summarised in Table 11.7.
Elimination of M3G, like M6G, appeared to be slow, with
detectable levels of both metabolites at 24 hours.
Because of this, it was not possible to derive any
pharmacokinetic parameters for the elimination of the
glucuronides since no further plasma samples were taken
after 24 hours. Intraoperative hepatic arterial blood
flow, which was very variable, did not appear to relate
to the postoperative clearance. Recovery of morphine at
the lng/ml level (the limit of detection) was 89%»
Recovery from plasma and urine for both glucuronides
was greater than 90%. The mean recovery of morphine, M3G
and M6G from urine is presented in Figure 11.9.
Page 379
0.1 I ' 1
0 5 10 15 20 25
Time (h)
Figure 11.8: Plasma concentrations of morphine (O)/ M3G
(□) and M6G (4^) following intravenous administration
of lOmg morphine sulphate in patients following liver
transplantation.
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Patient Body Age T^a T^B Vj Vd CI ADC
Weight (yrs) (nin) (min) (1/kg) (1/kg) (1/kg/iin) (ng h/1)
(kg)
1 96 52 28.5 252 1.53 3.78 0.62 125.8
2 71.8 36 31.3 198 1.94 4.8 1.09 103.9
3 41 35 15.0 130 3.26 10.7 3.44 53.4
4 82 19 27.4 231 1.49 3.9 0.70 130.3
5 55 37 43.3 320 3.27 14.3 1.86 73.7
6 50.8 26 15.5 212 1.26 7.0 1.38 107.5
7 37 44 20.1 175 2.51 10.3 2.46 82.7
Mean 61.9 36 26 217 2.2 7.8 1.65 96.8
SEM 8.3 4 4 23 0.3 1.5 0.4 10.6
Table 11.7: Pharmacokinetic parameters calculated after
lOmg morphine sulphate administered iv in patients

















Figure 11.9: Mean urine recovery of morphine, M3G and
M6G following intravenous administration of lOmg
morphine sulphate in patients following liver
transplantation.
Page 382
Morphine was predominantly recovered as M3G (85%)^ with
3.6% as M6G and only 4.5% as the unchanged drug. The
remainder of the morphine dose may be accounted for
either in the systemic circulation or excreted in the
bile. An attempt was made to analyse morphine, M3G and
M6G in bile specimens but this did not prove
sufficiently reliable,owing to coeluting compounds, for
inclusion in the pharmacokinetic analysis.
Discussion
A biexponential decline in plasma morphine
concentration was evident in each patient. A more rapid
distribution phase has been observed in other studies
but the first sampling point in our study was 30
minutes after drug administration and this phase was
therefore not seen. The elimination half life was 2.4
hoursJearlier workers using specific assays for morphine
have found similar elimination half lives of about 2
hours (Berkowitz et al 1975; Stanski, Greenblatt and
Lowenstein 1978; Dahlstrom et al 1979).
The plasma clearance of morphine [mean (SEM)] in this
study^ 1.65 (0.47) litre/kg, was higher than previous
estimates in healthy volunteers and surgical patients
(Goldberg 1970) and the recovery of morphine and its
glucuronides from urine indicates that the excretion of
morphine was virtually complete. In addition the wide
range of clearances found may be a reflection of the
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interpatient variability in chronically - ill subjects
with pre-existing liver disease. Clearance values
greater than hepatic arterial blood flow were observed
in four of the seven patients. However, the contribution
of portal blood flow to the clearance was not assessed
and probably explains this discrepancy. Alternatively
some extrahepatic sites of morphine metabolism may
exist.
Patients with chronic liver disease may have impaired
renal function^although perioperative renal protection
with low dose dopamine may improve this (Chapter 15).
Additionally, the periods of stress, surgical trauma and
drug therapy may induce a period of oliguria when renal
elimination of drug metabolites is impaired (Bion et al
1986). The patients in this study had adequate renal
function during the period of investigation,as indicated
by a creatinine clearance in excess of 50ml /minute.
Although the elimination half life would appear to
coincide with documented values, the estimates for
volume of distribution and clearance differ. Hepatic
arterial blood flow was greater than expected,but since
this was measured intraoperatively the importance of the
measured value to a study performed in the following 24
hours requires careful interpretation. The influence of
direct surgical trauma in the denervated hepatic artery
with concurrent dopaminergic stimulation is unknown.
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The disposition of morphine in patients with liver
disease has received limited study. The combination of
age, disease, anaesthesia and surgery may have
contributed to the observed values found for the volume of
distribution and clearance, and may explain the
discrepancy with other pharmacokinetic studies. In this
group of patients the metabolism of morphine was found
to be almost complete ,with only 4.5% of unchanged
morphine recovered in urine after 24 hours. Total
clearance was found to be greater than liver blood flow^
indicating the possibility of extrahepatic metabolism.
Since no second peaks were seen during this study, those
seen during the first study described in this chapter
probably represented cross-reactivity between morphine,
M3G and M6G. The radioimmunoassay used was known to
cross react with M3G to some extent but was unable to
distinguish morphine from M6G (Aherne 1982). Further
support for this hypothesis is gained by studying the
individual peak values in the study. In some patients
the second peak has a greater value than the first peak.
M6G is now known to have an affinity of approximately
150% (Morphine = 100%) for the antibody and the
appearance of this metabolite at this time would explain
the phenomenon.
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SITE OF MORPHINE METABOLISM
Historically the liver has always been considered the
major organ of morphine metabolism. This was contested
by a study suggesting normal pharmacokinetics in
patients with cirrhosis (Patwardhan et al 1981). However)
a more recent study has shown a decrease in the
clearance of morphine (Mazoit et al 1987) in cirrhotic
patients. The differences between these studies may be
related to the severity of the liver disease in the
patients studied, but comparisons between patients are
made difficult as conventional tests of liver function
are poor predictors of changes in the pharmacokinetics
of drugs (Secor and Schenker 1987). The metabolism of
other drugs which undergo glucuronidation shows that
glucuronidation (Kraus, Desmond and Marshall 1978) may
be relatively spared compared with other metabolising
functions, like oxidation, in severe liver disease. An
alternative explanation is that the enzyme system UDP
glucuronyl transferase is found in other extrahepatic
sites such as the gut or kidney, and that these may be
significant sites for metabolism in man. The primary
site of metabolism after therapeutic doses has been
debated. Clinical and laboratory studies have suggested
two significant sites for morphine metabolism, the liver
and the kidneys. In vitro studies of isolated kidney and
liver have shown the presence of uridinediphospho-
glucuronyltransferase (UDP glucuronyl transferase)
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(Pacifi and Rane 1982; Pacifi et al 1982) although these
do not necessarily relate to function in vivo. Renal
metabolism of morphine has been postulated (McQuay and
Moore 1984a,b; Moore et al 1984b; Ball et al 1985) based
on observations in patients with renal failure.
To resolve the speculation about the importance of the
liver in the metabolism of morphine, the
pharmacokinetics of morphine were studied during the
anhepatic phase of liver transplantation. I was
assisted with the sample collection by Dr A Bodenham
(Registrar) and Mr K Quinn (Ph D student).
EXTRA-HEPATIC METABOLISM OF MORPHINE DURING THE
ANHEPATIC PHASE OF ORTHOTOPIC LIVER TRANSPLANTATION
British Journal of Anaesthesia (1989) 63; 380-384
Patients and Methods
Seven adult patients who were likely to run an
uncomplicated intraoperative course were studied. Apart
from the patients with small intrahepatic tumours, most
patients undergoing liver transplantation have advanced
liver disease with associated portosystemic shunts and
coagulation problems. Surgery may be technically
difficult with large blood losses which would give rise
to difficulties in performing this study. The patients
in this series were chosen as having a low
risk of this complication^ i.e. those with good
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coagulation, lack of concurrent medical problems and no
previous intra-abdominal surgery.
Anaesthesia was conducted as previously described using
an oral benzodiazepine for premedication. Analgesia was
provided by intermittent bolus injections of fentanyl.
Baseline blood and urine samples were taken immediately
before the anhepatic phase. Three minutes after the
anhepatic phase had started lOmg of morphine, diluted in
10ml of saline, was administered into a central vein.
Blood samples were collected at 2, 5, 10, 15, 20, 30, 40
minutes after the injection and immediately before
reperfusion. Although the perfusion of the kidneys and
intestines is compromised during the anhepatic phase
these patients usually produce 50-100ml ''of urine during
this period and samples were therefore collected at 5
and 30 minutes and immediately before reperfusion.
On reperfusion the sampling protocol was repeated with
blood and urine samples taken at the same times as
during the anhepatic phase. Blood loss and replacement,
urine output and body temperature were recorded for each
stage. Blood samples were placed in lithium heparin
tubes, centrifuged at 3000 rpm for 5 minutes, and then
separated into plain, glass siliconised tubes with screw
caps to minimise adsorption. Urine and plasma samples
were stored at -20°C for later analysis by HPLC.
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Results
The details of the seven patients studied are shown in
Table 11.8. All patients had significant hepatic
dysfunction except for patient 2 who had a solitary
hepatoma.
Table 11.9 lists some of the operative details of these
patients. The blood losses,although large by general
surgical standards,are not unusual for an uncomplicated
liver transplant operation. All patients produced urine
during the anhepatic period. The cold ischaemic times
of 406 (138) minutes were also typical.
Results of assays for morphine and its metabolites in
plasma and urine are shown in Figure 11.10 and Table
11.10. Plasma concentrations of morphine decreased
during the anhepatic period, consistent with the
distribution phase after injection, followed thereafter
by little change. During the anhepatic phase, M3G was
detectable in low concentrations in plasma (less than
7ng /ml) and urinary concentrations increased to a
maximum of 137ng/ml during the anhepatic phase.
Morphine-6-glucuronide was detected at a maximum of
1.4ng/ml in plasma and 22.3ng/ml in urine during this
phase. Normorphine was undetectable in both plasma and





























Table 11.8: Demographic data and presenting diagnosis of
the seven patients.
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Phase Blood loss Duration Urine volume
(mis) (mins) (mis)
Dissection 1788 (1147) 135 (45) 345 (279)
Anhepatic 1657 (1029) 56 (9.4) 57 (47)
Reperfusion 2862 (2288) 95.7 (19.5) 282 (182)






Figure 11.10: Plasma concentrations of morphine (•),
M3G (Q ) and M6G (Q) during the anhepatic and
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Table 11.10: Urinary concentrations [mean (SEM)] of
morphine, morphine-3-glucuronide and morphine-6-
glucuronide during the anhepatic and reperfusion phases
of liver transplantation in seven patients.
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Mean concentrations of both plasma and urinary M3G
increased rapidly on reperfusion of the transplanted
liver to a maximum of 236ng/ml and 132 ng/ml
respectively. Plasma concentrations of M6G increased to
a maximum of 7.1ng/ml and decreased slightly in urine to
11.4ng/ml during this period of study.
Discussion
Hug and his colleagues (1979) measured morphine
metabolism during the anhepatic phase of liver
transplantation in man but could not measure the
metabolites directly. They similarly found insignificant
metabolism during this period. In contrast, studies in
the functionally anhepatic dog showed that morphine was
glucuronidated to approximately equal extents by hepatic
and extrahepatic tissues (Jacqz et al 1986). The lung is
known to metabolise and take up certain
endogenous and exogenous substances (Bakle 1982).
Studies in anaesthetised and postoperative patients
showed significant uptake but no metabolism of morphine
(Persson et al 1986; Roerig et al 1987). Although not
metabolically active, the lung is thought to act as a
reservoir for morphine and other basic drugs between the
right and left circulations,although this remains to be
proved in humans (Chapter 10).
The appearance of morphine metabolites in the urine
during the anhepatic period^ despite the plasma
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concentrations being undetectable,may be explained in
two ways. The kidney may be concentrating small
quantities of morphine metabolites in the plasma which
are undetectable by the HPLC. Alternatively, the kidney
could be an extrahepatic site for morphine metabolism^
although if it were significant larger concentrations of
metabolites would be expected in the urine.
The lack of significant metabolism of morphine in our
patients during the anhepatic period of liver
transplantation suggests that,in the group of patients
studied, the liver is the predominant organ of morphine
metabolism. It is also clear that the transplanted liver




ANALGESIA: THE NEW OPIOIDS
The increasing recognition of the problems associated
with the established narcotics, particularly long and
unpredictable duration of action and respiratory
depression, led to the development of new agents. The
characteristics of two of these agents, alfentanil, with
its short duration of action,and nalbuphine, a mixed
agonist-antagonist with a ceiling effect on respiratory
depression; might make them useful analgesics in patients
after liver transplantation.
ALFENTANIL
Alfentanil is a potent opioid analgesic with a rapid
onset and short duration of action. It has a small
volume of distribution (0.45 1/kg) and a short
elimination half life of 98 minutes in the healthy
subject (Bower and Hull 1982). In common with other
opiates, alfentanil produces respiratory depression,
which has been shown to be comparable with fentanyl
(Andrews et al 1983) although recovery is predictably
faster. The cardiovascular effects of alfentanil have
also been compared with fentanyl in anaesthetised
patients (Rucquoi and Camu 1983). Both drugs showed no
profound cardiovascular depression and improved
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myocardial oxygen demand. These effects lasted for a
shorter period with a bolus dose of alfentanil than
with fentanyl. Alfentanil is widely used as an analgesic
during anaesthesia and by infusion in artificially
ventilated patients. The advantage of a short acting
agent, given by continuous intravenous infusion, would
be the ability to provide intense analgesia but still be
able rapidly to terminate its effects, especially
respiratory depression, when the infusion is
discontinued.
Metabolism and excretion
Alfentanil is eliminated almost completely by hepatic
biotransformation, only 0.4% of the dose being excreted
in the urine as unchanged drug (Schuttler and Stoeckel
1982). The main metabolic pathways are oxidative N and
O-dealkylation (Meuldermans et al 1988). No active
metabolites have been found.
The estimated hepatic extraction ratio suggests that the
total body clearance of alfentanil could be influenced
by both changes in hepatic blood flow and intrinsic
clearance (Reitz 1986). In contrast to fentanyl,, the
duration of effect of a single dose of alfentanil is
more dependent on its total body clearance than on
redistribution to tissues.
A decreased clearance has been demonstrated in patients
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with cirrhosis (Ferrier et al 1985) but this is
unchanged in patients with renal failure (Van Peer et
al 1986). Its use, by continuous intravenous infusion,
to provide sedation and analgesia to patients
requiring intensive care has been investigated by
several groups. A wide variability in clearance of the
drug and the response of patients was shown in two of
these studies (Yate et al 1986; Sear, Fisher and
Summerfield 1987). Alfentanil is bound in plasma to
o^-acid glycoprotein (AAG), an acute phase protein
which increases in concentration following
injury and stress including cardiopulmonary bypass
(Hug et al 1983) and after liver transplantation
(Chapter 6).
A study of the pharmacokinetics of alfentanil on two
occasions in the first 24 hours after liver
transplantation was performed to assess the importance
of the various factors influencing its
pharmacokinetics. In addition, this study evaluated
whether changes in alfentanil pharmacokinetics (a
drug clinically useful unlike test substances such as
antipyrine) could be used to assess changing liver
function after hepatic transplantation; recovery of
liver function being associated with more rapid
elimination whereas deterioration would result in slower
elimination. This study was performed at the same time
as the one entitled "Serum Acute Phase Proteins After
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Orthotopic Liver Transplantation" described in Chapter
6. I was assisted with the sample collection by Dr Maire
P Shelly and sample analysis by Dr Sue Walker
(Department of Clinical Biochemistry).
THE PHARMACOKINETICS OF ALFENTANIL IN PATIENTS
FOLLOWING LIVER TRANSPLANTATION
In: J Cros, J-Cl Meunier, M Hamon (eds). Progress in
Opioid Research, Advances in the Biosciences. Oxford:
Pergamon Press, (1989) 75: 643-646
Patients and Methods
Seven consecutive patients were studied within
three hours of return to the Intensive Care Unit after
liver transplantation. At this time a baseline blood
sample was collected and alfentanil, 20 |ig/kg diluted
to 10 ml in 0.9% saline, was administered as a
bolus over 1 minute through a centrally placed
venous cannula. Samples of arterial blood were removed
at 2, 5, 10, 20, 30, 60, 90, 120, 180, 360, 480, 600
and 720 minutes. At the end of this period, a further
20 pig/kg of alfentanil was administered in a similar
manner and an identical sampling protocol followed.
Blood was collected into lithium heparin tubes,
centrifuged and the supernatant plasma separated and
stored at -20°C. Subsequent analysis was performed
using a radioimmunoassay technique (Michiels et al
1983). Elimination half life, plasma clearance and
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apparent volume of distribution were calculated using
standard methods (Gibaldi and Perrier 1982).
Results
The preoperative diagnosis and details of the patients
are shown in Table 12.1. In all patients pre- and
postoperative liver function tests were abnormal (Table
12.2). Of particular note is the correction of low
plasma concentrations of albumin in some patients to
almost normal values postoperatively.
There was considerable variation in the pharmacokinetic
parameters of alfentanil between the patients^ this
is guantified in Table 12.3 for individual patients
during both study periods. Only one patient had
essentially normal pharmacokinetic values throughout
the study period. Four patients had an increased
volume of distribution during the first study which
decreased during the second study period. Two
patients demonstrated a considerably reduced
clearance of alfentanil.
Throughout the study period c^-acid glycoprotein levels
increased to just above the normal range and these
results,and the changes observed in liver function tests^
are presented in Chapter 6. No relationship between
changes in the liver function tests and alterations in














Chronic Active Hepatitis 3
Polycystic liver 1
Table 12.1: Details of the patients studied
following liver transplantation. Figures shown as

















































































Table 12.2: Liver function tests (a) before and (b)









1 11 1 11 1 11
1 730 330 0.425 0.956 447 455
2 158 66 6.220 3.620 1413 345
3 120 217 8.710 2.210 1502 689
4 82 67 6.630 5.070 780 492
5 267 231 4.110 3.840 1581 1279
6 365 385 0 . 833 0.807 438 448
7 257 347 3 .470 1.930 1284 965
Normal 90 6.4 860
Values
Table 12.3: Elimination half life, clearance and
volume of distribution of alfentanil in patients
following liver transplantation. 1 = first study period,
11 = second study period.
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Discussion
Alfentanil elimination is dependent upon hepatic
clearance and this is decreased in patients with
cirrhosis (Ferrier et al 1985). In this study, all the
patients had abnormal liver function tests and the
clearance of alfentanil varied considerably. The most
marked change in pharmacokinetic parameters was seen in
the volume of distribution, which decreased in four
patients during the study period, in one subject
(patient 2) to a quarter of its starting value.
Alfentanil is significantly bound to AAG, which increases
in concentration with acute stress. Large changes in
the concentration of AAG might be expected to alter the
volume of distribution of alfentanil. In this study(
plasma concentrations of AAG were slightly increased
above the normal range, but they did not increase
sufficiently to explain the large decreases in the
volume of distribution. This change may be a reflection
of recovery from anaesthesia and surgery as well as
diminishing fluid losses and shifts. Unfortunately, too few
other studies of this drug report concentrations of AAG
to enable comparisons to be made.
In addition to the changes in volume of distribution,
all four of these patients had a reduced plasma
clearance of alfentanil during the second study
period. A considerably reduced clearance of
alfentanil was seen in two other patients. A reduced
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clearance has also been seen in patients with cirrhosis
(Ferrier et al 1985), the elderly (Helmers et al 1982)
and the critically ill (Yate et al 1986; Sear et al
1987). A subset of the normal population are poor
oxidizers of certain drugs, for example sparteine,
phenacetin and debrisoquine, because they possess an
abnormal cytochrome P 450 isoenzyme (Sloan et al 1978).
It has been suggested that this group (about 3-10% of
the Caucasian population) are extremely slow
metabolisers of alfentanil (McDonnell et al 1982;
McDonnell, Bartkowski and Kahn 1984). Other studies have
shown that the reduced clearance demonstrated by these
authors is not due to debrisoquine polymorphism
(Meuldermans et al 1988; Lavrijsen et al 1988; Henthorn
Avram and Krecie 1989)
No correlation could be found between changes in
alfentanil pharmacokinetics and alterations in liver
function tests. There are several influences that will
change the pharmacokinetic variables for alfentanil in
addition to liver function. Losses and alterations of
body fluids and recovery from the combined effects of
surgery and anaesthesia (including changes in hepatic
blood flow) are the most significant. These changes
probably affect other drugs in a similar way but have
not been previously recognised.
The pharmacokinetic alterations observed in this study
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appear to be unpredictable and may result in
unwanted narcosis and respiratory depression.
Alfentanil should therefore be used with care in
patients after liver transplantation since a
prolonged effect is possible. Owing to the large number
of factors that affect the elimination of alfentanil,
measures of this are unreliable indicators of liver
function.
NALBUPHINE
Nalbuphine is a semisynthetic opioid agonist-antagonist
of the phenanthrene series and is structurally related
both to the potent narcotic analgesic oxymorphone, and to
the narcotic antagonist naloxone. It provides analgesia
comparable with morphine when used to relieve moderate to
severe pain (Bahar, Rosen and Vickers 1985; Beaver and
Feise 1978) and has been used for premedication
(Chestnutt, Clarke and Dundee 1987), to reverse opioid
induced respiratory depression (Moldenhauer et al 1985)
and as an adjunct in balanced anaesthesia (Fahmy 1980;
Fahmy, Sunder and Roberts 1982). Other properties of
the drug include a low abuse potential (Ciarmelli 1984),
haemodynamic stability (Lake et al 1982a) and a ceiling
to ventilatory depression (Gal, DiFazio and Moscicki
1982), properties which may be considered advantageous
in an analgesic used after liver transplantation. The
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pharmacokinetic data available for nalbuphine are at
present limited to healthy individuals and none is
available for patients with liver disease. The purpose
of this study was to investigate the disposition and
elimination of nalbuphine in the period immediately
following orthotopic liver transplantation. I was
assisted with the sample collection by Dr A R Manara
(Registrar); DuPont Pharmaceuticals Ltd arranged the
assay of the samples by the Department of Anaesthesia at
the University of Leicester.
THE DISPOSITION OF INTRAVENOUS NALBUPHINE FOLLOWING
ORTHOTOPIC LIVER TRANSPLANTATION
British Journal of Anaesthesia
In Press (Subject to Modification)
Patients and Methods
Twelve patients participated in this study of nalbuphine
pharmacokinetics following liver transplantation
immediately after arrival in the Intensive Care Unit.
A baseline sample of blood was collected,as were bile,
urine and nasogastric aspirate samples,when available.
Once haemodynamic stability was achieved, 0.15 mg/kg of
nalbuphine hydrochloride, diluted to 10 ml in 0.9%
sodium chloride, was administered over a fixed time
interval of 1 minute via a central venous catheter and
flushed in with a further 10 ml of 0.9% saline. Blood
samples were collected from the indwelling radial artery
cannula at 2, 5, 10, 15, 30, 45 and 60 minutes after the
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nalbuphine was administered and at half-hourly intervals
until six hours had elapsed. Further samples were
collected at 12, 18 and 24 hours. Nasogastric, bile and
urine samples were collected at hourly intervals for 6
hours and at 12, 18 and 24 hours after the
administration of nalbuphine. The nasogastric samples
were taken by aspirating the nasogastric tube, whereas
bile was collected from the bile bag attached to the
T-tube. The T-tube itself was not aspirated to avoid
the danger of introducing infection into the biliary
tree. No further nalbuphine was administered to the
patients for the duration of the study. Additional
analgesia was provided as required, initially using
intermittent, intravenous bolus doses of fentanyl or
morphine sulphate and later using bilateral intercostal
nerve blocks with bupivacaine.
The blood samples were collected in glass lithium
heparin tubes, centrifuged at 3000 rpm for 15 minutes, and
the supernatant plasma separated and stored in plain
glass tubes at -20°C until analysed. Bile, urine and
nasogastric samples were collected in plain glass tubes
and stored immediately at -20°C until analysis. Samples
were analysed, in duplicate ;by high pressure liquid
chromatography with electrochemical detection using
naltrexone as the internal standard (Aitkenhead, Lin and
Achola 1988). The limit of sensitivity of the assay was
<1 ng/ml and the coefficient of variation was less than
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5% throughout the range 1-1000 ng/ml. Spiked blank
plasma showed no chromatograms of fentanyl, morphine,
midazolam or bupivacaine at the elution times for
nalbuphine or naltrexone.
Plasma concentration-time profiles were analysed by
nonlinear regression analysis to determine the
elimination rate constant. The AUC and its first moment,
the AUMC between 0 and the final sampling point "t"^were
determined by the linear trapezoidal rule; the
additional areas AUC.
_ and AUMC. _ were calculated byr—oo t—00
routine formulae. Clearance was calculated as
dose/AUCQ^ and Vss (apparent volume of distribution at
steady state) and MRT (mean residence time) by model
independent noncompartmental methods.
The renal clearance (ml/min) of unchanged nalbuphine was
calculated as: |xg excreted in 24 hours/AUCQ_24h.
Results
Patient details are shown in Table 12.4. Plasma
creatinine was normal preoperatively and remained so in
all patients postoperatively. No haemodynamic
instability was seen following the administration of
nalbuphine. Blood loss was minimal in all patients
during the study period. Postoperative liver function
tests, obtained during the period of study, are shown in
table 12.5.
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Patient Sex Age Weight Diagnosis
(M/F) (years) (kg)
1 F 39 53.8 PBC
2 F 53 48 PBC
3 F 46 61 PBC
4 F 32 37 PBC
5 M 58 80 Hepatoma, cirrhosis
6 F 38 65 CAH
7 F 53 40 Chronic rejection
8 F 52 41.5 PBC
9 F 22 69.4 CAH
10 M 39 67 Haemangioendothelioma
11 F 46 65.8 PBC
12 F 49 63 PBC
Table 12.4: Patient information. PBC = Primary biliary
cirrhosis; CAH = chronic active hepatitis; SC =
sclerosing cholangitis.
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Patient Bilirubin Alkaline Albumin ALT PT
p.mol/1 Phosphatase (g/1) (U/L) (sec)
(U/L)
1 91 636 28 1692 19/15
2 444 1940 26 128 15/14
3 228 441 29 398 19/16
4 391 271 26 524 21/16
5 29 94 35 293 18/15
6 43 84 30 526 18/14
7 192 610 25 522 15/13
8 233 454 36 1530 17/15
9 244 108 28 575 25/16
10 69 132 23 868 18/15
11 102 110 20 590 20/15
12 150 48 34 776 26/17
Table 12 .5: Liver function tests in the immediate
postoperative period.
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The mean plasma concentration/time curve for nalbuphine
is shown in Figure 12.1. The mean (SD) elimination half
life was 230 (144) min. mean residence time 278
(185) min, plasma clearance 17.5 (8.7) ml/kg/min and
volume of distribution at steady state 3.91 (2.08) 1/kg
(Table 12.6) .
Samples of bile and nasogastric fluid were not available
at sufficiently regular intervals in each patient to
allow any further analysis or conclusions to be drawn,
but the mean concentrations that were obtained are
illustrated in Figure 12.2.
The total amount of nalbuphine excreted in the urine
ranged from 16.2-378.6 ng (mean 164.01). This
represents 0.17-6.82% (mean 2.14%) of the total dose
administered, and 85.5-100% (mean 96.5%) of this had
been excreted within 12 hours of the administration of
nalbuphine (Figure 12.3). The mean renal clearance was
0.30 ml/kg/min (range 0.04-0.61).
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2 0 4-0 60 8 0 10 0 120 180 20 0 24-0
TIME (HOURS)
Figure 12.1: Mean (SEM) plasma concentration of
nalbuphine against time after the IV administration of
0.15 mg/kg following orthotopic liver transplantation.
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Patient MRT Vss CI
























































Mean 230 278 3.91 17.5
SD 144 185 2.08 8.7
Volun¬
teers 222 - 315* 1.5**
Patients 135.5 150 156* 1.1**
Table 12.6: Pharmacokinetic parameters in 11 patients
after the IV administration of 0.15 mg/kg nalbuphine
following orthotopic liver transplantation. Normal
values for volunteers (Aitkenhead, Lin and Achola 1988)
and anaesthetised patients (Sear, Keegan and Kay (1987);
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Figure 12.2: Mean (SEM) concentration of nalbuphine in
bile and nasogastric aspirate after the administration













Figure 12.3: The mean (SD) cumulative renal excretion




The pharmacokinetic data available for nalbuphine before
this study were limited to healthy volunteers, fit
anaesthetised patients or those undergoing
cardiopulmonary bypass (Lake et al 1982b; Sear, Kegan
and Kay 1987; Aitkenhead, Lin and Achola 1988). In this
study, although interpatient variability was great, the
mean elimination half life of 230 minutes is similar to
that of 222 minutes reported in healthy volunteers by
Aitkenhead and his colleagues (1988), but longer than
the mean elimination half life of 135.5 minutes in
anaesthetised patients reported by the Oxford group
(Sear, Kegan and Kay 1989).
Although the elimination half life, after liver
transplantation, was similar to that measured in
volunteers, this reflected a decrease in both the
clearance and the volume of distribution of nalbuphine,
probably due to the effects of surgery and anaesthesia.
Reductions in the clearance and volume of distribution
have been reported by the Oxford group, although the
relative decrease in clearance was greater, thus
explaining the shorter elimination half life. Mean
residence time was also longer in patients after liver
transplantation than in those studied during
anaesthesia.
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High concentrations of nalbuphine were found in the
nasogastric fluid,indicating that nalbuphine is excreted
by the stomach. An alternative explanation might be that
bile is draining through an open pylorus into the
stomach. Since the concentration of nalbuphine in bile
was lower 'than that in nasogastric fluid this is an
unlikely explanation. Furthermore,the presence of a
T-tube, draining the common bile duct, would have
prevented most of the nalbuphine excreted in the bile
from reaching the gastrointestinal tract. Gastric secretion
of opioids has been previously demonstrated with
fentanyl (Stoeckel, Hengstmann and Schuttler 1979).
Only two percent of the drug was excreted in the urine
during the study period and the remaining 98% was
probably excreted as a metabolite which was not
measured. Some unchanged nalbuphine may have been
excreted in the faeces as a consequence of gastric
excretion, once the postoperative ileus had resolved.
Despite the advantages of nalbuphine as an analgesic it
has not become adopted for use in this group of
patients. The reasons for this are unclear) but several
patients appeared not to obtain satisfactory pain relief
and felt nauseated after receiving the drug. The wide
variation in pharmacokinetic parameters, which may





Postoperative respiratory complications are common in
patients following liver transplantation and good pain
relief is an essential part of their prevention. While
the patient is receiving artificial ventilation,
analgesia can be easily provided by opiates. During
weaning from artificial ventilation and when the patient
is breathing spontaneously good analgesia is
particularly important to prevent splinting of the
diaphragm and to enable deep breathing and coughing. A
cooperative patient, without respiratory depression, is
essential for adequate physiotherapy. Opiates can be
used to provide postoperative analgesia; but the
surgical incision following liver transplantation is
large and in the doses needed to provide adequate
analgesia their use may result in depression of
consciousness, respiratory depression and suppression of
the cough reflex. Intercostal nerve blocks have been
shown to be an effective method of providing analgesia
following both thoracic and abdominal incisions and may
be superior to opiate analgesia? resulting in fewer
adverse pulmonary effects (Engberg 1975).
The "Mercedes" incision starting at the xiphisternum and
extending down to midway between the xiphisternum and
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the umbilicus, with subcostal extensions, makes it
necessary to block the intercostal nerves T5-T10
bilaterally. The nerves are usually blocked as they lie
in the subcostal groove in the midaxillary line
(Lofstrom 1979). The local anaesthetic agent,
bupivacaine, is used since it has a long duration of
action. Pneumothorax is a rare complication
of their use, occurring in less than one percent of
patients after liver transplantation. Despite the low
incidence of this risk, and their effectiveness,
intercostal nerve blockade is not performed whilst the
patient is receiving artificial ventilation because of
the risk of a tension pneumothorax.
A pneumothorax occurring during spontaneous ventilation is
unlikely to be under pressure,and arterial hypoxaemia is
usually the only accompaniment.
Thoracic epidural analgesia, although theoretically
offering many advantages, is not employed in this group
of patients because of the bleeding disorders
frequently encountered in patients with liver
disease. An additional risk, when using local
anaesthesics (but not opioids) for epidural analgesia,
is hypotension due to sympathetic nerve
blockade. This may be potentiated in these patients by
an abnormal splanchnic circulation. Intrapleural
analgesia is effective (Reiestad and Stromskag 1986) but
is not used because of the risk of pneumothorax and
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of introducing infection into the pleural cavity.
Intercostal nerve blockade is widely used in adult
patients both intraoperatively and for postoperative
analgesia (Moore 1975) but it is not popular in
paediatric practice. It has, however, been suggested
for the same indications in children as in adults
(Shulte-Steinberg 1980). Small children developing pain
from the surgical incision following liver
transplantation will often develop marked respiratory
distress. The risk of pneumothorax is the main
disadvantage of intercostal nerve blockade but its
reported incidence in adults varies widely (Moore 1975)
and appears to be operator dependent; no incidence has
been quoted in children.
Administration of local analgesic blocks to children
has a number of problems, particularly for the
occasional paediatric anaesthetist (Brown 1985).
These include the practical difficulties of dealing
with small children; their variations from the more
familiar adult anatomy; the different equipment or
techniques that may be appropriate and the lack of
information regarding the pharmacokinetics of local
anaesthetics in paediatric patients. In the awake
child, the mobility and distress produced by
repeated injections further complicate administration
of local analgesic blocks. Since intercostal nerve
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blockade conferred significant advantages in adults, the
application of this technique was investigated in
children. The standard method for intercostal nerve
blockade was modified and developed to provide
postoperative analgesia to paediatric patients
following liver transplantation. I was assisted by Dr
Maire P Shelly with the data collection.
INTERCOSTAL NERVE BLOCKADE FOR CHILDREN
Anaesthesia (1987) 42; 541-547
Technique of intercostal nerve block
The technique of intercostal nerve blockade was a
modification of that described for adults in the mid
axillary line (Lofstrom 1979). The local analgesic
used was bupivacaine hydrochloride without
adrenaline, 2mg/kg being diluted to give a volume of
lml for each intercostal space to be blocked. A 100cm
length of low dead space manometer tubing was primed
with the solution so that a remote needle technique
could be used, with a second operator to inject the
solution (Winnie 1969). The patient was placed either
in the lateral position or supine and firmly
restrained. The skin was cleaned and the rib palpated
in the midaxillary line. A 25 gauge needle was
introduced perpendicularly through the skin, on to the
rib and gently walked down the rib to its caudad edge.
At this point, the needle was angled posteriorly and
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advanced slightly medially and posteriorly so that it
was almost parallel to the rib, until the tip of the
needle lay l-2mm beneath the edge of the rib, with the
bevel of the needle facing cephalad (Figure 13.1). A
loss of resistance was frequently experienced and
the needle felt to slide into the subcostal space.
Holding the needle firmly in position,with the back of
the right hand supported against the patient and the
left hand palpating the rib or steadying the needle
(Figure 13.2), the assistant holding the syringe was
asked to aspirate and, if no blood or air was
withdrawn, lml of solution was injected and the
needle removed.
Patients
Twenty children under the age of ten had undergone
liver transplantation at this centre at the time of
this study. Intercostal nerve blockade was performed
in the immediate postoperative period to
facilitate weaning from controlled ventilation. Not
all of the children received intercostal nerve blocks
during this period either because of the absence of
an operator familiar with the technique or because of a
continuing need for controlled ventilation. Regional
analgesia was routinely supplemented by bolus









Figure 13.1: Diagram to show the position of the
needle relative to the rib when performing
intercostal nerve blockade by the conventional and the
modified technigue.
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Figure 13.2: The position of the hands and
needle during intercostal nerve blockade in
children using the modified technique.
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The records of all twenty patients were reviewed to
assess the efficacy of intercostal nerve blockade in
this group and the incidence of any complications.
To assess analgesic efficacy, opiate requirements
on the third postoperative day were converted to
morphine equivalents (Morrison 1970) and expressed as
mg morphine/kg for that day. Intercostal nerve
blocks were performed on the Intensive Care Unit during
the first four days postoperatively. However, the third
postoperative day was chosen to assess analgesic
requirements because weaning from artificial
ventilation had generally been achieved by this time
and pain from the surgical incision was still
sufficiently severe to impair respiration as well as
causing distress. At least one erect chest Xray was
taken daily in each child, enabling prompt and
accurate identification of any pneumothorax.
Results
Twenty children had a total of 21 operations, one
patient undergoing retransplantation in the early
postoperative period. Ten of the children received
intercostal nerve blockade on a total of 29
occasions after 11 operations, and on each occasion 10
intercostal nerves were blocked. The other ten children
did not receive intercostal nerve blockade, analgesia
being provided solely by intravenous administration
of opiates. Analgesic requirements on the third
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postoperative day were not determined for seven
patients. Two patients received intercostal nerve
blockade as part of their postoperative analgesic
regimen but this was omitted on the third
postoperative day because no skilled operator was
available. The other five patients did not receive
intercostal nerve blockade; two had died by
the third postoperative day and information for the
other three was incomplete and analgesic requirement
could not be assessed for that day. The details of the
14 patients whose analgesic requirements were
reviewed are summarised in Table 13.1 and shown in
greater detail for all children in Tables 13.2 and 13.3.
Nine of the patients had received intercostal
nerve blockade and were extubated on or before the
third postoperative day. Of the five patients who did
not receive intercostal nerve blockade, two were
extubated on the third postoperative day; the other
three were receiving controlled ventilation.
The nine patients who received intercostal nerve
blockade required 0.16 (0.27) mg/kg morphine [mean (SD)]
on the third postoperative day and five (56%) of these



































Table 13.1: Details of the paediatric patients who
received intercostal nerve blockade (ICB) and those who
did not.
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Patient Age Sex Weight Diagnosis
Number (years) (kg)
1 3.5 F 22 Angiocarcinoma
2 7.0 F 24 Idiopathic Cirrhosis
3 2 . 0 M 12 Biliary Atresia
4 2.0 M 14 Biliary Atresia
5 7.0 F 22 Biliary Atresia
6 3.8 M 15 Biliary Atresia
7 5.8 M 16 a1~antitrypsin
Deficiency
8 4.5 F 16 -antitrypsin
Deficiency
9 0 . 7 F 6 Biliary Atresia
10 2.5 M 10 Biliary Atresia
11 6.3 F 15 Neonatal Hepatitis
12 3 . 0 F 10 a .^-anti trypsin
Deficiency
13 3 . 5 M 14 Biliary Atresia
14 2.7 F 8 Neonatal Hepatitis
15 4.3 F 18 Biliary Atresia
16 2.0 M 12 Biliary Atresia
17 3 . 0 F 12 Biliary Atresia
18 5.3 F 17 Tyrosinosis
19 4.0 F 13 Drug induced
Cirrhosis
20 1.1 M 10 Biliary Atresia
Table 13.2: Details of the first 20 children who
underwent liver transplantation after 1983.
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Patient ICB Opiate Ventilation Total
No Number Need Mode ICB
1 0 2.2 SV 0
2 N/A
3 2 0.79 SV 3
4 2 0 SV 3
5a 0 0.6 SV 2





10 0 0.33 CMV 0
11 2 0.04 SV 2
12 1 0 SV 3
13 1 0 SV 3
14 0 0.7 CMV 0
15 1 0.41 SV 1
16 0 2.09 CMV 0
17 0 2 . 3 SV 0
18 0 0.58 SV 3
19 0 0.21 CMV 0
20 1 0 SV 2
Table 13.3: Opiate requirement of all 20 patients on
the third postoperative day (morphine equivalents
mg/kg). CMV = continuous mandatory ventilation, SV
spontaneous ventilation.
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All patients who did not receive intercostal nerve
blockade received opiate analgesia. On the third
postoperative day, the patients who did not receive
intercostal nerve blockade required 1.52 (0.93) mg/kg
morphine. The three patients still requiring
controlled ventilation on the third postoperative
day had more severe illness and were sedated with
midazolam in addition to morphine. They received a
mean of 1.04 mg/kg morphine on that day; the two
patients extubated on the third postoperative day,
however, received a mean of 2.25 mg/kg morphine on that
day. Most of the children received intercostal nerve
blockade on two or three occasions during and after
weaning from artificial ventilation. The duration
of analgesia on each occasion was approximately 12
hours.
The complication rate of this technique was low.
Although two of the twenty children developed a
unilateral pneumothorax, one child had not received
intercostal nerve blockade and the other had received
intercostal nerve blockade three days previously and was
the first patient on whom the technique was
performed. The patients frequently slept after
administration of the blocks, but none had evidence of
systemic local anaesthetic toxicity. Two patients
developed sputum retention after early discharge from
the Intensive Care Unit. Both received intercostal nerve
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blockade initially but were subsequently given
relatively high doses of morphine for analgesia and
sedation on the ward.
Discussion
Children undergoing liver transplantation are a small
but uniform group, each having the same operation
performed through the same incision. In children,
few other abdominal procedures are performed that
require the same degree of effective analgesia to
relieve severe postoperative pain over a prolonged
period. Intercostal nerve blockade has been shown to
reduce postoperative opiate requirements and
respiratory impairment (Shulte-Steinberg 1980). The
main disadvantage of intercostal nerve blockade is
the incidence of pneumothorax and, in children, the
smaller anatomical distances involved may increase this
risk. In the technique described above, a mid axillary
approach is used to reduce the likelihood of
pneumothorax (Brown and Feik 1979) and since the
needle enters the intercostal space at an acute angle,
almost parallel to the rib, the risk of pleural
puncture is further decreased.
The importance of avoiding the respiratory depressant
effects of opiates is illustrated by the two children
who developed sputum retention due to sedation
following opiate analgesia.
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This study reports only a small number of patients
but use of intercostal nerve blockade immediately
prior to weaning from artificial ventilation, and
repeated as necessary afterwards, has reduced opiate
requirements significantly during this period and
diminished the incidence of problems associated with
their use. The complications of intercostal nerve
blockade include pneumothorax, haematoma formation
and local anaesthetic toxicity from inadvertent
intravascular injection. Only one child who received
intercostal nerve blockade suffered a small unilateral
pneumothorax and that three days after his last
intercostal nerve blockade. Since he was the first
patient to receive intercostal nerve blocks, this may
reflect lack of experience of the technique; no
subsequent patient developed this complication.
Pneumothorax is a complication of artificial ven¬
tilation itself, particularly in children,and one other
child who did not receive intercostal nerve
blockade also suffered a unilateral pneumothorax. The
pneumothorax in this patient was associated with
barotrauma during controlled ventilation of
noncompliant lungs following the development of the
respiratory distress syndrome after inadvertent
administration of cyclosporin into a central vein
(Powell-Jackson et al 1984). The incidence of
pneumothorax was 3.5% in those children who received
intercostal nerve blockade.
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All patients had slightly impaired clotting indices
at the time of their intercostal nerve blockade but
neither bleeding nor haematoma formation proved to
be a problem. Systemic local anaesthetic toxicity was
not observed. Although a maximum bupivacaine dose of
4mg/kg has been recommended (Rothstein et al 1982), a
dose of 2mg/kg was administered to these patients
because of their impaired liver function. Sleep
following intercostal nerve blockade was a consistent
feature. This may be due to several factors; sedation
is a side-effect of local anaesthetic agents and may
be particularly apparent when relatively large doses
are used or when rapid uptake occurs, satisfactory
analgesia may cause a tired child to sleep and finally
performing the blocks or subsequent physiotherapy may
itself tire the child. Although sleepy, the
children were always rousable and cooperative. No
other complications of the procedure have been noted
and the children appeared to forget quickly the
temporary discomfort of the repeated injections. The
modified technique of intercostal nerve blockade
described has been found to provide effective
postoperative analgesia with a reduction in opiate
requirements in children following liver
transplantation. The technique may also benefit other
children undergoing thoracic or abdominal surgery.
Although intercostal nerve blockade is effective in
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children,the multiple injections do cause them distress.
Different ways of alleviating this discomfort were
therefore investigated.
At the time this problem was being considered Astra
Pharmaceuticals Ltd introduced EMLA cream into the
United Kingdom. This cream is a eutectic mixture of two
local anaesthetics, prilocaine and lignocaine. The
eutectic phenomenon is a spontaneous lowering of the
melting point of two substances when they are mixed
together. When prilocaine and lignocaine are mixed
together their melting points are brought into the range
of room temperature,allowing a much higher concentration
of both to be achieved. The final concentration of each
agent is 25 mg/ml which is sufficiently high to enable
penetration of intact skin. Without the eutectic
phenomenon both local anaesthetic agents, in this
concentration, would crystallise at room temperature.
The mixture is combined with arlatone, an emulsifier,
and carbapol, a thickener.
When applied to the skin EMLA has been shown to decrease
the pain of venepuncture for intravenous induction of
anaesthesia (Cooper et al 1987; Hopkins, Buckley and
Bush 1988) and for obtaining venous blood specimens
(Wahlstedt et al 1984; Clarke and Radford 1986).
Furthermore it has been shown to be as effective as
infiltration analgesia fusing lignocaine) for providing
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adequate surgical analgesia for split skin grafting
(Goodacre et al 1988). A small pilot study,using EMLA
applied before intercostal nerve block,was performed to
attempt to reduce some of the discomfort felt by these
children.
THE USE OF EMLA CREAM TO REDUCE THE DISCOMFORT OF
INTERCOSTAL NERVE BLOCKS
Patients and Methods
At least 60 minutes before the planned time of
intercostal nerve blocks one tube of EMLA cream was
applied to both sides of the chest in the midaxillary
line so as to overlie the site of injection of the
intercostal nerve blocks. The cream was then covered
with an occlusive dressing. The nerve blocks were
performed in the manner described above. Six children
were studied.
It became apparent that although the skin was
anaesthetised there were other components to the pain of
intercostal nerve blockade in these children. In a
later study, when I received an intercostal nerve block,
it became apparent that there are three components to
the pain produced by intercostal nerve blockade. These
are:
1. The needle passing through the skin. This is
readily blocked by EMLA cream.
Page 436
2. Some discomfort is experienced when the needle
strikes the rib, due to periosteal stimulation.
3. As the local anaesthetic tracks posteriorly in
the subcostal groove discomfort is experienced. This
may be because the solution is cold and as a consequence
causes irritation to the nerves in the subcostal groove.
Alternatively, the fluid may separate tissues away from
the rib and in so doing produce significant pain. Which
tissues are separated is not clear. If the periosteum
is stripped from the rib,this would explain the pain,but
this is unlikely because of the method of insertion of
the needle and the ease with which it is felt to slip
along the subcostal groove. A further explanation is
that the normal anatomy of the vascular structures and
nerves found in the subcostal groove is disrupted, with
the resultant stretching of their attachments, causing
pain.
One further disadvantage of this technique is that
unless great care is taken the operators fingers become
analgesic. Since the use of EMLA cream did not appear
effective its use was not pursued further. Reports from
Stoke-on-Trent (Seddon and Clayton 1984) of the efficacy
of performing intercostal nerve block by jet injection
led to an investigation of its use after liver
transplantation.
The compressed gas injector gun has been available for
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some time and is principally used for mass inoculation.
Its use has also been evaluated for inferior dental
nerve blockade (Sowray 1981), for paracervical blockade
(McKenzie and Shaffer 1978; Kovacs 1982) and for the
administration of low dose heparin (Black, Nagle and
Strachan 1978). It utilises pressurised carbon dioxide,
drawn from a cylinder in the handle, to drive up to 1ml
of the solution through a nozzle. As the solution
passes through the nozzle it is broken up into particles,
each six thousandths of an inch in diameter (Figure 13.3). The
speed and size of each particle allow it to travel
through skin and a considerable distance into the
tissues. Cooke and his colleagues (1980) have shown
that the bioavailability of lignocaine using jet
injection is the same as that when it is administered
using a needle and syringe.
The use of a compressed gas gun for intercostal nerve
blockade was claimed to offer several advantages over
the conventional needle technique including:
a. The risk of pneumothorax is eliminated since the
pleura is not penetrated. This may enable intercostal
nerve blockade to be performed even while the patient
is receiving artificial ventilation.
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Figure 13.3: The Med-E-Jet gas powered injector gun.
Page 439
b. Damage to blood vessels is reduced since they are
moved aside by shock waves generated by the gun. This
would be a particular advantage in patients with a
coagulopathy.
c. Since no needles are involved in the technique,
patient acceptability of the procedure may be increased,
particularly in children.
The main disadvantage of the gas injector is that only
small volumes (<lml) can be used. In the initial study,
in adults, Seddon and Doran (1981) used 0.5% bupivacaine
for intercostal nerve blockade following thoracotomy and
demonstrated some benefit, although they felt that
better results could be obtained with a higher
concentration of local anaesthetic. In a further study,
also in adult patients who this time required
cholecystectomy, Seddon and Clayton (1984) used a higher
concentration of bupivacaine (1.5%) and obtained better
results. Astra Pharmaceuticals Ltd were approached
before investigating this method,but would not release
bupivacaine of this concentration because of lack of
information about its neurotoxicity. However, since this
study was to be performed in children, with their
smaller dose requirements, it was felt this volume of
0.75% bupivacaine solution should produce analgesia, if
the method is effective.
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AN EVALUATION OF THE EFFICACY OF A COMPRESSED GAS
INJECTOR GUN FOR INTERCOSTAL NERVE BLOCKADE.
Patients and Methods
Four consecutive patients, both adults and children,
requiring intercostal nerve blocks after liver
transplantation were studied. Informed verbal consent
was obtained from the patient and/or their parent. When
the patient was ready to be weaned from artificial
ventilation a set of intercostal nerve blocks was
performed using the established needle injection method>
since there is a clinical need for good analgesia at
this time. The technique of intercostal nerve blockade
was then alternated between the needle method and the
gas injector gun. Bupivacaine 0.5% was used when the
needle technique was employed and bupivacaine 0.75% with
the gas injector gun. Intercostal nerve block using the
gas injector gun was performed by palpating the inferior
aspect of the rib in the midaxillary line and placing
the nozzle of the gun firmly against the skin and
perpendicular to it. One ml of 0.75% bupivacaine was
then injected. On the occasions the gas injector gun
was not used a 23 gauge needle was used to inject 2-3
mis of 0.5% bupivacaine (unless the total dose exceeded
2mg/kg when 0.25% bupivacaine was used) in the
midaxillary line (Lofstrom 1979).
A note was made of the duration of analgesia produced by
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the two techniques and any requirement for additional
analgesia. Bruising or haematoma formation at the site
of administration was also noted. Clinical evidence of a
pneumothorax was sought after each set of intercostal
nerve blocks.
Results
All the patients studied were unanimous after the first
attempt to produce intercostal nerve blockade using the
gas injector gun that they did not want to experience it
again; the noise and percussion on the chest wall
frightened the patients. It is of note that in the two
previous studies the majority of patients were receiving
general anaesthesia when the intercostal nerve blocks
were performed (Seddon and Clayton 1984; Seddon and
Doran 1981) and this problem would not have been noted.
Bruising and bleeding from the site where the nozzle was
placed was considerable. In some instances the entry of
the fluid under pressure appeared to have torn the skin.
Haematoma formation also occurred, indicating that some blood
vessels had been disrupted. These features highlight
the frail nature of these very ill patients. Analgesia
produced by the injector gun was unsatisfactory and did
not last for more than 2 hours.
The absence of adequate analgesia




surprising and a radiographic study was
performed comparing intercostal nerve blockade using a
needle and injection using the compressed air gun. In
this study Dr Maire P Shelly performed the intercostal
nerve block using the gas injector gun, Dr M J Lindop
(Consultant Anaesthetist) performed the two intercostal
nerve blocks using the standard needle injection method
and Dr A Dixon (Consultant Radiologist) performed the
computerised tomography scan. I was the volunteer.
A RADIOGRAPHIC AND CADAVERIC STUDY
OF THE GAS INJECTOR GUN
Intercostal nerve blockade was performed using the gas
injector gun on the sixth rib on the right side. One ml
of a solution containing 10% lopamidol was injected and
a computerised tomography scan of that area was
undertaken. The results are shown in Figure 13.4.
Two further intercostal nerve blocks were performed on
the tenth ribs on both sides using the conventional
adult method (Moore 1975). The lower site was chosen to
be below the reflection of the pleura and so decrease
any risk of pneumothorax to the volunteer. One ml of a
solution containing 10% lopamidol was injected so that
the subsequent CT scan would be as similar as possible
to the previous study. The results of this study are
shown in Figure 13.5.
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Figure 13.4: Computerised tomography scan after 1 ml
10% lopamidol injected using the compressed gas jet
injector gun into the subcostal groove of the sixth rib.
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Figure 13.5: Computerised tomography scan after 1 ml of
10% lopamidol has been injected into the subcostal
groove of the tenth rib using needle injection.
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When the two sets of CT scans are compared it is
apparent that significant differences in the disposition
of the radio-opaque dye are seen. With the gas injector
gun contrast medium is seen lying under the skin and
diffusely spread throughout the subcutaneous tissue.
Only a small amount has been deposited in the subcostal
area. The pleura is seen to bulge (a feature previously
noted in the original description (Seddon and Doran
1981) of the technique) and there is discontinuity
between the subcutaneous and the subcostal dye,
indicating haematoma formation . When the CT scan from
the intercostal blocks performed using a needle is
studied, contrast medium is seen to be predominantly
deposited in the subcostal area,with little in the
subcutaneous tissue. Furthermore, contrast medium is seen
to spread along the rib.
To further examine the disposition of local anaesthetic
solutions, a cadaver study was performed. Methylene
blue was injected through the skin using the gas
injector gun as previously described. This section of
rib was removed and shown in Figure 13.6. It can be
seen that dye lies over the outer aspect of the rib cage
and Figure 13.7 shows the rib from the medial aspect
with little bulging of the pleura. It is important to
note that no spread of dye was seen anteriorly or
posteriorly from the site of injection.
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Figure 13.6: Section of the thoracic wall viewed from
the outside after 1ml of methylene blue has been
injected using the gas injector gun.
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Figure 13.7: Section of the thoracic wall viewed from
within the pleural cavity after injection of 1ml of
methylene blue using the gas injector gun.
Page 448
Both the CT and cadaver study demonstrate that the
disposition of local anaesthesia is very localised
following administration using the gas injector gun, with
little lateral or medial spread^ compared with injection
using a needle. This may be an explanation of why
inadequate analgesia was obtained with this method.
Three studies, using needle injection in cadavers and
patients, have demonstrated the spread of the local
anaesthetic solution from the site of injection both
medially and laterally (Murphy 1984; Nunn and Slavin
1980; Moore, Bush and Skulock 1980). Murphy (1984) and
Nunn and Slavin (1980) suggested that spread of local
anaesthetic solutions cephalad and caudad may also be an
important mechanism in the analgesia provided by
intercostal nerve blockade, although Moore (1981)
strongly contests that. A further mechanism involves
inadvertent intraneural injections during intercostal
nerve blockade resulting in a spinal nerve block
(Selander and Sjostrand 1978). The importance of spread
by all of these mechanisms is emphasised when variations
in the position of the proximal intercostal nerve are
considered (Hardy 1988). In addition, significant
haematoma was associated with use of the gas injector in
patients and it was also demonstrated on the volunteer
CT scan in the area of the injection. This latter
feature will dilute the concentration of local
anaesthetic solution in the area of the intercostal
nerve. All of these factors may contribute to the lack
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of efficacy of the gas injector gun in patients.
Since this method did not provide satisfactory analgesia
a further method using direct wound perfusion with local
anaesthetic solutions was evaluated.
Wound perfusion with a local anaesthetic solution might be expected
to produce a decrease in opiate requirement not only by
its effect on pain fibres, but also by diluting pain
producing substances, such as bradykinin and histamine
in the wound. The first study of the direct perfusion of
surgical wounds with local anaesthetic solutions was reported by
Cappelle in 1935 (Levack, Holmes and Robertson 1936) and
subsequently by Blades and Ford (1950) for thoracotomy
incisions. Both investigators noted a decrease in
opiate requirements. Other investigators looked at
direct wound infiltration with local anaesthetic solutions and
similarly noted a decrease in opiate requirements
(Gerwig, Thompson and Blades 1951; Lewis and Thompson
1953). Although opiate requirements were again reduced
none of these studies was controlled. This method was
more fully investigated by two groups on patients
following cholecystectomy (Thomas, Lambert and Lloyd
Williams 1983; Levac, Homes and Robertson 1986). Both
groups randomly allocated patients to receive
bupivacaine or saline placebo and observers and patients
were blind to the nature of the solutions. Their
findings were also similar,' those patients who received
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bupivacaine wound perfusion having a similar decrease in
opiate requirements to those patients who received
saline perfusion. In the trial by Levac and his
colleagues (1986), however, there was a significant
reduction in the forced vital capacity of the placebo
group compared with the group receiving bupivacaine,
possibly indicating some decrease in wound pain during
deep breathing.
DIRECT WOUND PERFUSION WITH LOCAL ANAESTHETIC SOLUTIONS
Patients and Methods
To investigate any advantage of this simple technique in
patients following liver transplantation, three modified
infusion catheters with attached microbiological filters
were inserted into each limb of a Mercedes incision
(Figure 13.8). In the two previous studies (Thomas,
Lambert and Lloyd-Williams 1983; Levac, Holmes and
Robertson 1986) a wound drainage catheter was used to
place local anaesthetic solution into the wound. These
catheters have large holes to permit drainage and have a
low resistance to flow at each orifice. When local
anaesthetic is injected any local obstruction will tend
to increase the resistance at that orifice, leading to
preferential flow out of other portions of the catheter
and patchy anaesthesia. For the purposes of this study
a specially designed and made catheter was used [supplied
by Portex (Hyde, Kent)] which had orifices made by
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puncturing the catheter with the tip of a sewing needle
in the first 10 cm of their length. There was no end
orifice. Since the catheter was made of a soft pliable
plastic these orifices only open when fluid is injected.
The small orifices in the catheter gave a high
resistanceto flow and thusa partial obstruction did not
prevent flow out of that slit. This ensures even
distribution of local anaesthetic solution along the
terminal 10 cm portion of the catheter without pooling
(Figure 13.9).
A formal clinical trial was proposed and ethical
approval obtained. However, before proceeding with the
study a pilot study was performed. After weaning was
complete (initial analgesia having been provided with
intercostal nerve blocks) and when the patient next felt
pain 10 ml . of 0.25% bupivacaine was injected into each
infusion catheter. Patients were observed for pain
relief (decrease in respiratory and heart rate, change
in facial grimacing etc) and asked to cough and comment
on pain relief. Three patients were studied in this
open way and following the infusion of bupivacaine no
physiological change, or increase in the ability to
cough or relief in pain^was noted in any patient.
Although the risk of infection was diminished by the
microbiological filters it was felt still to be present
and particularly hazardous in an immunosuppressed
patient receiving corticosteroids.
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Figure 13.8. Wound perfusion catheter with attached
microbiological filter.
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Figure 13.9. Small orifices in the wound perfusion
catheter. A 10ml syringe, filled with water has been
attached to the filter/catheter. The water is then being
injected which requires the application of some pressure
to the syringe.
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Since an open trial did not show any benefit and there
appeared to be a small risk to the patient the proposed
trial was abandoned. It is of note that subsequently
others (Chester et al 1989) claim to have shown some
benefit from a prospective, placebo-controlled study of
wound perfusion catheters. On the first postoperative
day after cholecystectomy the patients' analgesic
demands for pethidine were identical, irrespective of
whether they received bupivacaine or placebo, but the
group receiving the bupivacaine had lower pain scores.
It would appear that if regional analgesia is to be used
there is no suitable alternative to intercostal nerve
blockade. To prevent distress in children ;low dose
ketamine can be administered immediately prior to
intercostal nerve block.
Having decided that intercostal nerve blocks are the
most suitable form of regional anaesthesia, it became
apparent that there was only limited data about the use
of local anaesthetic agents in patients with liver
disease. The long duration of action of bupivacaine
makes it the drug of choice for intercostal nerve
blockade. Bupivacaine is metabolised by the liver, with
a lower hepatic extraction ratio than lignocaine (Tucker
and Mather 1979; Tucker et al 1977). Clinical studies
have shown that clearance of lignocaine, the other
commonly used amide local anaesthetic, may be impaired
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in cirrhotic patients (Thompson et al 1973), after
hepatectomy (Aldrete et al 1970), and during viral
hepatitis (Williams et al 1976). No such data exists
for bupivacaine. Furthermore^patients with severe liver
disease develop portal hypertension and extensive
collateral vessel formation. The effect of these
enlarged vessels on the speed of drug absorption was not
known.
Total plasma concentrations of bupivacaine were
therefore measured after intercostal nerve blockade in
patients who had recently undergone liver
transplantation. Since bupivacaine is bound to a^-acid
glycoprotein (AAG)^this was also measured.
I was assisted in this study with the sample collection
by Dr A Bodenham, the bupivacaine assays by Mr J
Goudie (Department of Biochemistry, St Albans City
Hospital) and the AAG assays by Dr Jacqui Calvin
(Department of Clinical Biochemistry, Addenbrookes
Hospital).
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PLASMA CONCENTRATIONS OF BUPIVACAINE AFTER INTERCOSTAL
NERVE BLOCKADE IN PATIENTS FOLLOWING ORTHOTOPIC LIVER
TRANSPLANTATION.
British Journal of Anaesthesia 1990 64; 436-441
Patients and Methods
Eleven patients who required analgesia on the first or
second day after liver transplantation were
consecutively divided into two groups;
Group 1 included 6 patients having a single set of
bilateral intercostal nerve blocks using plain
bupivacaine (2mg/kg).
Group 2 consisted of 6 studies in 5 patients having two
sets of bilateral intercostal nerve blocks separated by
6 hours using bupivacaine plus adrenaline 1/200,000
(2mg/kg on each set of injections). One patient was
studied on two occasions 4 months apart after her first
and second liver transplant.
The intercostal nerve blocks were performed when the
patient was ready for tracheal extubation, usually on
the first postoperative day. A baseline blood sample
was withdrawn from a radial arterial cannula,
previously inserted for other purposes. Bilateral
intercostal nerve blocks (T5-T10) were then performed
using the standard technique described earlier. A total
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dose of 2mg/kg bupivacaine with or without adrenaline
was injected on each occasion. In smaller,wasted patients
the dose of bupivacaine was made up to a minimum volume of
30 ml allowing an adeguate volume of solution.
Arterial blood (5ml ) was then sampled at
5,10,15,30,60,120,240 and 480 minutes after the
injection of bupivacaine. In group 2 the sampling
protocol was slightly changed with an extra sample taken
at 2.5 minutes and the final sample taken at 360
minutes, immediately before the intercostal blocks were
repeated, following which the sampling procedure was
repeated.
Blood was collected in tubes containing lithium heparin
as an anticoagulant and separated by centrifugation at
3000 rpm. Plasma was then stored at -20°C until
analysis. Liver function tests (albumin, total protein
and a1~acid glycoprotein) were also measured from a
baseline serum sample. Any adverse reactions such as
blood pressure changes or neurological deterioration
were recorded during this period. Detailed neurological
assessment was not possible due to residual opiate and
benzodiazepine effects and the process of tracheal
extubation.
Bupivacaine concentrations in groups 1 and 2 were
compared by Student's t test for paired data. The
relationship between bupivacaine concentrations and AAG
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concentrations was determined using analysis of linear
regression.
Analysis of samples
The assay was performed using HPLC as described by
Nation and his colleagues (1979). After the addition of
an internal standard (etidocaine)^ the sample was
alkalinised with sodium hydroxide and extracted with
dichloromethane. An aliquot of extract was evaporated to
dryness at 50°C and redissolved in a mobile phase of 1%
triethylamine in water, adjusted to a pH of 3.0 with
phosphoric acid and organic modifier (30% acetonitrile)
prior to injection. The solution was injected into a 150
x 4.6 mm column containing 5 micrometre ultrasphere
"ods" and the flow rate was adjusted to 1.5 ml/min at
ambient conditions. An ultraviolet detector at 205nm was
used. The assay was calibrated with spiked standards.
To exclude interference from the other drugs patients
received during their period of intensive care, control
samples of serum from other liver transplant recipients,
who had not received bupivacaine were analysed and
showed no interference with the assay. In addition to
this study^ further 2000 samples have been analysed,and
no interference from other substances detected. The
sensitivity of the assay was 50 ng/ml with a within-
batch variation of 3.9% and a between-batch variation of
4.0%.
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The AAG assay was performed by an automated
turbidimetric immunoassay using an IL Monarch analyser
utilising "Dako" antiserum to AAG.
Analysis of areas under the concentration time curves
were performed using an "Apple Fitter" programme. The
values for elimination half life and clearance in this
study were not calculated ,as sampling was not carried
out for the recommended three elimination half — lives
owing to the need to repeat the injections for analgesia.
Results
The details of the 11 patients studied are shown in
Table 13.4.
The injections were performed a mean time of 15.7 (8.5)
hours [mean (SD)] after the transplanted liver had been
reperfused. The concentrations of plasma proteins and
liver function tests at the time of each study are
listed in Table 13.5.
The mean time to complete the bilateral intercostal
nerve blocks was 4.5 (1.8) minutes. The mean (SEM) total
plasma concentrations of bupivacaine in the two groups
plotted against time are shown in figures 13.10 and
13.11.
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Patient Age Sex Weight Presenting diagnosis
(yrs) M/F (kg)
Grout) 1
1. 17 F 55 Chronic active hepatitis.
2. 56 F 45 Primary biliary cirrhosis.
3 . 39 M 67 Sclerosing cholangitis.
4 . 58 F 37 Primary biliary cirrhosis.
5. 29 F 60 Alcoholic cirrhosis.
6 . 45 F 54 Primary biliary cirrhosis.
Grout 2
7. 26 F 55 Primary biliary cirrhosis.
(Patient studied twice> after two separate transplants)
8. 52 M 80 Alcoholic cirrhosis +
hepatoma.
9. 40 F 68 Chronic rejection of
previous transplant for
sclerosing cholangitis.
10. 59 F 64 Primary biliary cirrhosis
+ polycystic disease.
11. 21 F 43 Wilson's disease.
Table 13.4: Demographic data and presenting diagnosis
of the patients in groups 1 and 2.
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Patient Albumin Total AAG Bilirubin ALT AP
(g/i) protein (g/i) (pol/1) (0/1) (0/1)
(g/i)
Group 1
1. 46 58 0.9 108 610 43
2. 37 67 0.9 150 534 206
3. 20 80 0.7 123 78 179
4. 35 74 2.3 62 684 783
5. 24 55 0.7 14 371 180
6. 25 63 2.4 59 456 1200
Group 2
7. 27 51 1.4 867 115 978 *
31 45 1.6 249 674 963 **
3. 32 53 1.4 368 506 173
9. 40 62 1.7 100 969 271
10. 38 61 1.1 109 547 200
11. 31 45 1.5 18 34 30
* 1st transplant ** 2nd transplant
Table 13.5: Concentrations of plasma proteins and




Figure 13.10: Plasma concentrations of bupivacaine
[mean (SEM)] in group 1 after a single set of
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Figure 13.11: Plasma concentrations of bupivacaine
[mean (SEM)] in group 2 after a 2 sets of intercostal
injections 6 hours apart using 2mg/kg bupivacaine
containing 1/200,000 adrenaline.
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In group 1 (plain bupivacaine) the mean (SEM) maximum
concentration (Cmax) was 1.75 (0.07) jj.g/ml. The time
taken to reach Cmax (Tmax) occurred at 5, 10 and 15 minutes
in three, two and one patients respectively. The mean
value of Cmax in group 2 (bupivacaine + adrenaline)
was 1.69 (0.35) M-g/ml after the first injection. Tmax
occurred at 5, 10, 15 and 30 minutes in one, two, two and
one patients respectively. After the second set of
injections in group 2 Cmax was 1.99 (0.34) |ig/ml. Tmax
occurred at 5, 10, 15, and 30 minutes in two, one, one,
and two patients respectively. The results of Cmax from
group 1 and the first set of injections in group 2 were
not statistically different (p>0.05)j indicating that the use
of adrenaline-containing solutions did not reliably slow
absorption. The plasma concentrations of bupivacaine
had not returned to zero after 6 hours in group 2, the
time when the second set of injections was performed.
In addition,the area under the mean concentration time
curve increased by 44% in group 2 after the second set
of injections. These two factors indicate accumulation
of bupivacaine. Eight patients had serum concentrations
of AAG above the reference range (Table 13.5)^ but these
high concentrations did not correlate with high
measured concentrations of total bupivacaine (p>0.05).
The patient who was studied twice had similar plasma
concentrations of bupivacaine on each occasion.
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Discussion
There has been one other short report of plasma
concentrations of bupivacaine after intercostal blocks
following liver transplantation in 3 patients (Goldberg
et al 1987). This study used smaller total doses of
50-100mg making comparison of data difficult but Cmax
occurred at similar times to our data at 5 mins, the
first sampling time.
High plasma concentrations of local anaesthetic drugs
may be a problem with intercostal blocks (Moore et al
1976; Rothstein et al 1986) owing to the large total
volumes of drug solution required for the multiple
injections into a highly vascular area. In patients with
advanced liver disease the chest wall may have
unusually large venous vessels due to portosystemic
anastomoses. These collateral vessels might alter the
speed of drug absorption after intercostal injection.
The mean concentrations of bupivacaine were within
similar ranges to those reported in other series (Moore
et al 1976; Rothstein et al 1986; Johnson et al 1987).
There was no statistical difference between Cmax for
the two groups with and without adrenaline. In group 1
the fact that Cmax occurred at 5 minutes in 2 patients
without adrenaline suggests that Cmax may have been
missed in some of these patients. Following reports of
Cmax occurring early (Johnson et al 1987) an additional
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sample was collected at 2.5 minutes in group II. No
Cmax values were seen at 2.5 minutes in group 2. Tmax
was variable between patients in both groups, but these
cannot be reliably compared owing to the spacing of
sampling times and the relatively small numbers of
patients studied. The addition of adrenaline in the
bupivacaine solution did not consistently increase the
time taken to reach Cmax; this is in disagreement
with other studies measuring arterial concentrations of
bupivacaine after intercostal injection (Johnson et al
1987). The abnormal vasculature present in patients
with liver disease may not vasoconstrict normally in the
presence of injected adrenaline. In addition, the size
alone of the collateral vessels may not be important.
Studies in children with extensive collateral vessel
formation, secondary to coarctation of the aorta, have
demonstrated that absorption of bupivacaine is no
different compared with children with other forms of
congenital heart disease, without collateral vessel
formation (Rothstein et al 1986).
No adverse reactions attributable to bupivacaine were
seen in these patients despite plasma levels of
bupivacaine within the putative toxic range in 6
patients (2 in group 1, 4 in group 2 following both
sets of injections). This may reflect an inaccuracy of
the reported toxic threshold of 2-4 p.g/ml (Fitzgibbons,
Moore and Balfour 1981; Tucker 1986) for bupivacaine.
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The reported toxic values have been derived from studies
using short intravenous infusions of bupivacaine to
obtain steady state concentrations; however, differences
in the analytical method, sampling sites and infusion
regimen used in each of these studies make:
interpretation of these values complicated (Tucker and
Mather 1979). Alternatively,the lack of adverse side-
effects may be due to the protective effects of residual
benzodiazepine sedation, which had been administered
prior to tracheal extubation (DeJong and Heavner 1971).
All patients in the study were rousable but had
background sedation and analgesia, making precise
neurological assessment impossible. In addition, the
total bupivacaine concentrations measured in our study
may not reflect the free, nonprotein — bound
concentration of the drug which is thought to cause CNS
side-effects (Denson, Myers et al 1984).
Bupivacaine is extensively bound to AAG (Denson, Coyle
et al 1984), an acute phase reactant whose levels were
increased in these and other patients following liver
transplantation, owing to acute surgical stress and liver
disease (Chapter 6). In the presence of elevated
concentrations of AAG high total concentrations of
bupivacaine would be measured but toxicity would not
occur, as the free concentration would be normal. The
concentrations of AAG were above the reference range
(0.5-1.0 g/1) in 7 of the patients in this study but did
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not correspond to those with increased total bupivacaine
concentrations. Unfortunately, it was not possible to
measure free bupivacaine concentrations nor the
differing subtypes of AAG (Serbource-Goguel et al 1983;
Serbource-Goguel et al 1986) and their differing effects
(if any) on drug binding. The relatively normal albumin
and total protein concentrations reflect aggressive
treatment of hypoalbuminaemia with the infusion of
albumin- containing solutions in the perioperative
period.
Other factors may also have contributed to the high
plasma concentrations of bupivacaine. Uptake of
bupivacaine by the lungs is significant (Rothstein et al
1983) and may be competitively inhibited by drugs such
as propranolol (Rothstein and Pitt 1983). Three patients
had been receiving long term propranolol for control of
portal hypertension before their liver transplant.
However^ these three patients did not develop
consistently higher bupivacaine concentrations than the
other patients studied. The presence of functional
intrapulmonary shunting in patients with liver disease
(Williams et al 1979) may also increase the availability
of the drug to the systemic circulation. This has been
shown experimentally, in animals, using lignocaine
(Bokesh et al 1987). The potential importance of these
mechanisms was not investigated in this study.
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Extrapolation of these results to other patients with
liver disease requires caution,since differences in the
mechanisms of liver injury may alter the livers capacity to
eliminate bupivacaine. However, the results suggest that
caution may be necessary in this group of patients when
intercostal blocks are performed. Some patients will
achieve potentially toxic levels of bupivacaine a
variable time after performing the intercostal nerve
blocks. Although clinical evidence of toxicity has not
been seen^ the recommended maximum dosage of 2mg/kg
should not be exceeded in these patients. The use of
adrenaline - containing solutions did not consistently
reduce the speed of absorption nor the maximum
concentration of bupivacaine. Furthermore) bupivacaine
accumulation after repeated intercostal nerve blocks
within 6-8 hours will occur in some patients following




CONCLUSIONS ABOUT SEDATION AND ANALGESIA
AFTER LIVER TRANSPLANTATION
The liver is central to drug metabolism and when hepatic
injury occurs, alterations in the elimination of drugs
are observed. In addition,poorly understood changes in
the CNS receptors also occur, making the patient
sensitive to sedatives and analgesics. It is therefore
not surprising that a considerable amount of this thesis
is devoted to the problems of excessive sedation, its
mechanisms and how it may be avoided. However, the
importance of the patients' need for opioids for
adequate pain relief, respiratory depression and
antitussive effects and sedative drugs to allay anxiety
after liver transplantation has been discussed in
Chapter 7.
Many of the studies in this section of this thesis have
illustrated the importance of the liver in the
elimination of sedatives and analgesics. The studies
after liver transplantation, showing significant
alterations in pharmacokinetic variables, generally
illustrated delayed elimination. Three studies were
performed during the anhepatic period and these
demonstrated the absolute need for the liver to
metabolise morphine (Chapter 11) and the presence of
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extrahepatic sites able to metabolise midazolam (Chapter
8) and propofol (Chapter 10). Although the latter two
studies both demonstrated extrahepatic metabolism}
further increases in metabolic activity were seen when
the donor liver was revascularised. The anatomical
location of extrahepatic metabolic sites remains to be
fully elucidated. The lungs have been suggested as a
site of metabolism for many drugs, including
propofol. Many of the studies have been performed in
whole experimental animals or humans and have inferred
results based on plasma sampling. The study in Chapter
10 did not confirm the suggestion of pulmonary
metabolism made in some of these studies. The relative
importance of the gastrointestinal tract, muscles,
kidneys and other organs as sites for drug metabolism
remains to be evaluated.
The original drugs used for sedation and analgesia were
morphine and diazepam*, if a muscle relaxant was required
then pancuronium or curare was administered. These were
given by intravenous bolus injection, primarily because
only these "long acting" drugs were available and there
was little need to administer them using continuous
intravenous infusions. In the late 1970s "short
acting" induction agents (Althesin and Etomidate) became
available for use during anaesthesia. These were soon
investigated as agents to be given by prolonged
continuous intravenous infusion to the critically ill,
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producing a controllable depth of sedation from which
patients would rapidly awake when they were
discontinued. A short acting, predictable analgesic,
sedative or muscle relaxant is particularly attractive
in this group of patients. Although both of the original
drugs have now been withdrawn for this purpose, other
drugs with a similar reported duration of action,
including chlormethiazole, midazolam, alfentanil, and
propofol, have been investigated to varying degrees in
this thesis.
Infusion of these newer drugs^ as well as some of the
more established ones such as morphine, has gained
widespread acceptance in all groups of critically ill
patients, which might indicate improved efficacy
compared with bolus administration but little scientific
evidence is forthcoming to support this view. Although
early uncontrolled studies with infusions of opioids,
for example that by Fry (1979), suggested improved
analgesia, this has not been confirmed when placebo
controlled, blind, randomised trials have been
performed (Marshall et al 1985; Owen et al 1989). It has
been argued that all of these studies occurred in a
research environment and generated an interest in
analgesia such that intramuscular injections, or other
forms of pain relief^ will be administered more
frequently than would otherwise be the case. Whilst this
may apply to a busy, general surgical ward it should not
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occur in a well staffed intensive care unit with a high
nurse/patient ratio.One of the reasons for the failure of
infusions to provide superior analgesia may be the rapid
development of tolerance to opiates (McQuay, Bullingham
and Moore 1981; Schafer et al 1983; Marshall et al
1985), a feature demonstrated also with midazolam (Chapter
8). In uncomplicated, postoperative patients, not
requiring intensive care, pain decreases as this
phenomenon develops. Patients after liver
transplantation have severe pain from their Mercedes
incision which requires excellent pain relief for
several days to facilitate weaning from artificial
ventilation. There is little doubt that, if opiates are
being infused^ increasing the rate of infusion will
achieve analgesia, and in appropriate circumstances
increasing the rate of infusion of sedative or
neuromuscular blocking drugs will achieve similar
results. The simplicity of administering sedative drugs
by continuous infusion and the desire to keep patients
comfortable may lead to the patient's attendant
inadvertently administering excessive sedative and
analgesic drugs. Problems with continuous infusions of
these drugs have arisen when they are discontinued and
their effects do not end as expected. Prolonged
sedation of several days' duration has been reported with
midazolam (Chapter 8) and subsequently chlormethiazole
(Chapter 10). Similar unexpected prolongation of effect
has been described in one patient following an infusion
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of alfentanil (Yate et al 1986) and in several patients
with renal failure after infusions of vecuronium
(Griffiths, Hunter and Jones 1984). The prolonged
duration of effect of the drugs may not be recognised
and has misled clinicians into thinking that cerebral
impairment has occurred due to the original illness.
This may result in unnecessary investigations such as
cranial computerised tomography and inappropriately
influence major management decisions. Furthermore,
unnecessary excessive sedation may result in other
difficulties, such as those discussed in Chapter 7.
Why do some patients respond to drugs in an unexpected
manner? Much of the early work on the pharmacokinetics
and pharmacodynamics of drugs is performed on healthy
experimental animals, volunteers and ASA class 1 or 2
patients. This thesis has attempted to resolve some of
the problems encountered in clinical practice by
describing pharmacokinetic and pharmacodynamic studies
during periods of acute illness. Furthermore, it
attempts to identify some of the effects of acute organ
support (such as CWHD) on drug action. Hepatocellular
function also changes in the postoperative period, and
although in the majority of patients continued
improvement is seen^in some deterioration due to sepsis
and rejection will also be experienced. An additional
factor is the changes in both portal venous and hepatic
arterial blood flow, not only as a result of anaesthesia
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and surgery (Gelman et al 1976) but also because of
subsequent episodes of sepsis and surgery. The effects
of any of these events on the denervated, human hepatic
artery and portal vein are unknown. Certainlyj as
hepatocellular function and blood supply to the liver
change, so alterations in drug elimination can be
expected. This is so even with the newer drugs which
have been thought to have more predictable
pharmacokinetics than the older agents. Marked changes
in the pharmacokinetic variables with both nalbuphine
and alfentanil are reported in Chapter 12. Changes in
hepatic blood flow and hepatocellular function may not
always correlate with alterations in metabolic activity
(MacNab et al 1986) and the possibility of small
molecular weight substances interfering with drug
metabolism, particularly in renal failure, has been
raised (M.Tarbitt Personal Communication).
Pharmacogenetic abnormalities might also explain some of
the difficulties in this group of patients. Six percent
of the population have been demonstrated to be slow
metabolisers of midazolam (Dundee et al 1986). It is
interesting to speculate about the patient presented in
Chapter 8, who during the anhepatic period of liver
transplantation initially did not metabolise midazolam
but did after revascularisation of the donor liver. Were
her extrahepatic sites of benzodiazepine metabolism
similarly affected? Liver transplantation can reverse
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genetically acquired enzyme defects and this may have
been an example of this. In one other patient a low
plasma concentration of pseudocholinesterase,
before liver transplantation, associated with apnoea
after suxamethonium,became normal afterwards. In both of
these patients an improvement in their ability to
metabolise drugs was seen, but other patients may
experience the reverse. The importance of
pharmacogenetic changes does not lie during and immediately
after anaesthesia (since termination of drug effect at
this time is usually due to redistribution), but when
the drug has been administered for a longer period of
time. In these circumstancesta significant prolonged
effect may be expected,since the drug is no longer
redistribution-limited but is now dependent upon metabolism
and excretion.
What is the answer to the effects of prolonged duration
of action of sedative and analgesic drugs in patients
after liver transplantation? Specific antagonists now
exist for opiates (naloxone) and benzodiazepines
(flumazenil). They may be given by bolus injection but
because of their short duration of action, they may need
to be administered by repeated bolus injection or
continuous intravenous infusion (Chapter 9). Both
naloxone and flumazenil are expensive and infusions of
both drugs may be costly. Although they may reverse the
prolonged effects of analgesics and sedatives their routine
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use in this group of patients might indicate and
encourage unnecessary sedation. One way to prevent
oversedation whilst ensuring adequate patient comfort is
to monitor and record the effect of the drug and alter
the dose accordingly. This is done routinely for many
other drugs that have easily defined endpoints, such as
vasoactive drugs, but is rarely performed for sedatives
and analgesics. A simple but effective scale, developed
during the period of this thesis, has proved invaluable
in improving patient care. A further method, used
particularly after liver transplantation, is to
recognise the need for analgesia or sedation and give an
appropriate drug by bolus injection (the drugs most
commonly used for these purposes are midazolam and
morphine,whose elimination has been evaluated in detail
in Chapters 8 and 11) to produce that effect. The result
is assessed and when the effect of the drug is wearing
off, a repeat bolus dose is given and this procedure
repeated several more times. Only if the time interval
between the doses is short is an infusion started. If an
infusion is necessary, then once it has been started,
unless it is obvious the patient is not excessively
sedated, it should be stopped or the dose drastically
reduced each day, and the patient allowed to recover; to
ensure accumulation is not occurring. Should the
infusion require restarting, the need to give the drug at
the same rate should be questioned. Used in this way the
need for the drug and its method of administration are
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assessed. This method of sedation and analgesia
minimises the risk of overdose and accumulation but has
the disadvantage that in some patients unwanted effects
may occur. Should the effect of the drug wear off
unexpectedly or before a further dose can be given,
sudden agitation, patient discomfort, cardiac
instability and high airway pressures may develop. This
method was recently tested by a physician working on the
intensive care unit who managed to achieve several hours
of sedation with a small, single bolus dose of propofol.
As the patient emerged from the sedative effects of
propofol) reassurance was given and no further anxiolytic
was needed. Sedating this patient for a brief period
appeared to break a vicious cycle of anxiety, producing
restlessness, leading to more discomfort and so more
anxiety.
A further option is to produce drugs that do not
accumulate. Propofol is a drug currently under
investigation in this field. Continuous infusion of
propofol in the critically ill is now being increasingly
advocated, its short duration of action and lack of
accumulation giving it many of the properties of the
ideal sedative. Initial experience has shown it to be
an effective and easily controlled sedative with rapid
recovery on termination of infusion (Grounds et al 1987;
Aitkenhead et al 1989). However, adverse cardiovascular
effects have been reported both in fit patients
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(Committee for the Safety of Medicines 1989) and in the
critically ill (Penfold et al 1987). Briggs and his
colleagues (1987) have shown that the concurrent
administration of fentanyl with propofol alters propofol's
pharmacokinetics and leads to an increase in its plasma
concentrations. It is not known if interactions with
fentanyl and perhaps other drugs will lead to
difficulties with its use during prolonged infusions.
If parenterally administered sedatives cause so many
difficulties should inhaled agents be investigated
again? Isoflurane has recently been studied for sedating
critically ill patients for a 24 hour period and shows
promise as an agent for short term use (Kong, Willatts
and Prys-Roberts 1989). However, when used for longer
periods of time will isoflurane be found to have
unrecognised difficulties, as did nitrous oxide, perhaps
related to delayed elimination of fluoride ions if renal
or hepatic insufficiency develops (Chapter 7)?
When there is no longer a need for artificial
ventilation intercostal nerve blockade is the preferred
method of analgesia in these patients, since it appears
to offer better analgesia with no clinical evidence of
toxicity, although the study in Chapter 13 showed plasma
concentrations in the putative toxic range. Perhaps in
this instance the residual effects of benzodiazepines
were beneficial! This final point highlights the need
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for all clinicians and researchers in this field
critically and continuously to appraise the action of all
drugs both old and new. Many adverse effects and
alterations in drug action remain to be described.
Page 481
CHAPTER 15
RENAL DYSFUNCTION AND ITS PREVENTION AFTER
LIVER TRANSPLANTATION
Mortality after liver transplantation is closely
related to the development of renal failure and
preventative measures to reduce the incidence of this
complication decrease mortality (Chapter 15).
Impairment of renal function may occur during the
procedure or in the early postoperative period.
Occasionally^ haemodialysis or continuous
haemofiltration with dialysis may be required. The most
important causes of renal dysfunction include major
blood loss occurring in the perioperative period and the
hepatorenal syndrome.
Haemorrhage results in sympathetic vasoconstriction,
which mainly affects the afferent glomerular arterioles,
with a decrease in renal blood flow and consequent renal
ischaemia. Septicaemia and the use of potentially
nephrotoxic drugs, such as the cephalosporin or
aminoglycoside groups of antibiotics (especially in
combination with loop diuretics) and the
immunosuppressant cyclosporin A (Bennett and Pulliam
1983), may also be causally implicated.
Numerous theories exist about the causes of renal
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dysfunction in patients with hepatic disease
(hepatorenal syndrome) and probably reflect the
multiple factors producing this problem. Hormonal
changes predominate in the hepatorenal syndrome. The
first involves increases in aldosterone levels. Adrenal
secretion of this hormone increases and since its
destruction is dependent upon liver function,
particularly liver blood flow, its breakdown is reduced
in severe liver disease. Increases in the concentration
of aldosterone result in sodium retention. The second
feature is a decrease in effective plasma volume due to
the redistribution of fluids from the intravascular
space to the interstitial fluid compartment^ including
ascitic fluid. Hypovolaemia stimulates volume receptors,
found in the atria and elsewhere, leading to an increase in
secretion of renin and the production of angiotensin I.
This enzyme is then changed by converting enzyme, found
predominantly in the lung, to angiotensin II.
Production of these substances leads to atrial
vasoconstriction and an increased resorption of sodium
and water in the distal tubule. Antidiuretic hormone
levels are also increased in hepatic disease( and this^
combined with the decreased filtrate delivered to the
distal convoluted tubules and collecting system, leads to
further water retention. Thus total body sodium
increases and free water clearance decreases.
Other changes in patients with hepatic failure that
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influence renal function include an increase in plasma
noradrenaline levels to 2-5 times normal. This will
increase further if patients develop renal failure. In
addition there may be, as yet unknown^ changes in
endogenous renal prostaglandins and vasoactive
intestinal polypeptides in hepatic failure that further
alter intrarenal mechanisms of salt and water excretion
(Koppel et al 1969).
There are no significant morphological changes
demonstrable in the kidneys of patients with the
hepatorenal syndrome. The deterioration in fluid and
electrolyte state is purely functional, with the kidneys
responding appropriately to various neurohumoural
mechanisms. Tubular function is normal and the urine
produced by these patients is usually concentrated.
Koppel and his colleagues (1965) transplanted kidneys
from patients with the hepatorenal syndrome into
patients without hepatic dysfunction but with renal
failure, and found that the transplanted kidneys
recovered normal function. Urine from patients with
hepatorenal failure has a sodium concentration of <20
mmol /I with no cells, sediment or protein detectable, a
urine/plasma creatinine ratio of >30:1 and a urine
osmolality of at least 100 mosm/kg greater than the
plasma osmolality (Epstein 1982a). Other investigations
are compared with those seen in normal and disease states
in Table 15.1.
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Hepatorenal Prerenal Renal Normal
Failure
Urinary sodium <20 <20 70-100 1-150
(mmol/1)
Urine/plasma >1.5 >2:1 1:1 >1.5
osmolality
Casts No No Yes No
Table 15.1: Laboratory findings in hepatorenal failure,
other causes of renal dysfunction and normal values.
(From Epstein 1982b, Park and Manara 1989)
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Electrolyte Changes in Patients Presenting for Liver
Transplantation
Martin (1986) studied 28 patients before liver
transplantation and found that 48% of these patients
were hypokalaemic. This may be a reflection of sodium
retention, inadequate dietary intake, vomiting,
prolonged diuretic therapy or the development of
secondary hyperaldosteronism. Abnormalities of the
plasma sodium concentration occurred in 52% of the
patients. Hyponatraemia may have been due to excessive
administration of fluids not containing sodium and the
effects of an increased concentration of ADH.
Hypernatraemia is usually caused by the incautious use
of sodium-containing fluids. Phosphate was abnormal in
70% of the patients, 37% were hypocalcaemic, and hyper-
or hypoglycaemia was a problem in 48%.
Assessment of Renal Function
Routine tests of renal function before and after liver
transplantation include the estimation of plasma urea,
creatinine and creatinine clearance. In the majority of
patients} these tests will provide an adequate guide to
renal function. Interpretation of these results in some
patients requires caution. Plasma urea may be falsely
low in patients with severe liver failure } particularly
if the hepatic injury follows an acute overwhelming
event, such as a viral infection, poisoning or
idiosyncratic drug response. In this situation the
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liver may no longer be able to break down protein and
produce urea. However, if the liver failure is less
acute then plasma urea may be artificially elevated as a
consequence of recent gastrointestinal bleeding
resulting in breakdown of blood to urea by bacteria. In
cachectic patients plasma creatinine may be falsely low
even in the presence of severe renal dysfunction and
prolonged liver disease. These patients have a reduced
muscle bulk and fail to produce creatine for the liver
to break down to creatinine. Creatinine clearance will
be reduced according to the degree of renal
dysfunction, but continues to provide an adequate guide
to renal function. Deeply jaundiced patients (plasma
bilirubin >300 p.mol /l) may provide further
difficulties. In these patients the estimation of
creatinine itself is unreliable. In one patient studied
over 2 6 days, plasma creatinine was measured by five
different methods and a five fold variation in the value of
creatinine was demonstrated. Following storage at 4°C,
plasma from this patient was reanalysed and the original
values obtained by all methods had changed. The
mechanism for this is obscure but may represent a small
molecular weight substance that changes on storage
and interferes with assay. The original results from this
patient are shown in Figure 15.1. Since the initial





26 days after LTX
Figure 15.1: Plasma creatinine values in one patient
after liver transplantation measured using 5 different
assay methods: Technicon SMA2 analyser, a continuous
flow end point reaction (^), Perspective discrete
analyser (Q), Perspective analyser applying correction
factor for elevated bilirubin ( ■ ), Traditional picrate
kinetic method measured using a Beckman analyser (Q),
BCL kit (^). (Measured by Dr L Culank, Consultant
Chemical Pathologist, Addenbrooke's Hospital)
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RENAL PROTECTION
Renal failure developing in the critically ill,
jaundiced patient in the perioperative period carries a
high mortality. Prevention of this complication not only
reduces mortality but also is more cost-effective than
its treatment. Prophylactic measures may be applicable
in the circumstances surrounding liver transplantation
to decrease the incidence of this complication. Dawson
(1965) demonstrated that the intraoperative
administration of mannitol to jaundiced patients during
surgery reduced the incidence of renal failure by
promoting an osmotic diuresis; from the beginning of the liver
transplant programme mannitol has been infused throughout the
intraoperative period. Massive haemorrhage may also
occur perioperatively resulting in sympathetic
vasoconstriction, mainly affecting the afferent
glomerular arterioles, with a decrease in renal blood
flow and consequent renal ischaemia. Dopaminergic
stimulation may reverse this sympathetic
vasoconstriction, maintaining or increasing renal blood
flow and glomerular filtration rate (Goldberg 1972).
Studies in animals and humans, when dopamine has been
infused, have shown increases in cardiac output, with
concomitant decreases in systemic and pulmonary vascular
resistance and increases in renal blood flow (Angehn et
al 1977), without significant changes in systemic blood
pressure (Winso et al 1988). There is also an increase
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in renal plasma flow and glomerular filtration rate.
However, other effects such as intrarenal vascular
changes may be responsible for the natriuresis (Carriere
et al 1971; Earley and Friedler 1965) and alterations in
the tubular transport of sodium have been suggested by
Davis and his colleagues (1968). Studies in rats with
fenoldopam suggest that these natriuretic and diuretic
effects can be independent of alterations in intrarenal
haemodynamic changes and a direct effect on tubular DA^^
receptors has been shown (Hegde et al 1989).
Furthermore. Licrhtman and
Forsling (1980) have demonstrated that dopamine may
inhibit vasopressin release in man, although this action
was not repeatable in animal experiments.
A study of the dopamine precursor, Y-glutamyl dopa , to
assess protection against glycerol induced renal failure in rats
by Lee (1982), demonstrated an increase in creatinine
clearance and less histological damage and systemic
upset in the treated group than was seen in the
untreated group. Used in the dose range 2-5 |J.g/kg/min
dopamine is a potent renal dopaminergic agonist and is
commonly used to treat patients with incipient renal
failure (Parker et al 1981). Barnardo and his colleagues
(1970) gave dopamine to 10 patients with renal failure
due to cirrhosis using a dose of 1.3-3 p,g/kg/min and
demonstrated a significant improvement in renal function
in these patients. Others have also shown that during
abdominal aortic aneurysm surgery the use of low dose
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dopamine can improve renal function (Salem et al 1988).
Furthermore; a low dose infusion of dopamine (4p.g/kg/min)
has been shown in dogs to ameliorate the vasoconstrictor
effects of noradrenaline on the renal artery (Schaer,
Fink and Parrillo 1985). The administration of a low dose
infusion of dopamine prior to and during the major
haemorrhage sometimes experienced during liver
transplantation, to see if a reduction in renal
insufficiency could be achieved, seemed worthy of
consideration. I was assisted with the data collection
for this study by Dr R Poison (Registrar)
THE PREVENTION OF RENAL IMPAIRMENT IN PATIENTS




In the 18 month period from 1st May 1983 until 31st
October 1984, 34 patients were treated by orthotopic
liver transplantation. One patient with primary
hyperoxaluria and renal failure, who had a combined
liver and repeat kidney graft operation, was treated
electively with haemodialysis both before and after
operation and is therefore excluded from further
analysis. All patients received 10% mannitol lg/kg
during the procedure and all were given
benzylpenicillin, cefoxitin and tobramycin during the
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operation and for 48 hours postoperatively. For
immunosuppression, prednisolone and azathioprine were
used; oral cyclosporin A was introduced in the second
postoperative week in order to avoid the renal and
pulmonary toxicity associated with intravenous
administration immediately after operation
(Powell-Jackson et al 1984).
Nineteen patients (21 transplant operations) received a
low dose dopamine infusion of 2 jig/kg/min, begun with
the induction of anaesthesia and continued for 48 hours
postoperatively (Group 1), while 15 patients (15
transplant operations) did not (Group II). A patient
who required retransplantation for chronic rejection six
months after her first transplant operation was treated
with dopamine prophylactically only during her second
operation and so is included in both groups. During this
period there was no formal policy about the use of
prophylactic dopamine, the decision whether or not to
use it being made by the consultant anaesthetist
involved.
The perioperative details of these two groups were
compared, as was the incidence of renal impairment
defined as oliguria (less than 0.5 ml/kg/hr urine
output) in the presence of an adequate central venous or
pulmonary capillary wedge pressure and a urine/plasma
osmolality ratio of 1.1 : 1.0 or less (Lee 1979), or
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acute renal failure requiring haemodialysis. In
accordance with conventional management a dopaminergic
dose of dopamine was begun immediately a patient in
Group II developed renal impairment.
To determine whether partial cardiopulmonary bypass
support had a beneficial effect on renal function, the
results for the five patients in the dopamine treated
group in whom veno-arterial bypass (Calne et al 1984)
was used and for the six patients in the untreated group
in whom veno-venous bypass (Shaw et al 1984) was used,
were compared with the remaining patients in their
respective groups. Similarly, since younger patients
have better survival rates than older patients after
liver transplantation (Williams et al 1985), the renal
function of those aged 21 years or under was compared
with that of the older patient within each treatment
group.
Six pairs of patients were matched for age, sex and
diagnosis and as closely as possible for preoperative
weight, plasma creatinine concentration and
intraoperative blood loss and degree of hypotension.
One of each pair was receiving low dose dopamine. The
one patient who required retransplantation for chronic
rejection six months after her first operation was
included as the seventh "pair".
Page 493
Statistical analysis was by Student's t-test for
unpaired data, Mann-Whitney U test and Fisher's test of
exact probability where appropriate.
Results
The two groups of patients were similar with respect to
age, sex, diagnoses, preoperative plasma creatinine,
and operative blood loss (Table 15.2).
In Group 1, 19 patients received low dose dopamine
prophylactically and only 2 (9.5%) of the 21 transplant
operations were complicated by acute renal failure. A
13 year old female who had compromised renal function
before operation, with a plasma creatinine concentration
of 150 M.mol/1, required haemofiltration from 6 days
postoperatively and haemodialysis from 13 days, while a
second patient (a 46 year old man) required
haemofiltration from two days and haemodialysis from ten
days postoperatively.
In contrast, of the 15 patients (15 transplant
operations) in Group II not electively treated with
dopamine, ten patients (67%) developed renal
impairment, a statistically highly significant
difference (p = 0.001). In three patients this occurred
during the operation; one patient subsquently required
haemodialysis from the sixth postoperative day; six
patients required dopamine within the first 24 hours
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after operation and three of these required
haemodialysis within the first postoperative week, while
the remaining patient started dopamine during the
second postoperative day.
The incidence of renal impairment in patients in whom
bypass support was used was not significantly different
from the remaining patients in their respective groups.
Likewise, no difference was found when the results
within the two treatment groups were analysed with
respect to age.
When the results for the paired patients were compared
it was found that the volume of urine produced on the
first postoperative day and the creatinine clearance in
the period 24-48 hours after operation were
significantly better in those patients who received
prophylactic dopamine than in those who did not (p <
0.05, Table 15.3). There was no significant difference
in preoperative renal function, operative blood loss and
lowest systolic blood pressure between the two groups.
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2/21 (9.5%) 10/15 (67%)
2/21 (9.5%) 4/15 (27%)
Table 15.2: Patient information and results in 34
consecutive patients undergoing orthotopic liver
transplantation from 1 May 1983 - 31 October 1984. One
group received 2n.g/kg/min of dopamine prophylactically





Patient muter 166 164 165 145 159 150 157 124 170 147 162 117 148 148
Age (yearn )/sex 46F 46F 50F 40F 2M 2M 17F 17F 13F 10F 52M 47M 11F
Diatyioeis PBC PBC BA CAH Hepatoma AC R SAW
M»l<*t(kq) 50 44 58 60 13.8 12.0 52 50 35 36 80 81 40 36
Pre-op plasma craatlninefumol/lltzv) 91 64 70 69 - - 61 119 49 58 97 108 46 107
Blnnrl lnsa( litre*) 3.8 6.0 7.9 5.0 0.7 2.3 7.4 4.1 0.3 3.9 16.6 7.9 11/3 3.9































































Table 15.3: Renal function in paired patients. The first




This study suggests that the prophylactic administration
of dopamine, begun prior to the onset of surgery,
decreases the incidence of renal impairment
postoperatively in patients undergoing liver
transplantation. Furthermore, although the numbers are
small, renal failure requiring haemodialysis or
continuous arteriovenous haemofiltration occurred less
often and much later when prophylactic dopamine was
given.
The problems associated with results obtained from a
retrospective study are well known. The dramatic
decrease in morbidity and mortality associated with the
continuing use of prophylactic dopamine has been
maintained since the end of the study period and for
ethical reasons a prospective study in these patients
could not be considered. The inclusion in this study of
a matched pair group overcame some of the difficulties
associated with a retrospective study and tends to
reinforce the conclusions drawn from the findings of the
larger, unmatched group. The use of bypass, to
decompress the portal circulation and to maintain
systemic blood pressure and renal perfusion, made no
difference to the frequency with which renal impairment
occurred (Shaw et al 1984). Also, the patients age did
not appear to alter the incidence of renal impairment,
in contrast to its effect on overall mortality in which
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the older patients did less well (Williams et al 1985).
The introduction of cyclosporin A has improved
immunosuppression following organ transplantation (Calne
et al 1979). However, its use in the early
postoperative period following liver transplantation is
limited by its nephrotoxicity. This necessitates the use
of azathioprine, with the hazards of marrow
suppression, and of high dose steroid therapy, with the
disadvantages of an increased risk of and difficulty in
the diagnosis of infection and adverse effects on
carbohydrate metabolism which make parenteral nutrition
difficult. Preliminary studies have shown that
intravenous cyclosporin A results in a marked decrease
in renal blood flow (P R Powell-Jackson, personal
communication) and it may be that simultaneous low dose
dopamine infusion would prevent, or at least lessen,
this decrease and thus reduce the toxicity. Shortly
after this study was completed a patient who was treated
immediately after operation with cyclosporin A, given
through a central venous line, developed severe
pulmonary toxicity^ but the anticipated nephrotoxicity
did not develop, possibly owing to the continued
administration of dopamine. Since this study was
performed and low dose dopamine became part of the
routine management of these patients^ earlier
postoperative use of this agent has been possible. It
remains to be determined whether initially avoiding severe
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cyclosporin A nephrotoxicity reduces the
chances of long term kidney damage.
Despite the use of dopamine in this study 10% of
patients in the treated group still developed renal
failure. Other agents need to be evaluated to see if
this figure can be decreased. Dopexamine hydrochloride
is a new synthetic catecholamine. Like dopamine,
dopexamine stimulates dopaminergic receptors of the DA-j^
and DA2 subtypes, though there is considerably less
affinity for the DA2 receptor than is seen with
dopamine. Unlike dopamine, dopexamine has an action at
the B2 receptor, stimulation of which also results in an
increase in renal blood flow due to a direct effect on
the renal vasculature (Brown et al 1985; Smith and
O'Conner 1988). There is no activity at alpha
adrenoreceptors, and only minimal B1 adrenoreceptor activity
(Brown et al 1985). There is therefore reason to
believe that dopexamine will have similar renal effects
to dopamine, and its B2 agonist activity and lack of
alpha effects suggest that it may be even more effective
clinically, although when administered to human
volunteers it was shown to increase renal blood flow but
not to the same extent as dopamine (Mousdale et al
1988). In addition to its renal effects^dopexamine also
has a mild positive inotropic activity and may be of
particular use when deterioration in renal function
follows a decrease in cardiac output (such as that associated
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with acute or chronic heart failure) which then leads to
a decrease in renal blood flow and consequently renal
arteriolar vasoconstriction. Both Leier (1988) and Tan
(1987) and their colleagues demonstrated the benefits of
dopexamine in this situation. Beta adrenergic
stimulation resulted in an increase in cardiac output, a
decrease in systemic vascular resistance, and an
increase in urine volume and sodium excretion was due to
dopaminergic stimulation. A further, unpublished study
comparing dobutamine with dopexamine has shown that the
increase in renal function with dopexamine is not
entirely attributable to an increase in cardiac output
but is due to its specific effects on the renal
vasculature.
These advantages and encouraging initial clinical
experience with dopexamine in the management of oliguria
(Dawson et al 1985; Bodenham and Park 1988) led to a
comparison of dopexamine with dopamine for renal
protection in a further study in the perioperative
period of liver transplantation. I was assisted with the
data collection by Dr P A Gray (Registrar).
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A COMPARISON OF LOW DOSE DOPEXAMINE AND DOPAMINE
INFUSIONS IN PREVENTION OF RENAL IMPAIRMENT IN PATIENTS
UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION.
Anaesthesia (1991) (In Press)
Patients and Methods
The trial was an open study involving two groups, each
of twelve patients, undergoing orthotopic liver
transplantation. After induction of anaesthesia a
continuous intravenous infusion of dopexamine at a rate
of 2 n-g/kg/min was started in the first group. If the
heart rate did not increase by more than 20 beats per
minute on the initial dose then the infusion was
increased to 3 ng/kg/min. If an increase in heart rate
was seen then the rate was reduced to 2p.g/kg/min.
However^ if on starting the infusion the heart rate
increased by greater than 20 beats per minute,
lpig/kg/min was used as the infusion rate. Similarly;
systolic blood pressure was not allowed to increase or
decrease by more than 20 mmHg from baseline value. The
infusion of dopexamine was continued for 48 hours after the
end of surgery or until renal protection was no longer
required.
Each patient was matched for age, preoperative
creatinine clearance, blood loss and, as far as possible,
diagnosis with another patient requiring liver
transplantion who received an infusion of dopamine (2
|ig/kg/min) from induction of anaesthesia and also continued
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for 48 hours after the end of surgery. Mannitol 1
g ,/kg/6hr was infused throughout the operation. For
immunosuppression, prednisolone was administered from
the time of surgery and cyclosporin A was introduced
two days postoperatively, after the study was finished
and if renal function was adequate.
In order to compare the efficacy of dopexamine and
dopamine, urine output was measured hourly for 48 hours
postoperatively. The urine/plasma osmolality ratio was
measured preoperatively, on admission to the intensive
care unit and on days one and two postoperatively.
Creatinine clearance rates were also measured
preoperatively and over the first and second 24 hour
periods postoperatively. Patients were observed for
seven days postoperatively to record the incidence of
renal impairment or failure. The same criteria were
used, as described earlier,for the recognition of these
complications, except that renal failure was defined as the
need for continuous haemofiltration with dialysis. Since
the effects of the two drugs on the splanchnic,
peripheral and other circulations may differ because of
their different adrenoreceptor specificity^ a note was
made of the lowest systolic arterial blood pressure,
blood loss and its replacement. Frusemide is usually
administered immediately prior to weaning from
artificial ventilation (Chapter 5). It is not given if
the patient is polyuric at this time or if the patient
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is not weaned from artificial ventilation during the
study. Diuretic usage which may therefore have affected
urine volumes was also recorded.
Statistical methods used to asses the effects of each
drug are described below.
Results
The demographic information for the two patient groups
is shown in Table 15.4. The second patient, who was
female, was inadvertently matched with a male patient.
There were no statistically significant differences in
age, weight, operative blood loss or its replacement or
the lowest systolic blood pressure observed in either
groups (Mann-Whitney U test). Table 15.5 shows the
results of the measurements that were made in these
patients. Preoperative urine/plasma osmolality ratios
(prior to drug administration) were significantly
greater in the dopexamine group than in the dopamine
group (p=0.028). There were, however, no other significant
differences between treatment groups during the infusion
period (Freidman test, Mann-Whitney U-test) for
creatinine clearance values or urine volumes produced in
the first and second 24 hour periods (either between
the first and second 24 hour periods in each patient
[Student's t test for paired data] or between treatment
groups [Student's t test for unpaired data]).
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Dopexamine group Dopamine group
Age (years) Mean 43.7




















































Table 15.4. Information for the two patient groups.
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Dopexamine group Dopamine group
Urine output(l) n=ll n=12
0-24 hrs 2.35 (0.45) 2.03 (0.80)
25-48 hrs 2.21 (1.09) 2.21 (0.60)
Urine plasma osmolality ratio n=10 n=6
Preoperative 2.1 (0.25) 1.5 (0.14)
Postoperative 1.4 (0.09) 1.3 (0.10)
Day 1 after surgery 2.0 (0.17) 1.6 (0.21)
Day 2 after surgery 2.3 (0.13) 2.1 (0.33)
Creatinine clearance (ml /min) n=9 n=7
Preoperative 61.3 (8.0) 51.7 (4.7)
0-24 hours 57.6 (8.7) 58.6 (10.0)
24-48 hours 72.3 (13.5) 55.6 (14.4)
Renal dysfunction
renal impairment 3 8
renal failure 1 3
Table 15.5. Urine volumes [mean (SD)] for the first and
second 24 hour periods, urine/plasma osmolality ratios
[mean (SEM)], creatinine clearance values [mean(SEM)*|
and incidence of renal dysfunction for the 2 groups of
patients receiving renal protection.
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Five patients in the dopexamine group and nine patients
in the dopamine group received frusemide , but this
difference was of doubtful statistical significance
(p=0.ljFishers Exact test). The mean amount of frusemide
administered was 32.9mg in the group receiving
dopexamine and 43.3mg in the group receiving dopamine,
which approached statistical significance (p=0.078 Mann
Whitney U Test).
The incidence of both renal impairment and failure was
greater in those patients who received dopamine than
those who received dopexamine. However, these differences
were not statistically significant (Fisher's exact test)
but this may also reflect the small numbers of patients
studied.
Discussion
In this study^ dopexamine has been shown to be as
effective as dopamine for renal protection in patients
i
undergoing orthotopic liver transplantation. The
incidence of renal impairment and failure was greater in
the dopamine group than in the dopexamine group,but this
did not achieve statistical significance. The lack of
statistically significant difference in this parameter
and also in the others may have been due to the small
groups of patients.
The lack of alpha agonist properties shown by dopexamine
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(Brown et al 1985) may be a potential advantage compared
with dopamine. Renal vasoconstriction and a decrease in
renal blood flow is seen with alpha stimulation in some
circumstances. Dopamine has alpha agonist properties at
doses in excess of lOng/kg/min and may in some patients
have such an effect even at low doses (Bodenham and Park
1988). Furthermore, dopamine should be administered
through a centrally placed venous catheter to avoid the
risk of extravasation into the superficial tissues.
Should this occur, the high local concentrations of
dopamine lead to intense vasoconstriction, due to alpha
stimulation, and subsequent skin necrosis. Dopexamine
with its lack of alpha effects does not cause
vasoconstriction and so where necessary can be
administered by infusion through a peripheral vein. In
addition, dopexamine has the added benefit of producing
generalised vasodilation, mediated through B2
adrenoreceptors, and therefore potentially an increase
in tissue perfusion in other organs, including the
liver, which may be advantageous in many clinical
situations, especially in the critically ill.
In the earlier study, with dopamine the incidence of both
renal impairment and failure was reduced to 9.5% in
patients who received dopamine compared with 67% and 27%
respectively in those who did not. In this, study, the
incidence of both renal impairment and failure in
patients receiving dopamine had increased to 66% and 25%
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respectively. Even with dopexamine the incidence of
renal impairment was 25%, greater than that reported in
the earlier series, although renal failure occurred with
a similar frequency. There are three possible reasons
for this difference. In the initial study children were
included and this is reflected in the age (mean, range,
years) of the patients receiving dopamine (29.7, 2-58)
and placebo (34.5, 2-57). Owing to the difficulties of
using novel compounds in children they were specifically
excluded from this study with a resultant increase in
the age of the patient groups. In the group receiving
dopexamine the mean (range) age was 43.7 (24-56) years
and in the dopamine group it was 48.5 (24-56) years.
Children tolerate the major physiological insults of
this and other operations better than adults, presumably
because of the lack of the degenerative disease found in the
older age groups. In the intervening four years more
seriously ill patients have been transplanted and are
thus at greater risk of renal dysfunction. Unfortunately,
the lack of severity scoring makes this difficult to
substantiate scientifically. Finally^ the two studies
differed in their design, the first being retrospective
and this one prospective. This difference might have led
to under — recognition of renal impairment in the
retrospective study. This argument might be supported
by the similar incidence of renal failure, which is more
easily recognised, in the treated groups.
Page 509
The prophylactic use of a dopexamine infusion has been
shown to be as effective as dopamine for renal
protection in patients undergoing liver transplantation,
but the need for further prospective double blind
studies involving larger groups of patients is
illustrated.
Despite their widespread use,little is known about
catecholamine pharmacokinetics in disease states. The
liver is thought to be a major site for metabolism of
catecholamines (Sacca et al 1986) and in liver disease
alterations in their elimination may be expected. As
dopexamine is metabolised in a similar way to other
catecholamines (Neale et al 1986) any alterations in
plasma concentration seen with dopexamine may also occur
with other catecholamines.
This next study was designed to investigate the plasma
concentrations of dopexamine hydrochloride in patients
undergoing orthotopic liver transplantation who were
receiving low dose dopexamine infusions as part of the
above study for renal protection. Dr Gray assisted with
the sample collection.
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PLASMA CONCENTRATIONS OF DOPEXAMINE HYDROCHLORIDE IN
PATIENTS DURING AND AFTER ORTHOTOPIC LIVER
TRANSPLANTATION
Patient and Methods
The trial was an open study in seven patients undergoing
orthotopic liver transplantation. After induction of
anaesthesia a continuous intravenous infusion of
dopexamine at a rate of 2 ng/kg/min was started through
a centrally placed venous catheter. The dose was
titrated in the same manner as described in the previous
study. The infusion of dopexamine continued for 48
hours after the end of surgery or until renal protection
was no longer required.
Blood was removed from a previously sited radial
arterial line immediately prior to starting the
dopexamine infusion and at 10 and 20 minutes. Sampling
was not continued during the period of dissection since
this would have lead to an excessive blood loss and it
was assumed that a steady state would have been reached
after 20 minutes (about six half-lives). Further blood
samples were taken at 2, 5, 10, 20 and 40 minutes after
the start of the anhepatic period and at 2, 5, 10, 20,
and 40 minutes, 1, 2, 12, 24, and 48 hours after
reperfusion of the donor liver. The blood was
immediately put into sequestrene tubes, rapidly frozen
by immersion in liquid nitrogen and stored at -20°C
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until analysed for dopexamine concentration by high
performance liquid chromatography (Method on File,
Fisons PLC).
Results
The demographic information for the seven patients, all
of whom were female, is summarised in Table 15.6. Plasma
concentrations, which are shown in Figure 15.2,increased
in the 20 minute dose titration phase. Sampling
restarted 2 minutes into the anhepatic phase and plasma
concentrations of dopexamine increased further. Tmax
occurred at the end of the anhepatic period and Cmax
(SD) was 253.54ng/ml (75.77).
When the donor liver was reperfused plasma
concentrations of dopexamine decreased, reaching a steady
state in one to two hours. The lowest plasma
concentration of dopexamine [mean (SD)] of 105.74 ng/ml
(30.23) was reached after 2 hours, a value which is less
than half that seen at the end of the anhepatic period.
Discussion
The changes in plasma dopexamine concentrations seen in
the anhepatic and reperfusion phases, in the presence of
low blood loss and cardiovascular stability for the
majority of the study period, demonstrate alterations in
dopexamine elimination.
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Patient Age Dose Diagnosis Blood Lowest
number (Yrs) (|ig/kg/min) loss Systolic
(1) BP (mmHg)
1 56 2 Retransplant for 3 90
chronic rejection
2 32 2 Cryptogenic 15 65
cirrhosis
3 24 1 Retransplant for 3.5 100
chronic rejection
4 51 3 Cholangiocarcinoma 4.2 75
5 55 2 Hepatocellular 2.5 0 *
carcinoma
6 56 2 Primary biliary 1.5 100
cirrhosis
7 44 2 Primary biliary 3.9 85
cirrhosis
Table 15.6: Information for the 7 patients receiving
dopexamine infusion during orthotopic liver
transplantation. * This patient suffered a short period
of asystole at reperfusion of the liver due to





dose titration anhepatlc period reperfuslon period Time (minutes)
Figure 15.2: Mean (SD) plasma concentrations of
dopexamine during the dose titration and anhepatic
periods and for the 2 hours after revascularisation.
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At the start of the anhepatic period plasma
concentrations of dopexamine increasej suggesting that
elimination is reduced. Plasma concentrations of
dopexamine increase less rapidly as the anhepatic period
progresses! suggesting that a steady state is being
reached. When the liver is reperfusedj plasma
concentrations of dopexamine decrease as elimination
increases. This suggests that the donor liver rapidly
regains the capacity to metabolise dopexamine; which
corresponds with the rapid recovery of metabolic
capacity for midazolam and morphine previously
demonstrated (Chapters 8 and 11).
Dopexamine is known to be metabolised by O-methylation
and sulphation (Neale et al 1986) and is thought to be
metabolised primarily in the liver. Other
catecholamines including dopamine and dobutamine are
thought to be metabolised in the same manner. It is
likely that alterations in plasma concentrations similar
to those shown with dopexamine will be observed with
other catecholamines in the absence of hepatic function.
In the presence of severe hepatic failure plasma
catecholamine concentrations may be higher than
predicted.
Although this study shows that dopexamine elimination is
reduced in liver failure, plasma catecholamine
concentrations are of limited value in trying to predict
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a haemodynamic or pharmacodynamic end point. However^
there are many peripheral effects of catecholamines such
as metabolism and leucocyte function (Unpublished
observation) which are not yet understood.
Unnecessarily high plasma concentrations of these drugs
may in these circumstances be detrimental.
Although the effects of dopaminergic and P>2 stimulation
on renal function have been presented in this chapter,
effects on other organs may also occur. These may
include a general increase in splanchnic blood flow
which may decrease the incidence of stress ulceration
(MacNaughton and Wallace 1989) and improve anastomotic
healing. Dopamine has been shown to increase estimated
hepatic blood flow (EHBF) under many conditions
including peritonitis and haemorrhagic shock
(Hasselgren, Biber and Fornander 1983; Townsend et al
1987; Trachte and Lefer 1977)} possibly by increasing the
portal venous supply rather than hepatic artery flow
(Hirsch, Ayabe and Glick 1976). The increase in EHBF is
usually associated with an increase in cardiac output}
though the percentage increase in EHBF is greater than
the increase in cardiac output^implying some selective
dilatation of the hepatic vasculature (Maestracci 1981).
Dopaminergic stimulation increases portal vein blood
flow. The hepatic artery also has P>2 receptors which
result in an increase in flow when stimulated, although
the precise location of the receptors is unclear
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(Hirsch, Ayabe and Glick 1976). One patient is presented
in whom the use of dopexamine may have resulted in an
increase in hepatic blood flow. I was assisted with the
data collection by Dr R Munglani (Registrar) and Dr P
Gray.
INCREASES IN OXYGEN CONSUMPTION DURING
ADMINISTRATION OF DOPEXAMINE IN LIVER FAILURE.
Journal of Clinical Intensive Care 1990 1: 187-188
Patient
A 22—year-old male with o^-antitrypsin deficiency
developed fulminant hepatic coma, precipitated by
pneumoccocal peritonitis and complicated by the subsquent
development of hyponatraemia of 109 mmol/L. Urgent liver
transplantation was considered to be the treatment of
choice and shortly thereafter a donor liver became
available.
Preoperatively the patient was transferred to the
intensive care unit; where he was artificially ventilated
and pulmonary and systemic arterial catheters were
inserted to optimise his haemodynamic stability. Since
this patient was oliguric (urine output <20 ml /hr),
despite volume resuscitation, it was decided to use a
dopaminergic agonist to improve urine output. Dopexamine
was therefore infused at 1 (xg/kg/min and increased every
15 minutes to a maximum of 4 ixg/kg/min. This unusual
situation of a patient in hepatic failure about to
Page 517
undergo liver transplantation enabled us to study the
pathophysiological effects of B^ and dopaminergic
agonism on hepatic function and shortly thereafter
remove the organ for histological examination without
antemortem changes. Haemodynamic variables and oxygen
delivery and consumption were measured both before
starting the dopexamine and at the maximum dose (Table
15.7) .
With increasing dose of dopexamine there was little
change of the haemodynamic parameters or oxygen
delivery, but oxygen consumption doubled. Liver
transplantation occurred 3 hours after this study. The
histological examination of the diseased liver revealed
cirrhosis with most of the right lobe being infarcted as
well as smaller infarcts in the left lobe (Figure 15.3).
Discussion
Increases in oxygen consumption may be due to several
reasons. Improvements in oxygen delivery, redistribution
of blood flow and changes in the metabolic activity of
the patient are amongst the commonest. Oxygen delivery
did not change in this patient. Redistribution of blood
flow is the most likely explanation for the changes seen
in this patient since no changes occurred in the measured
cardiovascular parameters.
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Dose of Dopexamine (ng/Kg/min) 0 12 3 4
Mean Systemic Arterial Pressure 60 69 63 62 61
(mmHg)
Right Atrial Pressure 10 9 8 8 8
Mean Pulmonary Artery Pressure 15 15 14 14 14
Pulmonary Capillary Wedge Pressure 15 15 15 13 13
(mmHg)
Cardiac Index (1/min/m2) 4.98 5.24 5.01 5.19 4.99
Systemic Vascular Resistance 408 470 449 423 433
5
(dynes/sec/cm )
Pa02 (kPa) 22.2 14.6
PvO (kPa) 7.8 7
PaC02 (kPa) 4.2 4.3
Oj Oxygen Delivery (mls/min/m ) 1176 1176
2
. 2
0 Consumption (mls/mm/m ) m 196
Table 15.7: The effect of increasing dose of dopexamine
on haemodynamics and oxygen consumption and delivery in a





Figure 15.3: Section through diseased liver showing
most of the right lobe infarcted (pale area) and smaller
infarcts in the left lobe.
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The increase in oxygen consumption can be attributed to
a redistribution of blood flow to the splanchnic bed
and; in particular, the liver, which accounts for 20% of
resting oxygen consumption of the body. Dopexamine may
have exerted its effect by increasing portal vein and
hepatic artery blood flow. Alternatively, since
cirrhotic livers have been shown to have portal
vein-hepatic vein anastomoses (Strunin 1977),
alterations in intrahepatic flow may have occurred with
no increase in total hepatic blood flow. Either of these
two possible effects might result in reperfusion of
existing ischaemic areas and an increase in oxygen
consumption.
Catecholamines are known to increase metabolic rate in
humans, although this is a feature usually associated
with doses in excess of the ones used in this patient.
However, little is known about the effects of this group
of drugs on metabolic activity in critically ill
patients with this degree of liver failure. The
practical difficulties of further investigation in this
group of patients are great, but of importance, since
these drugs may help provide a bridge to transplantation




Chronic liver disease frequently results in portal
hypertension with large, abnormal blood vessels in both
the skin and peritoneum. These are divided during liver
transplantation and despite meticulous attention to
haemostasis, torrential bleedingimay occur which can be
impossible to stop intraoperatively. On rare occasions
the liver, a large vascular organ, may also be
inadvertently lacerated,resulting in bleeding. Should
the bleeding be impossible to control then it is usual
to close the patient's abdomen and return them to the
Intensive Care Unit for a period of 6 to 36 hours,during
which time the abdomen is allowed to tamponade. The
increasing abdominal pressure will compress the bleeding
points and stop the haemorrhage. Once bleeding has
stopped, the patient is again taken to the operating
theatre and blood clot evacuated from the abdomen. The
immediate changes following decompression of the abdomen
had not been reported. Both measurement and
interpretation of these changes had proved difficult in
the past because of the presence of anaesthetic agents
and concurrent rapid blood transfusion. However,
increasing familiarity with this problem allowed the
opportunity to measure these haemodynamic changes in a
controlled manner on four occasions in three patients
Page 522
immediately before and after release of abdominal
tamponade resulting from intra-abdominal bleeding.
Measurements made during the release of tamponade in the
first patient studied indicated that rapid blood
transfusion at the time of decompression was
inappropriate. Observations were, therefore, made in a
more controlled manner on the three subsequent
occasions, when more personnel were available to assist
with frequent intensive monitoring. I was assisted
during these operations by Dr Maire P Shelly and Dr A A
Robinson (Registrar) and with the monitoring by Mr J W
Hesford (Department of Clinical Measurements).
THE HAEMODYNAMIC EFFECTS FOLLOWING SURGICAL
RELEASE OF RAISED INTRA-ABDOMINAL PRESSURE.
British Journal of Anaesthesia (1987) 59; 800-805
Patient 1
The first patient was a 35 year old man who underwent
orthotopic liver transplantation for hepatic failure
secondary to sclerosing cholangitis. After surgery he
continued to bleed from intra-abdominal sites and
required massive blood transfusion; although some blood
was lost from abdominal drains these functioned
inadequately and he developed a tense distended abdomen.
His coagulation screen was slightly abnormal in spite of
infusion of fresh frozen plasma and platelet
concentrate but there was no clinical evidence of a
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significant coagulation disorder, such as bleeding from
his nose, mouth, pharynx or the sites of venous or
arterial cannulation.
Eight hours after his liver transplant operation,
laparotomy was undertaken to evacuate intra-abdominal
clot and to achieve haemostasis. During re-exploration,
cardiovascular parameters were measured: heart rate (HR)
was taken from the electrocardiogram, mean arterial
pressure (MAP) was measured via an indwelling radial
artery catheter and mean right atrial pressure (RAP),
mean pulmonary artery pressure (MPAP) and pulmonary
capillary wedge pressure (PCWP) were measured using a
pulmonary artery catheter (Edwards Laboratories)
positioned immediately before surgery. Cardiac output
(CO) was measured by a thermodilution technique and
values were calculated for systemic (SVR) and pulmonary
(PVR) vascular resistances.
On opening the peritoneal cavity, approximately six
litres of blood and clot were removed. No arterial
bleeding points were found to account for the
haemorrhage but there was a generalised ooze from many
intra-abdominal sites. Intraoperative hypotension was
treated with blood transfusion; however, since
calculation of systemic vascular resistance showed it to
be low, methoxamine 20mg and ephedrine 30mg were
administered.
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The measurements obtained are shown in the Figure 16.1.
Heart rate decreased immediately after decompression.
There was a decrease in mean arterial pressure but
little change in mean pulmonary arterial pressure. Both
right atrial pressure and pulmonary capillary wedge
pressures initially decreased following decompression
but then increased to baseline levels. There was a
prompt increase in cardiac output and pulmonary vascular
resistance and a decrease in systemic vascular
resistance. Following treatment with methoxamine and
ephedrine, mean arterial pressure increased slightly
accompanied by an increase in cardiac output but
systemic vascular resistance remained low.
Patients 2 and 3
Two other patients underwent orthotopic liver
transplantation for sclerosing cholangitis and continued
to bleed in the postoperative period. The details of
all three patients are compared in Table 16.1.
Patients 2 and 3 also required massive
blood transfusion to replace blood lost from abdominal
drains and intra-abdominal losses. Both underwent
laparotomy for decompression of abdominal tamponade,
one patient on two occasions (3a and 3b).
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Time (min) 0 10 20 30 40 50 60 70 80 90
Time (min)
Figure 16.1: Changes in cardiovascular variables
following release of increased intra-abdominal pressure
(Patient 1). The dotted area represents the time during
which decompression occurred. Methoxamine and ephedrine
were administered at 55 minutes.
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Patient Patient Patient 3
1 2 a b
Age (years) 35 25 33
Sex M M M
Weight (Kg) 62 55 62
Transfusion Reguirement between ooerations
FFP (mis) 1000 3500 1250 1000
Platelets 6 6 12 6
(units)
Blood 13.6 22.4 14.7 16.2
(litres)
HAS (mis) 1600 0 8000 1200
Time between operations
(hours) 8 20 37 26
Tamponade Volume
(litres) 6 11
Table 16.1: Details of the three patients who underwent
laparotomy for release of abdominal tamponade on four
occasions. * Additional external blood loss through
intra-abdominal drains.
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Infusions of morphine and midazolam, administered for
analgesia and sedation on the Intensive Care Unit^ were
continued up to the time of surgery at a dose of
3-5mg/hr for each agent. A period of stabilisation was
allowed following induction of anaesthesia with fentanyl
50M.g and ketamine lOOmg; no neuromuscular blocking
agents were administered. On account of the results of
the intensive intraoperative monitoring of the first
patient these two patients were monitored using the same
techniques and rapid blood transfusion withheld. Peak
airway pressures were noted and arterial blood was
sampled at intervals for estimation of oxygen and carbon
dioxide tensions and electrolyte concentrations. In one
patient, end tidal C02 partial pressure (ETC02) was
monitored, together with both core and peripheral
temperatures using temperature probes in the nasopharynx
and on the foot. Haemodynamic measurements were made
frequently throughout the perioperative period.
The haemodynamic measurements made before and after
decompression of abdominal tamponade in patients 2 and 3
are shown in Table 16.2.
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Parameter Patient Before After Before After
Induction Induction Decompression Decompression
H8 (bpm) 2 122 121 120 107
3a 125 120 120 110
3b 125 113 111 109
MAP (muHg) 2 69 80 76 35
3a 70 60 69 67
3b 56 57 59 38
MPAP (mmHg) 2 40 35 31 15
3a 20 22 25 25
3b 27 37 36 19
RAP (nnHg) 2 23 23 23 12
3a 10 18 14 17
3b 10 22 20 10
PCWP (mmHg) 2 30 30 32 18
3a 13 14 19 17
3b 13 22 22 10
CO (1/nin) 2 5.0 4.3 3.6 4.9
3a 7.5 6.4 7.4 10.2
-5
SVR (dyn s cm )
3b 11.4 11.7 10.3 12.2
2 1008 1060 1177 376
3a 644 525 594 392
PVR (dyn s cm 5)
3b 322 239 302 183
2 160 93
3a 75 100 65 63
3b 98 102 108 59
CT (deg C) 3b 37.3 37.1 37.0 36.7
PT (deg C) 3b 25.3 27.1 28.8 30.7
3b 5.5 5.7 5.6 7.2
Table 16.2: The haemodynamic changes seen before and after
induction of anaesthesia and before and after
decompression of abdominal tamponade in patients 2 and 3
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Heart rate decreased on all occasions as did mean
arterial pressure; there was an increase in cardiac
output and a sharp decrease in systemic vascular
resistance. Patient 3, during his first laparotomy
(3a), was able to maintain cardiovascular stability
better than on the subsequent occasion; mean arterial
pressure was maintained by a considerable increase in
cardiac output. During decompression, core temperature
decreased slightly while foot temperature increased by
2°C. There were marked increases in hydrogen ion
concentration, PaCC>2 and ETCC>2 and a smaller increase in
potassium concentration. There was no consistent change
in Pa02 or in ionised calcium or sodium concentrations.
The responses of the heart rate, mean arterial pressure,
cardiac output and systemic vascular resistance of
patients 2 and 3 to different sympathomimetic agents
are shown in Table 16.3. Methoxamine had no effect on
mean arterial pressure, cardiac output or systemic
vascular resistance,' however, ephedrine increased mean
arterial pressure slightly by increasing cardiac output.
Vasopressin increased mean arterial pressure to a
greater extent and in a more appropriate way by
increasing systemic vascular resistance but a greater
rise in systemic vascular resistance was seen with bolus
adrenaline administration. There was no evidence of an
additive effect between the various agents
administered.
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Patient Before After Before After Before After Before After
Methox- Methox- Ephed- Ephed- Vasop- Vasop- Adren- Adren¬
aline amine rine rine ressin ressin aline aline
2 10 u b 0.3 mg
i 4.0 mg/h
3a 10 ng 15 mg
3b 20 mg 7 u b 0.3 mg
10 u
HR (bpm) 2 107 120 b 120 127
i 127 137
3a 109 111 109 133
3b 102 100 126 115 b 100 82
111 101 i 110 111
MAP (mmHg) 2 35 44 b 44 53
i 53 57
3a 56 58 48 60
3b 44 51 65 87 b 51 107
45 67 i 48 74
MPAP (mmHg) 2 15 18 b 18 18
i 18 15
3a 22 27 26 22
3b 16 17 32 36 b 17 27
20 25 i 20 24
RAP (mmHg) 2 12 18 b 18 10
i 10 9
3a 15 19 15 12
3b 10 13 19 24 b 13 16
6 19 i 7 13
PCWP (mfflg) 2 18 20 b 20 18
18 15
3a 17 16 16 11
3b 8 8 20 28 b 8 24
10 19 i 13 14
CO (1/min) 2 4.9 3.9 b 3.9 4.1
i 4.1 2.5
3a 9.7 11.7 11.4 13.6
3b 10.3 9.9 12.9 11.3 b 9.9 10.0
10.6 9.7 i 10.9 12.9
SVR (dy^es 2 376 533 b 533 839
sec cm ) i 839 1560
3a 338 267 231 282
3b 264 307 285 446 b 307 728
294 395 i 300 378
PVR (dy^es 2
sec ca ) 3a 41 75 70 64
3b 62 72 74 56 b 72 24
75 49 i 51 62
CT (*C) 3b 35.8 35.8 35.7 35.7 b 35.8 35.8
PT (*C) 3b 28.8 28.3 30.6 30.2 b 28.3 27.7
Table 16.3: Cardiovascular changes observed in response
various sympathomimetic agents in patients 2 and 3.
b = bolus i = infusion page 531
Discussion
The immediate haemodynamic changes seen following
release of raised intra-abdominal pressure have not been
described previously. Richards and his colleagues
(1983) reported the haemodynamic measurements from three
patients before and after the release of abdominal
tamponade - but over a longer time course and not during
the operation. They observed decreases in mean arterial,
central venous and pulmonary capillary wedge pressures
after decompression but little alteration in cardiac
output or systemic vascular resistance. Other studies
on the effects of increased intra-abdominal pressure
have been performed in patients undergoing laparoscopy
(Kelman et al 1972; Lewis et al 1972; Motew et al 1973).
These have produced less comprehensive results and
conflicting measurements which appear to be dependent on
the intra-abdominal pressure.
Studies in dogs have reported the changes seen with
increasing intra-abdominal pressure (Richardson and
Trinkle 1976; Toomasian 1978; Kashtan et al 1981 );
cardiac output decreased and systemic vascular
resistance increased with increasing intra-abdominal
pressure. This effect was most marked in dogs rendered
hypovolaemic. The reduction in cardiac output was
thought to reflect not only an increased systemic
vascular resistance but also myocardial depression and a
decrease in venous return. Alterations in pleural
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pressure were insignificant and thought not to
contribute to the haemodynamic changes.
The variability in cardiovascular indices observed in
man may be the result of different degrees of arterial
compression, of cardiovascular instability at the time,
and of the concurrent treatment of this instability.
The latter factors were minimized as far as possible
while these patients were studied. Although
intra-abdominal pressure was not measured, these
patients appear to have had arterial compression as well
as venous occlusion in the splanchnic and lower limb
vessels. The increases in temperature at the foot, and
in PaCC>2, ETCC>2 and hydrogen ion and potassium
concentrations on decompression are evidence of
re-established distal circulation following arterial
compression. The increase in ETCC>2 has been noted
previously in similar patients (J V Farman, personal
communication) and on several occasions since.
Before abdominal decompression, mean arterial pressure
was maintained by blood transfusion; all patients had a
tachycardia and right atrial and pulmonary capillary
wedge pressures were increased. Patients 1 and 2 had a
reduced cardiac output and normal systemic vascular
resistance, but patient 3 had an increased cardiac
output, with a low systemic vascular resistance. All
three patients had a low pulmonary vascular resistance
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but high mean pulmonary artery pressure.
Following abdominal decompression, there was an
immediate increase in cardiac output^ which was
associated with a decrease in heart rate and an increase
in stroke volume. There was a sharp decrease in
systemic vascular resistance. Since the increase in
cardiac output was smaller than the decrease in systemic
vascular resistance, mean arterial pressure decreased,
and since the main cause of the hypotension was a low
systemic vascular resistance, vasoconstrictors were the
most appropriate form of treatment.
Sympathomimetic agents were relatively ineffective in
increasing systemic vascular resistance. Methoxamine
had no effect and ephedrine, although it increased mean
arterial pressure, did so by increasing cardiac output;
systemic vascular resistance remaining low. Vasopressin
is an endogenous vasoconstrictor with an important
action on the splanchnic vascular bed. In these
patients, it caused an increase in mean arterial
pressure by increasing systemic vascular resistance.
Adrenaline, which also causes splanchnic
vasoconstriction, increased mean arterial pressure by
increasing systemic vascular resistance when given by
bolus administration. When given by infusion,
adrenaline again increased systemic vascular resistance,
and in Patient 2 this was sufficient to decrease cardiac
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output so that mean arterial pressure did not increase.
Vascular pooling may also occur as a result of
vasodilatation of the splanchnic circulation and loss of
tone of the intestinal smooth muscles - the latter
occurring because of hypoxia resulting from the
increased intra-abdominal pressure in these patients.
The action of adrenaline is complex and may depend upon
smooth muscle tone (Weiner 1985). Intensive monitoring
is, therefore, advisable during its administration,
particularly in this situation.
The haemodynamic changes described following abdominal
decompression are compatible with the release of a high
intra-abdominal pressure and the re-establishment of
splanchnic and lower limb circulation. The splanchnic
venous system is known to be an important blood
reservoir (Greenway 1983) and maximal dilatation of
these vessels would produce a system with a large
capacity. Constriction of the splanchnic vasculature is
mediated by alpha adrenoreceptors (Corday and Williams
1960; Hirsch and Rone 1982). These patients, however,
responded poorly to sympathomimetic agents and required
large doses of endogenous vasoconstrictors with a
specific effect on the splanchnic circulation. This may
be because of the presence of an abnormal circulation
with maximally dilated vessels unresponsive to normal
doses of sympathomimetic agents. This, in turn, may be
a mechanical problem, with the vessels splinted open by
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fibrous adhesions formed as a result of the patient's
original pathology, or it may be that the alpha
adrenoreceptors are poorly responsive, possibly on account
of the release of vasoactive substances or toxins
produced during tamponade. Chernow (1985) has
postulated this type of mechanism based on a theory
described by Berridge and Irvine (1984) and future
pharmacological developments in alpha receptor modulators
may elucidate its importance.
Although all these patients died eventually, none died
with the ventilatory complications seen previously in
similar patients, which may have been the result of
overtransfusion. Since these patients,many others have
been managed along the lines described above, with a
large percentage now surviving to be discharged from the
Intensive Care Unit; in particular, pulmonary
complications resulting from fluid overload are
uncommon. The frequent pulmonary complications
previously seen in these patients may have been the
result of inappropriate treatment of hypotension with
excessive blood transfusion following abdominal
decompression. Although some volume replacement is
necessary during such operations, vasoconstrictors may
be required in addition. Noradrenaline was not
investigated in these patients because of the fear of
adverse effects on renal function. Subsequently its use
in this and other circumstances when a low systemic
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vascular resistance has been encountered has shown this
fear to be unfounded and its use associated with an
improvement in renal function (vide infra).
Allowing the abdomen to tamponade, followed by laparotomy,
will usually result in the bleeding stopping. Abdominal
tamponade may be hastened by abdominal binding (van
Obbergh et al 1989) or by use of pneumatic antishock
garments (Aberg 1989). In a few patients,bleeding will
continue despite these measures, and in such
circumstances vasopressin might be expected to be
useful. Vasopressin has long been known to reduce
portal pressure (Clark 1928) and this has led to its use
in the control of bleeding, particularly from
oesophageal varices. Direct administration into the
superior mesenteric artery was used to produce local
haemostasis and to attempt to minimise systemic effects
(Millette et al 1975; Melson et al 1976)*, however,
intravenous administration has the same haemostatic
efficacy and systemic effects (Barr, Lakin and Rosch
1975; Millette et al 1975; Johnson et al 1977) and is
much simpler. Intermittent bolus administration of
vasopressin reduces bleeding from oesophageal varices
(Kehne, Hughes and Gomptez 1956; Shaldon and Sherlock
1960) but frequent short infusions (Conn and Dalessio
1962) or a continuous infusion (Barr, Lakin and Rosch
1975) may be more effective.
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The ability of vasopressin to reduce pressure in the
splanchnic vascular bed therefore prompted a trial of
the intravenous use of vasopressin in an attempt to
control intra-abdominal bleeding when conventional
treatment proved ineffective. This study demonstrates
the benefits of research in liver transplant patients to
other groups of patients. Initially vasopressin was used
in two patients, following liver transplantation, to
control intra-abdominal haemorrhage when other
therapeutic manoeuvres, including laparotomy, had
failed. However, as experience with the drug grew it was
used prior to laparotomy in other patients who had
required surgery for other conditions. Ten patients are
reported; six of whom were liver transplant patients and
the remaining four had other causes for their intra-abdominal
bleeding. Dr Maire P Shelly and Mr R Greatorex (Senior
Registrar - General Surgery) assisted with the data
collection.
THE PHYSIOLOGICAL EFFECTS OF VASOPRESSIN WHEN USED TO
CONTROL INTRA-ABDOMINAL BLEEDING
Intensive Care Medicine (1988) 14; 526-531
Patients
Ten patients suffering from major postoperative
intra-abdominal bleeding received vasopressin over an
eight year period and the case notes of these patients
were reviewed retrospectively.
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All the patients were exsanguinating from their
intra-abdominal bleeding and all had impaired
renal function from prerenal failure or acute tubular
necrosis; four were reguiring haemodialysis. Nine
patients were receiving artificial ventilation. All
were receiving infusions of fresh frozen plasma and
platelet concentrates as well as calcium supplements;
none had disseminated intravascular coagulopathy.
Vasopressin was diluted in 5% dextrose to form a
solution containing 1 or 2 units/ml and administered
using an accurate syringe driver. The dose administered
was similar to that used for the treatment of
oesophageal varices (Johnson et al 1977; Shaldon and
Sherlock 1960) since the detailed pharmacokinetics of
exogenous vasopressin in critically ill patients have
not been evaluated.
Arterial and central venous pressures were measured
directly via intra-arterial and central venous
catheters; in addition,a continuous electrocardiogram,
core temperature, urine output and nasogastric drainage
were monitored in all patients. Additional parameters
were measured as indicated. Hourly blood loss was
calculated from measurements of external blood loss.
The volume of blood and colloid required to maintain
cardiovascular stability and any adverse effects of
vasopressin were noted. The records of postmortem
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examinations, performed on six of the patients, were
reviewed. Student's paired t test was used to compare
results where appropriate.
Results
The details of the patients and their surgical treatment
before vasopressin was administered are shown in Table
16.4. Six patients had bled following liver
transplantation, two after other forms of hepatic
surgery and the remaining two had reguired surgery for
intra-abdominal sepsis.
The duration of bleeding was 32.9 (17.3) hours [mean
(SD)]^ with a measured nonoperative blood loss of 10.5
(4.9) litres and a blood transfusion requirement of
18.4 (11.2) litres prior to vasopressin treatment. In
spite of the infusion of coagulation factors and
platelets, the prothrombin ratio was 1.5 (0.3) and the
9
platelet count was 84.7 (61.7) xlO /I.
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Patient Age Sex Weight Diagnosis
Number (yrs) (kg)
1 14 F 59 chronic active
hepatitis
2 57 M 67 ^-antitrypsin
deficiency
5 22 F 46 chronic rejection
7 23 M 76
8 38 F 83
10 28 F 55
3 15 F 45
4 60 M 78
6 39 M 65









































Table 16.4: Details of patients who received vasopressin
and their surgical management before vasopressin
treatment. Numbers refer to chronological order.
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Bleeding
External blood loss was used as an index of bleeding and
the change in the measured loss was used to assess response to
vasopressin. Although occult losses are undetected,
this provides an estimate of blood loss and follows the
same trend as the change in transfusion requirement in
individual patients. The estimated blood loss during the
four hour period before giving vasopressin compared
with the same period after its administration is shown
in Table 16.5, together with vasopressin dosage for
individual patients and the outcome of their bleeding.
In all but one of the patients blood loss decreased
following vasopressin and the overall decrease in blood
loss was significant (p<0.05). In the liver transplant
group, patient 1 had bleeding that was controlled by
vasopressin alone. Of the remaining five patients, four
required additional haemostatic laparotomy either before
the vasopressin or afterwards to successfully control
the haemorrhage (patients 2, 5, 7 and 10). Haemorrhage
could not be controlled in patient 8. Patient 2 had an
unsuccessful laparotomy to control haemorrhage before
starting vasopressin and in patient 8 vasopressin was
started before laparotomy to increase the time available
for preparation.
Page 542
Patient 4 h before 4 hours after decrease in vasopressin treatment Bleeding controlled
Number vasopressin vasopressin blood loss(%]
1 750 360 52 20 units bolus x 2 vasopressin alone
2 845 445 47 20 u/hr infusion 14 h vasopressin following
laparotomy
5 3500 3040 13 12-24 u/hr infusion 10 h laparotomy following
vasopressin
7 1593 966 40 lOu/hr infusion 4 h laparotomy following
vasopressin
*8 325 170 48 20 units bolus x 1 not controlled
1-10 u/h infusion 132 h
10 165 144 13 5-10 u/hr infusion laparotomy following
12.5 h vasopressin
3 5459 5865 +7 10 units bolus x 2 not controlled
20 units bolus x 1
4 2495 1460 42 20 units bolus x 1 vasopressin following
10 u/h infusion 12 h laparotomy
6 600 500 17 2.5-10 u/hr 90 h not controlled
9 945 730 23 2-7 u/hr infusion 124 h vasopressin following
laparotomy
Table 16.5: Blood loss during the 4 hour period before
vasopressin administration compared with the 4 hour
period immediately after, together with vasopressin dosage
for individual patients and the outcome of their bleeding.
♦Figures for 1 hr before and after vasopressin.
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In the four patients who had not received a liver
transplant, laparotomy to control the haemorrhage had
been performed in patients 3, 4 and 9 before starting
vasopressin and although specific bleeding points were
controlled,massive haemorrhage continued. Bleeding was
controlled by vasopressin in two of these patients, but
patients 3 and 6 it was uncontrolled.
Mortality
Two patients (7 and 10) survived in the liver transplant
group and were discharged from hospital. No patients in
the other group survived. The three patients with
bleeding uncontrolled by vasopressin or laparotomy died
of their intra-abdominal bleeding within 24 hours of
cessation of the vasopressin infusion. Patient 2 died
of unrelated colonic bleeding (probably resulting from a
rectal temperature probe) 18 days after control of his
intra-abdominal bleeding by vasopressin. The other
patients died of multisystem failure 15.2 (4.1) days
after receiving vasopressin.
Cardiovascular Parameters
Changes in mean arterial pressure, heart rate and
central venous pressure for periods before and after
commencement and cessation of vasopressin infusion are
shown in Figure 16.2 for both groups because of the
small numbers in each group.
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KEAN ARTERIAL PRESSURE
vasopressin on vasopressin off
Figure 16.2: Mean (SD) arterial pressure, heart rate
and central venous pressure for 3hr periods before and





















Figure 16.3: Core temperature (mean SD), for four hour
periods before and after commencement and cessation of
vasopressin infusion.
Mean arterial pressure increased with the start of the
infusion (p<0.025) but subsequently returned to baseline
values when the infusion was stopped. A tachycardia was
present in all patients before administration of
vasopressin. Heart rate decreased during treatment but a
tachycardia returned upon its cessation. The changes in
central venous pressure were less marked but a transient
increase coincided with the decreased heart rate on
starting the infusion.
Urine output
The urine output of individual patients,for the 4 hour
period before vasopressin treatment)compared with the 4
hour period immediately after, is shown in Table 15.6
Although the overall changes fail to reach statistical
significance, they were of clinical significance. All
patients initially had impaired renal function;but three
of the liver transplant group (Patients 1, 2, 10) and
two in the other group (3, 9) had a prompt diuresis when
vasopressin was initiated.
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Patient 4 hours before 4 hours after % change
Number vasopressin vasopressin
1 48 141 194
2 45 105 133
5 0 8
7 38 34 -11
8* 26 22 -15
10 164 470 187
3 43 165 284
4 84 75 -11
6 214 250 17
9 50 101 102
Table 16.6: Urine output for individual patients for the
four hour period before vasopressin compared with the
four hour period immediately after. * Figures for one
hour before and after vasopressin
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Ischaemia
Myocardial. Dysrhythmias were documented
electrocardiographically in two liver transplant
patients (patient 2 had an episode of supraventricular
tachycardia, patient 8 a period of bradycardia) and one
other patient (patient 9 had a bradycardia together with
ventricular ectopic beats) during vasopressin treatment.
All these changes disappeared when the rate of infusion
was reduced. two patients in the liver transplant group
(i and 5) had diffuse myocardial myocytolysis noted at
postmortem examination.
Intestinal. Two patients after liver transplantation
had evidence of ischaemia. Patient 1 had pancreatic
infarction and patient 2 colonic ulceration. The latter
patient started to bleed profusely from his rectum
postoperatively and it proved impossible to identify the
site and control the bleeding. At postmortem a small
circumscribed ulcer was identified at the presumed site
of the rectal temperature probe. Colonic ulceration
from rectal temperature measurement has not been
reported previously and was not suspected in this
patient. One patient (9) with intra-abdominal sepsis,
after a vasopressin infusion lasting 125 hours, was
found to have an infarcted appendix which was removed.
Hepatic. Four patients, all of whom were in the liver
transplant group, had some evidence of hepatic
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ischaemia. Patient 1 had areas of recent infarction 13
days after vasopressin administration, patient 2 had
centrilobular necrosis, patient 8 had discrete areas of
infarction and patient 5 had ischaemic necrosis.
Gastrointestinal motility
All the patients had an ileus immediately prior to
treatment; nevertheless, evacuation of bowel motions
occurred in three patients (patients 1, 9, 10) and the
volume of nasogastric aspirate increased in patients 5
and 7. Patient 1 was in hepatic coma after liver
transplantation and, in an attempt to improve her
conscious level, she had a 4 litre enema before
vasopressin treatment. The enema had been unproductive
but vasopressin caused a prompt evacuation of her bowels
and a slight improvement in her conscious level.
Other physiological effects
Temperature changes. The changes in core temperature,
rectal or axillary, for the 4 hour periods before and
after starting vasopressin and before and after its
cessation are shown in Figure 16.3 for all ten
patients. The increase in core temperature with the
start of vasopressin infusion was statistically highly
significant (p<0.0005). In three patients, the core to
peripheral temperature difference was monitored and
remained unchanged.
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Tachyphylaxis. Two of the patients, one in each group,
who received prolonged vasopressin infusions appear to
have shown tachyphylaxis. In patient 8 the infusion was
continued at the same rate after bleeding was eventually
controlled^in an attempt to allow haemostasis^ but after
12 hours bleeding restarted with the infusion still in
progress. Patient 9 required increasing doses of
vasopressin to control his bleeding and when the
infusion rate was reduced bleeding restarted.
Discussion
There have been a number of reports of the efficacy of
vasopressin in the control of bleeding, particularly
from oesophageal varices (Melson, Geisse and Stanley
1976; Shaldon and Sherlock 1960; Hussey 1985). These
have stressed the haemostatic effect of vasopressin and
mentioned various side effects. The group of patients
reported here had massive intra-abdominal bleeding
uncontrolled by conventional treatment. While the
haemostatic effect of vasopressin was the primary
objective of the treatment, the intensive monitoring of
these patients during treatment allowed documentation of
the physiological effects of vasopressin in critically
ill patients during haemorrhage.
Vasopressin is a powerful vasoactive substance, known to
decrease splanchnic blood flow (Eiseman et al 1960) and
thought to act by constriction of splanchnic arteriolar
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sphincters (Drapanas et al 1961; Nusbaum 1975). The
haemostatic effect of vasopressin is, however, variable
(Hussey 1985; Silva, Moffat and Walt 1969). This has
been attributed to individual differences in hepatic
blood flow characteristics and hepatic function (Hussey
1985; Nusbaum 1975) and vasopressin may be more
effective in critically ill patients (Hussey 1985). The
results from this group compare favourably with other
reported series (Johnson et al 1977; Drapanas et al
1961). Vasopressin may, therefore, be used together
with laparotomy in the management of patients with
uncontrolled intra-abdominal bleeding following liver
transplantation and major abdominal or hepatic surgery. A
response to an initial bolus dose of vasopressin may
indicate a more sustained response to its infusion.
However, continued bleeding requiring a prolonged
infusion of vasopressin indicates a poor response and
increases the risk of complication. The high mortality
rate seen in this group of patients reflects their
severe illness and the influence of vasopressin cannot
be determined accurately.
Patient 3 was the only patient who did not respond at
all to vasopressin; she continued to bleed from the
liver surface following an emergency partial hepatectomy
for bleeding into a hepatoma. Patients 4 had similar
bleeding following a partial hepatectomy for a hepatoma
but he responded well to vasopressin. An important
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difference between these patients was that patient 4 had
a patent portal vein but the portal vein of patient 3
was occluded by tumour. The entire hepatic blood supply
of patient 2 was, therefore, through her left hepatic
artery (the right lobe of the liver having been
surgically removed). While portal venous pressure
decreases in response to vasopressin, the response of
the hepatic artery is different, a biphasic response
having been demonstrated in dogs (Bynum and Fara 1980).
Initially, hepatic arterial flow decreases but this
rapidly reverses so that 15-20 minutes after
administration of vasopressin, hepatic artery flow
increases to double the control value. The failure to
achieve haemostasis in patient 3 may result from an
increased hepatic arterial flow in response to
vasopressin. Similar bleeding in patient 4 responded to
vasopressin since he had a patent portal vein and total
hepatic blood flow decreased.
The hypertensive effects of vasopressin have been
previously reported in patients with oesophageal varices
(Drapanas et al 1961; Edmunds and West 1962; Silva et al
1969; Nusbaum 1975). The increase in mean arterial
pressure and central venous pressure and the decreased
heart rate seen in these patients at the start of
vasopressin administration may be due to the
autotransfusion effect of splanchnic vasoconstriction,
since the splanchnic vascular bed is a significant blood
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reservoir (Hanson 1970).
When mentioned at all, previous studies have reported an
antidiuretic effect of vasopressin (Edmunds and West
1962)j and normally, release of vasopressin from the
posterior pituitary causes an increase in renal tubular
reabsorption of water. All the patients reported here
had impaired renal function before treatment with
vasopressin; the impressive diuresis experienced by five
patients is, therefore, all the more significant and no
patients became anuric. The mechanism for this
increased urine output is unknown but may be related to
an increased renal perfusion pressure with the increased
mean arterial pressure. It is of note that
noradrenaline, an agent also associated with the
production of oliguria, has also been shown to increase
urine flow in patients with septic shock (Meadows et al
1988; Desjars et al 1989; Hesselvik and Brodin 1989).
Myocardial ischaemia has been reported following
vasopressin (Slotnik and Tiegland 1951) and it has been
used as a stress test to provoke ischaemic changes
(Ruskin 1947). Dysrhythmias related to vasopressin
administration were seen in three patients. In
addition, diffuse myocardial myocytolysis was found at
postmortem examination in two other patients; this is a
nonspecific change but vasopressin may have contributed
to its development.
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Intestinal ischaemia has been described following
infusion of vasopressin into the superior mesenteric
artery (Roberts and Maddison 1976; Beradi 1974; Renert
et al 1972) but not following intravenous
administration. The pancreatic and mucosal lesions are
unlikely to have been due entirely to vasopressin,
although it may have contributed to their development.
The third patient had an infarcted appendix following
prolonged vasopressin infusion and this would seem to be
attributable to vasopressin.
Hepatic ischaemia has not been described before, and in
this study, vasopressin cannot be conclusively
incriminated since all the patients had livers that had
been compromised by transplantation. It may, however,
have contributed to the ischaemic changes seen.
Active peristalsis is a known feature of vasopressin
administration and previous reports have described
vomiting, diarrhoea and abdominal discomfort among its
side effects (Collins and Root 1936; Shaldon and
Sherlock 1960; Melson et al 1976). The increase in core
temperature during vasopressin administration was a
constant finding. In no patient did core temperature
decrease. The corresponding increase in peripheral
temperature suggests that this is not due to central
diversion of blood flow with peripheral vasoconstriction
but may be the result of increased heat production.
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Vasopressin controlled intra-abdominal bleeding in two
patients after liver transplantation and in two
other patients. In a further two patients, vasopressin
significantly reduced the rate of bleeding. The
physiological effects of vasopressin varied between
patients but there was a general improvement in
haemodynamic parameters and six patients (three after
liver transplantation and three after other surgery) had
a diuresis following its administration. In some
patients, vasopressin appears to be useful in the
management of massive and uncontrolled intra-abdominal
bleeding. However, because of the risk of ischaemic
damage to other organs, vasopressin should only be used




THE CAUSES OF MORTALITY AFTER LIVER TRANSPLANTATION
IN THE INTENSIVE CARE PERIOD
Liver transplantation has been performed for 21 years
in the joint programme between Cambridge and Kings
College Hospital. In 1987 a retrospective analysis of
the experience in the Cambridge/Kings College Series
during the first 20 years of the programme attempted to
identify the major causes of mortality of patients
during their period in the Intensive Care Unit and
provide information on the changing patterns of
problems which have contributed to mortality. It was
completed in the middle of 1988. I was assisted in this
study with the data collection by Dr J Gomez-Arnau
(Visiting Fellow).
MORTALITY DURING INTENSIVE CARE AFTER
ORTHOTOPIC LIVER TRANSPLANTATION
Anaesthesia (1989) 44: 959-963
Patients and Methods
During the period 1968 to the end of October 1987, 335
adult patients (over 14 years of age) have had at
least one liver transplant in the Cambridge/Kings
College Hospital Series. These patients were grouped
according to a chronological scheme with the earliest
group of 41 patients from 1968-1975, 60 patients from
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1976-1980, 45 patients from 1981-1983 and 27-60 pa¬
tients from each of the years 1984 to 1987. These
groups were chosen as being of comparable size. The
numbers in the groups from 1984 onwards represent a
major increase in transplant activity in this hospital.
Paediatric liver transplantation (now an increasing part
of our practice) is not included in this study.
The place of death, time between operation and
death, number of reoperations (if any), intraoperative
blood transfusion, duration of stay in the ICU and the
time of tracheal intubation were recorded on all
patients who died. In the early part of the series,
intensive care measures such as artificial
ventilation, tracheal intubation, catecholamine
infusion and invasive monitoring were practised
outside the ICU but, for statistical purposes, these
patients have been considered as if they had received
this therapy and died in the ICU. The main cause of
death was obtained from the postmortem results (when
available) or from clinical data in the remaining patients,
using criteria described previously (Cuervas-Mons et al 1986).
When possible,only one (the major) cause of death was
identified for each patient. Multisystem organ failure
(MOF) was recorded as a cause of death when failure of
two or more major organ systems was present. In this
group of patients there are predominately three causes
of multisystem organ failure; infection, infarction or
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rejection of the donor liver. Infection was coded as
the cause of death if there was microbiological
confirmation of an organism (culture or serology).
Infarction of the liver is characterised by a marked
increase in the transaminases and prothrombin time and
by sudden deterioration in the patients condition.
Rejection can be diagnosed histologically or by the
response to pulsed bolus doses or steroids (Chapters 5
and 6). Infection, infarction or rejection was coded
the primary cause of death if proven; multisystem organ
failure was coded if no cause was identified. Renal
failure was defined as the presence of a plasma
creatinine level of >217 y.mol/1; or if there was a
need for haemodialysis or haemofiltration. All other
concurrent pathology present at the time of death
was coded as an associated diagnosis. Students t test
for unpaired data was used for statistical analysis
where applicable.
Results
The numbers of patients who underwent orthotopic liver
transplantation in each time period is shown in Table
17.1. One hundred and ninety five of the 335 patients
who have received a liver transplant have died, 86 of
them in the ICU (44%). Table 17.1 also shows the numbers
of patients who died in the ICU during either their
first admission or on readmission.
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1968-75
Nimber of patients 41
Age (years)(SD) 41.2(12.8)
Deaths in ICD








8 (13!) 12 (27!) 7 (26?)
5 (8?) 8 (18?) 6 (22?)




6 (13?) 7 (12?) 5 (8!)
4 (9?) 3 (5?) 2 (3?)
10 (22?) 10 (17?) 7 (11?)
Table 17.1: Number (percentage of group) of deaths that
occurred in the intensive care unit after orthotopic liver
transplantation in the seven time periods.
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The age and gender of adult patients who underwent
liver transplantation did not change significantly
during the study period, although the number of
orthotopic liver transplants performed each year has
increased steadily, particularly since 1984. The
mortality rates for both the first and subsequent ICU
admissions have decreased significantly since 1984.
The main indications for transplantion are shown in
Table 17.2. Initially a large number of patients were
transplanted for malignancy but this has now become an
uncommon indication. Alcoholic cirrhosis had the
lowest ICU mortality and Wilson's disease the highest,
although the small numbers prevent meaningful
statistical analysis. The groups associated with the
largest decreases in ICU mortality over the years are
those with cryptogenic cirrhosis and malignancy.
The main causes of death are shown in Table 17.3.
Infection has remained the most important cause of
death (55%)) with haemorrhage being the next most common
(19%). Associated causes of death are shown in Table
17.4. Multisystem failure and renal failure make up 60%
of all contributory causes of deaths. Multisystem
(which would include renal) failure became increasingly
recognised in the period 1981-1983 as the commonest
cause of death.
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1968-75 1976-80 1981-83 1984 1985 1986 1987
n d (t) n d (1) n d (1) n d (1) n d(*) n d (1) n am
Biliary Cirrhosis 3 1 (33) 14 3 (21) 16 9 (56) 7 5 (71) 7 3 (43) 19 4 (21) 16 2 (12)
Chronic Active
Hepatitis 2 0 (0) 7 1 (14) 7 3 (43) 5 3 (60) 9 2 (22) 8 1 (12) 13 1 (8)
Alcoholic Cirrhosis 1 0 (0) 3 0 (0) 1 0 (0) 1 0 (0) 1 0 (0) 1 0 (0) 5 1 (20)
Cryptogenic Cirrhosis 5 2 (40) 5 2 (40) 3 1 (33) 2 1 (50) 3 1 (33) 6 1 (16) 5 0 (0)
Sclerosing
Cholangitis - - - 2 0 (0) 2 2 (100) •- - - 4 1 (25) 4 0 (0) 4 1 (25)
Acute Liver Failure 3 1 (33) 1 0 (0) 5 2 (40) 6 0 (0)
Malignancy 29 10 (34) 21 4 (19) 11 3 (27) i5 1 (16) 13 1 (8) 5 0 (0) 5 1 (20)
Wilson's Disease - - - - - - 1 0(0) 1 1 (100) 2 1 (50) 1 0 (0) 1 1(100)
Budd Chiari - - - 5 2 (40) 3 1 (33) :2 1 (50) 3 0 (0) 3 1 (33) 1 0 (0)
Other 1 0 (0) 3 1 (33) 1 0(0) ■- - - 2 1 (50) 5 1 (20) 1 0 (0)
Table 17.2: Primary diagnosis and mortality in the
intensive care unit after orthotopic liver
transplantation, n = number of patients, d = ICU deaths
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Deaths in the Intensive Care Unit Deaths outside
ICO
1968-75 1976-80 1981-83 1984 1985 1986 1987 1968-87*
Rejection ....... 9 (9$)
Infarction 2 (151) 1 (81) 1 (51) 1 (8%) 1 (10%) - - 6 (61)
Infection 8 (621) 7 (541) 11 (551) 8 (621) 4 (401) 4 (40%) 5 (71%) 30 (29%)
Haemorrhage - 3 (23%) 3 (15%) 2 (15%) 3 (30%) 4 (40%) 1 (14%) 1 (1%)
Multisystem
failure 1 (8%) 1 (8%) 4 (20%) 2 (15%) 1 (10%) -
Recurrence 1 (8%) ------ 30 (29%)
Biliary
anastomosis - - - - - - - 3 (3%)
Pulmonary
embolus ....... 3 (3%)
GI Haemorrhage - - 1 (5%) - - - - 2 (2%)
Cerebral
haemorrhage 1 (8%) 1 (8%) - - 1 (10%) 1 (10%) 1 (14%) -
Other .... 1 (10I) - - 10 (11%)
Unknown ....... 7 (7$)
Table 17.3: Main cause of death. Percentages refer
all deaths in that location in each time period.
* excluding theatre deaths.
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1968-75 1976-80 1981-83 1984 1985 1986 1987
Rejection 1 (81) ......
Infarction - 1 (8!) - - 1 (101) 1 (101) -
Haemorrhage - - 1 (51) - - - 1
Multisystem
failure 1 (15%) 2 (15%) 14 (70%) 6 (46%) 3 (30%) 2 (20%) 2 (28%)
Biliary
problems 1 (8%) 2 (15%) 1 (5%) - - - -
Pulmonary
embolus 2 (15%) 1 (8%) - - - - -
GI haemorrhage - - - - 1 (10%)
Renal failure 1 (8%) - 9 (45%) 3 (23%) 1 (10%) 1 (10%) 1 (14%)
Cardiac
failure 1 (10%) 1 (10%) -
Disseminated
intravascular
coagulation - - - 1 (8%) ...
Mesenteric
thrombosis 1 (10%) -
Miscellaneous 1 (8%) - - 1 (8%) - 1 (10%) -
Table 17.4: Associated causes of death in patients who
died in ICU. Percentages are related to ICU deaths for
that period.
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During that period,renal failure occurred in 45% of
patients who died in the ICU, much more frequently
than previously. The relationship of renal failure to
ICU mortality and one year survival can be seen from
Figure 17.1. Many factors will influence survival, but
the development of renal failure in critically ill
patients is associated with high mortality. The
decreasing incidence of renal failure in this group
appears to be associated with a decrease in ICU
mortality (except for 1987) and an increase in one year
survival.
Table 17.5 presents further information on patients who
died during admission to the ICU or after discharge.
There is no statistically significant difference in age
or gender. The average number of days spent in the ICU
was shortest for those patients who survived but there
was no statistically significantly difference in
duration of ICU stay between patients who died during
their first ICU admission and those who died in
their second ICU admission. Patients who died had a
longer period of tracheal intubation in both admissions
and required more intraoperative blood transfusion. The
incidence of the main causes of death for all patients
is shown in Figure 17.2.
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Figure 17.1: The incidence of renal failure during the
period of intensive care in patients following liver
transplantation from 1968 to 1987. Mortality (as a
percentage of all deaths) and one year survival for the
same period is also shown.
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Deaths outside
ICO (n = 81)*
Deaths during
first admission
to ICU (n = 49)
Deaths during
readmission
to ICU (n = 30)
Age 41 (12) 41 (10) 39 (12)
Sex 34 M 47 F 25 M 24 F 13 M 17 F
Survival time (days) 350.7 (600.6) 11.6 (10.6)/ 89.1 (136.2)$
ICU time (days) 6.1 (10.1) 11.6 (10.6) 10.9 (14.4)
Patient days 424 593 293
Intubation time (hours) 38.5 (78.9) 162.5 (200.4)6 124.2 (245.3)/
Intraoperative blood
transfusion (litres) 8.1 (6.9) 19.6 (15.0) 9.8 (7.6)**
Total number of
reoperations 43 34 16
Number of patients (1
of total) re-operated 35 (431) 24 (49?) 12 (40?)
Re-operation/ patient ratio 1.2:1 1.5:1 1.3:1
Table 17.5: Risk factors associated with death after liver
transplantation. Values are expressed as mean (SD). *
excluding deaths in theatre. # p<0.01 (with respect to














Figure 17.2: Main cause of death following liver
transplantation for the period 1968 to 1987.
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Discussion
The current one year survival after liver
transplantation at this centre is 66%. This is higher
than that reported by the European Transplant Registry
(Bismuth et al 1987) and compares well with other
series (Starzl 1986; Wall et al 1987? Memsic 1986).
Survival has improved steadily from 12% during the first
8 years up to 49% in 1985 and 66% in 1986. The
percentage of deaths in the ICU increased from 31% in
the initial period to 48% in 1984 but since that time
it has decreased each year to 11% in 1987.
Major changes in the management of these patients
occurred in the study period. Postoperative artificial
ventilation for the first 24 hours was introduced in
1976; prior to this period^patients were extubated at
the end of operation and allowed to breath spontaneously
(Farman et al 1976).
The period with the maximum incidence of multisystem
organ failure including renal failure (1981-1984)
coincides with the introduction of cyclosporin A,
given immediately after liver transplantation, into
clinical practice. This high incidence of renal failure
caused a change in our therapeutic regimen. Cyclosporin
is now administered 48 hours from the end of
operation when the patient is haemodynamically stable
and has adequate renal function. Further research
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into renal protection led us to introduce low dose
dopamine infusion as part of the routine management of
these patients (Chapter 15). These changes and other
more general measures (see below) were associated
with reductions in the incidence of renal failure in
patients who died, from 45% in the period 1981-1983
to 23% in 1984 and 10% in 1986. Simultaneously the
one year survival rate increased to 49% and 66% in 1985
and 1986 respectively (Figure 17.1).
Infection continues to be the major cause of
death in the ICU, an experience others have suffered
(Cuervas-Mons et al 1986). Its total incidence appears
not to have changed with time; it remains the primary
cause of death in 35-45% of all patients and
contributes to 55% of all ICU deaths. The high
incidence of infection is a reflection of the severity
of pre-existing illness, the magnitude of the operation
and the need for immunosuppression. Selective
decontamination of the digestive tract may help in
reducing this problem)although its exact role in the
critically ill remains to be defined (Johanson 1989;
Sanderson 1989). New drugs for immunosuppression, such
as FK506 (Starzl et al 1989), are currently under
investigation in many parts of the world and their
impact on the balance between prevention of rejection
and the risk of infection remains to be determined.
Almost all of the deaths caused by haemorrhage,
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multisystem failure and cerebral problems occurred in
the ICU. Multisystem organ failure is of considerable
concern since there is so little that is treatable and
the disease often exhibits a slow, remorseless
progression until the patient dies. The Pittsburgh group
(Miyata et al 1989) have demonstrated a correlation
between the plasma concentration of endotoxin during the
anhepatic period and the need for platelet transfusion,
ventilatory support and mortality. Endotoxins are
thought to mediate the majority of their effects
principally through Tumour Necrosis Factor (TNF), a 17
kDalton protein produced principally by macrophages
(Tracey et al 1986). If this theory is substantiated
then the role of agents such as oxypentifylline, which
prevents the formation of TNF by inhibiting the
formation of the mRNA essential for its production (Zabel et
al 1989)> and monoclonal antibodieSjwhich will inactivate
TNF after its release (Celltech Ltd, Slough, Unpublished
Information)^ may diminish mortality from this cause. An
alternative approach to the prevention of MOF has been
suggested by Fiddian-Green (1988). He believes that
splanchnic ischaemia is a possible cause for MOF and
following revascularisation of an ischaemic area free
oxygen radicals are released>which produce organ damage.
Free oxygen radicals are produced by xanthine oxidase,
found principally in the mucosal epithelium, an enzyme
which can be inhibited by drugs such as allopurinol
(Grisham and Ganger 1989). If this theory is proved; then
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pretreatment with allopurinol may also reduce mortality
from MOF. Half of the deaths associated with ischaemic
damage to the donor organ occurred in the ICU. No
deaths attributed primarily to rejection, pulmonary
embolism or biliary problems occurred in the ICU.
The volume of blood transfusion required
intraoperatively appeared to be related closely to the
ICU deaths occurring early in the postoperative period
(Table 17.5). The mean blood usage in those patients
who died in the ICU was 19.6 litres, more than reported
by others (Butler et al 1985) . This may reflect
differences between patient groups or the routine use by
other centres of veno-venous or veno-arterial bypass
during the anhepatic period to reduce venous
hypertension. Periods of hypotension, residual perito¬
neal blood clot and tamponade of renal vessels by large
amounts of blood, resulting from bleeding, may lead to
an increased risk of renal failure and infection.
Patients who died in a subsequent ICU admission also
had a larger blood loss than in survivors.
The duration of stay in the ICU and of tracheal
intubation were, as might be expected, longer in the
nonsurvivors (on average more than 10 days and 120
hours respectively).
Less quantifiable aspects of postoperative intensive
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care concern the adoption of a management protocol in
1984, subsequently revised annually. Medical and nurse
staffing levels have also improved during this time.
Although no attempt has been made to analyse the
effects of these developments others have shown that
outcome in an ICU with adequate numbers of trained staff
is better than in a unit with low staff numbers (Knaus
et al 1986). During the review period^other factors, not
directly related to the intensive care these patients
received, will have also contributed to the improved
survival. Improvements in donor maintenance and organ
preservation (Chapter 2) and antibiotic prophylaxis have
occurred and there has been a change in the diagnostic
groups transplanted. Originally, a large number of
patients were transplanted for malignancy.
Unfortunately, many of these patients developed
recurrence of their tumours and it is not now a common
indication for transplantation. Patients with malignancy
are usually transplanted more rapidly than others^ with
the result they tend to be less unwell than those with
end-stage liver disease and so pose fewer perioperative
problems, a feature demonstrated in their low overall
mortality since 1975.
Eleven percent of patients died during the period of
intensive care in 1987 despite improvements in
management. Two major causes of mortality, infection
and haemorrhage, require attention. It is of note that
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these have remained essentially unchanged during
this period. Some of the deaths diagnosed as
infection may have been due to rejection and the fine
balance between excessive immunosuppressiony which may
result in infection,and inadequate immunosuppression,
with a consequent increased risk of rejection, requires
careful management. Postoperative haemorrhage continues
to be a problem and may represent surgical problems,
derangement in the coagulation mechanism due to the
preexisting poor synthetic liver function and failure
of synthetic function of the new liver.
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APPENDIX I
ABBREVIATIONS AND NORMAL VALUES
Commonly used abbreviations
ABG Arterial blood gas






APII APACHE II score
AUC Area under the time/concentration curve
CAVH Continuous arterio-venous haemofiltration




Cmax Maximum plasma concentration
CMV Continuous mandatory ventilation
CO Cardiac output
C
^^ Plasma concentration at time t
CRP C reactive protein
CT Computerised tomography
CVP Central venous pressure
CWH Continuous veno-venous haemof iltration




EHBF Estimated hepatic blood flow
ETC02 End carbon dioxide
FFP Fresh frozen plasma
FjC>2 Fractional inspired oxygen concentration
FRC Functional residual capacity
GC-ECD Gas chromatography with electrochemical detection
GC-MS Gas chromatography with mass spectroscopy
detection
GCS Glasgow coma score
HABF Hepatic arterial blood flow
HAS Human albumin solution
HIV Human immunodeficiency virus
HPLC High performance liquid chromatography
HR Heart rate
ICB Intercostal nerve block
ICU Intensive care unit
IMV Intermittent mandatory ventilation
IPPB Intermittent positive pressure breathing
IV Intravenous
IVC Inferior vena cava
KPTT Kaolin partial thromboplastin time
LFT Liver function test
MAP Mean systemic arterial pressure
MAC Minimum alveolar concentration
MOF Multisystem organ failure








PBF Portal blood flow
PCWP Pulmonary capillary wedge pressure
PT Prothrombin time
PEEP Positive end expiratory pressure
PVR Pulmonary vascular resistance
R Respiratory quotient
RAP Right atrial pressure
REM Rapid eye movement
RIA Radioimmunoassay
Sa02 Arterial oxygen saturation
SD Standard deviation
SEM Standard error of the mean
SIMV Synchronised intermittent mandatory ventilation
SV Spontaneous ventilation
SVR Systemic vascular resistance
t^a Distribution half life
t^B Elimination half life
Tmax Time to maximum concentration
V1 Volume of distribution of the central compartment
Vd Volume of distribution
V Volume of distribution at steady statess 1
V/Q Ventilation perfusion ratio
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Normal values
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Small doses of frusemide increase urine flow in the
critically ill
We observed that the administration of a single 20 mg
dose of intravenous frusemide (the dose recommended
in the manufacturer's data sheet and the British National
Formulary1) to critically-ill patients could produce a
profound diuresis leading to In povolaemia. dehydration
and hypokalemia. This particular group ol patients arc
the least able to tolerate this embarrassment. These
adverse effects have been noted previously in general
medical patients.2 We therefore recorded the diuretic
response of critically-ill patients to low doses of frusemide.
Fifty-two critically-ill patients (30 male, 22 female,
mean age 53.2 years [range 17 to 85]) received 5, 10 or
20 mg of fruscmidc intravenously, either to maintain
fluid balance, or as part of the management of pulmonary
and peripheral oedema. Eight patients received fruse¬
mide at more than one dose strength. Patients were
excluded if they were hypovolaemic or if they had
abnormal renal function. Pre-existing treatment was not
changed in any patient; some may therefore have been
receiving a renal dose of dopamine. When urine volumes
in the four hours before and four hours after admini¬
stration were compared they increased by 90°/), 147%
and 190% at the respective doses (p<0.05). When the
change in urine output was compared to the dose of
frusemide, expressed as mg/kg body weight, the dose
response relationship was highly significant (pcO.IHM).
The urine output increasd by 133% for each 0.1 mg/kg of
frusemide administered (one-way analysis of variance).
It has been reported previously that the oral admini¬
stration of 20 mg frusemide produced a significant
diuresis in water-loaded normal volunteers.3 This study
demonstrated greater increases in urine output with
smaller doses and may be a reflection of the increased
and more rapid bioavailability of frusemide when given
by the intravenous route.
We would suggest that the initial dose of intravenous
frusemide in critically ill patients who do not have
significant renal impairment should be 5 or 10 mg. Only




1. Cardiovascular system. In: British National Formulary.
London, British Medical Association and The Pharma¬
ceutical Press, 1987; 74-5.
2. Lowe J, Gray J, Henry D, Lawson D. Adverse reactions
to frusemide in hospital inpatients. Br Med J 1979; 2: 360-2
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Table 1 Change in urine output after 5,10 and 20 mg frusemide administered intravenously to 52 critically-ill patients
Dose offrusemide 5 mi; 10mtf 20 mg
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Bacterial tiunslocution occurred in the endotoxin
treated animals but not the controls. Xanthine oxidase
and dehydrogenase ,u to its were highest in the jejunums
of both groups but wcu -ignilk .mtly reduced in the
treated mice, llowcset in the ileum, caecum and liver,
xanthine oxidase and delisdi.igeiiase activity increased
significantly. I lislologk.il minis in the endotoxin treated
was limited to the ileum and i.iccum
The finding that histological injury occurs in the same
areas as increased xanthine oxidase and dehydrogenase
activity does not establish a causal relationship between
the two. However, the previous observation that inhibi¬
tion of xanthine oxidase activity reduced mucosal injury
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SERUM ACUTE PHASE PROTEINS AFTER ORTHOTOPIC
LIVER TRANSPLANTATION
A. M. BURNS, M. P. SHELLY, S. WALKER AND G. R. PARK
SUMMARY
Acute phase proteins were measured in six
patients before liver transplantation and for 72 h
after orthotopic liver transplantation. The ability
of the donor liver to mount an acute phase
response was demonstrated, although the re¬
sponse was less than that seen in other groups of
patients in whom this has been studied. Because
of the reduced response to stress, the value of
these measurements as indicators of liver func¬
tion in this group of patients is limited.
KEY WORDS
Liver: transplantation. Liver function: acute phase protein
synthesis.
Surgical trauma induces an acute phase reaction
in which the liver is stimulated to switch from
synthesis of albumin to production of a series of
acute phase proteins [1]. These changes include
normally a rapid increase in the synthesis of C-
reactive protein and oq-antichymotrypsin, with a
consequent increase in serum concentrations.
Synthesis of cq-acid glycoprotein (AAG) is in¬
creased also, but to a smaller extent. Serum
concentrations of pre-albumin decrease during an
acute phase reaction more rapidly than those of
albumin, and it may be regarded therefore as a
"negative" acute phase reactant.
Immediately after orthotopic liver transplan¬
tation, the function of the donor liver is impaired
because of the stress of two surgical procedures
(donor and recipient) in addition to the cold and
warm ischaemic damage sustained during the
period between these operations. This study has
investigated the ability of the recently trans¬
planted donor liver to mount a stress response and
synthesize acute phase proteins, and to assess
their value as indicators of liver function im¬
mediately after liver transplantation.
METHODS AND RESULTS
The study was approved by the District Ethics
Committee and informed consent was obtained
before operation from seven consecutive patients.
Patients received routine postoperative care in the
intensive care unit and had an uncomplicated
postoperative course, except for one patient who
bled excessively and was excluded from further
study.
Serum samples were collected immediately
before orthotopic liver transplantation and after
operation on arrival in the intensive care unit,
then at 4-h intervals over a period of 24 h. Two
further samples were collected at 48 h and 72 h.
Subsequent analysis for C-reactive protein, oq-
antichymotrypsin, AAG and pre-albumin was
performed using specific immunoassay methods
[2-5].
Changes in serum concentrations of the acute
phase proteins in the 72 h after liver trans¬
plantation are shown in figure 1. There was
a marked and sustained increase in serum con¬
centrations of C-reactive protein and oq-anti-
chymotrypsin after surgery. The increase in AAG
concentration was not as rapid, with the maximal
mean values being just above the upper limit of
the normal range. Although serum concentrations
of pre-albumin increased after operation, they
remained well below the lower limit of the normal
reference range.
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Fig. 1. Mean (sem) concentrations of the acute phase proteins C-reactive protein (CRP), a,-
antichymotrypsin (ACT), c^-acid glycoprotein (AAG) and pre-albumin (PA) before surgery (pre) and
in the first 72 h after orthotopic liver transplantation (tx) in six patients. Normal ranges: CRP < 10 mg
litre-1; ACT 0.35-0.63 g litre-1; AAG 0.5-1.0 g litre-1; PA 150-355 mg litre-1.
COMMENT
Monitoring of liver function after operation is
important to detect adverse trends. This is
particularly important after liver transplantation
in patients who, in addition to the usual problems
faced by the critically ill, may have episodes of
rejection, infarction or infection. Conventional
liver function tests are measured routinely, but
alterations in enzyme and bilirubin concentrations
may be relatively non-specific, and their inter¬
pretation following liver transplantation may be
complicated by several factors [6].
Stress is a complex series of metabolic, endo¬
crine and physiological processes. The acute
phase response includes the de novo synthesis and
secretion of proteins by the liver; the rate of
production might be used to assess liver function.
The stimuli for the hepatocyte to synthesize these
proteins, and the underlying cellular mechanisms,
are not understood fully and the role of the stress
response, particularly its prognostic significance,
remains unclear. However, the stress response
may reduce tissue injury and promote healing in
association with enhanced host resistance [1].
In the immediate period after liver transplan¬
tation, when the stress response is still present,
serum concentrations of acute phase proteins
might be expected to provide an indicator of the
synthetic function of the liver, improving liver
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function being associated with increased serum
concentrations of proteins and deterioration with
decreased serum concentrations. This study de¬
monstrated that the donor liver appears to be able
to synthesize acute phase proteins, despite the
ischaemic damage sustained before transplan¬
tation. However, the response was less than that
reported previously in association with major
tissue injury or bacterial infection. The moderate
increases in acute phase proteins in our patients
may reflect both dilution of the acute phase
proteins by transfused blood and ischaemic dam¬
age to the donor liver resulting in a less than
maximal response. Alterations in liver function
may be associated with only minimal changes in
protein concentrations and therefore their prog¬
nostic value as indicators of liver function is
limited. Acute phase proteins may be used to
complement conventional liver function tests as a
guide to the function of the donor liver. However,
further studies are necessary to define their exact
role.
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Increases in oxygen consumption during administration
of dopexamine in liver failure
We report a 22-ycar-old male with u-1 antitrypsin
deficiency who developed fulminant hepatic coma pre¬
cipitated by pneumoccocal peritonitis. This was compli¬
cated by the subsequent development of a hyponatraemia
of 109 mmol/L. Urgent liver transplantation was con¬
sidered to be the treatment of choice and shortly
thereafter a donor liver became available.
Since the patient was oliguric (urine output < 20 mis/
hour) following volume resuscitation, it was decided to
use a dopaminergic agonist to improve urine output.1
Dopexamine Hydrochloride2 was infused at 1 /xg/Kg/min
and increased every 15 minutes to a maximum of 4 pg/
Kg/min. Haemodynamic variables and oxygen delivery
and consumption were measured before starting the
dopexamine and at the maximum dose (Table 1).
With increasing the dose of dopexamine there was
little change in the haemodynamic parameters or oxy¬
gen delivery however, oxygen consumption increased
markedly. Orthotopic liver transplantation occurred
three hours after this study. Histological examination of
the diseased liver revealed cirrhosis with infarction of
most of the right lobe as well as smaller infarcts in the left
lobe.
The increase in oxygen consumption can be attributed
to either a redistribution of blood llow to or within the
splanchnic bed, or to an increase in metabolic rate
induced by the administration of a sympathomimetic
agent.
Dopamine has previously been shown to increase
estimated hepatic blood flow (EHBF) under many con¬
ditions including peritonitis and haemorrhagic shock.1 4 S
The increased EHBF is usually associated with an
increased cardiac output though the percentage increase
in EHBF is greater than the percentage increase in
cardiac output, implying some selective dilatation of the
hepatic vasculature.'' Dopexamine, like dopamine, sti¬
mulates dopaminergic receptors of the DA| and DA>
subtypes, though there is considerably less affinity for
the DAi receptor than is seen with dopamine. Unlike
dopamine, dopexaminc has an action at the (T receptor.
P-receptor stimulation has been shown to increase
hepatic artery flow in dogs but the precise location of the
receptors is unclear.7 The most likely cause for the
increase in oxygen consumption seen in our patient is
an improvement of distribution of blood flow to the
Table 1 Effect of increasing dose of dopexamine hydrochloride on haemodynamics and oxygen consumption and
delivery in a patient with fulminant liver failure
Dose ofdopexamine 0 1 2 3 A
(fj.g/Kg/min)
Lt
Heart Rate 120 115 115 123 120
Mean Systemic Arterial 60 69 63 62 61
Pressure (mmflg)
Right Atrial Pressure (mmHg) 10 9 8 8 8
Mean Pulmonary Artery 15 15 14 14 14
Pressure (mmHg)
Pulmonary Capillary Wedge 15 15 15 13 13
Pressure (mmHg)
Cardiac Index (l/min/m2) 4.98 5.24 5.01 5.19 4.99
Systemic Vascular Resistance 408 470 449 423 433
(dynes/sec/cm5)
Pa02 (KPa) 22.2 14.6
Pv02 (KPa) 7.8 7
Sv02 (%) 87.5 83.9
PaC02 (KPa) 4.2 4.3
0/?fiVe7„ 1176 1176(mls/min/m-)
02 Consumption (mls/min/m2) 98 196
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splanchnic bed. including the Incr Since cirrhotic livers
have been shown t" have poital vein - hepatic vein
anastomoses, d<'pc\,mniic inav have exerted an addi¬
tional clleci in.au patient bv altering intrahepatic flow,
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Complicated diabetic ketoacidosis
The management of severe diabetic ketoacidosis (DKA)
is frequently complicated by gross systemic disturbances,
accounting for the mortality of 5-1.5%.1 We report a case
of DKA which illustrates many of these complications.
A previously healthy 27-year-old woman presented in
ketoacidotie coma. On admission she was noted to be
obese, apyrexial, dehydrated, comatose (Glasgow Coma
Scale 6), taehyeardic (100 beats/min) but normotensive.
She was profoundly acidotie (pH 0.79, PaCO. I 45kPa,
PaOj 20.7kP;i, l'I()2 0.21. base excess —.39.2 mmol/1,
arterial blood lactate 1.3 mmol/l) and ketonaemic.
Biochemical analysis revealed a plasma glucose of
38.8 mmol/l, sodium 120 mmol/l, urea 15.8 mmol/l and
amylase 1000 iu/l. The haemoglobin concentration was
I7.9g/dl and the white cell count 45.4x 10'Vl (pre¬
dominantly neutrophils).
Conventional treatment with isotonic saline, intra¬
venous actrapid and potassium chloride together with
ampicillin, penicillin and metronidazole resulted in
normoglycaemia within 10 hours but there was no
improvement in her conscious level nor her acidosis.
Blood samples screened for paracetamol and salicylate
were negative. The chest X-ray was clear and urine
microscopy and culture showed no organisms. Abdomi¬
nal and pelvic ultrasound revealed no obvious infection
nor pancreatic abnormality and cerebrospinal fluid
(CSF) was clear.
Her condition deteriorated and she was admitted to
the intensive care unit (ICU) with cardiovascular insta¬
bility (heart rate 120 beats/min, central venous pressure
21 cmH20, systolic arterial pressure 70 mmHg), respira¬
tory embarrassment (rate 40/minute and widespread
coarse crepitations) and renal failure (urine output
6 ml/hour, plasma urea 22.5 mmol/l, plasma creatinine
366 p.mol/1, urine/plasma osmolarity ratio 0.52 and
plasma potassium 7.7 mmol/l). Despite inotrope support
with dobutamine and adrenaline, she remained hypo¬
tensive. Initial haemodynamic measurements were pul¬
monary artery occlusion pressure 13 mmHg, cardiac index
4.9 l/min'.m2, oxygen delivery (D02) 747 ml/min'.m2,
oxygen consumption (V02) 112 ml/min1 .m2 and systemic
vascular resistance index 538 dynes.see/cm5.m2. Nor¬
adrenaline was started and her cardiovascular status
improved subsequently.
Over the next six hours, her diabetic control became
diflieult and infusions of up to 40 U/hour of actrapid
insulin were needed; this appeared to be related to her
catecholamine requirement. In the four hours following
admission to the ICU, she received 500 mmol sodium
bicarbonate; after this her pH remained above 7.0 with¬
out further treatment. Her plasma potassium returned
to normal though her renal function continued to deteri¬
orate in spite of dopamine and frusemide (250 mg).
By 48 hours her haemodynamic profile still suggested
sepsis and aggressive efforts were made to find a source
of infection. Examination of her ears, nose, throat,
repeat abdominal and pelvic ultrasound scans, gynaeco¬
logical assessment and abdominal laparoscopic examina¬
tion revealed no abnormality. Repeated blood, sputum
and urine cultures, viral studies and swabs from ears,
nose, throat and vagina all failed to identify an infective
source. At no stage was she pyrexial. She remained
inotrope-dependent and at 60 hours continuous arterio¬
venous haemofiltration and parenteral feeding were
started. Thereafter her condition gradually improved.
Diabetic control with insulin consistently produced
hypoglycaemia and six weeks after presentation her
blood glucose was controlled by diet alone. She was
generally well, neurologically intact and was discharged
home.
This patient illustrated many of the biochemical
abnormalities associated with severe DKA,2 namely
hyperglycaemia, deranged arterial blood gases, hypo-
natraemia, uraemia, hypophosphataemia, raised amyl¬
ase, abnormal clotting and leucocytosis in the absence of
infection. Despite standard treatment, multiple organ
dysfunction supervened. She remained profoundly acido-
tic and comatose until NaHCO^ was administered2 and
it is reassuring that, in spite of prolonged severe acid-
aemia, she made a full neurological recovery. The most
likely reason for the patient's cardiovascular instability
was septicaemia, with the underlying infection having
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PLASMA CONCENTRATIONS OF BUPIVACAINE AFTER
INTERCOSTAL NERVE BLOCK IN PATIENTS AFTER
ORTHOTOPIC LIVER TRANSPLANTATION
A. BODENHAM AND G. R. PARK
SUMMARY
Bilateral intercostal nerve blocks were performed
on 12 occasions in 11 patients after liver trans¬
plantation. Group 1 (six patients) received
bupivacaine 2mgkg1 on one occasion; in
group 2 (five patients) bupivacaine 2mgkg1
with adrenaline 1:200 000 was injected on two
occasions separated by 6 h. Arterial blood was
sampled repeatedly and analysed for total
bupivacaine concentrations by high performance
liquid chromatography (HPLC). Six patients had
bupivacaine concentrations within the putative
toxic threshold of 2-4 jig ml1. The use of
adrenaline-containing solutions neither slowed
absorption reliably nor decreased peak con¬
centrations of bupivacaine. Cumulation of bupi¬
vacaine occurred in group 2. No patient had
adverse effects attributable to the bupivacaine.
KEY WORDS
Anaesthetics local: bupivacaine, plasma concentration.
Anaesthetic techniques: intercostal.
Intercostal nerve blocks are an effective method of
providing analgesia following both thoracic and
abdominal incisions. This technique has been
used successfully at this centre for several years to
provide analgesia and reduce opioid requirements
in patients after liver transplantation. There are,
however, only limited data on the use of local
anaesthetic agents in patients with liver disease.
Patients with severe liver disease develop portal
hypertension and extensive collateral vessel for¬
mation. The effects of these enlarged vessels on
the rate of drug absorption is not known. In
addition, the ability of the recently transplanted
liver to metabolize drugs has not been established.
The long duration of action of bupivacaine
makes it the drug of choice for intercostal nerve
block. We therefore measured total plasma concen¬
trations of bupivacaine after intercostal blocks in
patients who had undergone liver transplantation.
Two groups were studied using bupivacaine with
and without adrenaline, and after single and
repeated injections.
PATIENTS AND METHODS
Eleven patients who required analgesia on the first
or second day after liver transplantation were
allocated consecutively to two groups:
Group 1 comprised six patients given a single
set of bilateral intercostal nerve blocks using plain
bupivacaine 2 mg kg-1.
Group 2 consisted of six studies in five patients
having two sets of bilateral intercostal nerve
blocks separated by 6 h using bupivacaine with
adrenaline 1:200000 (2 mg kg"1 for each set of
injections). One patient was studied on two
occasions, 4 months apart, after her first and
second liver transplant.
Approval was obtained for the study from the
hospital Ethics Committee and written informed
consent was obtained before operation from each
patient. The intercostal nerve blocks were per¬
formed when the patient was ready for tracheal
extubation, usually on the first day after operation.
A baseline blood sample was withdrawn from a
radial arterial cannula, inserted previously for
other purposes. Bilateral intercostal nerve blocks
(T5-T10) were performed using a standard
technique [1] by the same operator (A.B.). In
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smaller, wasted patients the dose of bupivacaine
was made up to a minimum volume of 30 ml
allowing an adequate volume of solution. Arterial
blood (5 ml) was sampled at 5, 10, 15, 30, 60, 120,
240 and 480 min after injection of bupivacaine. In
group 2 an extra sample was taken at 2.5 min and
the final sample taken at 360 min, immediately
before the intercostal blocks were repeated. Blood
was collected in tubes containing lithium heparin
as an anticoagulant and centrifuged at 3000 g.
Plasma was stored at — 20 °C until required for
analysis. Liver function tests (albumin, total
protein and alpha-1-acid-glycoprotein (AGP))
were measured also in a baseline serum sample.
Any adverse reactions such as changes in arterial
pressure or neurological deterioration were re¬
corded during this period. Detailed neurological
assessment was not possible because of residual
effects of opioids and benzodiazepines and the
process of tracheal extubation. Care of the patient
was, in all other respects including other drug
therapy, as described previously [2],
Bupivacaine concentrations in groups 1 and 2
were compared by Student's t test for paired data.
The relationship between bupivacaine concen¬
trations and AGP concentrations was determined
using linear regression analysis. Values are given
as mean (sem) except where indicated.
Analysis of samples
The assay was performed using HPLC as
described by Nation, Peng and Chion [3]. After
the addition of an internal standard (etidocaine),
the sample was alkalinized with sodium hydroxide
and extracted with dichloromethane. An aliquot
of extract was evaporated to dryness at 50 °C and
redissolved in a mobile phase of 1 % triethylamine
in water, adjusted to pH 3.0 with phosphoric acid
and organic modifier (30% acetonitrile) before
injection. The solution was injected onto a
150x4.6-mm column containing 5-gm ultra-
sphere "ods" and the flow rate was adjusted to
1.5 ml mim1 at ambient conditions. An ultraviolet
detector as 205 nm was used. The assay was
calibrated with spiked standards. All patients
were receiving different medications, including
morphine, midazolam, dopamine, prednisolone,
azathioprine, cefotaxime, tobramycin, nystatin,
ranitidine, folic acid and vitamin K. Control
samples of serum from other liver transplant
recipients who had not received bupivacaine
revealed no interference with the assay. In
addition to this study a further 2000 samples have
been analysed and no interference from other
substances detected [J. Goudie, personal com¬
munication]. The sensitivity of the assay was
50 ng ml-1 with a within-batch variation of 3.9 %
and a between-batch variation of 4.0%.
The AGP assay was performed by automated
turbidimetric immunoassay using an IL Monarch
analyser utilizing "Dako" antiserum to AGP.
Analysis of areas under the concentration-time
curves were performed using an "Apple Fitter"
programme. The values for 7IP and clearance in
Table I. Demographic data and presenting diagnosis of the patients in groups 1 and 2
Patient Age Weight
No. (yr) Sex (kg) Presenting diagnosis
Group 1
1 17 F 55 Chronic active hepatitis
2 56 F 45 Primary biliary cirrhosis
3 39 M 67 Sclerosing cholangitis
4 58 F 37 Primary biliary cirrhosis
5 29 F 60 Alcoholic cirrhosis
6 45 F 54 Primary biliary cirrhosis
Group 2
7 26 F 55 Primary biliary cirrhosis
(patient studied twice after
two separate transplants)
8 52 M 80 Alcoholic cirrhosis + hepatoma
9 40 F 68 Chronic rejection of previous
transplant for sclerosing
cholangitis
10 59 F 64 Primary biliary cirrhosis
+ polycystic disease
11 21 F 43 Wilson's disease
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Table II. Concentrations of plasma proteins and liver function tests in the 11 patients studied. ALT =
Alanine transaminases AGP = alpha-1-acid-glycoprotein; Alk. Phos. — alkaline phosphatase. * 1st
















Normal 30-51 61-77 0.5-1.0 2-17 7^0 30-135
range
Group 1
1 46 58 0.9 108 610 43
2 37 67 0.9 150 534 206
3 20 80 0.7 123 78 179
4 35 74 2.3 62 684 783
5 24 55 0.7 14 371 180
6 25 63 2.4 59 456 1200
Group 2
7 27 51 1.4 867 115 978*
31 45 1.6 249 674 963**
8 32 53 1.4 368 506 173
9 40 62 1.7 100 969 271
10 38 61 1.1 109 547 200
11 31 45 1.5 18 34 30
this study were not calculated, as sampling was
not carried out for the recommended three
elimination half-lives because of the need to repeat
the injections for analgesia.
results
The details of the 11 patients studied are shown in
table I. The injections were performed at a mean
time of 15.7 (sd 8.5) h after the transplanted liver
had been reperfused. The concentrations of
plasma proteins and liver function tests at the
time of each study are shown in table II.
The mean time to complete the bilateral
intercostal nerve blocks was 4.5 (sem 1.8) min.
In group 1 (plain bupivacaine) the mean
maximum concentration (Cmax) was 1.75 (sem
0.07) pg ml-1 (fig. 1). The time at which Cmax
was achieved (7max) was 5, 10 and 15 min in
three, two and one patients, respectively. The
mean value of Cmax, in group 2 (bupivacaine +
adrenaline), was 1.69 (0.35) pg mL1 after the first
injection (fig. 2). Tmax occurred at 5, 10, 15 and
30 min in one, two, two and one patients,
respectively. After the second set of injections in
group 2, Cmax was 1.99 (0.34) pg ml-1. 7max
occurred at 5, 10, 15 and 30 min in two, one, one
and two patients, respectively.
Cmax in group 1 was not significantly different
from that after the first set of injections in group
2 (P > 0.05), indicating that the use of adrenaline
containing solutions did not reliably slow ab¬
sorption. The plasma concentrations of bupi¬
vacaine had not returned to zero after 6 h in group
2, the time when the second set of injections were
performed. In addition, the area under the mean
concentration-time curve increased by 44% in
group 2 after the second set of injections. These
two factors indicate cumulation of bupivacaine.
Eight patients had serum concentrations of AGP
- 2.0
Injection
Fig. 1. Plasma concentrations of bupivacaine (mean, sem) in
group 1 after a single set of intercostal injections using bupi¬
vacaine 2 mg kg-1.











Fig. 2. Plasma concentrations of bupivacaine (mean, sem) in group 2 after two sets of intercostal
injections 6 h apart using bupivacaine 2 mg kg-1 containing adrenaline 1:200 000.
greater than the reference range (table II), but
these increased concentrations did not correlate
with the measured concentrations of total bupi¬
vacaine (P > 0.05). The patient who was studied
twice had similar plasma concentrations of bupi¬
vacaine on each occasion.
DISCUSSION
Intercostal nerve blocks using bupivacaine are an
effective method of providing analgesia following
liver transplantation and are used routinely at this
centre [2]. The technique is chosen in order to
limit the dose of opioid. There has been one other
short report of intercostal blocks after liver
transplantation using bupivacaine in three pati¬
ents [4], This study used smaller total doses of
50-100 mg, making comparison of data difficult,
but Cmax occurred at times similar to our data at
5 min, the first sampling time.
Increased plasma concentrations of local an¬
aesthetic may be a problem with intercostal blocks
[5, 6] because of the large total volumes of drug
solution required for multiple injections in a
normally vascular area. In patients with advanced
liver disease, the chest wall may have unusually
large venous vessels because of porto-systemic
anastomoses. These collateral vessels may alter
the rate of drug absorption after intercostal
injection.
The mean concentrations of bupivacaine were
within ranges similar to those reported in other
series [5-7]. There was no statistical difference
between Cmax for the two groups with and
without adrenaline. In group 1, the observation
that Cmax occurred at 5 min in two patients not
given adrenaline suggests that Cmax may have
occurred earlier in some of these patients. In
group II an additional sample was collected at
2.5 min, following reports of Cmax occurring
early [7], No Cmax values were seen at 2.5 min in
group 2. 7'max was variable between patients in
both groups, but these cannot be compared
reliably because of the spacing of sampling times
and the relatively small numbers of patients
studied. The addition of adrenaline to the bupi¬
vacaine solution did not consistently increase the
time taken to reach Cmax and this is in dis¬
agreement with other studies measuring arterial
concentrations of bupivacaine after intercostal
injection [7], The abnormal vessels of patients
with liver disease may not vasoconstrict normally
in the presence of injected adrenaline. In addition,
the size of the collateral vessels may not be
important. Studies in children with extensive
collateral vessel formation secondary to co¬
arctation of the aorta have demonstrated that
absorption of bupivacaine is the same as that of
children with other forms of congenital heart
disease without collateral vessel formation [6].
No adverse reactions were seen in these pati¬
ents, despite plasma concentrations of bupi-
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vacaine within the putative toxic range in six
patients (two in group 1, four in group 2 following
both sets of injections). This may reflect an
inaccuracy of the reported toxic threshold of
2-4 pg ml"1 [8, 9] for bupivacaine. The reported
toxic values have been derived from studies using
short i.v. infusions of bupivacaine to obtain steady
state concentrations. However, differences in the
analytical method, sampling sites and infusion
regimen used in these studies make interpretation
difficult [10]. Alternatively, the lack of adverse
side effects may be a reflection of residual
benzodiazepine sedation, which had been
administered before tracheal extubation [11]. All
patients in the study were rousable but had
residual sedation and analgesia, making neuro¬
logical assessment difficult. In addition, the total
bupivacaine concentrations measured in our study
may not reflect the free, non-protein-bound
concentration of the drug which is thought to
cause CNS side effects [12].
Bupivacaine is bound extensively to AGP [13],
an acute phase reactant with concentrations that
were increased in these and other patients fol¬
lowing liver transplantation, because of acute
surgical stress and liver disease [Shelly, Walker,
Burns and Park, unpublished observation]. In the
presence of increased concentrations of AGP,
increased total concentrations of bupivacaine
would be measured, but toxicity might not occur,
as the free concentration would be less. The
concentrations of AGP were greater than the
reference range (0.5-1.0 g litre"1) in seven of the
patients in this study, but did not correspond to
those with increased total bupivacaine concen¬
trations. Unfortunately, it was not possible to
measure free bupivacaine concentrations or the
differing subtypes of AGP [14, 15] and their
differing effects (if any) on drug binding. The
relatively normal albumin and total protein con¬
centrations reflect aggressive treatment of hypo-
albuminaemia by infusion of albumin-containing
solutions in the perioperative period.
Other factors also may have contributed to the
increased plasma concentrations of bupivacaine.
Uptake of bupivacaine by the lungs is significant
[16] and may be inhibited competitively by drugs
such as propranolol [17]. Three patients had been
receiving propranolol for control of portal hy¬
pertension before liver transplant. However, these
three patients did not develop consistently greater
bupivacaine concentrations than the other pati¬
ents studied. The presence of functional intra-
pulmonary shunting in patients with liver disease
[18] may also increase the availability of the drug
to the systemic circulation. This has been shown
experimentally in animals, using lignocaine [19].
Bupivacaine is metabolized by the liver, with a
lesser hepatic extraction ratio than lignocaine
[10,20]. Little is known of drug metabolism
shortly after liver transplantation, but studies to
date have shown both normal and abnormal
pharmacokinetics for several drugs. The trans¬
planted liver is subject to insults during two
operations (removal from the donor and insertion
into the recipient), with a varying ischaemic time
between. Clinical studies have shown that clear¬
ance of lignocaine may be impaired in patients
with cirrhosis [21], after hepatectomy [22], and
during viral hepatitis [23]. No data exist for
bupivacaine.
Extrapolation of these results to other patients
with liver disease requires caution, as differences
in the mechanisms of liver injury may alter its
capacity to eliminate bupivacaine. However, the
results suggest that caution may be necessary in
this group of patients when intercostal blocks are
performed. Some patients may achieve potentially
toxic plasma concentrations of bupivacaine at a
variable time after performing the intercostal
nerve blocks. The use of adrenaline-containing
solutions did not consistently reduce the speed of
absorption or the maximum concentration of
bupivacaine. Furthermore, bupivacaine cumu¬
lation after repeated intercostal nerve blocks
within 6-8 h may occur in some patients following
liver transplantation, and possibly others with
hepatic dysfunction.
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CHANGES IN ALVEOLAR-ARTERIAL OXYGEN PARTIAL
PRESSURE DIFFERENCE DURING ORTHOTOPIC LIVER
TRANSPLANTATION
K. R. BURCHETT, M. F. SMITH AND G. R. PARK
SUMMARY
Changes in the alveolar-arterial oxygen partial
pressure difference (PA02—Pa0J were measured
in 39 patients undergoing orthotopic liver trans¬
plantation without veno-arterial or veno-venous
bypass. The operation can be divided into an
initial dissection phase, an anhepatic phase when
the hepatic artery, portal vein and vena cava are
damped, and a post-anhepatic phase after the
vascular damps are released. There was an initial
increase in (PAq2— Pa0J during the dissection
phase, followed by an immediate decrease when
the liver was removed. This decrease continued
throughout the anhepatic period, but a further
increase in(PA02—Pa0J occurred after release of
all the vascular damps and during abdominal
closure.
KEY WORDS
Oxygen: (PA02—PaoJ. Surgery: liver transplantation.
The observation during an orthotopic liver trans¬
plant operation that the arterial oxygen tension
(PaQ ) remained low despite increasing the in¬
spired oxygen concentration (Pio2) until removal
of the liver, when a marked increase in Pa() was
noticed, prompted us to review the anaesthetic
records of the previous 20 liver transplant opera¬
tions. This suggested an improvement in arterial
oxygenation during the anhepatic phase. We
therefore studied prospectively 40 consecutive
patients undergoing liver transplantation and
measured the alveolar-arterial oxygen partial
pressure differences (Pa02 — Pa0,) at various stages
during the procedure.
patients and methods
We studied 40 consecutive patients undergoing
orthotopic liver transplantation. The anaesthetic
technique used was at the discretion of the
anaesthetist, and consisted of artificial ventilation
using either air-oxygen and isoflurane or nitrous
oxide-oxygen with isoflurane, fentanyl, or both.
Neuromuscular block was maintained by an
infusion of either atracurium or vecuronium.
As part of the routine monitoring of these
patients, arterial blood samples were taken and
analysed immediately for oxygen (PaQJ and
carbon dioxide (Paco,,) tensions (Corning 178
pH/blood-gas analyser) at the following stages
during the procedure: (A) after induction of
anaesthesia, and before the start of surgery; (B)
during dissection of the liver; (C) at the beginning
of the anhepatic phase; (D) at the end of the
anhepatic phase (after unclamping of the supra-
hepatic vena cava and the hepatic portal vein); (E)
after full restoration of inferior vena cava flow and
(F) during abdominal closure. The inspired
oxygen concentration (Fi0J was measured con¬
tinuously throughout the operation (Engstrom
Eliza Duo 02/C02 analyser). The values for Pa0i
and PaC02 were corrected for the patient's core
temperature at the time of sampling using a
standard nomogram [1], and the alveolar oxygen
tension was estimated using the formula Paq =
Pi02-(PaC02/P) + (Pac02.Fi02.(1-/?)/P). The
respiratory quotient, R, was assumed to be 0.8,
and it was assumed that Pacc,2 = Pacc,2.
Changes in blood volume and composition were
minimized by utilizing invasive haemodynamic
monitoring and measurements of packed cell
volume at each time point.
Data were analysed using Student's paired t
test adjusting for the Bonferroni inequality [2].
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Table I. Mean (sem) F/0j, Paco , Pa0i. A = After induction of anaesthesia; B = during the dissection
phase; C = at the beginning of the anhepatic phase; D = at the end of the anhepatic phase; E = after
the inferior vena cava is undamped; F = on completion of the operation
A B C D E F
Fl0> 0.42(0.02) 0.42(0.01) 0.43(0.02) 0.44(0.01) 0.43(0.01) 0.44(0.01)
PaCo (kPa) 3.9(0.13) 4.0(0.14) 3.8(0.11) 4.8(0.11) 4.5(0.12) 4.4(0.12)
PaG '(kPa) 21.4(1.61) 18.5(1.64) 22.5(1.53) 24.2(1.21) 23.0(1.2) 20.1(1.56)
Fig. 1. Mean (sem) changes in (Paq —PaQ) liver transplan¬
tation in 39 patients. A = After induction; B = during liver
dissection; C = start of anhepatic phase; D = end of an¬
hepatic phase; E = inferior vena cava anastomosis; F = ab¬
dominal closure. Statistically significant differences (P <
0.01): *B-D and D-F; fE-F.
Four comparisons were made (A with B, B with D,
D with F and E with F). All data are presented as
mean (sem).
results
Complete records were available for 26 female and
13 male patients, with a mean age of 33 yr (range
1-63 yr). There was an initial decrease in Pa„„ and
an increase in (Pa0i — Pa02) during dissection of
the patient's liver (A to B) from 16.0 (1.5) to 19.1
(1.6) kPa (table I, fig. 1). The increase in
(Pa02—Pa0z) failed to reach statistical significance.
During the anhepatic phase there was a decrease
in (Pa02 — Pa0 ) which continued to a nadir at D
(14.3 (1.6) kPa). After revascularization of the
donor liver, the alveolar-arterial gradient again
increased, and this continued through E (15.1
(1.5) kPa) to abdominal closure at F (19.1 (1.8)
kPa). The differences between B and D, E and F,
and D and F were significant (P < 0.01). No
correlation was found between the changes in
(Pa„2 —Pa„,) and the anaesthetic technique used.
Packed cell volume and the amount of fluid
transfused at each stage are shown in table II.
Despite the large volumes transfused, there was
little change in arterial pressure. The haematocrit
increased during the anhepatic period, because of
the infusion of blood with a high haematocrit
from the cell saver system used for autotransfusion
[3].
discussion
An increase in (PAq2 —Pa0z) during routine,
uncomplicated anaesthesia is well recognized, and
is attributed to a 20% decrease in functional
residual capacity (FRC) and an increase in
ventilation/perfusion (V/Q) mismatch. The re¬
duction in FRC with general anaesthesia occurs
during artificial and spontaneous ventilation, but
increasing the FRC following induction of an¬
aesthesia does not reverse abnormal gas exchange.
Atelectasis occurs in the dependent parts of the
Table II. Mean (sem) packed cell volume (PCV), systolic arterial pressure (SAP) and volume of fluid
transfused (Fluid). A = After the induction of anaesthesia], B = during the dissection phase; C = at the
beginning of the anhepatic phase; D = at the end of the anhepatic phase; E — after the inferior vena cava
is undamped; F = on completion of the operation
A B C D E F
PCV(%) 30.9(1.1) 32.1(1.1) 36.6(0.9) 39(1.0) 33.8(1.2) 34.5(1.1)
SAP (mm Hg) 111(3.2) 116(3.1) 105(3.0) 106(4.5) 111(4.6) 111(3.3)
Fluid (ml) 226(87) 1420(219) 3345(456) 5339(649) 6278(739) 10833(2478)
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lung, the low compliance of this part and the
immobility of the adjacent portion of the dia¬
phragm preventing full expansion of the de¬
pendent lung [4]. (Pa02 —Pa02) is increased also by
a reduction in cardiac output, an increase in Pa0i
or a reduction in haemoglobin concentration [5].
The increase in (Pa0i —Pa„j during the dissection
phase and towards the end of the procedure
during abdominal closure may be explained by an
initial reduction in FRC because of cranial
displacement of the diaphragm, leading to atel¬
ectasis in the dependent parts of the lungs and
consequent increase in V/Q mismatch. When the
liver has been removed (during the anhepatic
phase) this process may be reversed because the
reduction in abdominal contents and surgical
retraction allow freer movement of the dia¬
phragm. These mechanisms result in an increase
in FRC, or a decrease in atelectasis, or both, in the
dependent part of the lung, which may account
for the gradual improvement in the (Pa02—Pa0j).
These factors would be reversed when the donor
liver was in place, and may explain the subsequent
increase in (Pa0s, —Pa02). The reduction in cardiac
output at the beginning of the anhepatic phase as
the vena cava is cross clamped [6] may be expected
to increase (Pa0,—Pa02), but the reduction in
oxygen consumption of some 25 % seen on
removal of the patient's liver [7] may balance this
to some extent. If the reduction in oxygen
consumption results in an increase in the mixed
venous oxygen content, and if there is a significant
pulmonary shunt, there should be an increase in
arterial oxygenation, as the oxygen tension in the
shunted blood would have increased and have a
smaller effect in reducing Pan>. However, it is
more likely that the reduction in cardiac output
results in a decrease in mixed venous oxygen
saturation, albeit less than expected because of the
decrease in oxygen consumption. The most likely
explanation for the observed improvement in
(Pa0> — PaDJ is thus an improvement in the V/Q
ratio secondary to an increased movement of the
diaphragm. An alternative, but unlikely, explan¬
ation is that the liver is secreting a vasoactive
substance which is affecting the pulmonary vascu¬
lature.
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R. M. Kacmarek: Inspiratory pressure support
quire lengthy ventilator management and those pa¬
tients acutely ventilated for respiratory failure where
high peak airway pressures may be a concern, or who
consistently oppose volume-limited approaches to
ventilation. As with any new therapeutic modality, dis¬
cussion seems to generate more questions than an¬
swers. The introduction of IPS raises many issued con¬
cerning approaches to weaning and methods of opti¬
mizing ventilatory muscle function, as well as provid¬
ing ventilatory support in general. The data provided
by Tokioka et al. will clarify some of the questions
about its physiologic effects and application. Its use
should be encouraged but should be based on avail¬
able scientific data.
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Abstract. Successful organ transplantation offers pa¬
tients with end stage organ failure the chance of a nor¬
mal life. The recognition of brain death allowed the
use of beating heart donors and this has enabled mul¬
tiple organ procurement from a single donor. Suitable
patients with severe brain injury resulting in brain
death, who may be potential organ donors, are to be
found on both neurosurgical and general intensive
care units. The pathophysiological results of brain
death are similar, irrespective of the underlying cause.
Severe brain injury may result in the loss of tempera¬
ture regulation, and the development of diabetes in¬
sipidus and cardiovascular instability. The manage¬
ment of brain injury before death often results in ab¬
normalities of fluid balance, due to fluid restriction
and diuretic therapy. Other problems such as acute en¬
docrine failure and the impact of their correction on
ultimate organ function remains to be elucidated.
Good donor maintenance in the intensive care unit
and operating theatre is essential if optimal function
of the transplanted organ is to occur.
Key words: Organ donor - Critical care
The first successful transplantation of organs in hu¬
mans took place in 1954 with the transfer of a kidney
from one identical twin to another [1], This followed
the first reported human renal transplant by Yoronoy
in 1936 and later attempts in the early 1950s. Shortly
thereafter kidneys were successfully transplanted from
non-identical siblings using ionising radiation to pro¬
vide immunosuppression. Since these early beginnings
many different organs have been successfully trans¬
planted. The kidney is able to withstand periods of
ischaemia at body temperature for up to one hour
(warm ischaemic time) and still function satisfactorily
after transplantation. This allows the removal of kid¬
neys after the circulation has ceased. The heart, liver
and lungs will tolerate only short periods of warm
ischaemia before irreversible cellular damage occurs.
These organs must be isolated whilst the donor circu¬
lation is intact and cooled with cold perfusion fluids
whilst in situ. The concept of brain stem death was co-
incidently becoming accepted at the same time as
these needs were recognised and this has allowed the
use of beating heart organ donors.
Brain death was first described by Mollaret and
Goulon in France during 1959 [2] and was formally
accepted in the United Kingdom (UK) during 1976 [3].
The initial aim was to to prevent the unnecessary
prolongation of therapy when a hopeless prognosis ex¬
ists. Since then large studies have repeatedly shown the
validity of the diagnosis of brain death [4].
The success of transplantation has increased the
demand for organs which has resulted in the removal
of multiple organs from one donor. Studies after mul¬
tiple organ procurement have shown no individual dif¬
ference in organ function when compared with single
organ donation [5]. It has been estimated that there
are approximately 4000 potential donors per year in
the UK but only 15-20% of these actually donate or¬
gans [6, 7], These figures are derived from epidemio¬
logical studies of the incidence of subarachnoid haem¬
orrhage and severe head injuries. They do not take in¬
to account regional variations in medical practice or
pathology. In addition changes in patient admissions
relating to seat belt and drunk driving legislation may
have reduced the incidence of major head injury. As¬
sertions, based upon these figures, that many potential
organ donors are missed each year [8] may not be true.
Studies in this centre have demonstrated that few suit¬
able donors are lost (unpublished observations). The
exact numbers of potential organ donors in the UK is
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still unknown and it is hoped that a national study in
1989 will provide this information.
It is vital, for optimal organ function after trans¬
plantation, that the donor organs are kept in good
condition [9] with particular emphasis placed on the
maintenance of organ perfusion. Furthermore, if dur¬
ing life, the patient wanted to donate organs then the
medical team have an obligation to ensure that organs
are in the best possible state for the recipient.
The diagnosis of brain death
In the UK the donor must have satisfied the brain stem
death criteria as defined by the Medical Royal Colleg¬
es in 1976 [3]. Other countries in the western world
have set similar criteria. In the UK these criteria are
based on clinical findings [10—12] and do not include
electroencephalograph (EEG) examination and cere¬
bral blood flow measurements that are mandatory
elsewhere [13, 14]. The causes of death in beating
heart donors during one year (1987), as reported to the
United Kingdom Transplant Service, are shown in Ta¬
ble 1.
Tests for the criteria in the UK must be performed
by 2 consultants or a consultant and senior registrar,
who must be clinically independent and unconnected
with the transplant team. The diagnosis must be cer¬
tain, the patient having suffered severe and irreversible
brain damage, the aetiology of which must be known
and be totally dependent upon artificial ventilation. If
any doubt exists then the diagnosis of brain death
must not be made. Hypothermia, metabolic and endo¬
crine abnormalities should be excluded. Prolonged
drug action including alcohol should always be con¬
sidered and can only be excluded by the passage of
time. Measurement of plasma concentrations of seda¬
tive and analgesic drugs has been shown to correlate
poorly with central effects [15] and cannot be relied
Table 1. The causes of death in beating heart organ donors during




Head injury (road traffic accident) 188
Head injury (other causes) 94











Table 2. Clinical criteria for diagnosing brain death in the United
Kingdom
Known cause of irreversible and severe brain injury
Absence of hypothermia, electrolyte and endocrine abnormalities
No residual sedative drug effects
No pupillary response to light
Absent corneal reflex
Absent caloric responses
No motor response within distribution of cranial nerves
No gag or bronchial reflex
Apnoea in the presence of adequate PaC02 (6.65 kPa/50mmHg)
upon. The tests used to confirm brain death are sum¬
marised in Table 2 and must be repeated by the same
two doctors. The exact timing of the second set will
vary according to the clinical condition of the patient
and may be up to 24 h from the first set. Inevitably
some patients will become asystolic whilst the diagno¬
sis is awaited but may be suitable for cadaveric organ
donation if consent has been granted.
Prolonged elimination of drugs such as the ben¬
zodiazepines and opiates in critically ill patients is in¬
creasingly recognised [16-19], The pharmacokinetic
and pharmacodynamic effects of hypotension, hypo¬
thermia and endocrine failure on sedative and analge¬
sic drugs has not been studied in the brain dead pa¬
tient, but delayed drug elimination must be consid¬
ered. In addition 6-10% of the population have been
demonstrated to have pharmacogenetic abnormalities
leading to delayed drug metabolism [20, 21]. The use
of the specific opiate and benzodiazepine antagonists
naloxone and flumazenil has been proposed as a test
to exclude drug accumulation.
Improvement in conscious level, as shown by the
return of reflexes or purposeful movements within the
cranial distribution, after the administration of these
antagonists disproves brain death. Conversely, with
the lack of current clinical information, no improve¬
ment cannot guarantee lack of residual sedative ef¬
fects. If there is doubt about the presence of sedative
drugs then the diagnosis of brain death cannot be
made.
Adverse effects of the two antagonists on
haemodynamics and intracranial pressure make their
use in the brain injured patient dangerous [22, 23]. If
they are to be used then this should be postponed until
all other tests have demonstrated brain death. A pe¬
ripheral nerve stimulator should be used if the patient
has renal failure and muscle relaxants have been used
to exclude prolonged myoneural blockade.
Ventral pontine infarction ("the locked in syn¬
drome"), idiopathic polyneuritis (Guillain-Barre syn¬
drome), and brain stem encephalitis have been listed as
conditions mimicking brain death [24]. The "locked in
syndrome" is characterised by retained consciousness,
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spontaneous respiration and vertical eye movements
[25]. Polyneuritis has a characteristic history and pre¬
sentation, consciousness is not lost although all mus¬
cle groups may be paralysed. Brain stem encephalitis
is characterised by rousable stupor and retained pur¬
poseful limb movements [26]. All these conditions dif¬
fer from the common causes of brain death (traumatic
head injury, intracranial haemorrhage and cerebral
hypoxia) in that they lack a defined severe cerebral in¬
jury as stipulated in the critera. Furthermore, if a care¬
ful clinical examination is performed patients with
these conditions will not fulfill the criteria either.
Time of death in the UK is legally defined as the
time when the second set of tests has confirmed brain
death. Details of testing are best documented on a sin¬
gle form, variations of which are available in many
hospitals.
Consent to organ donation
Consent may have been granted before death occurred
and this will usually have been recorded on a donor
card. If the patient carried a donor card there is no le¬
gal requirement to discuss consent with the relatives
but it is usual and recommended practice to do so. Al¬
ternatively permission may be obtained from relatives.
This is best discussed with them after the first set of
tests has been performed. Waiting until after the sec¬
ond set of tests has been completed can result in un¬
necessary distress for the relatives and delay in obtain¬
ing the organs. When brain death and organ donation
are being discussed with relatives the concept of the
beating heart donor should be clearly explained. This
will avoid the possibility of future distress should the
media hightlight the issue at a later date.
If there are no relatives, the Hospital Administra¬
tor (as the legal possessor of the body) may grant per¬
mission to donate organs. Where the nature of the pa¬
tient's death requires statutory reporting, the consent
of the Coroner, Procurator Fiscal or Medical Examin¬
er may need to be obtained. This should also be
sought after the first set of tests to avoid later delays.
Both good and bad publicity have surrounded the
practice of organ donation leading to fluctuations in
supply but there is still a large deficit of donor organs.
Many people wish their organs to be donated after
death but may not communicate this to their next of
kin. In The UK an "opting in" system is practiced in
the form of widely available donor cards. These were
at one time issued as part of the driving license. This
latter practice has been withdrawn to comply with Eu¬
ropean Economic Community (EEC) regulations. Do¬
nor cards have not been successful due to low accep¬
tance rates by the public or the cards not being carried
or lost at the time of accident or hospital admission.
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"Opting out" procedures have been implemented in
some countries where the individual have to register
on a central computer that they do not wish to donate
organs.
"Required request" has been introduced as federal
law in many states in the USA [27, 28] but there is no
scientific evidence that the supply of donors has in¬
creased as a result. This legislation requires that the
physician looking after a potential organ donor dis¬
cusses the possibility of organ donation with the rela¬
tives. A compromise has been suggested in the form of
"required discussion" where physicians must discuss
potential donors with the local transplant team who
could then approach the relatives [6],
At present in the UK it is usually a senior member
of the medical team looking after the patient who asks
for consent. They should have previously met the rela¬
tives and discussed the poor prognosis. The majority
of relatives will gain some comfort out of the act of
donating organs and this provides some relief from an
otherwise tragic situation [29], some may even feel ag¬
grieved if not approached about donation. A volun¬
tary group "BODY" (British Organ Donor Society1)
has recently been set up in the UK to offer help to rela¬
tives in these situations. Transplantation programmes
are more successful in children than adults but are
hampered by the lack of donors in children under five
years. Children may cause particularly strong emo¬
tions both in favour and against organ donation.
Organ retrieval
The UK Transplant Service (UKTS) in Bristol main¬
tains a computerised record of all patients in need of
organ transplantation and acts as a coordinating cen¬
tre for the use of organs. Local organisation of the
surgical organ retrieval is performed by regional trans¬
plant coordinators. The different organs retrieved
from a single donor may be used in several different
centres around the UK. Organs are also exchanged
throughout the EEC. Within Europe there are a num¬
ber of different coordinating organisations including
Eurotransplant (the Benelux countries, FRG and Aus¬
tria), France-Transplant, Scandia Transplant, Swiss
Transplant, North Italy Transplant, Barcelona Trans¬
plant and Luso Transplant (Portugal). The activities of
these organisations have been reviewed in depth [30].
Unavoidable delays at the transplantation centre
may be seen as procrastination by the donor hospital
and may lead to frustration. These delays may be caus¬
ed by the difficulties in organising several retrieval
teams simultaneously and the frequent shortage of
1 "BODY", Balsham, Cambridge CB1 6DL, England, Tel.:
(0223)893636
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ICU bedspace for the recipient. Early referral of po¬
tential donors may reduce later delays to a minimum.
Emotional differences may exist between the medi¬
cal personnel looking after the potential donor who
feel their therapeutic efforts have failed and the mem¬
bers of the transplant team who are encouraged by the
opportunity to help another patient. These differences
have, on occasions, led to misunderstandings and both
groups need to appreciate the other's feelings if these
problems are to be prevented in the future.
Criteria for organ donation
A few absolute contraindications apply to all potential
donor organs including Hepatitis B infectivity, the
demonstration of antibodies to human immune defi¬
ciency virus (HIV), other known viral infections, a his¬
tory of intravenous drug abuse, malignancy (apart
from primary central nervous system (CNS) tumours)
and concurrent bacterial sepsis (Tables 3 and 4). The
potential donor who is known or suspected of being
an active promiscuous homosexual should be carefully
considered. It is possible to be infective with HIV de¬
spite negative serology (see below). The decision to use
organs in these situations can only be resolved by indi¬
vidual discussion of each case with the surgeon repon-
sible for the recipient operation. Age, diabetes mellitus
and the presence of other disease processes are relative
contraindications. Some organs which do not fulfil
the usual criteria may be used if there is a desperate
need, such as in a patient with fulminant hepatic fail¬
ure.
Kidney donors should have a urine output greater
than 0.5 ml/kg/h and normal plasma urea and
creatinine concentrations. However, kidneys have been
sucessfully transplanted after a period of anuria or
oliguria in the donor [31].
The potential heart donor must be carefully as¬
sessed for ischaemic and other cardiac disease. The
history, clinical examination, chest X-ray and ECG ex¬
amination must all be within normal limits. No period
of prolonged cardiac arrest should have occurred and
the heart should not require significant inotropic sup-
Table 3. General criteria for organ donation
<70 years




Hepatitis B antigen negative
HIV antibody negative
No widespread atherosclerosis
No trauma, infection or chronic disease in organ to be
transplanted
Free of malignant disease except primary CNS
Table 4. Specific criteria for individual donor organs
Corneas <90 years
No past history of intraocular disease or surgery
May be removed up to 12 h after cessation of the
circulation
Kidneys <70 years




Satisfactory donor height, weight, abdominal girth
Liver function tests normal
No alcohol abuse
Heart < 50 years
Satisfactory donor height, weight, chest cir¬
cumference
Chest X-ray and ECG normal
No long period of cardiac arrest
High dose inotropic support not required
Heart/lung As for heart plus:
No pulmonary trauma or infection
Artificial ventilation less than 24 h if possible
Good gas exchange required FIO2<30%
Satisfactory thoracic measurements for recipient
Non-smoker
Heart valves < 60 years
No history of valve disease
May be removed up to 12 h after cessation of the
circulation
Pancreas < 50 years
Normal plasma amylase
No family history of diabetes mellitus
3 In certain instances kidneys can be removed from donors who are
anuric/oliguric
port. Most heart transplant units will not accept do¬
nors over the age of 50 years because of the high inci¬
dence of unrecognised ischaemic heart disease.
Lung donors require special attention. Pulmonary
gas exchange must be good and a fractional inspired
oxygen concentration of less than 30% inspired oxy¬
gen, to achieve normal arterial oxygen tensions, is re¬
quired. The trachea should ideally have been intubated
for less than 24 h because of the rapid bacterial coloni¬
sation of the airways in artificially ventilated patients.
The match of donor lung size to that of the recipient
pleural cavity is important and guidelines exist for
measuring the lung size from the chest X-ray. These
are available from transplant coordinators.
Donor transmitted disease
Transmitted bacterial infection should be avoidable by
careful screening of donors for clinical and laboratory
signs of sepsis and the use of routine prophylactic
broad spectrum antibiotics during organ procurement.
Viral and protozoal infections are more of a problem
due to their silent carriage in donor organs, and once
recognised, the lack of effective drugs for their treat-
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ment. Screening for hepatitis and HIV is routinely
performed in potential donors. However, using cur¬
rently available assays, seroconversion occurs several
weeks after primary infection. Antibody titres against
HIV may be diluted by massive blood transfusion and
blood products may themselves transmit infection to
the donor. Testing the blood samples originally sent to
the transfusion laboratory for crossmatching when the
patient was first admitted may be helpful in such
cases. Thus tests failing to demonstrate antibodies to
HIV in donors cannot exclude HIV infection. Both
HIV [32] and Hepatitis B [33] have been transmitted
via transplanted organs and are likely to run a fulmi¬
nant course in the immunosuppressed patient.
Cytomegalovirus and toxoplasmosis gondii both
exist in latent forms in the normal population and may
be reactivated in the immunosuppressed patient, par¬
ticularly in the presence of other infections [34—36].
Both organisms may be transmitted to seronegative re¬
cipients via infected donor organs or blood transfu¬
sions and subsequently cause a primary infection. In
the immunosuppressed patient both organisms may
give rise to life threatening infections. Heart and
heart/lung recipients appear particularly at risk from
these organisms; some transplant units routinely
screen all donor organs for them and then avoid giving
seronegative recipients seropositive organs or blood
[37]. Pyrimethamine may be given prophylactically to
prevent toxoplasmosis gondii infection in mismatched
donors [38].
Donor maintenance
After the criteria for brain stem death have been satis¬
fied and consent obtained, patient care becomes do¬
nor maintenance and there is a change in emphasis
from cerebral to donor organ protection. Failure to en¬
sure that the organs are in optimal condition on re¬
moval may result in graft failure or malfunction in the
recipient. Special problems arise when managing these
donors, due to the nature of the severe intracerebral
damage and resultant disturbances of cardiovascular
function, temperature regulation and diabetes in¬
sipidus.
The cardiovascular system
Hypotension is a common finding in the brain dead
patient. The vasomotor centre is damaged in common
with the rest of the brain stem resulting in progressive
vasodilatation. Dehydration from fluid restriction and
diuretic administration is a recognised treatment for
cerebral oedema and may result in hypovolemia. Myo¬
cardial function has also been shown to deteriorate in
the brain dead baboon with increasing anaerobic me¬
tabolism [39], Bradycardias are common in the pres¬
ence of severe cerebral injury due to loss of sympathet¬
ic drive. The destruction of the nucleus ambiguus in
the brainstem abolishes resting vagal tone, therefore
atropine fails to reverse bradycardia in this situation
and this has been used as a diagnostic test for brain
stem death [40, 41]. Bradycardias continue to respond
to sympathomimetic drugs which act directly on beta-
adrenergic receptors in the heart such as isoprenaline.
The first step in the correction of hypotension is to
expand the intravascular volume using the measure¬
ment of central venous pressure (CVP) as a guide to
adequate replacement. Urine output and core to
peripheral temperature gradients are additional useful
guides in this situation. Blood losses should be re¬
placed with whole blood or packed cells to maintain
a haematocrit of 30%. This haematocrit maximises
oxygen supply by optimising the balance between oxy¬
gen transport by the red blood cell mass and blood
flow related to changes in viscosity [42], The choice of
other fluids for the correction of hypovolaemia is con¬
troversial, particularly when large volumes need to be
given quickly to resuscitate a hypotensive donor. At
this centre a modified gelatin solution is used but it re¬
mains to be determined whether crystalloid or colloid
solutions are better in this situation. If a low blood
pressure persists after correction of hypovolaemia the
circulation may be supported by infusion of an in¬
otropic agent. Dopamine is currently the most popular
drug because it causes renovascular dilatation at doses
up to 5 pg/kg/min. Higher doses of it and other in-
otropes lead to progressive renal and systemic
vasoconstriction. Drugs with predominantly vasocon¬
strictor properties (eg. aramine, ephedrine, metarami-
nol) should only rarely be required if the above steps
are followed. Their inappropriate use may cause splan¬
chnic vascoconstriction reducing liver and kidney per¬
fusion. With worsening brain damage it may well be¬
come impossible to maintain an adequate circulation
[4], The blood pressure should not be considered in
isolation, as a maximally vasodilated circulation may
provide good organ perfusion despite low measured
blood pressures.
Fluid balance
Fluid restriction and diuretic therapy are routine prac¬
tice in many units looking after acute neurological in¬
juries. Diabetes insipidus, glycosuria (due to steroid
therapy), and hyperthermia (before brain death) are
also common and increase water losses. When assess¬
ing organ donors, fluid intake and losses should be
calculated for the previous period of intensive care.
Clinical assessment of skin turgor and mucous mem¬
brane hydration, together with measurement of
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peripheral temperature, urine output and central ve¬
nous pressure and the laboratory estimation of plasma
urea and electrolytes and haematocrit guide fluid re¬
placement.
The urinary losses in diabetes insipidus should be
replaced by 5% dextrose with added potassium [43] or
preferably with a solution based on the measured uri¬
nary losses of electrolytes. The inappropriate use of
0.9% sodium chloride or plasma expanders containing
0.9°/o sodium chloride over a period of days may lead
to progressive hypernatraemia.
Temperature control
Extensive damage to the brain stem causes loss of the
normal central control of body temperature, the body
effectively becoming poikilothermic. Without control
of the temperature by passive warming the donor tem¬
perature will fall to that of its environment. Hypother¬
mia is harmful as it causes progressive vasoconstric¬
tion and cardiac instability as the core temperature
falls. Monitoring of body core temperature should be
carried out and steps taken to conserve heat. Intrave¬
nous blood and fluids should be warmed, inspired gas¬
es should be heated and humidified, the donor should
be placed on a warming mattress and covered by re¬
flective insulating blankets.
Endocrine failure
The incidence of posterior pituitary failure manifest
by diabetes insipidus is high in brain death [44]. Au¬
topsy findings in such cases have shown necrosis, in¬
farction or oedema of the pituitary as a consequence
of the initial injury [44]. Polyuria results from lack of
antidiuretic hormone with excretion of large volumes
of dilute urine and this needs to be replaced on an
hourly basis if marked fluid depletion is not to occur.
Fluid therapy is discussed elswhere in the text. A
diuresis greater than 150ml/h in an adult can be con¬
trolled using vasopressin or its synthetic analogues.
Early use of vasopressin considerably simplifies the
fluid management of these patients. Vasopressin may
be effectively given as intramuscular injections or a
low dose infusion of 1—2 units per hour [45]. The
synthetic form dDAVP is more potent as an an¬
tidiuretic, has a longer duration of action and has less
vasoconstrictor properties.
It would be surprising if anterior pituitary func¬
tion was not damaged in a similar fashion to posterior
pituitary function when brain death occurs and this
has been confirmed experimentally in animals with
brain stem injury [39], Studies in humans have been
less clear. Hall et al. [46] measured thyroid stimulating
hormone, prolactin and Cortisol in 5 patients with
brain death and could demonstrate no abnormality ex-
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cept loss of the diurnal Cortisol variation. Novitsky et
al. [47] measured triidothyronine (T3), insulin and
Cortisol in 21 brain dead patients and found a decreas¬
ed T3 and a low normal Cortisol and insulin concen¬
tration. On the basis of this and their animal work
they gave T3, Cortisol and insulin to all their subse¬
quent organ donors and appeared to have less cardio¬
vascular and metabolic problems in them, compared
to historical controls who did not receive hormone
therapy. This study was both uncontrolled and retro¬
spective with the attendant methodological problems
but does indicate the need for further studies in this
area.
Protection of organ function
In addition to the maintenance of adequate blood
pressure, cardiac output and the avoidance of
vasoconstriction specific protective treatments for in¬
dividual organs are used. Renal protection is thought
to be aided by low dose dopamine (2 pg/kg/min),
mannitol infusions and frusemide (10 mg intravenous
boluses). Most transplantation units give mannitol as
a bolus of 20 g over 30 min immediately before kidney
removal. Adequate flushing of kidneys before removal
is important to wash out residual red cells. Handling
of the renal vessels during donor nephrectomy may
precipitate vascular spasm. This spasm has been re¬
duced in experimental models by the administration of
chlorpromazine, phenoxybenzamine, phentolamine,
verapramil and prostaglandins [48], There is a lack of
comparative clinical studies for all these treatments
and little information regarding other organs like the
heart and liver.
There have been major advances in artificial organ
preservation fluids for use immediately before organ
removal and afterwards during storage. Many are still
being investigated with different units using varied so¬
lutions. All are based on cold solutions, containing
sugars as an impermeant and usually having a high
potassium content. Together these reduce cellular
swelling and metabolism. There has also been consid¬
erable interest in continuous hypothermic perfusion of
organs in vitro. These topics have been reviewed in
depth elsewhere [48, 49].
Ventilatory support
Continued artifical ventilation is necessary in the or¬
gan donor. The ventilator should be adjusted to give
a PaC02 of 5.3 —5.6KPa and added oxygen given to
maintain Pa02 greater than 10 KPa. Oxygenation
may be a problem if aspiration of stomach contents,
acute lung injury, neurogenic pulmonary oedema or
traumatic damage have occurred and arterial blood
gases should be measured frequently. Positive end ex-
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piratory pressure (PEEP) should not be used unless
there are problems with oxygenation not responsive to
increases in inspired oxygen concentration. PEEP in¬
creases mean intrathoracic pressure leading to decreas¬
es in thoracic venous return and a fall in cardiac out¬
put and renal blood flow. Other humoral mechanisms
including release of antidiuretic hormone (ADH) and
activation of the renin/angiotensin/aldosterone sys¬
tem have also been implicated [50], PEEP should be
avoided in the presence of haemodynamic instability
and when not indicated specifically to improve Pa02.
Carbon dioxide production is low in the absence of ce¬
rebral blood flow, sympathetic drive and muscle tone
[51, 52]. Low minute volumes or the addition of a
dead space to the ventilator circuit may be necessary
to maintain normocapnia.
Lung transplantation requires special consider¬
ation. Oxygen at unnecessarily high concentrations
(greater than 60%) should be avoided due to the risk
of pulmonary oxygen toxicity. Low pressures of PEEP
(5 cm water) are routinely used in these cases to pre¬
serve lung volume by preventing alveolar collapse. Salt
and water overload must be avoided. The lungs must
not become infected and "aseptic techniques" of
tracheal suctioning continued.
The donor operation
Reflex movements, particularly in the limbs, may oc¬
cur following stimuli in the presence of brain death.
The intact lower spinal cord retains certain spinal re¬
flexes which may give rise to muscle spasms and
twitches on stimulation. Superficial reflexes are more
common than deep muscle reflexes [53], No reflexes
occur in the distribution of the cranial nerves. Anxi¬
eties may arise as to the validity of brain stem death
criteria, unless these changes are anticipated and un¬
derstood by the attending staff. True decerebrate or
decorticate posturing implies intact pathways within
the brain and is not seen in brain stem death.
Tachycardia and hypertension may also occur after
surgical incision. The neuronal pathways for these
haemodynamic responses are not clear but may reflect
a spinal vasoconstrictor response or a humoral mecha¬
nism such as adrenal medullary stimulation by a spi¬
nal reflex [54].
Tubocurarine is often recommended for abolishing
muscle movement but usually causes a drop in blood
pressure due to histamine release and ganglionic
blockade. Pancuronium or vecuronium, more car-
diostable muscle relaxants are a better choice, given
the high incidence of hypotension in donors.
The question of the use of analgesic and anaes¬
thetic agents is difficult. Their use depresses the possi¬
bly harmful tachycardia and hypertension related to
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surgical incision, otherwise their use is illogical in a
brain stem dead donor. Nevertheless they are used by
some experienced anaesthetists. The addition of vola¬
tile anaesthetic agents, in anaesthetic concentrations,
to the inspired gases, overcomes some of the objec¬
tions to organ donation expressed by some clinicians
but others would regard this as an illogical position
(D. Hill, personal communication). Most anaesthetists
continue to use nitrous oxide as a carrier gas to avoid
the administration of 100% oxygen from anaesthetic
machines without a supply of compressed air.
Exact operative details differ between centres [55]
and the procedure described is that used at this centre
[56], If all transplantable organs are to be removed the
chest and abdomen are opened with a long midline in¬
cision from the jugular notch to the symphysis pubis.
After a thorough inspection to exclude an unsuspected
disease all organs are dissected out until attached only
by their vascular pedicles. This dissection may take up
to three hours, the most frequent delay being due to
the presence of accessory vessels. The liver is dissected
first followed by kidneys and pancreas.
When dissection is completed heparin is given in¬
travenously to avoid coagulation around perfusion
cannulae (15,000 units in an adult). Cannulae are then
placed in the lower abdominal aorta, the inferior vena
cava, and the portal vein in preparation for cold perfu¬
sion of the abdominal organs. The heart is perfused
first with cold cardioplegic solution via a cannula in
the aorta and fluid is vented by incising the superior
pulmonary vein. Artificial ventilation is then discon¬
tinued. The liver is then perfused with ice-cold Ring¬
er's lactate followed by 4.5% albumin solution. The
kidneys are perfused with ice-cold Marshall's hyper¬
tonic citrate solution.
After cold perfusion the organs are removed and
put in sterile bags and transported packed in ice to the
recipient. Kidneys may be stored for up to 48 h (al¬
though organ survival after 72-96 h has been docu¬
mented), livers up to 10 h, and heart and heart/lungs
4 h using these techniques. However, recent advances
in preservation fluids may allow longer times in the fu¬
ture. Successful organ retrieval requires close coopera¬
tion between the different surgical teams from differ¬
ent centres. Efforts are being made in some areas to
organise and train one surgical team to remove all or¬
gans rather than different teams each removing one
organ.
Losses of fluids by bleeding and evaporation from
an open abdomen and chest during the dissection
phase are significant. Blood transfusion may be re¬
quired during this dissection phase and blood should
be crossmatched in anticipation.
Hypothermia may be a problem in the operating
theatre when the donor has an open chest and abdo-
r
A. Bodenham and G. R. Park: Care of the multiple organ donor
men. Open body cavities give rise to large heat losses
from evaporation and radiation. Heat losses should be
minimised by a warm theatre, warming all infused flu¬
ids, using heated humidifiers on ventilator circuits and
using warming blankets beneath the donor.
Conclusions
The demand for organ donors is likely to increase each
year and is likely to outstrip available supplies in the
foreseeable future. Every effort should be made both
to encourage organ donation and when offered, the
donor organs should be kept in the best possible con¬
dition. This will mean allocation of medical and nurs¬
ing time, plus resources similar to that given to other
intensive care patients. Further studies need to be per¬
formed to identify all the consequences that result
from brain death, in order that these may be corrected
before organ removal.
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Organs for donation are in short supply in the United
Kingdom, resulting in allegations that relatives
of potential donors are not being asked for consent.
Legislation on "required request" has been proposed
to overcome this. The incidence, causes, complica¬
tions, and patterns of organ donation in brain stem
dead patients in one referral centre were studied
over 12 months. Data were collected on all patients
fulfilling criteria for brain stem death or considered
suitable for donating organs after circulatory arrest.
Forty two patients fulfilled the criteria for brain stem
death, and in 10 further patients circulatory arrest
occurred before formal testing was finished. The
major causes of brain stem death were head injury
(28) and intracranial haemorrhage (17). Consent
to organ donation was obtained for 24 potential
donors, and organs were donated by 23 of them.
Twenty nine patients did not donate organs. The
commonest reasons for failure to donate were
medical unsuitability (13) and the coroner not
releasing the body (eight). Consent was not sought in
three cases, and the relatives refused consent in the
remaining five.
This study suggests that required request will not
considerably increase the supply of donor organs.
Introduction
Transplant surgeons have alleged that organs
from many potential donors arc not made available
because of the reluctance of doctors to ask relatives to
consent to donation and have therefore called for new
legislation requiring clinicians to ask for consent.1 This
assertion, however, was made without knowledge of
the true incidence of brain stem death, the number of
cases of brain stem death in which donation is possible,
or how often the question of organ donation is raised
and consent is refused. The often misquoted figure of
4000 potential donors a year in the United Kingdom
was published in 198 T but reported the number of
patients in whom brain stem death was a possible
diagnosis, not the number of organ donors.
The transplant teams at Addenbrooke's and nearby
Papworth Hospitals are pioneers in organ trans¬
plantation. This generates much interest in the local
and national media. Awareness of transplantation is
thus high in the local population and the medical and
nursing staff. It might therefore be expected that
consent for organ donation would be considered
by both medical staff and relatives more readily
than in other centres. To determine the causes and
complications of brain stem death in a major teaching
hospital and to investigate whether required request
would make an important difference to the numbers
of potential donors failing to donate organs we
prospectively studied for one year all patients admitted
to the four intensive care units (general, paediatric,
neurosurgical, and neurotrauma) at this hospital who
were declared brain stem dead or considered suitable to
donate organs after circulatory arrest.
Subjects and methods
From 18 November 1987 to 17 November 1988 all
cases of brain stem death that occurred were reported
to us. At diagnosis of brain stem death the following
information was collected: age, general diagnosis,
duration of artificial ventilation in the intensive care
unit after the declaration of death, and number and
type of organs donated. If organs were not donated
by a potential donor then the reasons for this were
examined and allocated to one of four categories:
medical contraindications, consent not requested,
consent denied by relatives, and consent denied by the
coroner. In addition, any complications directly
attributable to brain stem death were recorded.
These included hypotension (systolic blood pressure
<80 mm Hg without inotropic support), diabetes
insipidus (urine output greater than 200 ml/h in
patients not receiving diuretics and without other
causes ofpolyuria), and hypothermia (temperature less
than 35°C without warming).
Results
Forty two patients (25 male and 17 female) fulfilled
the criteria for the diagnosis of brain stem death during
the period of study.' In 10 other patients (three male
and seven female) circulatory arrest occurred before
formal testing could be completed. The mean (SD)
age of the subjects was 37-3 (22-4) years (range
0-5-89 years), and the mean duration of artificial
ventilation after testing was 123 minutes (range
10-3070 minutes). The large range in duration of
ventilatory support reflects the need in one instance to
wait until relatives arrived from the Far East to give
consent. The major causes of brain stem death were
head injury (28 cases) and spontaneous intracranial
haemorrhage (17 cases), with intracranial tumour,
hypoxic brain injury, and hydrocephalus the remaining
diagnoses (table I). All 52 subjects had at least one
complication of brain stem dysfunction, with diabetes
insipidus and hypotension occurring in most (table II).
Consent to organ donation was obtained for 24 of the
potential donors, with organs being donated by 23.
One subject was found to have peritonitis at operation,
which precluded organ retrieval. In four cases consent
was restricted to donation of corneas, leaving 19 donors
of solid organs, three of whom had had circulatory
arrest. Table III shows the number of organs donated
compared with the number for which consent to
removal was granted. At the donor operation one
kidney was found to have been traumatised previously
and was not removed. Lack of a suitable recipient
prevented the removal of a pair of kidneys, a liver, and
three hearts. Three livers were not used because of a
shortage of intensive care facilities for the recipients.
table iii—Xumber and type of organs donated by 19 donors
compared with number oforgans for which consent to removal given.
In four further cases consent was restricted to corneal donation
Organ Consented Donated Not used
Kidnevs 38 35 3
Liver
Liver-pancreas } .6* 1 91 1 }'
Heart
Heart-lung j 16* 1 1\ 1
Total 70 54 16
*Donor cannot donate liver and liver-pancreas or heart and heart-lung
separately.
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table iv—Causes offailure to
donate for 29 potential organ
donors
No of







Denied by coroner 8
Denied by relative 5
Not requested 3
The age criteria for donations prevented the use of two
livers and four hearts.
Twenty nine subjects failed to donate any organs
(table IV). This was due to medical contraindications
in 13 (profound hypotension, sepsis, trauma, or renal
failure). In eight cases the injuries leading to brain stem
death resulted in serious criminal charges being
brought against another person. In such circumstances
the coroner felt unable to grant permission for organ
donation. There were five cases in which the relatives
refused permission: in three they thought that the
patient had "been through enough," in one the patient
had expressed a wish not to donate organs, and in one
the relatives had doubts about donation. Consent was
not requested in only three.
Discussion
The shortage of organs for transplantation has been
highlighted recently, accompanied by calls for changes
in the law on consent to donation.14 In our study,
though solid organs were donated from only 19 of
52 patients with brain stem death, in only three of the
remaining 33 cases was consent for donation not
requested. We suggest that failure to request donation
after brain stem death is uncommon at our hospital. If
this level of requesting donation is representative of
that at most other centres then legislation to make
request compulsory would not considerably increase
the number of organs available for transplantation.
Wakeford and Stepney, in a survey of attitudes to
organ donation, concluded that coercive measures
were less likely to increase the supply of donor organs
than improved education of the public and the medical
profession.'
Sixteen organs were not used when consent to their
removal had been granted because of lack of intensive
care facilities or shortage of recipients matched for
blood group and presence of cytomegalovirus. In this
series organs from eight potential donors could not be
used because the coroner would not release the body, a
feature others have experienced with the procurator
fiscal in Scotland (J D Miller, personal communica¬
tion). The prevalence of traumatic causes of brain stem
death suggests that this is a nationwide feature and is
unlikely to change, though individual coroners and
procurators fiscal have widely differing opinions on
this subject, some releasing bodies when others would
not.
Of concern is the large proportion (a quarter)
of potential donors whose poor general condition
rendered them unsuitable for donation. This, coupled
with the high incidence of complications, means that
such patients require careful medical and nursing care
with particular attention to cardiovascular function.
Perhaps by attention to these factors not only would
absolute numbers of donors increase but there would
also be an improvement in the condition of organs that
are donated.
We thank our neurosurgical, neuroanaesthetic, and other
medical colleagues and the Cambridge transplant coordinators
for their cooperation with the collection of this information.
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Mortality during intensive care after orthotopic liver transplantation
G. R. PARK, J. GOMEZ-ARNAU, M. J. LINDOP. J. R. KLINCK, R. WILLIAMS and R. Y.
CALNE
Summary
The postoperative course of 335 adult patients who underwent orthotopic liver transplantation from 1968-1987 was reviewed
retrospectively to identify patients who died in the intensive care unit and the causes of death. Forty-four percent of all deaths
occurred in the intensive care unit. The mortality rate in the intensive care unit peaked in 1984 (48%), but decreased to 11% in
1987. The main causes for death in the intensive care unit were infection (55% J and haemorrhage (19%>). The patients who died
spent more time in the intensive care unit, had a longer period of tracheal intubation and received a larger intra-operative blood




Orthotopic liver transplantation (OLT) was pioneered
originally in the United States by Moore1 and Starzl.2 The
first orthotopic liver transplant in man was performed by
Starzl in 1963. The operation was first performed in the
United Kingdom by Calne in 1968. It is now accepted as a
therapeutic modality in end-stage liver disease, acute
hepatic failure, inborn errors of metabolism and some liver
tumours.'
Liver transplantation has been performed for 20 years in
the joint programme between Cambridge and King's
College Hospital. This retrospective analysis of the exper¬
ience in the Cambridge/King's College series attempts to
identify the major causes of mortality of patients during
their stay in the intensive care unit and to provide informa¬
tion on the changing patterns of problems which have
contributed to mortality.
Patients and methods
Three hundred and thirty-five adult patients (over 14 years
of age) have had at least one liver transplant in the
Cambridge/King's College Hospital series during the
period from 1968 to the end of October 1987. These
patients were grouped according to a chronological
scheme: 41 patients from 1968-1975; 60 patients from
1976-1980; 45 patients from 1981-1983; and 27-60 patients
from each of the years 1984 to 1987. These groups were
chosen as being of comparable size. The numbers in the
groups from 1984 onwards represent a major increase in
transplant activity in this hospital. Paediatric liver trans¬
plantation (now an increasing part of our practice) is not
included in this study
Indications for transplantation include chronic advanced
hepatobiliary disease (CAHD) (biliary cirrhosis, chronic
active hepatitis, alcoholic cirrhosis, cryptogenic cirrhosis
and sclerosing cholangitis), acute liver failure (viral infec¬
tion or poisoning), hepatic malignancy, inborn errors of
metabolism (Wilson's Disease, alpha-1-antitrypsin defi¬
ciency, oxalosis) and the Budd Chiari syndrome. Surgical,
anaesthetic and medical management is described in detail
elsewhere.4
The place of death, time between operation and death,
number of re-operations (if any), intra-operative blood
transfusion, duration of stay in the intensive care unit
(ICU) and the time of tracheal intubation were recorded
for all patients who died. In the early part of the series
intensive care measures such as artificial ventilation,
tracheal intubation, catecholamine infusion and invasive
monitoring were practised outside the ICU but, for statis¬
tical purposes, these patients are considered as if they had
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Table 1. Number (percentage of group) of deaths that occurred in the intensive care unit after orthotopic liver
transplantation in seven time periods.
1968-75 1976-80 1981-83 1984 1985 1986 1987
Number of patients 41 60 45 27 45 57 60
Age, years (SD) 41.2 (12.8) 40.4 (12.2) 39.7 (12.5) 37.4 (13.5) 40.5 (10.3) 41.4 (10.8) 39.8 (12.2)
Deaths in ICU
(first admission) 9 (21%) 8 (13%) 12 (27%) 7 (26%) 6 (13%) 7 (12%) 5 (8%)
Deaths in ICU
(readmission) 4 (10%) 5 (8%) 8 (18%) 6 (22%) 4 (9%) 3 (5%) 2 (3%)
Deaths in ICU
(Total) 13 (31%) 13 (21%) 20 (45%) 13 (48%) 10 (22%) 10 (17%) 7 (11%)
received this therapy and died in the ICU. The main cause
of death was obtained from the postmortem results (when
available) or clinical data according to criteria used
previously.5 When possible, only one (the major) cause of
death was identified for each patient. Multisystem organ
failure (MOF) was recorded as a cause of death when
failure of two or more major organ systems was present.
There are predominantly three causes ofmultisystem organ
failure in this group of patients; infection, or infarction, or
rejection of the donor liver. Infection was coded as the
cause of death if there was microbiological confirmation of
an organism (culture or serology). Infarction of the liver is
characterised by a marked increase in the serum concentra¬
tions of transaminases and prothrombin time and by
sudden deterioration in the patient's condition. Rejection
can be diagnosed histologically or by the response to pulsed
bolus doses of steroids. Infection, infarction or rejection
was coded as the primary cause of death if proven; multi¬
system organ failure was coded if no cause was identified.
Renal failure was defined as the presence of a plasma
creatinine concentration of >217 /rmol/litre or if there was
a need for haemodialysis or haemofiltration. All other
concurrent pathology present at the time of death was
coded as an associated diagnosis. Student's /-test for
unpaired data was used for statistical analysis where
applicable.
Results
The numbers of patients who underwent OLT in each time
period are shown in Table 1. One hundred and ninety-five
of the 335 patients who have received OLT have died, 86 of
them (44% of deaths) in the ICU. Table 1 also shows the
numbers of patients who died in the ICU during either
their first admission or on readmission. The age and gender
of adult patients who underwent OLT did not change
significantly during the study period although the number
of orthotopic liver transplants performed each year has
increased steadily, particularly since 1984. The mortality
rates for both the first and subsequent ICU admissions
have fallen significantly since 1984. The main indications
for transplantation are shown in Table 2. Initially a large
number of patients were transplanted for malignancy but
this has now become an uncommon indication. Alcoholic
cirrhosis had the lowest ICU mortality and Wilson's
disease the highest although the small numbers prevent
meaningful statistical analysis. The groups associated with
the largest decreases in ICU mortality over the years are
those with cryptogenic cirrhosis and malignancy.
The main causes of death are shown in Table 3. Infection
has remained the most important cause of death (55%)
with haemorrhage the next most common (19%). Asso¬
ciated causes of death are shown in Table 4. Multisystem
failure and renal failure make up 60% of all contributory
causes of death. Multisystem (which includes renal) failure
became increasingly recognised in the period 1981-1983 as
the commonest cause of death. During that period renal
failure occurred in 45% of patients who died in the ICU,
much more frequently than previously. The relationship of
renal failure to ICU mortality and one-year survival can be
seen from Figure 1. Many factors influence survival, but
the development of renal failure in critically ill patients is
associated with high mortality. The decreasing incidence of
Table 2. Primary diagnosis and mortality in the intensive care unit after orthotopic liver transplantation.
i
1968-75 1976-80 1981-83 1984 1985 1986 1987
n d % n d % n d % n d % n d 0//o n d % n d %
Biliary cirrhosis 3 I (33) 14 3 (21) 16 9 (56) 7 5 (71) 1 3 (43) 19 4 (21) 16 2 (12)
Chronic active
hepatitis 2 0 (0) 7 1 (14) 7 3 (43) 5 3 (60) 9 2 (22) 8 I (12) 13 1 (8)
Alcoholic cirrhosis 1 0 (0) 3 0 (0) 1 0 (0) I 0 (0) 1 0 (0) 1 0 (0) 5 1 (20)
Cryptogenic cirrhosis 5 2 (40) 5 2 (40) 3 1 (33) 2 1 (50) 3 1 (33) 6 I (16) 5 0 (0)
Sclerosing cholangitis — — — 2 0 (0) 2 2 (100) — — — 4 1 (25) 4 0 (0) 4 1 (25)
Acute liver failure — — — — — — — — — 3 1 (33) 1 0 (0) 5 2 (40) 6 0 (0)
Malignancy 29 10 (34) 21 4 (19) 11 3 (27) 6 1 (16) 13 1 (8) 5 0 (0) 5 1 (20)
Wilson's disease 1 0 (0) 1 1 (100) 2 1 (50) I 0 (0) 1 1 (100)
Budd Chiari — — — 5 2 (40) 3 1 (33) 2 1 (50) 3 0 (0) 3 1 (33) 1 0 (0)
Other 1 0 (0) 3 1 (33) 1 0 (0) — — — 2 1 (50) 5 1 (20) 1 0 (0)
n, number of patients; d, ICU deaths.
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1968-75 1976-80 1981-83 1984 1985 1986 1987
IV I
1968-87*
Rejection — — — — — — — 9 (9%)
Infarction 2 (15%) 1 (8%) I (5%) 1 (8%) 1 (10%) — — 6 (6%)
Infection 8 (62%) 7 (54%) 11 (55%) 8 (62%) 4 (40%) 4 (40%) 5 (71%) 30 (29%)
Haemorrhage — 3 (23%) 3 (15%) 2 (15%) 3 (30%) 4 (40%) 1 (14%) 1 G%)
Multisystem failure 1 (8%) 1 (8%) 4 (20%) 2 (15%) — 1 (10%) — —
Recurrence 1 (8%) — — — — — — 30 (29%)
Biliary anastomosis — — — — — — — 3 (3%)
Pulmonary embolus — — — — — — — 3 (3%)
Gastrointestinal haemorrhage — — 1 (5%) — — — — 2 (2%)
Cerebral haemorrhage I (8%) 1 (8%) — — 1 (10%) I (10%) 1 (14%) —
Other — — — — 1 (10%) — — 10 (11%)
Unknown — — — — — — 7 (7%)
*Excluding theatre deaths.
Table 4. Associated causes of death in patients who died in ICU. Percentages are related to ICU deaths for that period.
1968-75 1976-80 1981-83 1984 1985 1986 1987
Rejection 1 (8%) — — — — — —
Infarction — 1 (8%) — — 1 (10%) 1 (10%) —
Haemorrhage — — 1 (5%) — — — 1 (14%)
Multisystem failure 1 (15%) 2 (15%) 14 (70%) 6 (46%) 3 (30%) 2 (20%) 2 (28%)
Biliary problems 1 (8%) 2 (15%) 1 (5%) — — — —
Pulmonary embolus 2 (15%) 1 (8%) — — — — —
Gastrointestinal haemorrhage — — — — 1 (10%) — —
Cerebral haemorrhage — 1 (8%) — — — — —
Renal failure 1 (8%) — 9 (45%) 3 (23%) 1 (10%) 1 (10%) 1 (14%)
Cardiac failure — — — — 1 (10%) 1 (10%) —
Disseminated intravascular
coagulation — — — 1 (8%) — — —
Mesenteric thrombosis — — — — 1 (10%) — —
Miscellaneous I (8%) — — 1 (8%) — 1 (10%) —
renal failure in this group appears to be associated with a
decrease in ICU mortality (except for 1987) and an increase
in one-year survival.
Table 5 presents further information on patients who
died during admission to the ICU or after discharge. There
is no statistically significant difference in age or gender. The
average number of days spent in the ICU was shortest for
patients who survived but there was no statistically signifi¬










Fig. I. The incidence of renal failure during the period of intensive
care in patients who had undergone liver transplantation between
1968 and 1987. Mortality (as a percentage of all deaths) and one-
year survival for the same period are shown also. —O—, one-year
survival; —9—, renal failure; —□—. ICU deaths.
who died during their first ICU admission and those who
died in their second ICU admission. Patients who died had
a longer period of tracheal intubation and required more
intra-operative blood transfusion. The incidences of the
main causes of death for all patients are shown in Figure 2.
Discussion
The current one-year survival after OLT at this centre is
66%. This is higher than that reported by the European
Year
Fig. 2. Main causes of death after liver transplantation for the
period 1968 to 1987. mi, rejection; infarction; □, infection; gj,
haemorrhage.
1975 1980 1984 1985 1986 1987
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Table 5. Risk factors associated with death after liver transplantation. Values are expressed as mean (SD).
Deaths outside
ICU (n = 81)*
Deaths during
first admission
to ICU (n = 49)
Deaths during
readmission
to ICU (n = 30)
Age 41 (12) 41 (10) 39 (12)
Sex 34 M, 47 F 25 M, 24 F 13 M, 17 F
Survival time (days) 350.7 (600.6) 11.6 (10.6)t 89.1 (136.2)tJ
ICU time (days) 6.1 (10.1) 11.6 (10.6) 10.9 (14.4)
Patient days 424 593 293
Intubation time (hours) 38.5 (78.9) 162.5 (200.4)t 124.2 (245.3)t
Intra-operative blood
transfusion (litres) 8.1 (6.9) 19.6 (15.0) 9.8 (7.6)§
Total number of
re-operations 43 34 16
Number of patients
(% of total) re-operated 35 (43%) 24 (49%) 12 (40%)
ratio 1.2: 1 1.5 : 1 1.3 : 1
*Excluding deaths in theatre.
tp < 0.01 (with respect to column 1).
Jp < 0.01, §p < 0.05. (with respect to column 2).
Transplant Registry6 and compares well with other series.7"9
Survival has improved steadily from 12% during the first 8
years up to 49% in 1985 and 66% in 1986. The percentage
of deaths that occurred in ICU increased from 31 % in the
initial period to 48% in 1984 but since that time it has
fallen each year and was 11% in 1987.
Major changes in the management of these patients
occurred during the study period. Postoperative artificial
ventilation for the first 24 hours was introduced in 1976;
prior to this period patients were extubated at the end of
operation and allowed to breathe spontaneously.10
The period with the maximum incidence of multisystem
organ failure including renal failure (1981-1984) coincides
with the introduction of cyclosporin A, given immediately
after OLT, into clinical practice. This high incidence of
renal failure caused a change in our therapeutic regimen.
Cyclosporin is now administered 48 hours after the end of
operation when the patient is haemodynamically stable and
has adequate renal function. Further research into renal
protection led us to introduce low-dose dopamine infusion
as part of routine management. This resulted in a reduced
incidence of renal impairment and less need for haemodia-
lysis." These changes and other more general measures (see
below) were associated with reductions in the incidence of
renal failure in patients who died in the period from 1981-
1983 (45%), to 23% in 1984 and 10% in 1986. Simulta¬
neously the one-year survival rates increased to 49% and
66% in 1985 and 1986 respectively (Fig. 1).
The major cause of death in the ICU continues to be
infection, an experience reported also by others.5 Its total
incidence appears not to have changed with time; it remains
the primary cause of death in 35-45% of all patients and
contributes to 55% of all ICU deaths. The high incidence
of infection is a reflection of the severity of pre-existing
illness, the magnitude of the operation and the need for
immunosuppression. Almost all of the deaths caused by
haemorrhage, multisystem failure and cerebral problems
occurred in the ICU. Half of the deaths associated with
ischaemic damage to the donor organ occurred during the
period of intensive care. No deaths attributed primarily to
rejection, pulmonary embolism or biliary problems
occurred in the ICU.
The volume of blood transfused intra-operatively
appeared to be related closely to the ICU deaths that
occurred early in the postoperative period (Table 5). The
mean blood usage in patients who died in the ICU was 19.6
litres, more than reported by others;12 this may reflect
differences between the patient groups or techniques in the
two centres. Periods of hypotension, residual peritoneal
blood clot and tamponade of renal vessels by large
amounts of blood13 may lead to an increased risk of renal
failure and infection. Patients who died in a subsequent
ICU admission also had a larger blood loss than survivors.
The durations of stay in the ICU and of tracheal intuba¬
tion were, as might be expected, longer in the nonsurvivors
(on average more than 10 days and 120 hours respectively).
Less quantifiable aspects of postoperative intensive care
concern the adoption of a management protocol in 1984,
subsequently revised annually. Medical and nurse staffing
levels have also improved during this time. We have not
attempted to analyse the effects of these developments but
others have shown that outcome in an ICU with adequate
numbers of trained staff is better than in a unit with low
staff numbers.14 Other factors, not related directly to the
intensive care these patients received, contributed also to
the improved survival during the review period. Improve¬
ments in donor maintenance,15 organ preservation16 and
antibiotic prophylaxis have occurred and there has been a
change in the diagnostic groups transplanted. Originally a
large number of patients were transplanted for malignancy.
Unfortunately many of these patients developed recurrence
of their tumour and it is not now a common indication for
transplantation. Patients with malignancy are usually
transplanted more rapidly than others with the result that
they tend to be less unwell than those with end-stage liver
disease and so pose fewer peri-operative problems, a
feature demonstrated in their low overall mortality since
1975.
Eleven percent of patients died during the period of
intensive care in 1987 despite improvements in manage¬
ment. Two major causes of mortality, infection and
haemorrhage, require attention. It is of note that these have
remained essentially unchanged during this period. Some of
the deaths diagnosed as being related to infection may have
Mortality after liver transplant 963
been caused by rejection and the fine balance between
excessive immunosuppression which may result in infection
and inadequate immunosuppression with a consequent
increased risk of rejection requires careful management.
Postoperative haemorrhage continues to be a problem and
may represent a complication of surgery, derangement in
the coagulation mechanism due to the pre-existing poor
synthetic liver function or failure of synthetic function of
the new liver.
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Postoperative analgesia for haemorrhoidectomy
A comparison between caudal and local infiltration
S. J. PRYN, M. M. CROSSE, M. S, C. MURISON and F. P. McGINN
Summary
This study compared the analgesic effectiveness of local infiltration of bupivacaine with caudal extradural bupivacaine in the first
48 hours after haemorrhoidectomy. Surgical and anaesthetic protocol was rigidly standardised. The caudal group had
significantly less pain in the first 6 hours after haemorrhoidectomy, and on first bowel opening, when compared to those who
received local infiltration of bupivacaine. There was no significant difference between the two groups with respect to further
analgesic requirements, complications, time to first bowel action, and duration of hospital stay. The definite advantage of caudal





Haemorrhoidectomy has been described as agonisingly
painful' and has unfavourable notoriety in this respect.
However, there is evidence that caudal epidural analgesia
offers patients some benefits.2-5 The study by Berstock3
showed that bupivacaine caudal analgesia dramatically
reduces the postoperative opiate requirement (by 79%) and
halves the time to first bowel action (from 4 to 2 days).
Presumably the two are related, since opiate drugs tend to
cause constipation.
Local infiltration of bupivacaine can also provide good
operative anaesthesia for haemorrhoidectomy,6'7 and
although to our knowledge there are no studies which
demonstrate continued analgesia into the postoperative
period, one can reasonably expect this to occur, since it
does at other injection sites.8
Both methods of administration of bupivacaine are regu¬
larly used in our hospital to provide postoperative pain
relief after haemorrhoidectomy. It is proposed that if the
technique of local infiltration can be shown to be as effec¬
tive as the already proven advantages of caudal analgesia,
then this may be a safer, quicker and more reliable method.
In addition, if one method provides superior analgesia
compared to the other, then one might expect a greater
opiate sparing effect, and hence a shorter time to bowel
action and discharge from hospital. This would add the
advantage of cheaper patient care.
Methods
Forty-four consecutive patients about to undergo elective
haemorrhoidectomy under general anaesthesia by one of
the two participating surgeons were randomly allocated
into two groups of 22. Group 1 received caudal analgesia
and Group 2 local infiltration analgesia with 0.25 ml/kg
bupivacaine 0.5% as part of the anaesthetic technique. The
only exclusion criteria were for those patients with specific
contraindications to caudal extradural analgesia (e.g.
coagulopathy, localised infection, pre-existing neurological
deficit, patient refusal, and those with known hypersensiti¬
vity to local anaesthetic agents). All patients gave their
informed consent before operation and approval for the
study was obtained from the district ethics committee.
The surgical protocol was rigidly standardised. All
patients had third-degree piles, or second-degree after
failed Barron's band ligation, and they received an enema
the day before surgery. The surgeon infiltrated around the
haemorrhoids 0.25 ml/kg of a solution of either 1 in
200 000 adrenaline (Group 1), or bupivacaine 0.5% with 1
in 200 000 adrenaline (Group 2), after induction of general
anaesthesia. Haemorrhoidectomy was performed by
Milligan-Morgan ligation excision' and the wound dressed
with a Jelonet pack which was left in place until the next
morning. The patients were treated with regular aperients
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CASE REPORT
Chlormethiazole sedation for critically ill patients in renal failure
P. A. GRAY AND G. R. PARK
) Summary
Chlormethiazole infusions were used successfully to provide night sedation for 10-19 nights in three patients with renal failure
managed by continuous veno-venous haemofiltration with dialysis. Fluid overload has accompanied the use of this drug previously
> because of its low concentration. The ability to remove large amounts of fluid during haemofiltration dialysis proved to be
effective in preventing this. All three patients had impaired liver function and showed evidence of chlormethiazole accumulation
after 4-6 days. The combination ofprogressive reduction in dose and daily withdrawal of infusions prevented a major problem.
Acceptance oj this technique by the patients was high. Chlormethiazole may be a useful addition to the drugs available to provide




Infusions of chlormethiazole are well established in the
management of alcohol withdrawal, status epilepticus, pre¬
eclampsia and short term sedation. The drug has been used
also for prolonged infusion in critically ill patients,1 in
whom it can produce effective sedation and permit artificial
ventilation whilst preserving cardiovascular stability.
Modig2 has suggested that chlormethiazole may have a
protective effect in endotoxic shock, minimising cardiovas¬
cular and pulmonary instability, which could be advan¬
tageous in the critically ill patient.
Intravenous administration of chlormethiazole by bolus
doses or by short infusions produces effective sedation with
rapid onset and recovery due to redistribution into a large
volume. It is eliminated mainly by hepatic metabolism,
with less than 1% of unchanged drug excreted in the
urine.3 Saturation of redistribution sites may occur during
long term infusions; its effect then is terminated by metab¬
olism alone.4 This problem may be exacerbated in the
elderly,5 the critically ill1 and in patients whose hepatic
function is chronically impaired.6 Scott et aid have
suggested that the decrease in metabolism may be due to a
reduction in hepatic blood flow. Thus recovery from long
term infusions (more than 24-A8 hours) may be prolonged
significantly in some patients.
Chlormethiazole is formulated for intravenous use as a
0.8% solution in 4% glucose buffered with approximately
30 mmol sodium hydroxide to achieve a pH in the normal
range. It is not available in a more concentrated form
because the incidence of venous thrombophlebitis is unac-
ceptably high and it may produce haemolysis if concentra¬
tions of 5% or more are used.7 Thus, a large fluid load may
be required if chlormethiazole is used for prolonged seda¬
tion. This feature has limited its usefulness, particularly in
patients with renal failure and those with fluid and electro¬
lyte problems.
Haemofiltration8 removes fluid and small molecular
weight substances (approximate molecular weight <
20 000) and can remove large volumes of fluid. The
patient's own blood pressure can be used to drive the blood
around the circuit (continuous arteriovenous haemofilt¬
ration; CAVH) if arterial and venous lines are inserted.
Alternatively, two venous lines with a blood pump can be
used to circulate the blood (continuous veno-venous
haemofiltration; CVVH). Large volumes of haemofiltrate
may be removed and replaced with a suitable solution.
Continuous arteriovenous haemofiltration with dialysis
(CAVHD) combines low volume arteriovenous haemofilt¬
ration with continuous perfusion of the filter using a
haemodialysis solution.9 Continuous veno-venous haemo¬
filtration with dialysis (CVVHD), like CVVH, uses two
venous lines and a blood pump, and provides a high and
consistent flow through the membrane. These latter two
techniques allow slow, gentle, continuous haemodialysis as
well as control of fluid balance.
We describe three patients in whom CVVHD allowed the
use of chlormethiazole.
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Fig. 1. Drug dose (mg), ■: recovery time (hours), □; sedation
score, H; for 19 nightly chlormethiazole infusions in patient 1.
*Marks the three occasions when patient 1 had not recovered
noticeably before the infusion was inadvertently recommenced.
Case histories
The first patient, a 49-year-old male, had undergone ortho¬
topic liver transplantation for cirrhosis due to ^-anti¬
trypsin deficiency. This had been complicated by the
development of acute lung injury and acute renal failure 12
days after operation. The second patient, a 62-year-old
male, had undergone resection of an abdominal aortic
aneurysm. Subsequently, the left femoral graft and mesen¬
teric artery became occluded and this caused infarction of
the large bowel. Acute renal failure developed 2 days after
operation. The third patient, a 44-year-old female, had
undergone orthotopic liver transplantation for primary
biliary cirrhosis. The patient had deteriorating renal func¬
tion before operation, due to the hepatorenal syndrome,
and developed acute renal failure on the second day after
operation. All three patients required continuous manda¬
tory ventilation (CMV) or synchronised intermittent
mandatory ventilation (SIMV) and CVVHD. Abnormal
liver function, predominantly obstructive in nature, deve¬
loped in patients 1 and 2. Patient 3 had abnormal liver
function (primarily hepatocellular in nature) which
improved significantly during the period of chlormethiazole
infusions (see Table 1).
Each night, chlormethiazole infusions were given to the
patients to facilitate sleep. Patient 1 received the drug from
the 21st to the 39th day, patient 2 from the 13th to the 29th
day and patient 3 from the 10th to the 19th day in the
Intensive Care Unit. Previously, sedation had been with
bolus doses of morphine and midazolam given when




Fig. 2. Drug dose (mg). ■: recovery time (hours), □: sedation
score, §1; for 16 nightly chlormethiazole infusions in patient 2.
(
Propofol infusions were not used because we have observed
that this method of sedation in deeply jaundiced patients
may result in bradyarrhythmias (unpublished observation). *
The rate of the chlormethiazole infusions were controlled
by the nursing staff within prescribed dose limits. The
infusions were stopped during the day to encourage a
normal circadian rhythm and to prevent drug accumu¬
lation. Sedation was assessed by the nursing staff each hour
using the sedation score routinely employed in the intensive
care unit:10 1, fully alert; 2, roused by voice; 3, asleep; 4,
roused by pain; 5, unrousable. This simple scoring system
may lack the sensitivity of more complex systems but has
proved effective and consistent in clinical use.
The following information was recorded for each infu¬
sion: the infusion rate; the total dose of chlormethiazole
given; the average sedation score during the infusion; and
the time taken for the patient to reach maximum
awakening after termination of the infusion. Figures 1-3
show these data for the three patients.
Adequate night sedation was defined as a score of 2 or 3.
This objective was not achieved on only two occasions in
the total of 45 nightly infusions. However, excessive seda¬
tion (score more than 3) occurred on six occasions, and on '
three occasions patient 1 had not recovered noticeably
before the infusion was inadvertently restarted (marked
with * in Fig. 1). It was necessary to withhold sedation for J
patient 1 on three occasions, and on one occasion for
patient 2, because of oversedation.
Recovery time increased rapidly after sedation on the
first 6 nights in all patients and improved only when the
drug dose was reduced (usually achieved by a decrease in
the duration of the infusion to approximately 3 to 4 hours
rather than a change in the rate of infusion). Recovery
Table 1. Range of liver function tests during the period of chlormethiazole infusion.
Patients
Normal
1 2 3 range
Bilirubin (/imol/litre) 24CM66 15-55 45-97 2-17
Alkaline phosphatase
(units/litre) 88-460 108-322 158-224 30-135
Alanine aminotransferase
(units/litre) 28-51 19-48 33-203 7—40





Fig. 3. Drug dose (mg), ■ recovery time (hours), □; sedation
score, B; for 10 nightly chlormethiazole infusions in patient 3.
times decreased towards the end of the period of chlor¬
methiazole infusions as experience was gained in adminis¬
tration of the appropriate dose of chlormethiazole, and the
doses administered were considerably lower than during
the first few days.
Large changes in heart rate or blood pressure were not
seen. The maximum decreases in systolic arterial pressure
were 20-25% of those before the chlormethiazole infusion
and probably not much greater than those which occur
during natural sleep. Chlormethiazole may cause an
increase in heart rate of about 2CM10 beats/minute1 but we
did not observe this.
No problems in fluid or electrolyte balance were encoun¬
tered that were not controlled easily by CVVHD.
Discussion
At the present time there is no ideal sedative for long term
use in critically ill patients. Chlormethiazole provides good
sedation with relative cardiovascular stability but one of its
major drawbacks has been the large fluid load associated
with its administration. CAVH, and more recently
CVVHD and CAVHD, are used increasingly in critically ill
patients with renal failure, and these techniques can be used
to solve the fluid balance problems.
Relatively large doses of chlormethiazole were needed
during the first 4-6 days and these were associated with a
rapid recovery time. This represents cessation of clinical
effect by redistribution. However, as the redistribution sites
became saturated, the recovery times increased dramati¬
cally as termination of effect became dependent on meta¬
bolism. The dose must be reduced to match this change if
acceptable recovery times are to be achieved.
Recovery time decreased later in the study period. This
may represent the development of tolerance described with
morphine," fentanyl12 and midazolam (unpublished obser¬
vation). Alternatively clearance may have been reduced
initially due to poor liver function, but may have increased
subsequently as hepatic function improved; this pheno¬
menon was observed during sedation with midazolam.11
Chlormethiazole infusions provided effective nocturnal
sedation with cardiovascular stability over many nights in
these three patients with renal failure. Once experience was
gained with chlormethiazole, particularly in down-titration
of the dose to avoid cumulation, it was found to be an
effective and safe technique that provided smooth and
consistent sedation in contrast to the previous difficulties
experienced in providing adequate sedation with bolus
doses of morphine and midazolam.
There is evidence from animal experiments that chlor¬
methiazole might attenuate the cardiovascular and
pulmonary instability associated with septic shock, which is
a major cause of morbidity and mortality in the critically
ill,2 particularly in those with renal failure. This remains to
be substantiated in man. Chlormethiazole may be used to
provide both effective sedation and possibly prophylaxis
against the adverse haemodynamic effects of sepsis. The
relatively cheap price of chlormethiazole is a further advan¬
tage in the current climate of fiscal restraint.
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CASE REPORT
A plea for noradrenaline
M. E. STUART-TAYLOR AND M. M. CROSSE
Summary
Hypotension induced by nifedipine and chlorpromazine is discussed, together with the role of noradrenaline in the correction of




Calcium channel blockers; nifedipine.
Case history
A 52-year-old man was admitted for elective aortobi-
femoral bypass graft for occlusive vascular disease and was
assessed 36 hours before surgery.
He had smoked 40 cigarettes per day for 40 years and
had severe chronic obstructive airway disease, for which he
received salbutamol and beclomethasone by inhaler. He
was also prescribed bendrofluazide for hypertension.
Psychiatrists were treating successfully with chlorproma¬
zine a mixed psychiatric problem of schizophrenia and
depression. He also took cimetidine and naftidrofuryi
oxalate (praxiline). He had shortness of breath on exertion,
with exercise tolerance limited to 0.25 mile on the flat, due
to intermittent calf claudication. The ECG was normal.
The patient was found to have a blood pressure of 185/
125 mmHg at the pre-operative assessment, but stated that
he always became very hypertensive when admitted to
hospital. However, the next day his blood pressure always
returned to his usual level of 150/80. Examination of the
records of his previous three admissions to hospital showed
this statement to be correct. Instructions were therefore
given for 4-hourly blood pressure measurements, no change
in treatment, and, provided his blood pressure decreased to
its usual level, surgery.
He was premedicated with temazepam 20 mg and meto-
clopramide 10 mg orally on the morning of surgery in
addition to his normal medication. On arrival in the anaes¬
thetic room his blood pressure was 150/95 mmHg. Periph¬
eral venous, central venous and arterial lines were inserted
under local anaesthetic. ECG, central venous (CVP) and
arterial pressures were on continuous display and the
patient was anaesthetised with midazolam 3 mg, fentanyl
250 pg, and vecuronium 8 mg. The blood pressure
decreased over several minutes to 110/75 mmHg. Tracheal
intubation resulted in an increase in blood pressure to 160/
95 mmHg. Anaesthesia was maintained with 67% nitrous
oxide in oxygen and end-tidal CO, was kept within normal
limits. Volatile anaesthetic agents were avoided in view of
the expected a-adrenergic block by chlorpromazine. The
patient's blood pressure decreased progressively to 85/55
mmHg over the next 10 to 15 minutes. There was no
response to intravenous infusion or to skin incision and, as
the patient's right heart filling pressure was adequate, a
dopamine infusion was commenced via the central venous
line to reverse the hypotension. The initial dose was rapidly
increased to 25 ^g/kg/minute with no effect on the blood
pressure. Incremental doses of 1:10 000 adrenaline were
given over the next 10 minutes to a total of 1 mg. There was
no change in arterial blood pressure which remained
between 60/40 and 80/50 and there was a mild increase in
pulse rate to 85 beats/minute.
A rapid assessment of possible causes of hypotension
was made; this included air embolism, myocardial infarc¬
tion, tension pneumothorax, cardiac tamponade from
insertion of the CVP line, incorrect medication adminis¬
tered, poor calibration of pressure monitors and anaphy¬
laxis. The first six possible causes were considered unlikely.
However, the patient did appear flushed and vasodilated
with bounding pulse; and in view of a recently administered
antibiotic, an allergic reaction was considered possible.
Chlorpheniramine 10 mg was given intravenously. The
surgeon cross-clamped the aorta at this stage which also
had no effect on blood pressure. A review of the patient's
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EXTRAHEPATIC MORPHINE METABOLISM IN
MAN DURING THE ANHEPATIC PHASE OF
ORTHOTOPIC LIVER TRANSPLANTATION
A. BODENHAM, K. QUINN AND G. R. PARK
The primary site of morphine metabolism has
been the subject of speculation [1, 2], Historically
it was assumed that the liver was the predominant
organ involved in the metabolism of morphine,
but the apparent sensitivity to morphine of
patients in renal failure [3] suggested that the
kidney might be a major alternative site. This
study has examined the role of the liver in the
metabolism of morphine in patients during the
anhepatic phase of liver transplantation.
The operation of liver transplantation has been
classified into several phases including dissection,
anhepatic and reperfusion phases. During the
dissection phase the diseased liver is "skel¬
etonized" onto its vascular pedicles, namely the
suprahepatic vena cava, the infrahepatic vena
cava, the hepatic artery and portal vein, before
removal. The anhepatic phase starts after clamp¬
ing these vessels, following which the diseased
liver is removed entirely. During this period,
vessels of the donor liver are anastomosed to those
of the recipient. When the anastomoses of the
portal vein and inferior and superior venae cavae
are completed the clamps are removed and the
liver is reperfused with portal blood. Finally, the
hepatic artery and biliary anastomoses are com¬
pleted [4],
i The altered physiology of the anhepatic period
has been described previously [5]. The venous
> drainage of the lower half of the body and
, abdominal contents relies on the presence of
collateral vessels which are present in the healthy
human and increase markedly in the presence of
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SUMMARY
The primary site for the metabolism of morphine
has been the subject of controversy for some
time. We studied morphine metabolism during
the anhepatic phase of orthotopic liver trans¬
plantation in seven adult patients. After injection
of morphine 10 mg at the beginning of this
phase, the plasma and urinary concentrations of
unchanged morphine, morphine-3-glucuronide,
morphine-6-glucuronide and normorphine were
measured by high pressure liquid chromato¬
graphy. Small but measurable concentrations of
morphine metabolites were found in the plasma
and urine whilst there was no functional liver
tissue in the body. Morphine metabolism in¬
creased markedly when the new donor liver was
reperfused. This suggests that, in these patients,
the liver is the primary site for metabolism of
morphine.
portal hypertension. These venous collaterals
provide a compromised venous return when the
inferior vena cava is cross clamped. Although the
perfusion of the kidneys and intestines is com¬
promised, these patients usually produce 50-
100 ml of urine during the anhepatic period. On
reperfusion of the donor liver there is a large
increase in venous return and improved cir¬
culation to the lower half of the body.
PATIENTS AND METHODS
We studied adult patients who were likely to have
an uncomplicated intraoperative course. The
study was approved by the Hospital Ethics
Committee and written informed consent was
obtained in all patients before operation.
With the exception of patients with small
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intrahepatic tumours, most patients undergoing
liver transplantation have advanced liver disease
with associated porto-systemic shunts and co¬
agulation problems. Surgery may be technically
difficult, with large blood loss. The patients in this
series were chosen to have a low risk of this
complication: those with good coagulation, lack of
concurrent medical problems and no previous
intra-abdominal surgery.
Anaesthesia was conducted as described pre¬
viously [6], Patients were premedicated with an
oral benzodiazepine and anaesthesia was induced
with thiopentone and maintained with nitrous
oxide and isoflurane in oxygen. Neuromuscular
block was provided with suxamethonium followed
by an infusion of atracurium. Analgesia was
provided by intermittent bolus injections of
fentanyl. Dopamine 2 |tg kg'1 min-1 and mannitol
10 gh'1 were infused to maintain urine output.
Central and peripheral venous cannulae, a radial
arterial cannula and urinary catheter were inserted
as routine.
Baseline blood and urine samples were taken
immediately before the anhepatic phase. Three
minutes after the anhepatic phase had started,
morphine 10 mg diluted in saline 10 ml was
administered into a central vein; the delay was to
allow acute haemodynamic changes to resolve.
Blood samples were taken at 2, 5, 10, 15, 20, 30
and 40 min after injection and immediately before
reperfusion. Urine samples were taken at 5 and
30 min and immediately before reperfusion.
On reperfusion the sampling was repeated, with
blood and urine samples taken at the same times
as during the anhepatic phase. Blood loss, blood
replacement, urine output and body temperature
were recorded for each stage. Blood samples were
placed in lithium-heparin tubes, centrifuged at
3000 g for 5 min, and then separated into plain
siliconized tubes with screw caps to minimize
adsorption. Urine and plasma samples were stored
at — 20 °C for later analysis of morphine, mor-
phine-3-glucuronide (M3G), morphine-6-
glucuronide (M6G) and normorphine, using a
method described previously [7, 8].
RESULTS
The details of the seven patients studied are
shown in table I. All patients had significant
hepatic dysfunction with the exception of patient
No. 2 who had a solitary hepatoma. Table II lists
some of the operative details of these patients.
Table I. Demographic data and presenting diagnosis of the
seven patients
Patient Age Sex Weight Presenting
No. (yr) (M/F) (kg) diagnosis
1 52 M 56 Primary biliary
cirrhosis + hepatoma
2 41 M 70 Carcinoma of liver
3 35 M 77 Sclerosing
cholangitis +
cholangiocarcinoma
4 51 F 60 Primary biliary
cirrhosis
5 29 F 60 Alcoholic cirrhosis
6 42 F 54 Chronic active
hepatitis
7 52 M 60 Alcoholic cirrhosis
+ hepatoma
Table II. Operative details of the seven patients (mean
(SEM))
Blood loss Duration Urine volume
Phase (ml) (min) (ml)
Dissection 1788(1147) 135 (45) 345 (279)
Anhepatic 1657 (1029) 56 (9.4) 57 (47)
Reperfusion 2862 (2288) 95.7 (19.5) 282 (182)
Although large by general surgical standards,
blood loss was not excessive for this operation.
All patients produced urine during the anhepatic
period. The mean cold ischaemic time, defined as
the period of cold storage of the livers before
transplantation, was 406 (SEM 138) min. Liver
survival is anticipated for a cold ischaemic time of
up to 12 h using modern preservation fluids (more
recently this has been extended to 24 h [9]).
Results of the assays for morphine and its
metabolites in plasma are shown in figure 1, and
for urine in table III. Plasma concentrations of
morphine during the anhepatic period decreased
rapidly, consistent with the distribution phase
after i.v. injection, followed thereafter by little
change. During the anhepatic phase, M3G was
detectable in low concentrations in plasma (less
than 7 ng ml-1), but urinary concentrations in¬
creased to a maximum of 137 ng ml-1. M6G was
detected at a maximum of 1.4 ng ml 1 in plasma
and 22.3 ng ml"1 in urine during this phase.
Normorphine was undetectable in both plasma
and urine throughout both the anhepatic and the
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Fig. 1. Mean (SEM) plasma concentrations of morphine (#), M3G (□) and M6G (O) during the
anhepatic and reperfusion phases of orthotopic liver transplantation.
Table III. Urinary concentrations (mean (SEAT)) of mor¬
phine, morphine-3-glucuronide and morphine-6-glucuronide
during the anhepatic and reperfusion phases of liver
transplantation in seven patients
Morphine M-3-G M--6-G
(ng ml" 0 (ng ml-1) (ng ml-1)
Baseline 0 0 0
Anhepatic phase
5 min 0 4.1 (2.1) 8.61(4)
30 min 315(105) 31 (15) 5.61 (3.2)
60 min 2167 (424) 137 (39) 22 (6)
Reperfusion phase
30 min 1402(305) 66 (24) 13 (7)
60 min 812 (307) 132 (44) 11 (6)
reperfusion phases of the study. Mean concen¬
trations of both plasma and urinary M3G in¬
creased rapidly on reperfusion of the transplanted
liver, to a maximum of 236 ngmf and 132 ng
ml"1, respectively. Mean M6G concentrations
increased in plasma to a maximum of 7.1 ng ml"1
and decreased slightly in urine, to 11.4ngml_1,
during this period of the study.
DISCUSSION
The primary site ofmetabolism ofmorphine after
therapeutic doses has been debated; so also has
the clinical importance of the glucuronide metabo¬
lites [10-12] which have been shown to be active
in animals [13] and man [14], Clinical and
laboratory studies have suggested two significant
sites for morphine metabolism: the liver and
kidneys. In vitro studies of isolated kidney and
liver have shown the presence of uridine di-
phosphoglucuronyl transferase (UDP glucuronyl
transferase) [15, 16], although these do not relate
necessarily to function in vivo (unpublished
observations).
The historical conception of the liver as the
major organ of morphine metabolism was con¬
tested by the studies in patients with renal failure
discussed above and by studies suggesting normal
pharmacokinetics in patients with cirrhosis [17].
However, a more recent study in such patients has
shown a decrease in the clearance of morphine
[18]. The differences between these studies may
be related to the severity of the liver disease in the
patients studied, but comparisons between pati¬
ents are difficult, as conventional tests of liver
function are poor predictors of changes in
pharmacokinetics of drugs [19]. The metabolism
of other drugs which undergo glucuronidation
suggests that glucuronidation [20] may be rela¬
tively spared compared with other metabolic
functions, such as oxidation, in severe liver
disease. The alternative explanation is that the
enzyme system UDP glucuronyl transferase is
found in other extrahepatic sites such as the gut or
kidney and these may be significant sites for
metabolism in man.
Hug and colleagues [21] measured morphine
metabolism during the anhepatic phase of liver
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transplantation in man, but could not measure the
metabolites directly. They found insignificant
metabolism during this period. In contrast,
studies in the functionally anhepatic dog showed
that morphine was glucuronidated in approxi¬
mately equal degrees by hepatic and extrahepatic
tissues [22].
The lack of significant metabolism of morphine
in our patients during the anhepatic period of
liver transplantation suggests that, in the group of
patients studied, the liver is the predominant
organ ofmorphine metabolism. It is clear also that
the transplanted liver begins to metabolize mor¬
phine rapidly, shortly after reperfusion. A pre¬
vious study in this centre, using an identical
technique measuring the metabolism of mida¬
zolam, demonstrated the presence of both major
metabolites of midazolam (alpha-hydroxy mida¬
zolam and 4-hydroxy midazolam) during the
anhepatic period [23], The difference between the
metabolism ofmidazolam and ofmorphine during
the anhepatic period may be explained by the
different metabolic pathways: midazolam under¬
goes phase I metabolism to its metabolites, whilst
morphine metabolism is principally phase II. It is
possible, therefore, that phase II metabolism is
limited primarily to the liver.
Blood loss and subsequent replacement during
the study would have a small dilution effect on
measured morphine and metabolite concentra¬
tions. However, the loss was continuous rather
than sudden in the patients studied. Bolus i.v.
administration of drugs results in a rapid increase
in plasma concentration and (with morphine)
rapid distribution outside the vascular compart¬
ment. During this time the amount of blood lost
and transfused was small. Similarly, during the
elimination period studied, the contribution of
blood loss and replacement, even of this mag¬
nitude, was small. Thus small changes in plasma
concentrations of morphine and its metabolites
resulting from blood losses and replacement may
have occurred, but significant changes in pharma¬
cokinetic parameters are unlikely.
The lung is known to metabolize and take up
selectively certain endogenous and exogenous
substances [24]. Studies in anaesthetized and
postoperative patients showed significant uptake,
but no metabolism of morphine [25,26], Al¬
though not metabolically active, the lung is
thought to act as a reservoir for morphine and
other basic drugs.
Increased clinical effects after morphine ther¬
apy in patients with renal failure suggested that
the kidney may be important in morphine metab¬
olism [2, 3]. This appeared to be supported by
pharmacokinetic studies using non-specific assays
which did not differentiate between unchanged
morphine and its metabolites [1]. More recent
work using HPLC [27] and a specific radio¬
immunoassay [28] has shown increased volumes
of distribution and cumulation ofmetabolites, but
no decrease in clearance of unchanged morphine
in patients with end-stage renal disease. Thus it is
thought that the cumulation of these metabolites
(which are pharmacologically active) is the cause
for the apparent sensitivity to morphine in
patients with renal failure.
The appearance of morphine metabolites in
urine during the anhepatic period, despite the
plasma concentrations being undetectable, may be
explained in two ways. The kidney may be
concentrating the small quantities of morphine
metabolites in the plasma which are undetectable
by HPLC. Alternatively, the kidney could be an
extrahepatic site for morphine metabolism (al¬
though, if it were, significantly larger concen¬
trations of metabolites would be expected in
urine).
Within the constraints of this model, we
conclude that the liver is the major site of
morphine metabolism in man.
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PA
PHARMACOKINETICS OF MORPHINE IN PATIENTS
FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION
M. P. SHELLY, K. G. QUINN AND G. R. PARK
Little information is available on the disposition
of morphine in patients following liver surgery.
« There have been several reports of morphine
pharmacokinetics in normal volunteers and sur¬
gical patients [1-3], but confusion remains on its
disposition because of differences between the
design of studies and analytical specificity for
morphine [4-6]. Investigations have shown both
normal [7] and abnormal [8] clearance of mor¬
phine in cirrhosis. It was proposed that these
differences were related to the severity of hepatic
dysfunction in the two groups studied. In ad¬
dition, morphine clearance has been found to be
decreased in septic shock [9],
Classically, the liver has been considered the
major site ofmetabolism, principally glucuronida-
tion, but a renal metabolic role has been postu¬
lated more recently [10-12], We studied the
pharmacokinetics of morphine, particularly to see
how, in the period immediately following ortho¬
topic liver transplantation, patients metabolize
and excrete morphine. At this time, the newly
transplanted liver has been subjected to two
operations (donor hepatectomy and recipient
operation). Additionally, there are periods of
warm and cold ischaemia during the operations
and transport of the donor liver which may
further impair hepatic function. We believed,
therefore, that study of these patients may provide
information that would be difficult to obtain
from othermore heterogeneous groups of patients.
This group of patients is of further interest
because it is possible to collect simultaneously
blood, urine and bile.
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m.a., f.f.a.r.c.s.; Department of Anaesthesia, Addenbrookes
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SUMMARY
Plasma and urine concentrations of morphine,
morphine-3-glucuronide and morphine-6-
glucuronide were measured in seven patients
after orthotopic liver transplantation. After a
single i.v. bolus of morphine sulphate 10 mg a
biexponential decay was observed. Although the
distribution and elimination half-lives for mor¬
phine were similar to those described in previous
studies, a greater total apparent volume of
distribution was observed. This was reflected in a
greater plasma clearance of morphine than has
been reported previously. The concentration of
morphine glucuronides remained increased 24 h
after administration of morphine; the clinical
significance of this remains to be established.
The metabolism of morphine was virtually com¬
plete, with 4.5% unchanged morphine recovered
in urine 24 h after drug administration.
PATIENTS AND METHODS
The study was approved by the Hospital Ethics
Committee and informed consent was obtained
from seven subjects (five female, two male; ages
19-52 yr (mean 36 yr); weights 37-96 kg (mean
64 kg) (table I)) before operation. Both the
anaesthetic technique and the surgical procedure
have been described previously [13-15]. The
perioperative use of morphine and its derivatives
was avoided and fentanyl used to provide an¬
algesia. After operation, patients were transferred
to the Intensive Care Unit and, when haemo-
dynamic stability had been achieved, a baseline
10-ml blood sample was taken from a radial
arterial cannula placed for perioperative monitor¬
ing. Samples of urine and bile were obtained
also. Morphine sulphate 10 mg was diluted to
10 ml with 0.9 % saline and injected over a 2-min
period through a centrally placed venous catheter.
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Table I. Details of patients studied
Patient Sex Age Weight








This dose of morphine was chosen after previous
studies with morphine 2.5 mg i.v. [16] and 5 mg
1.v. (unpublished observation) had demonstrated
the safety of the larger dose in this group of
patients. Blood was sampled further at 0.5, 1, 1.5,
2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 12, 18 and 24 h after
drug administration. Urine and bile specimens
were collected at 1,2, 3, 4, 5, 6, 12, 18 and 24 h
after drug administration.
Blood samples were placed in a tube containing
lithium-heparin anticoagulant and mixed. The
tubes were centrifuged at 3000 g and the super¬
natant plasma removed and stored in siliconized
tubes at —20 °C before analysis. During the study
period, the patient was managed as described
previously [17] and additional analgesia was
provided with bolus doses of fentanyl, which does
not cross-react with the assay method. Laboratory
investigations (including liver function tests and
creatinine clearance) were measured during the
24 h of the study period. In addition, during
surgery following revascularization of the liver,
hepatic arterial blood flow was measured using a
Statham SP12 electromagnetic flowmeter.
Morphine analysis
In order to obtain the required degree of
sensitivity and specificity, plasma and urine
morphine were measured by a radioimmunoassay
procedure validated previously. This utilized an
extraction procedure to exclude metabolites from
the measurement [18]. Plasma and urine mor-
phine-3-glucuronide (M3G) and morphine-6-
glucuronide (M6G) concentrations were meas¬
ured by a modification of a previously described
high pressure liquid chromatography (HPLC)
technique [19], The reference standards used
were morphine sulphate pentahydrate (Napp
Research Centre Ltd, Cambridge) and M3G
(Sigma Chemical Corporation Ltd, Poole, Dorset);
M6G was synthesized using a modification
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pared in control plasma or urine for calibration,
quality control and validation. Calibration curves
were constructed for all compounds.
Before HPLC, morphine metabolites were
extracted from plasma and urine using solid phase
Bond Elut CI8 cartridges (Jones Chromato¬
graphy, Llanbradach, Glamorgan). Subsequent
quantification was by HPLC using fluorescence
detection at 349 nm to estimate M3G concen¬
trations and coulometric detection at +0.9 V (v.
silver-silver chloride) to measure M6G concen¬
trations. The lower limit of detection for M3G
was lOngmL1 and for M6G by electrochemical
detection was 1-2 ng ml-1.
Pharmacokinetic analysis
Plasma morphine data was fitted to a two-
compartment model by the method of non-linear
least squares analysis [21], The curve-fitting
procedure gave calculations for the area under the
plasma concentration v. time profile (AUC),
distribution half-life (TP), the elimination half-
life (7IP), the volume of the central compartment
(F]), the apparent volume of distribution (Fdi,rea) '
and the total clearance (CI).
RESULTS
Postoperative liver function tests, creatinine clear¬
ance, ischaemic time and intraoperative hepatic
arterial blood flow for each patient are shown in
table II. No patient had major renal impairment
during the period of study; in all cases creatinine
clearance exceeded 50 ml min~l [22],
Following injection of morphine, an exponen¬
tial decline in plasma concentration was observed,
with no morphine detectable after 24 h (fig. 1).
Four hours after administration of morphine
(peak concentration for M3G), concentrations of
M3G exceeded the parent drug nearly 10-fold.
The results of the pharmacokinetic analysis are
summarized in table III.
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Table II. Postoperative liver function tests, plasma creatinine and hepatic ischaemic times in seven
patients. GPT = Plasma glutamic pyruvic transaminase; AP = plasma alkaline phosphatase ; HABF =


















1 76 84 223 54.8 391 130 420
2 328 136 387 101 267 47 140
3 228 2120 385 63.3 284 71 60
4 37 412 181 88 259 42 400
5 40 181 301 63.7 254 59 1000
6 47 148 258 54.3 231 34 213
7 79 104 484 54.6 236 31 600
NR 2-17 7-40 30-135 90-120
Time (h)
Fig. 1. Plasma concentrations of morphine (O)j M3G (□) and M6G (♦) following i.v. administration
of morphine sulphate 10 mg in patients following liver transplantation.
Table III. Pharmacokinetic parameters calculated after morphine sulphate 10 mg i.v. in patients
following orthotopic liver transplantation. T^a and Tf = distribution and elimination half-lives; =
volume of the central compartment; Wd = apparent volume of distribution; CI = total body clearance of





















1 96 52 28.5 252 1.53 3.78 0.62 125.8
2 71.8 36 31.3 198 1.94 4.8 1.09 103.9
3 41 35 15.0 130 3.26 10.7 3.44 53.4
4 82 19 27.4 231 1.49 3.9 0.70 130.3
5 55 37 43.3 320 3.27 14.3 1.86 73.7
6 50.8 26 15.5 212 1.26 7.0 1.38 107.5
7 37 44 20.1 175 2.51 10.3 2.46 82.7
Mean 61.9 36 26 217 2.2 7.8 1.65 96.8
SEM 8.3 4 4 23 0.3 1.5 0.4 10.6






















1 12 18 242 3 4 5 6
Time (h)
Fig. 2. Mean urine recovery of morphine, M3G and M6G following i.v. administration of morphine
sulphate 10 mg in patients following liver transplantation.
Elimination ofM3G, like M6G, appeared to be
slow, with detectable concentrations of both
metabolites at 24 h. Because of this it was not
possible to derive any pharmacokinetic para¬
meters for the elimination of the glucuronides,
since no further plasma samples were taken after
24 h. Intraoperative hepatic arterial blood flow,
which was very variable, did not appear to relate
to the postoperative clearance. Recovery of mor¬
phine at the 1 ng ml-1 level (limit of detection)
was 89%. Recovery from plasma and urine for
both glucuronides was greater than 90%.
Morphine was recovered predominantly as
M3G (85 %), with 3.6 % as M6G and only 4.5 %
as the unchanged drug (fig. 2). The remainder of
the morphine dose may be either accounted for in
the systemic circulation (fig. 1) or excreted in the
bile. An attempt was made to analyse morphine,
M3G and M6G in bile specimens, but this was
not reliable, because of co-eluting compounds.
DISCUSSION
This study determined the pharmacokinetics of
morphine following the i.v. administration of
morphine sulphate 10 mg to seven patients fol¬
lowing liver transplantation. The analytical
method combined solid phase extraction and
radioimmunoassay to measure unchanged mor¬
phine in plasma and urine, whilst excluding
morphine glucuronides [18]. In addition, the
glucuronides were analysed by a modification of
an HPLC technique to quantify M3G by fluori-
metric detection and M6G by coulometric de¬
tection [19],
A bi-exponential decrease in plasma morphine
concentration was evident in each patient. A more
rapid distribution phase has been observed in
other studies, but the first sampling point in our
study was 30 min after drug administration and
this phase was, therefore, not seen. The elim¬
ination half-life was 2.4 h; earlier studies using
specific assays for morphine have found similar
elimination half-lives ofapproximately 2 h [3, 5, 6],
The plasma clearance of morphine in this study
(1.65 (SD 0.4) ml min"1 kg^1) was greater than
previous estimates in healthy volunteers and
surgical patients [23] and the recovery of mor¬
phine and morphine glucuronides from urine
indicates that the excretion of morphine was
virtually complete. In addition, the wide range of
clearances found may be a reflection of the
interpatient variability in chronically ill subjects
with pre-existing liver disease. Clearance values
greater than hepatic arterial blood flow were
observed in four of the seven patients. However,
the contribution of portal blood flow to the
clearance was not assessed and probably explains
this discrepancy. Alternatively, some extrahepatic
sites of morphine metabolism may exist.
Patients with impaired renal function show
prolonged opioid action following morphine [10],
This has been attributed recently to cumulation of
M6G which is pharmacologically active [1,24,
25]. Patients with chronic liver disease may have
impaired renal function, although perioperative
renal protection with low dose dopamine may be
beneficial [26], In addition, the periods of stress,
surgical trauma and drug therapy may induce a
period of oliguria when renal elimination of drug
metabolites is impaired [27]. The patients in this
study had adequate renal function during the
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period of investigation, as indicated by a creatin¬
ine clearance in excess of 50 ml min-1.
Although the elimination half-life would appear
to coincide with documented values, the estimates
for volume of distribution and clearance differ.
The disposition ofmorphine in patients with liver
disease has received limited study. The com¬
bination of age, disease, anaesthesia and surgery
may have contributed to the observed values
found for volume of distribution and clearance
and may explain the discrepancy with other
pharmacokinetic studies.
In this group of patients the metabolism of
morphine was found to be almost complete, with
only 4.5 % of unchanged morphine recovered in
urine after 24 h. Total clearance was found to be
greater than liver blood flow, indicating the
possibility of extrahepatic metabolism. Further
use of these specific methods for morphine assay
may allow the exact sites of non-hepatic metab¬
olism to be determined.
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U.b. i^i /(?>
Without being informed that the NHS manage¬
ment board had invited district general managers
to "express an interest," our health authority, on
20 April 1989, debated how it might react if an
instruction was given in future that it would have
to choose some form of self governing status.
Various options were discussed and it was agreed
that if in future we were unable to remain with the
status quo perhaps the best option for patient care
would be for the whole district of North Devon to
become a self governing trust. No formal vote was
taken and the matter appeared to be hypothetical,
with the assumption that there would still be much
to be debated and discussed in the future.
You can therefore imagine the consternation
among the medical members of the health authority
when they were informed by the district general
manager on 10 May 1989—the day before the
Independent was due to publish the list of districts
"expressing an interest"—that he had written a
letter to the regional general manager on 3 May
formally to "express an interest in forming a
self governing trust for the whole district" and
indicating that this application had the full support
of all the medical members of the health authority.
It would be interesting to find out how many
other doctors in other districts have been similarly
misrepresented into becoming Mr Clarke's "willing
volunteers."
WILLIAM I' BRADFORD
North Devon District Hospital,
Barnstaple, Devon
I Warden J. Clarke steps out. BrMedJ 1989;298:1478. (3 June.)
Sir,—Bassetlaw has recently been quoted in the
House of Commons' and in the press as "express¬
ing an interest in becoming self governing" and we
are aware that pressure has been brought to bear on
other districts to follow, using our own as an
example. Clinicians and other staff, when con¬
sulted, have supported this on the basis that the
hospital and community services would be a part of
one composite unit. However, we are not prepared
to support the furtherance of this idea without
considerably more information.
We all believe that evaluation of the resource
management initiative and application of the
lessons learnt from it would be far more likely to
improve patient care than would the introduction
of self governing trusts and general practice
budgets in the way described in the white paper.
However, we have not objected to the "expression
of interest" by our district for specific local reasons.
Our district was established in 1982 because of
considerable local opposition to its incorporation
into nearby districts. It was at the time one of the, if
not the, most underfunded district in Britain and
facilities for medical care were appalling. This
situation has improved with the opening of the
first phase of the district general hospital, and
community and priority services have improved
dramatically despite continued underfunding.
This has occurred with persistent lobbying of
those directly responsible for funding, and we are.
convinced that the dissolution of the district, as
would happen with the implementation of the
white paper proposals, would undermine our
ability to provide appropriate care for our patients.
We fear that separating the district general
hospital services from community services would
introduce a damaging element of competition
between unlike services. A situation could easily
develop where patients would be discharged early
to community services, which could disclaim or
only grudgingly accept responsibility for their
care, leading to the sort ofdivide between authority
managed services and trusts which at present
bedevils community care of the mentally ill and
for which the second Griffiths report was com¬
missioned.
Our dilemma is that of protecting specific local
needs while supporting professional recommenda¬
tions. The government's intention to introduce
competition into the service by separating those
responsible for providing the service from those
operating it can probably be achieved by using
lessons from the resource management initiatives.
If the principle can be established that such
operators must provide both hospital and comple¬
mentary community services the danger of gaps
arising in services would be reduced. If agreement
on the maintenance of nationally determined,
although inevitably more flexible, standards, pay,
and conditions of service can be reached perhaps
we can preserve a National Health Service.









Basset law District General Hospital,
Worksop, Nottinghamshire S81 UBD
1 Owen D. Opposition day motion. House of Commons Official
Report (Hansard). 1989 April 18;151:cols 201 -43 (No 87.)
Isoflurane compared with
midazolam in the intensive
care unit
Sir,—We are concerned about certain features of
the study of sedation of the critically ill reported by
Dr K L Kong and others.1 They quote Geller et al
as reporting dangerous complications from the use
of flumazenil, but in this paper no untoward
haemodynamic or respiratory effects were re¬
ported.2 In one patient it was necessary to infuse
flumazenil for five hours, but this cannot be
considered dangerous in an intensive care unit. We
have infused flumazenil for prolonged periods'
without hazard, although it is expensive.4' Dr
Kong and others also correctly quote the rapid rise
in intracranial pressure associated with the reversal
of midazolam' as dangerous to the patient, but
such vulnerable patients are surely a group in
whom isoflurane sedation would also be inapplic¬
able and would have been excluded from the study.
The authors also state that the effective dose of
isoflurane in their study was confined to a narrow
range (01-0-4% concentration), whereas the re¬
quirement for midazolam showed considerable
variability among patients (0-014-0-140 mg/kg/
hour). The dose of isoflurane will depend on many
factors including the minute volume, alveolar
ventilation, and cardiac output. There was no
variation in the concentration of midazolam used
(0-1%). The way in which the authors discussed
dose equivalents is misleading.
We wish briefly to report on two patients in
whom other sedatives (midazolam, propofol,
ketamine, and narcotics) proved ineffective and
isoflurane was useful but presented other problems.
The first patient was a 21 year old girl who required
sedation after combined liver and kidney trans¬
plantation that was complicated by acute tubular
necrosis (managed with continuous haemofiltra-
tion and dialysis), recurrent sepsis, and life
threatening gastrointestinal haemorrhage. She re¬
mained agitated and distressed while receiving a
midazolam infusion at up to 15 mg/hour and bolus
doses of morphine. Effective sedation was finally
achieved with a combination of0-5-2-0% isoflurane
and continuous intravenous infusion of midazolam
(10 mg/hour) and subsequently of alfenlanil (8 mg/
hour). Because of concern about nephrotoxicity
from fluoride released from the breakdown of
isoflurane and her potential failure to eliminate it
the serum fluoride concentration was measured
after six days of treatment and found to be 18 pinol/
I (normal range 5-3-10-5 pmol/1). Although this is
not at the toxic level (50 pmol/1), it is greater than
that previously reported with isoflurane.',' Will
even higher concentrations be achieved in critically
ill patients who receive isofluranc for longer periods
or in whom an efficicnl method of renal replace¬
ment treatment is not used?
The second patient was a 15 year old boy who
required ventilatory support for a severe asthma
attack. He received 0-25-1-0% isofluranc in addi¬
tion to fentanyl and midazolam or propofol by
infusion.
Although it was a useful technique, ducting of
the expired gases away from the ventilator was a
problem. Dr Kong and others do not tell us
explicitly how this was achieved. When we used it
one of the limiting factors was having the patient
next to a window; perhaps activated charcoal may
be one answer to this problem. Cost must also be
considered. The ventilators used in Dr Kong and
others' study and for our patients were open circuit
ventilators needing large flows of fresh gas. The
estimated cost of isoflurane for our first patient was
£1200 over the six days (midazolam 10 mg/hour
cost £19.20 per 24 hours and alfenlanil 8 mg/hour
cost £107 per 24 hours), and for the second patient
the total cost of isoflurane fui three days was £ 1500.
We used higher concentrations than Dr Kong and
others described, and iheir method will result in
some savings in cost.
Isofluranc will probably be a valuable addition 10
our therapeutic options for sedation of the critic¬
ally ill, but it will require further evaluation over
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Acute mountain sickness
Sir,—It is disappointing that an essay by a
doctor should advocate drug treatment without
once mentioning simpler, much more effective
measures. Dr S B Blunt suggests that acetazolamidc
should be indicated for the prophylaxis of acute
mountain sickness; nowhere, however, docs she
mention acclimatisation.'
Acclimatisation (slow ascent) is the best prophy¬
lactic, and descent is the best treatment. Ignoring
these basic facts (with or without drugs) is a main
cause of illness and death on mountains. Dr
Blum's own rate of ascent on Kilimanjaro far
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SPECIAL ARTICLE
Anaesthesia and the law
Monitoring
D. Brahams, Barrister-at-Law, 5 New Square, Lincoln's Inn, London WC2A 3RJ.
Arguably, many deaths and injuries from hypoxia could be
avoided if more comprehensive monitoring equipment and
stricter standards of care were imposed on anaesthetists.
Those health authorities and private hospitals and clinics
who plead lack of cash as justification for operating with
outmoded and inadequate equipment and a shortage of
trained staff should think again. Leaving aside the human
tragedy of an anaesthetic injury or death, one large legal
claim for damages can cost more money than ever could be
saved by shortsighted economies. Having said that, it is
clear that limited cash resources must make for difficult
choices; the provision of a new ECG monitor or pulse
oximeter, for example, may deprive other departments of
valuable equipment and staff or reduce the number of
treatments given and so forth.
In Massachusetts, USA, stricter practice standards for
anaesthetists are paying off financially. Since these have
been in force claims have dramatically reduced and lower
premiums are the order of the day, with more reductions
planned if the trend continues. Anaesthesia will become a
low risk specialty for insurers.1 In New York State, regula¬
tions are being proposed that will require specific moni¬
toring devices to be used during anaesthesia. Further, and
in response to the Libby Zion case,2 there are hopes that
maximum hours of work per week will be imposed on
junior hospital doctors in New York State in the hope of
reducing medical misadventures occurring as a result of
fatigue. Though there is much concern about fatigue and
long hours in Britain, attempts to legislate in Britain seem
doomed to fail.
Similarly, recommendations for stricter standards in
anaesthesia remain counsels of perfection with no manda¬
tory force as, for example, suggestions that ECG moni¬
toring should be performed during all routine anaesthesia.3
The Association of Anaesthetists of Great Britain and
Ireland has published recommended standards of moni¬
toring (1988); but, again, these standards do not have the
force of law and are not uniformly complied with across
the country.
Following an anaesthetic disaster can the plaintiff or his
family claim that a failure to follow such recommendations
was negligent and caused the injury? In my view, though
such guidelines would be persuasive, noncompliance (often
through lack of resources) would not necessarily render the
anaesthetist or his hospital negligent and it would depend
on all the circumstances. The law requires a doctor to be
reasonably competent and to provide a reasonable stan¬
dard of care which may not be optimum. Thus, if the
doctor can satisfy the court that he (or she) has complied
with a practice considered proper by a responsible body of
medical opinion in his field and that he provided a reason¬
able standard of care to the patient he will not be found
negligent."
However, on 9 November 1988, following a Fatal Acci¬
dent Inquiry into a death arising from dental anaesthesia, a
Scottish Sheriff recommended that 'urgent anxious and
careful consideration be given by the Authorities to the
adoption' of ECG monitoring and the attendance of a state
registered nurse trained in resuscitation techniques 'in every
case where a general anaesthetic is administered in a dental
clinic or a dental surgery'.
In that case an 11-year-old girl was given nitrous oxide,
oxygen and halothane by a trained anaesthetist to allow for
extraction of four teeth. A standard inhalation technique
was used. After the third tooth had been extracted the
halothane was stopped and after removal of the fourth
tooth the mask was taken off. The child was still breathing
easily but then her breathing became shallow and intermit¬
tent. The anaesthetist tipped her chair back, gave oxygen
via a facemask and rubbed her sternum. This caused an
intake of breath but no movement. Her pulse became
weaker and he tilted the chair so that her head was below
her feet; she was breathing shallowly. She was placed on
the floor, breathing intermittently from the oxygen mask
but with no pulse.
The anaesthetist then requested a defibrillator from the
recovery room and an ECG trace confirmed that the child
had suffered a cardiac arrest. The trace showed ventricular
fibrillation. He then inserted a Brook airway and the
dentist performed expired air resuscitation. The anaesthe¬
tist believed there was sufficient oxygenation of the patient
to permit defibrillation but he was unable to restore the
heart rhythm, and after the first application asystole
occurred. Cardiac massage and lignocainc produced a very
slow heart trace three times but breathing could not be
maintained and the patient died 2 days later in hospital.
The sheriff determined that the child's death might have
been avoided if an electrocardiograph had been used to
monitor her heart, a state registered nurse trained in resus¬
citation techniques had been in attendance, and if the
patient's trachea had been intubated and her lungs venti¬
lated using a tracheal tube with 100% oxygen immediately
cardiac arrest had been diagnosed. (At the inquiry, the
anaesthetist was criticised by the sheriff s medical expert for
failing to intubate promptly and that this should have been
his first priority rather than defibrillation.)
The sheriff said that 'the most significant evidence in the
inquiry was the ready acceptance that acute cardiac failure
can occur during dental anaesthesia even when an impec¬
cable anaesthetic technique is employed by an experienced
anaesthetist. Anyone who has teeth extracted under general
anaesthetic is at risk. In these circumstances a requirement
to resuscitate a patient is to be anticipated. Adequate
personnel and equipment should be on hand to maximise
the possibility of a successful resuscitation.' The anaesthe¬
tist had the greatest difficulty in carrying out the resusci¬
tation attempt in the absence of skilled assistance as three
procedures were required immediately and he could not
carry them out by himself at the same time.
Another significant piece of medical evidence given to
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these symptoms may represent rapid awakening of the
patient in an apparently hostile environment. The apparent
safety of flumazenil does not preclude the need for careful
dose titration. Adverse cardiovascular responses similar to
those seen after naloxone13 may occur if patients are
awakened suddenly with a tracheal tube in place, although
this has not been reported to date. Cardiovascular instabi¬
lity has not been reported in studies of reversal of sedation
after coronary angiography,14 but these patients had
neither a tracheal tube in place nor a painful surgical
incision. The short duration of action of flumazenil (about
one hour) may necessitate repeated bolus doses or an
infusion in cases of significant benzodiazepine accumu¬
lation.
The prolonged benzodiazepine sedation in these patients
may be explained by drug accumulation due to the delayed
elimination that occurs in the elderly,15 the critically ill
(particularly those with sepsis)2-3 and a subgroup of the
normal population.4 This is supported by the observation
that several of the patients in this study required very small
daily doses of midazolam. Alternatives to the use of mida¬
zolam are few. Propofol is being investigated currently for
this purpose and may prove useful, although we have
noticed some haemodynamic instability with this agent,
especially in jaundiced patients (unpublished observation).
Volatile agents (particularly isoflurane) are also under
investigation and may prove useful in the future if the
problems of atmospheric pollution and cost are resolved.
The exact place of these alternatives compared to the use of
midazolam, combined in some patients with the use of the
antagonist, remains to be clarified.
The four patients who required a flumazenil infusion
needed less than has been calculated theoretically to be
necessary (1.44 mg/hour) by Klotz and Kanto.16 This may
indicate that flumazenil, an imidazobenzodiazepine, may be
subjected to similar alterations in elimination to those
demonstrated for midazolam.2^15
The patients who did not show an improvement of
conscious level after flumazenil are thought to have had
other causes for their depressed conscious level including
electrolyte abnormalities, tissue hypoxia, cerebral oedema,
and hepatic or septic encephalopathy. The last is a poorly
understood condition.11 All made a full neurological recov¬
ery except for one patient who had a hepatic resection and
died of liver failure.
Anecdotal reports have suggested that flumazenil may
reverse some features of hepatic encephalopathy, mediated
via the GABA system;18 further studies are in progress to
evaluate its value in this condition. Two patients who
responded to flumazenil had undergone liver transplan¬
tation but none of their laboratory investigations
supported the development of liver failure, and the
improvement in conscious level is thought to be due to
reversal of residual effects of midazolam.
Sudden awakening may occur, and result in sudden
discomfort, when flumazenil is used in patients who have a
tracheal tube in place. This resulted in airway obstruction
when the tube was bitten in one of our patients. We were
prepared for this eventuality and the addition of isoflurane
to the inspired gas resolved the situation rapidly. Not all
ventilators have the facility to add vapours to the inspired
gas. It may be prudent to have ready a suitable dose of a
short acting intravenous anaesthetic agent, such as thiopen¬
tone, when a patient whose trachea is intubated is to
receive flumazenil. The short action of flumazenil makes it
unlikely to be a problem of prolonged duration.
In conclusion, flumazenil appears to be a useful agent for
reversal of unexpectedly prolonged benzodiazepine seda¬
tion in critically ill patients. The short duration of action of
flumazenil necessitates either a continuous intravenous
infusion or repeated bolus doses if significant benzodiaze¬
pine accumulation has occurred. Other recoverable causes
of depression of conscious level must be considered if
flumazenil does not reverse sedation.
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Table 1. Sedation score used to assess change in conscious level of
critically ill patients after the administration of flumazenil. A
significant response was defined as an increase of three points or
more.
1. Alert, writing coherent messages
2. Alert, writing meaningless but legible letters
3. Alert, writing unintelligible scrawl
4. Alert, unable to write
5. Awake, but confused
6. Awake, agitated
7. Awakens with soft spoken voice
8. Awakens with loud voice
9. Awakens with gentle shaking
10. Awakens with glabellar tap
11. Responds to fingernail pressure in a purposeful way
12. Responds to fingernail pressure in an unpurposeful way
13. Does not respond to fingernail pressure
administration of flumazenil. The short duration of action
of flumazenil led to resedation in seven of these patients
within one hour of its administration. One patient required
resedation with isoflurane when she bit her tracheal lube
and caused partial airway obstruction. Four patients
received an infusion of flumazenil to maintain the improve¬
ment in conscious level (Table 3). The infusions were
required for a period of 8 hours to 10 days and were given
at a rate of 0.5-1 mg/hour. The patient who required
flumazenil for 10 days has been reported previously.11 The
success of flumazenil could not be related in a consistent
pattern to age, sex, pathological processes, or APACHE II
score due to the wide interpatient variability. In addition,
the midazolam dosage, duration of sedation and time after
discontinuation of midazolam did not correlate with the
effects of flumazenil.
There were no unwanted effects of flumazenil such as
nausea and vomiting in any of these patients. Blood pres¬
sure and heart rate increased in five patients by 5-20
mmHg and 12-25 beats/minute respectively.
Eleven patients received significant quantities of opioids
during the sedation period. These patients received
naloxone to evaluate whether opioid-related sedation was
present. Two patients (18%) exhibited an improvement in
conscious level of two points after naloxone but showed no
further improvement with flumazenil.
Five patients did not respond to the administration of
flumazenil. One of these had received a liver transplant.
The donor organ had been ischaemic for an unusually
prolonged period before revascularisation during the donor
operation. He was sedated for 48 hours postoperatively. A
cranial computerised tomogram was obtained when he did
not awaken after flumazenil, and this showed possible
cerebral oedema. Consequently, his lungs were ventilated
artificially to produce hypocapnia (Paco, 3.5-4.5 kPa);
neuromuscular blockade was used to prevent coughing and
struggling, and opioids to provide sedation. He had
awoken when the myoneural blocking agents were reversed
48 hours later. A second patient had also undergone liver
retransplantation due to chronic rejection after her first
Table 2. Details of the 13 patients who received flumazenil to
reverse the effects of midazolam. Data are presented as mean (SD).
Females/males 8/5
Age, years 49.2 (19.6)
APACHE II 18.6 (5.8)
APACHE II without GCS 10.6 (4.1)
Duration of sedation, days 5.6 (5.2)
Time since last midazolam administration, hours 28 (24)
Presenting diagnosis




transplant (for primary biliary cirrhosis). She required
small doses of both morphine and midazolam after oper¬
ation; only 10 mg of each was given in the first 24 hours.
She did not respond to either flumazenil or naloxone but
awoke spontaneously 12 hours later. One patient who
underwent a difficult hemihepatectomy, complicated by a
30-litre blood loss, did not show any improvement in
consciousness when either antagonist was administered,
and did not make a spontaneous neurological recovery. It
was thought that the coma was due to progressive hepatic
failure and encephalopathy, and eventually the patient died
without regaining consciousness. One patient had suffered
massive trauma that necessitated bilateral lower limb
amputations and several extensive operations to deal with
the degloving injury to her abdomen. A minor head injury
was sustained also. She developed acute renal failure as a
consequence of these injuries. She had received large
amounts of both midazolam and opioids; large, but care¬
fully titrated, doses of flumazenil (5 mg) and naloxone (1.2
mg) had no effect. She regained consciousness sponta¬
neously one week later. One patient required intensive care
after a difficult colectomy for diverticular disease. There
were extensive adhesions within the abdomen and the
operation was complicated by excessive bleeding (15 litres).
Her trachea was extubated after 48 hours of ventilatory
support, but she became progressively confused with deter¬
ioration in her respiratory function. She received fluma¬
zenil at this time in an attempt to reverse any residual
effects of benzodiazepines (including the confusion) and to
try to avoid the need for reinstitution of ventilatory
support. There was no response to the flumazenil, and
ventilatory support was restarted. She awoke gradually
over the next 48 hours.
Discussion
Flumazenil is a specific benzodiazepine receptor antagonist.
It has been shown to be a safe agent for the reversal of
short-term benzodiazepine sedation in patients who require
intensive care.12 The only adverse effects that have been
reported in critically ill patients have been nausea and
vomiting. Fear and anxiety have been described if large
doses (more than 10 mg) of flumazenil are given rapidly but
Table 3. Details of patients who received an infusion of flumazenil.
Total dose
Age APACHE Days midazolam Flumazenil
(years) Sex (-GCS) sedated (mg) infusion
67 F 14 4.0 50 1 mg/hour for 18 hours
78 M 9 4.0 33 0.5 mg/hour for 18 hours
22 M 11 5.0 800 0.5 mg/hour for 10 days
66 M 10 0.5 20 0.5 mg/hour for 8 hours
m.V>. Hqi
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Reversal of prolonged sedation using flumazenil in critically ill patients
A. Bodenham,* MB, BS, FFARCS, Research Registrar, G. R. Park, FFARCS, Consultant, Department of
Anaesthesia, Addenbrooke's Hospital, Cambridge CB2 2QQ.
Summary
Thirteen critically ill patients receivedflumazenil after multiple doses, or an infusion, ofmidazolam was used as part of a sedation
regimen to facilitate intensive care. Alt patients remained excessively sedated after the midazolam was stopped for 6 hours or
longer. An improvement in conscious level occurred in eight patients (61%). In four of these eight patients, the duration ofaction
offlumazenil necessitated its continued administration by an infusion to maintain the improvement in conscious level. The dose of
flumazenil required each hour was less than estimated previously; this indicates that it may be subjected to similar alterations of
' elimination as those describedfor midazolam. Flumazenil appears to be a useful drug for the reversal ofprolonged benzodiazepine




Midazolam, a benzodiazepine with a short duration of
action, is used frequently to provide sedation in critically ill
patients. The principal metabolite is a-hydroxymidazolam,
which is believed also to be active in man.1 Prolonged
sedation after midazolam administration is a recognised
problem in the critically ill despite the short duration of
action of the drug in healthy patients.2-3 In addition, 6-10%
of the population have a pharmacogenetic abnormality
which results in slow metabolism of midazolam.4 Both
these factors may result in accumulation when a conti¬
nuous intravenous infusion is administered, and may result
in excessive sedation, difficulty in assessment of neurologi¬
cal function, problems with weaning from artificial ventila¬
tion and cardiovascular instability. Furthermore,
unnecessarily long periods of sedation increase the duration
of admission to the intensive care unit, with inefficient
utilisation of that resource.
Benzodiazepine sedation is reversible with the benzodia¬
zepine antagonist flumazenil which has been available
commercially for some time in Europe.
We administered flumazenil to 13 critically ill patients
who remained undesirably sedated after administration of
multiple doses or an infusion of midazolam. The mida¬
zolam had been stopped for a variable time period of 6 to
72 hours.
Method
Patients were included in this prospective study when they
were known to have received during their treatment period
significant doses of midazolam which might have contri¬
buted to excessively prolonged sedation. Flumazenil was
given after a reasonable time for recovery had passed or
when it was desirable to awaken the patient for other
reasons (neurological assessment, to enhance coughing
ability, or to improve ventilatory effort to aid weaning
from artificial ventilation).
Patients with known hypertension or ischaemic heart
disease were excluded because of the theoretical risk of
acute hypertension or myocardial ischaemia which may
follow rapid awakening. If a tracheal tube was in place, an
isoffurane vaporizer was connected to the ventilator system,
to allow rapid resedation if cardiorespiratory instability
developed on re-awakening. Analgesia was provided with
intercostal nerve blocks if there was a recent abdominal
surgical incision. Blood pressure was measured con¬
tinuously in all patients by means of an intra-arterial
cannula, and heart rate and cardiac rhythm were displayed
on an electrocardiogram.
Opioids may cause prolonged sedation in critically ill
patients, in particular those with renal failure.5-7 Conse¬
quently, patients who were thought to have opioid-related
sedation were given naloxone in 0.1-mg increments to a
maximum of 0.4 mg for reversal of sedation. If there was
no significant improvement with naloxone, flumazenil was
given in 0.1-mg increments until satisfactory awakening
occurred or a total of 1 mg was given.
The APACHE II score8 without the Glasgow coma scale
(GCS) component was recorded before the administration
of naloxone and flumazenil. The GCS component of the
APACHE II score may be an entirely reversible element if
it is due to excessive sedation and so may increase the score
inappropriately.9
Sedation was assessed before and after administration of
naloxone and flumazenil using a score modified from that
described by Ramsay et a/.10 (Table 1). An improvement in
conscious level was defined as an increase of more than
three points on the scale.
Results
The 13 patients studied were of a heterogeneous nature
(Table 2). Eight (61%) of the 13 showed an improvement
of more than three points on the sedation scale after the
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ABSTRACT
The pharmacokinetics of alfentanil were investigated in seven patients
following liver transplantation. Alfentanil clearance was markedly reduced
in two patients and suggests that it should be used with care in these
patients since a prolonged effect is possible.
KEYWORDS
Pharmacokinetics, Alfentanil, liver transplantation.
1
INTRODUCTION
Alfentanil is a potent opioid analgesic with a rapid onset and short
duration of action. It is cleared almost completely by hepatic bio¬
transformation and is dependent on both hepatic function and blood flow for
its elimination. It has a decreased clearance in patients with cirrhosis
(Ferrier C et al, 1985) and in a subset of the normal population (McDonnell
TE et al, 1982); its clearance is unchanged in patients with renal failure
(Van Peer A et al, 1986). Because the action of alfentanil is terminated
by metabolism rather than redistribution, it has been used by continuous
intravenous infusion to provide sedation and analgesia to patients receiving
intensive care. Some patients, however, have demonstrated a decreased
clearance of the drug (Yate PM et al, 1986).
Alfentanil is bound in plasma to alpha 1 glycoprotein, an acute phase
protein which increases in concentration following injury. The
pharmacokinetics of alfentanil were studied on two occasions in patients
following liver transplantation to assess the importance of the various
factors influencing its pharmacokinetics and to observe any changes in
alfentanil pharmacokinetics as the graft liver regained function following
operative trauma.
Advances in the Biosciences Vol. 75
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METHOD
Seven consecutive patients were studied immediately following orthotopic
liver transplantation. Informed written consent for the study was obtained
from each patient and the study was approved by the District Ethics
Committee.
Within 3 hours of return to the Intensive Care Unit, a baseline blood sample
was collected and alfentanil, 20 mcg/kg diluted to 10 mis in 0.9* saline,
was administered as a bolus over 1 minute through a centrally placed venous
cannula. Samples of arterial blood were removed at 2, 5, 10, 20, 30, 60,
90, 120, 180, 360, 480, 600 and 720 minutes. At the end of this period, a
further 20 mcg/kg of alfentanil was administered in a similar manner and an
identical sampling protocol followed.
Blood was collected into lithium heparin tubes, centrifuged and the
supernatant plasma separated and stored at -20oc. Subsequent analysis was
performed using a radioimmunoassay technique -(Michiels M et al, 1983).
RESULTS
Details of the patients are shown in table 1 and their preoperative and
postoperative liver function tests in table 2.
Table 1 : Details of the patients studied following
liver transplantation. Figues shown as mean
+/- standard error, with range for duration
of cold ischaemia.
Age 37.9 +/- 3.21 years
Weight 61.7 +/- 3.38 kg
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Alpha 1 glycoprotein levels were normal in all patients throughout the study
period. There was considerable variation in the plasma concentrations of
alfentanil between the patients and this is quantified in table 3 which shows
the pharmacokinetic parameters for the individual patients during both study
periods.
4
Table 2 -iver function tests (a) before and (b)
immediately after liver transplantation.
• ■ no result available.
Patient Albumin Total Alkaline Alanine
Bilirubin Phosphatase Transferase
(g/1) (umol/1) (U/l) (U/l)
1 a 29 268 2810 444
b 29 • * *
2 a 27 284 115 25
b 29 103 32 84
3 a 14 332 228 86
b 29 226 111 1144
4 a 37 336 163 60
b 32 154 207 233
5 a 26 155 752 67
b 30 41 36 536
6 a 10 195 493 50
b 32 140 364 922
7 a 32 22 904 14
b 31 * 27 53 57
Normal 30- 44 2-17 30 - 135 oI
Range
Table 3 : Elimination half life, clearance and Volume
of distribution of alfentanil in patients
following liver transplantation. 1 • first
study period, 11 - second study period.
Patient T1/2 (min) Clearance (ml/min/kg) Vd (ml/kg)
1 II 1 II 1 II
i 730 330 0.425 0.956 447 455
2 158 66 6.220 3.620 1413 345
3 120 217 8.710 2.210 1502 689
4 82 67 6.630 5.070 780 492
5 267 231 4.110 3.840 1 581 1 279
6 365 385 0.833 0.807 438 448
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DISCUSSION
Alfentanil elimination is dependent upon hepatic clearance and alfentanil
clearance is decreased in patients with cirrhosis. In this study, all the
patients had abnormal liver function tests but their alfentanil clearance
varied considerably. Only one patient had an essentially normal
pharmacokinetic pattern of alfentanil throughout the study period. Four
patients had an increased volume of distribution during the first study
which decreased during the second study period. In addition all these
patients had a low alfentanil clearance during the second study period. Two
patients demonstrated considerably prolonged clearance of alfentanil.
These pharmacokinetic alterations suggest changes either in hepatic function
or, more likely, changes in hepatic blood flow during the period of
observation. However, these changes appear to be unpredictable and may
result in unwanted narcosis and respiratory depression.
CONCLUSION
Alfentanil clearance was considerably reduced in two of the seven patients
studied following liver transplantation.
Alfentanil should be used with care in patients following liver
transplantation since a prolonged effect is possible.
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Extra-hepatic metabolism of midazolam
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Six patients received 10 mg of midazolam intravenously during the anhepatic period of
liver transplantation. Arterial blood was sampled during this time and for a similar period
following revascularisation. The plasma was analysed using gas chromatography and
electron capture detection (GC-ECD) for midazolam a-hydroxymidazolam and a-
hydroxymidazolam glucuronide. Five of the six patients had small but significant concen¬
trations of metabolites detected during the anhepatic period, demonstrating the presence
of extra-hepatic sites of metabolism for this drug. The remaining patient had plasma
concentrations of metabolites below the lower limit of detection (2p.g l-1). This may
represent a pharmacogenetic abnormality or a temporary failure of midazolam meta¬
bolism secondary to the patients illness affecting the extra-hepatic sites of metabolism.
Keywords midazolam extra-hepatic metabolism
Introduction
Midazolam is a short acting benzodiazepine and
is commonly used to sedate patients requiring
brief procedures, to induce anaesthesia and for
prolonged sedation during intensive care. It is
hydroxylated by the cytochrome P450 system
predominately to a-hydroxymidazolam, which
has some pharmacological activity, and to
a smaller extent to 4-hydroxymidazolam, which
is thought to be inactive. Following this, glucuro-
nidation occurs making the compound more
water-soluble and allowing renal elimination. In
the postoperative period prolonged sedation has
been observed (Byatt et al., 1984; Byrne et al.,
1984). A reversible failure of metabolism has
been demonstrated in patients with sepsis (Shelly
et al., 1987) and in a child with acute derange¬
ment of liver function following cardiac surgery
(Lloyd-Thomas & Booker, 1986). These obser¬
vations prompted a study on the pharmacokinetics
of midazolam in patients following orthotopic
liver transplantation (when liver function is
deranged due to cold injury, ischaemia and the
effects of surgery and anaesthesia following the
donor operation and the liver transplant
procedure). This study demonstrated normal
pharmacokinetic parameters for the parent
drug but the plasma concentrations of the a-
hydroxy product were surprisingly high (Shelly
et al., 1989).
When orthotopic liver transplantation is
performed there is a period of no liver function.
This enables the importance of the liver in the
metabolism of a drug to be investigated. Several
phases in the surgical procedure can be identified.
Firstly, the diseased liver is dissected leaving it
with its vascular connections intact (skeletonisa-
tion). This is followed by clamping of all of the
hepatic vessels and removal of the diseased liver,
after which the suprahepatic inferior vena cava
of the donor liver is anastomosed to the recipient's
vena cava and the portal vein or the infra hepatic
cava of the donor liver anastomosed to the
recipient's vessel (anhepatic period). When these
anastomoses are complete the vascular clamps
are released (revascularisation). The remaining
anastomoses are completed (hepatic artery,
portal vein or inferior vena cava), the bilary
conduit is fashioned and the abdomen is closed
(Calne, 1987). The anhepatic period provides a
unique opportunity to study the metabolism of
drugs in man. Studies during this period have not
been performed previously because of the many
Correspondence: Dr G. R. Park, Department of Anaesthesia, Addenbrooke's Hospital, Hills Road, Cambridge
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difficulties that may occur at this time (Carmichael
et al., 1985); it is only with the increasing experi¬
ence of this centre that such studies have
now become possible without detriment to the
patient's well-being.
(3 p-g 1 ') a-hydroxymidazolam (2 (xg 1
and a-hydroxy-midazolam glucuronide (2p.g l"1).
Results
Method
The study was approved by the Hospital Ethics
Committee and written consent was obtained
from the six adult patients. The anaesthetic tech¬
nique was similar to that described previously
(Lindop & Farman, 1987) except that benzo¬
diazepine premedication was specifically avoided
and a narcotic and antisialogue was substituted.
Immediately before vascular isolation and
removal of the diseased liver a baseline blood
sample was taken from a previously sited radial
arterial line. As soon as haemodynamic stability
was achieved after vascular isolation and removal
of the diseased liver (approximately 2 min),
10 mg of midazolam hydrochloride was injected
into a central vein and flushed with 10 ml 0.9%
sodium chloride. Blood was removed at 2, 5, 10,
15, 20, 30, 40 min or at the end of the anhepatic
period and immediately before revascularisation
of the new liver. Following revascularisation the
sampling protocol was repeated. After removal,
blood was placed into tubes containing oxalate
anticoagulant, mixed and centrifuged at
3,000 rev min"1. The supernatant plasma was
then separated and frozen at —20°C until sub¬
sequent analysis by gas chromatography with
electron capture (GC/ECD) (Heizman & Von
Alten, 1981) for midazolam, a-hydroxy-
midazolam and a-hydroxymidazolam glu¬
curonide. The lower limits of detection of
midazolam and its metabolites were: midazolam
Patient information, details of the anhepatic
phase and preoperative liver function tests are
shown in Table 1. Liver function had been
deteriorating for many years in patients 2, 3, 4
and 5, whereas patient 1 had a 1 month history of
deteriorating liver function following administra¬
tion of an antidepressant, and liver function was
noiinal in patient 6.
The plasma concentrations of midazolam, a-
hydroxymidazolam and a-hydroxymidazolam
glucuronide in patients 2,3,4,5 and 6 during the
anhepatic period and following reperfusion are
shown in Figure 1. Metabolites of midazolam
were detected in the plasma during the first 15
min of the anhepatic period at low but sig¬
nificant concentrations. Patient 1 did not at any
time have detectable plasma concentrations of
a-hydroxymidazolam.
Discussion
Five of the six patients clearly demonstrated
metabolism of midazolam during the anhepatic
period of liver transplantation. Thus, significant
concentrations of both a-hydroxymidazolam
and a-hydroxymidazolam glucuronide were
detected, confirming the presence of extrahepatic
sites of midazolam metabolism. The possible
sites include the gut (which has been shown to
metabolise flurazepam in man (Mahon et al.,
1977)), the kidney (which has been implicated in
the metabolism ofmorphine (Moore etal., 1986)),
Table 1 Patient information, details of the anhepatic period and preoperative liver function tests (normal
values shown in brackets)
Patient
1 2 3 4 5 6
Sex F F F F F M
Age (years) 34 46 53 54 30 48
Weight (kg) 65 61 52 48 60 74
Diagnosis SAHN PBC PBC PBC SC HEP
Anhepatic
period (min) 32 42 43 50 52 86
Blood loss (ml) 200 970 180 130 768 174
Bilirubin (p,mol 1_1) (3-17) 868 428 112 134 309 12
Alanine aminotransferase (U L1) (7-40) 1124 188 138 111 99 32
Alkaline phosphatase (U l"1) (30-135) 167 1022 780 1968 344 127
Prothrombin ratio (1-1.3) 9.9 1.2 1.2 1.2 1.1 1.0
SAHN = subacute hepatic necrosis, PBC = primary biliary cirrhosis, SC = sclerosing cholangitis,
HEP = hepatoma.






Figure 1 Plasma concentrations (mean ± s.e. mean) ofmidazolam (□), a-hydroxymidazolam (A) and
a-hydroxymidazolam glucuronide (■) in five patients following administration of 10 mg of midazolam
intravenously at the start of the anhepatic period of liver transplantation.
and the lung (Heizman et al., 1983). Further
studies are necessary to determine the exact
site in the human and may be important to our
understanding of the metabolic fate of this and
other drugs in critically ill patients. The remaining
patient (patient 1) had only low plasma concen¬
trations of a-hydroxy midazolam glucuronide
at the final two time points of the anhepatic
period. Revascularisation of the donor liver
appeared to correct this abnormality. This patient
continued to be critically ill and subsequently
died of an overwhelming viral infection precluding
further studies.
Revascularisation of the liver was followed in
all patients by significant increase in the plasma
concentrations ofmidazolam metabolites. Patient
1 showed a similar rise in plasma concentrations
of metabolites to the other patients although the
concentrations were always lower. This would
be consistent with the transplanted liver contain¬
ing the normal amount or type of enzyme respon¬
sible for the metabolism of midazolam. Although
the number of time points are too few to make
definite conclusions the elimination half-life of
midazolam (0.52 ± 0.23 h) appeared to be shorter
than seen in healthy volunteers (Brown et al.,
1979; Dundee et al., 1980, 1986; Greenblatt et
al., 1981 and 1984). The duration of the anhepatic
period is necessarily short and the calculated
half-life may therefore represent a distribution
rather than an elimination half-life.
Caution in the application of these results to
patients with severe liver failure is necessary.
Although the failure of hepatic metabolism may
be partly offset by activity at extrahepatic sites of
metabolism, benzodiazepine receptors may be
abnormally sensitive to the drug or its metabo¬
lite^). Benzodiazepines used unnecessarily or
incautiously, especially in repeated doses, may
precipitate coma in patients with severe liver
disease. When they are indicated, small doses
must be titrated carefully to the needs of the
individual patient.
We are grateful to Professor Sir Roy Calne, Dr R.
Williams, Mr K. Rolles, Dr J. V. Farman, Dr M. J.
Lindop, Dr J. R. Klinck, Dr M. E. Tolley, Dr P. J.
Morris, Dr C. W. Glazebrook, Dr M. J. Herrick and
the operating department assistants who assisted us
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The pharmacokinetics of midazolam following orthotopic
liver transplantation
MAIRE P. SHELLY*1, J. S. DIXON2 & G. R, PARK1
The Intensive Care Unit, Addenbrooke's Hospital, Cambridge CB2 2QQ and 2Clinical Pharmacology Unit,
Royal Bath Hospital, Harrogate, North Yorkshire
Seven patients with chronic liver disease received a 10 mg intravenous bolus dose of
midazolam immediately following orthotopic liver transplantation. Plasma samples were
analysed for midazolam and a-hydroxymidazolam by gas chromatography with electron
capture detection. Data from three patients could not be evaluated. In the remaining four
patients the pharmacokinetics of midazolam were essentially normal but the plasma
concentrations of a-hydroxy-midazolam were higher than those found in healthy
subjects. All patients required further sedation between 0.5 and 5 h later indicating that
the duration of action of midazolam was not prolonged. These results suggest that
following liver transplantation, patients have considerable drug metabolising capacity
either in the liver or at extrahepatic sites.
Keywords midazolam pharmacokinetics liver transplant
Introduction
Midazolam is a benzodiazepine available as a
water soluble salt suitable for parenteral admi¬
nistration. In normal subjects, it is metabolised
to compounds which are rapidly cleared from
the body. These attributes have prompted its
use as a sedative in patients requiring intensive
care, usually in combination with an opioid
(Lloyd-Thomas & Booker, 1986; O'Dea & Hop-
kinson, 1987).
Following its use in critically ill patients,
however, there have been reports of a pro¬
longed duration of action (Byatt et al., 1984;
Byrne et al., 1984; Dundee et al., 1984). Since
midazolam is believed to be metabolised in the
liver (Allonen et al., 1981), its deranged phar¬
macodynamics and pharmacokinetics in criti¬
cally ill patients may be due to a failure of
hepatic metabolism of the drug (Dundee et al.,
1986). A recent prospective study demons¬
trated a reversible inhibition of midazolam
metabolism in the critically ill and suggested
that this was due to reduced organ perfusion
(Shelly et al., 1987a). Studies in patients with
chronic liver disease have given conflicting re¬
sults about the effects of midazolam (Hamdy et
al., 1986; Binetti et al., 1985; MacGilchrist et
al., 1986). The extrapolation of results from
patients with chronic liver disease to patients
who have suffered acute liver injury may not be
valid and acute hepatic dysfunction, following
disease or surgery, is more commonly seen in
patients receiving intensive care. In order to
clarify this point, patients were investigated
following orthotopic liver transplantation. The
donor liver for these patients is exposed to two
major surgical procedures, removal from the
donor and transplantation into the recipient. In
addition, the metabolic function of the graft
liver may be impaired by the period of
ischaemia that is inevitable between these oper¬
ations and, as a result, the transplanted liver is
acutely and profoundly insulted. Postoperative¬
ly, transplanted patients require a period of
controlled ventilation with appropriate sedation
and analgesia. Since it is our usual practice to
sedate these patients with intravenous bolus
doses of midazolam (Shelly et al., 1987b), this
offered the opportunity to study the pharmaco¬
kinetics of midazolam in patients with acutely
deranged liver function.
*Present position: Shackleton Department of Anaesthesia, Southampton General Hospital, Southampton
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Method
The study was approved by the Hospital Ethics
Committee and informed consent was obtained
from seven subjects preoperatively. Both the
anaesthetic and surgical techniques have been
described previously (Calne, 1987). During the
study period the care of the patient was along
conventional lines (Shelly etal., 1987b) with the
exception that sedation was provided by inter¬
mittent bolus doses of diazepam and morphine
as required.
Postoperatively the patient was transferred
to the intensive care unit and when haemodyna-
mic stability had been achieved a baseline blood
sample was taken from an intra-arterial line
sited as part of the operative procedure. Mida¬
zolam hydrochloride (10 mg) was diluted to
10 ml with 0.9% saline and injected over 2 min
through a centrally placed venous catheter.
Arterial blood was sampled at 2, 5, 10, 15, 30,
45,60 min and 1.5,2,2.5,3,3.5,4,4.5,6,12,18,
24 h after the injection of drug. At each sam¬
pling time, 10 ml of blood was removed, placed
in a tube containing an oxalate anticoagulant
and mixed. The tubes were centrifuged at 3,000
rev min"1 and the supernatant plasma removed
and stored at -20°C until analysis by gas liquid
chromatography (Heizmann & von Alten,
1981).
Drug and metabolite concentrations were
measured relative to standard curves contain¬
ing 50-1000 ng ml"1 midazolam and 25-375
ng ml"1 a-hydroxymidazolam. Mean preci¬
sions for the standards were ± 8.4% and ±
7.4%, respectively and virtually identical
values were found for quality assurance sam¬
ples (n=20) containing 250 ng ml"1 and
125 ng ml"1 of midazolam and a-hydroxy¬
midazolam, respectively. The latter were pre¬
pared and included in every analysis, and mean
accuracies of the quality assurance samples
were within 5% of the prepared values.
Pharmacokinetic parameters were calculated
by model independent analysis. Plasma concen¬
trations immediately after dosing (C(0)) were
determined by back-extrapolation of the log-
linear line for samples collected during the first
10-15 min after dosing. The initial volume of
distribution (Ex) was then calculated from
Dose/C(0). Elimination half-lives (/,/2) were
estimated from the log-linear decline of the last
four or five measurable plasma drug concentra¬
tions. Areas under the plasma drug concentra¬
tion - time curves (AUC) were calculated by
linear trapezoidal analysis between all samples
that contained measurable midazolam concen¬
trations. Values for the initial and terminal
proportions of the curve were then determined
by addition of (C(0) + C(2))/60and Ctxr1/m693,
respectively, where Ct was the last measured
concentration. Clearance (CL) was calculated
from Dose/AUC.
Results
Analysis of the plasma from three of the pa¬
tients revealed interference with the assay
probably from temazepam used as premedica¬
tion. This rendered pharmacokinetic interpreta¬
tion impossible and these patients have, there¬
fore, been excluded from further consideration.
The details of the remaining four patients in¬
cluding their postoperative liver function tests
are shown in Table 1. All had impaired liver
function in the postoperative period. The un¬
usually low alanine transferase of patient 3 sub¬
sequently rose rapidly and may represent a
spurious result. No delayed awakening was
seen in the patients studied; all patients re¬
quired further sedation at a mean time of 2 h
(range 0.5-5 h).
The derived pharmacokinetic parameters for
midazolam and a-hydroxymidazolam are
shown in Table 2 together with values from
normal subjects (Allonen et al., 1981; Heiz¬
mann et al., 1983). It was only possible to
calculate approximate values for the para¬
meters describing the distribution and elimina¬
tion of midazolam in these patients owing to the
biphasic decline and the relatively small num¬
ber of data points obtained. The pharmacokine¬
tic parameters estimated for midazolam were
similar to those obtained from healthy volun¬
teers. However, the plasma concentrations of
a-hydroxymidazolam were higher than ex¬
pected following intravenous administration of
a 10 mg bolus of midazolam. In healthy volun¬
teers, the mean maximum plasma concentra¬
tion (mean Cmax) of a-hydroxymidazolam is
approximately 0.076 (Heizmann et al., 1983) of
the mean Cmax of midazolam following intrave¬
nous administration of midazolam. In our pa¬
tients, the ratio obtained using the same method
of calculation was 0.18. Half-lives for the meta¬
bolite could not be determined owing to the
multiphasic nature of its plasma concentration
- time curve.
Discussion
Few agents are currently available for the seda¬
tion of patients receiving intensive care. Intra¬
venous midazolam has been used (Lloyd-
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52 484 145 220 2-17
ALT
(U r1)
840 >1200 20 500 7^10
AP
(U l"1)
62 231 43 652 30-135
RT = Retransplantation
ALT = Alanine transaminase
AP = Alkaline phosphatase
Table 2 The pharmacokinetic parameters for midazolam and a-
hydroxymidazolam for the individual patients. The normal values are from
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C(0) Plasma concentration at time 0
6/2 Approximate elimination half-life calculated from the last 4-5
measurable time points and quoted to the nearest 5 min
V, Volume of distribution of the central compartment
CL Total clearance
Cmax Maximum plasma drug concentration
AUC Area under the plasma drug concentration-time curve
rmax Time to reach maximum drug concentration
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Thomas & Booker, 1986; O'Dea & Hopkinson,
1987; Park et al., 1986) but concern has been
expressed regarding the occasional delayed re¬
covery of critically ill patients following its
administration (Byatt et al., 1984; Byrne et al.,
1984; Dundee et al., 1984). This has been attri¬
buted to impaired metabolism resulting in slow
clearance of the parent drug. Midazolam is
metabolised by hydroxylation and subsequent
conjugation with glucuronic acid before excre¬
tion in the urine (Allonen et al., 1981). The
cytochrome P450 system is thought to be in¬
volved in its biotransformation and because of
the extensive first pass metabolism of midazo¬
lam following oral administration, the liver is
thought to be the site of metabolism (Allonen et
al., 1981; Dundee et al., 1986). The explana¬
tions offered for the impaired metabolism of
midazolam include a congenital impairment of
cytochrome P450 function (Dundee et al.,
1986), or a reduced organ perfusion secondary
to sepsis (Shelly et al., 1987a).
Studies of the pharmacokinetics and pharma¬
codynamics of other benzodiazepines in pa¬
tients with liver disease suggest that those ben¬
zodiazepines undergoing predominantly phase
I metabolism, such as diazepam, tend to be
profoundly affected by liver disease (Reeves,
1981; Klotz etal., 1975) whilst those undergoing
mainly conjugation reactions, such as temaze-
pam, are relatively spared (Ghabrail et al.,
1986; Ochs et al., 1986). In addition, the clear¬
ance of benzodiazepines undergoing phase I
reactions is decreased by the concomitant
administration of cimetidine, which is thought
to act as an enzyme inhibitor; benzodiazepines
metabolised by phase II reactions are un¬
affected by cimetidine (Klotz & Reimann, 1980
a,b).
Midazolam does not fit into this pattern. It
undergoes predominantly phase I metabolism
and, therefore, its pharmacokinetics would be
expected to be affected profoundly by liver
impairment. The pharmacokinetic profile of
oral midazolam in patients with compensated
cirrhosis is similar to that of healthy volunteers
(Binetti et al., 1985). Only in patients with
severe cirrhosis are the pharmacokinetics and
pharmacodynamics of midazolam affected
(Hamdy et al., 1986; Binetti et al., 1985; McGil-
christ et al., 1986). In addition, the pharmacoki¬
netics ofmidazolam are not influenced by cime¬
tidine as are those of diazepam (Greenblatt et
al., 1986). Since patients with liver impairment
retain considerable metabolic capacity for
midazolam, this suggests that its metabolism
differs in some way from the phase I metabol¬
ism of other benzodiazepines. It may be that the
enzymes responsible for the metabolism of
midazolam are particularly resistant to damage
or that they occur in extrahepatic sites. Extra-
hepatic metabolism of lorazepam has been post¬
ulated in dogs (Gerkens et al., 1981).
Liver transplantation can be considered as a
severe, acute hepatic injury. Our patients stu¬
died under these conditions demonstrated nor¬
mal pharmacokinetics of midazolam but with a
higher than normal plasma concentration of a-
hydroxymidazolam, the primary metabolite.
The increased plasma concentrations of a-
hydroxymidazolam may be due either to an
increased rate of formation of the metabolite or
to a reduced rate of conjugation to the glucur-
onide. Since the pharmacokinetics of midazo¬
lam appeared normal, the latter is more likely.
This could have been confirmed by measuring
the plasma concentrations of the secondary
metabolite cx-hydroxymidazolam glucuronide
but this assay was not available at the time of
the study.
The pharmacokinetic data obtained from this
study were limited because of the small num¬
bers of patients and data points. However, the
fact that the initial metabolism of midazolam to
a-hydroxymidazolam was not substantially
impaired suggests that following liver trans¬
plantation patients retain considerable metabo¬
lic capacity for midazolam either within the
newly transplanted liver or at extrahepatic
sites. In addition the results demonstrate that
midazolam does not have a prolonged duration
of action in these patients.
We gratefully acknowledge the assistance of our col¬
leagues, Professor Sir R. Y. Calne, Dr R. Williams
and the medical and nursing staff of the Intensive
Care Unit. We are also grateful to Roche Products for
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Extra-hepatic metabolism of midazolam
G. R. PARK1. A. R. MANARA1 & S. DAWLING2
'Department of Anaesthesia, Addenbrooke's Hospital, Cambridge CB2 2QQ and 2The Poisons Unit, New
Cross Hospital, Avonley Road, London SE14 5ER
Six patients received 10 mg of midazolam intravenously during the anhepatic period of
liver transplantation. Arterial blood was sampled during this time and for a similar period
following revascularisation. The plasma was analysed using gas chromatography and
electron capture detection (GC-ECD) for midazolam a-hydroxymidazolam and a-
hydroxymidazolam glucuronide. Five of the six patients had small but significant concen¬
trations of metabolites detected during the anhepatic period, demonstrating the presence
of extra-hepatic sites of metabolism for this drug. The remaining patient had plasma
concentrations of metabolites below the lower limit of detection (2p.g l"1). This may
represent a pharmacogenetic abnormality or a temporary failure of midazolam meta¬
bolism secondary to the patients illness affecting the extra-hepatic sites of metabolism.
Keywords midazolam extra-hepatic metabolism
Introduction
Midazolam is a short acting benzodiazepine and
is commonly used to sedate patients requiring
brief procedures, to induce anaesthesia and for
prolonged sedation during intensive care. It is
hydroxylated by the cytochrome P450 system
predominately to ct-hydroxymidazolam, which
has some pharmacological activity, and to
a smaller extent to 4-hydroxymidazolam, which
is thought to be inactive. Following this, glucuro-
nidation occurs making the compound more
water-soluble and allowing renal elimination. In
the postoperative period prolonged sedation has
been observed (Byatt et al., 1984; Byrne et al.,
1984). A reversible failure of metabolism has
been demonstrated in patients with sepsis (Shelly
et al., 1987) and in a child with acute derange¬
ment of liver function following cardiac surgery
(Lloyd-Thomas & Booker, 1986). These obser¬
vations prompted a study on the pharmacokinetics
of midazolam in patients following orthotopic
liver transplantation (when liver function is
deranged due to cold injury, ischaemia and the
effects of surgery and anaesthesia following the
donor operation and the liver transplant
procedure). This study demonstrated normal
pharmacokinetic parameters for the parent
drug but the plasma concentrations of the a-
hydroxy product were surprisingly high (Shelly
et al., 1989).
When orthotopic liver transplantation is
performed there is a period of no liver function.
This enables the importance of the liver in the
metabolism of a drug to be investigated. Several
phases in the surgical procedure can be identified.
Firstly, the diseased liver is dissected leaving it
with its vascular connections intact (skeletonisa-
tion). This is followed by clamping of all of the
hepatic vessels and removal of the diseased liver,
after which the suprahepatic inferior vena cava
of the donor liver is anastomosed to the recipient's
vena cava and the portal vein or the infra hepatic
cava of the donor liver anastomosed to the
recipient's vessel (anhepatic period). When these
anastomoses are complete the vascular clamps
are released (revascularisation). The remaining
anastomoses are completed (hepatic artery,
portal vein or inferior vena cava), the bilary
conduit is fashioned and the abdomen is closed
(Calne, 1987). The anhepatic period provides a
unique opportunity to study the metabolism of
drugs in man. Studies during this period have not
been performed previously because of the many
Correspondence: Dr G. R. Park, Department of Anaesthesia, Addenbrooke's Hospital, Hills Road, Cambridge
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of different ventilators
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Abstract. We investigated six ventilator systems which
were designed to allow spontaneous breathing. The
time delay between initiation of inspiratory effort and
the beginning of inspiratory gas flow was measured, as
was the amount of negative (to ambient) pressure
generated in the airway needed to produce the gas
flow. We found that the flow-by program of the
Puritan-Bennett 7200 caused minimal time delay and
virtually no negative pressure was required to instigate
gas flow. This should be contrasted with the other ven¬
tilator systems, which caused significant delay and in¬
spiratory effort and hence increased work of
breathing.
Key words: Spontaneous breathing - Ventilators —
Work of breathing — Inspiratory pressure support —
Flow-by systems - IMV circuits
In 1982 Gibney, Wilson, Pontoppidan, and subse¬
quently other workers [1, 4, 6, 7, 10, 14] pointed out
that ventilator systems based on a demand valve create
an inspiratory resistance to spontaneous breathing
which is unacceptable in clinical practice. All authors
have suggested alternative sources of fresh gas supply
based around an IMV one-way valve and reservoir
bag, as illustrated in Figure 1. Various authors have es¬
timated the work of breathing using either the demand
valve systems or modifications of the circuit described
above. The work of breathing was found to be ex¬
cessive through the demand valves when compared to
that measured using the continuous flow systems [6,
10]. Prior to this, in 1979, Gherini [5] showed that the
inspiratory work of breathing on CPAP increased if
the airway pressure decreased during inspiration.
Since the early 1980's, the continuous flow system
illustrated above (Fig. 1) has been in use in the Royal
Free Hospital Intensive Therapy Unit and has proved
clinically acceptable during the weaning of over 600
patients. Among reasons for its success are that there
is minimal time delay between the instigation of in¬
spiratory effort and the start of gas flow, and that the
theoretical peak inspiratory flow is instantly available
and far in excess of that which most patients requiring
IMV could achieve. When used in conjunction with
CPAP, the bag is stretched tightly and it is this
tightness which has been thought to deliver a degree
of inspiratory pressure support, leading to a reduction
in the inspiratory work of breathing.
Manufacturers of ventilators have recognised the
disadvantages of the demand valve systems and the
last few years have seen the widespread introduction of
systems with inspiratory assistance (pressure support)
for the spontaneous phase of IMV. Whilst this will un¬
doubtedly reduce the inspiratory work of breathing
and thus the oxygen consumption [2, 8], the sensitivity
of the ventilator to the inspiratory effort is still critical
if no time delay before the onset of gas flow is to oc¬
cur. The most recent attempt to further reduce the in¬
spiratory work of breathing during the spontaneous
phase has been the introduction of "flowby" on the
Puritan-Bennett 7200.
The observed clinical advantages of the continuo¬
us flow systems led us to this investigation of recently
introduced breathing systems using, variously, in¬
spiratory pressure support (Siemens Servoven-
tilator900C, Engstrom Erica, Puritan-Bennett 7200,
Drager EV-A) and continuous flow systems (Modified
Siemens Servoventilator 900 B, Puritan-Bennett 7200
flow-by).
Materials and methods
The changes in airway pressure, gas flow rates and in¬
spiratory time lag were measured in the following
systems:
1
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been compromised by surgery or sepsis. It may, how¬
ever, have contributed to the ischaemic changes seen.
Active peristalsis is a known feature of vasopressin
administration and previous reports have described
vomiting, diarrhoea and abdominal discomfort
among its side effects [2, 6, 24]. The rise in core tem¬
perature during vasopressin administration was a con¬
stant finding. In no patient did core temperature fall.
The corresponding rise in peripheral temperature sug¬
gests that this is not due to central diversion of blood
flow with peripheral vasoconstriction but may be the
result of increased heat production.
Conclusion
Vasopressin controlled intra-abdominal bleeding in
four critically ill patients and reduced the rate of
bleeding in two others. The physiological effects of va¬
sopressin vary between patients but there was a general
improvement in haemodynamic parameters and six
patients had a diuresis following its administration.
Vasopressin may be useful in the management of pa¬
tients with massive and uncontrolled intra-abdominal
bleeding. However, because of the risk of ischaemic
damage to other organs, vasopressin should only be
used when conventional medical and surgical therapy
has failed.
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tachyphylaxis. In patient 8 the infusion was continued
at the same rate after bleeding was eventually controll¬
ed in an attempt to allow haemostasis but after 12 h,
bleeding restarted with the infusion still in progress.
Patient 9 required increasing doses of vasopressin to
control his bleeding and when the infusion rate was
reduced, bleeding restarted.
Discussion
There have been a number of reports of the efficacy
of vasopressin in the control of bleeding, particularly
from oesophageal varices [2, 6, 9], These have stressed
the haemostatic effect of vasopressin and mentioned
various side effects. The group of patients reported
here had massive intra-abdominal bleeding uncon¬
trolled by conventional treatment. While the
haemostatic effect of vasopressin was the primary ob¬
jective of treatment, the intensive monitoring of these
patients during treatment enabled documentation of
the physiological effects of vasopressin in critically ill
patients during haemorrhage.
Vasopressin is a powerful vasoactive substance,
known to decrease splanchnic blood flow [10] and
thought to act by constriction of splanchnic arteriolar
sphincters [11, 12]. The haemostatic effect of vaso¬
pressin is, however, variable [9, 13, 14]. This has been
attributed to individual differences in hepatic blood
flow characteristics and hepatic function [9, 12] and
vasopressin may be more effective in critically ill pa¬
tients [9]. The results from this group compare
favourably with other reported series [5, 11]. Vasopres¬
sin may, therefore, be used together with laparotomy
in the management of patients with uncontrolled in¬
tra-abdominal bleeding following major abdominal or
hepatic surgery. A response to an initial bolus dose of
vasopressin may indicate a more sustained response to
its infusion. However, continued bleeding requiring a
prolonged infusion of vasopressin indicates a poor
response and increases the risk of complications. The
high mortality rate seen in this group of patients
reflects their severe illness and the influence of vaso¬
pressin cannot be determined accurately.
Patient 3 was the only patient who did not respond
at all to vasopressin; she continued to bleed from the
liver surface following an emergency partial hepatec-
tomy for bleeding into a hepatoma. Patient 4 had
similar bleeding following a partial hepatectomy for a
hepatoma but he responded well to vasopressin. An
important difference between these patients was that
patient 4 had a patent portal vein but the portal vein
of patient 3 was occluded by tumour. The entire
hepatic blood supply of patient 3 was, therefore,
through her left hepatic artery (the right lobe of the
liver having been surgically removed). While portal
venous pressure decreases in response to vasopressin,
the response of the hepatic artery is different, a
biphasic response having been demonstrated in dogs
[15, 16]. Initially hepatic arterial flow decreases but
this rapidly reverses so that 15 - 20 min after ad¬
ministration of vasopressin, hepatic artery flow is
double the control value. The failure to achieve
haemostasis in patient 3 may result from an increased
hepatic arterial flow in response to vasopressin.
Similar bleeding in patient 4 responded to vasopressin
since he had a patent portal vein and total hepatic
blood flow decreased.
The hypertensive effects of vasopressin have been
previously reported in patients with oesophageal
varices [11-13, 15], The increase in mean arterial
pressure and central venous pressure and the decreased
heart rate seen in these patients at the start of vaso¬
pressin administration, may be due to the autotransfu-
sion effect of splanchnic vasoconstriction, since the
splanchnic vascular bed is a significant blood reservoir
[17].
When mentioned at all, previous studies have re¬
ported an antidiuretic effect of vasopressin [15] and
normally release of vasopressin from the posterior
pituitary causes an increase in renal tubular reabsorp-
tion of water. All the patients reported here had im¬
paired renal function before treatment with vasopres¬
sin; the impressive diuresis experienced by five patients
is, therefore, all the more significant and no patient
became anuric. The mechanism for this increased
urine output is unknown but may be related to an in¬
creased renal perfusion pressure with the increased
mean arterial pressure.
Myocardial ischaemia has been reported following
vasopressin [ 19] and it has been used as a stress test to
provoke ischaemic changes [20]. Dysrhythmias related
to vasopressin administration were seen in three pa¬
tients. In addition, diffuse myocardial myocytolysis
was found at post-mortem examination in two other
patients; this is a non-specific change but vasopressin
may have contributed to its development.
Intestinal ischaemia has been described following
infusion of vasopressin into the superior mesenteric
artery [21-23] but not following intravenous ad¬
ministration. The pancreatic and mucosal lesions are
unlikely to have been due entirely to vasopressin,
although it may have contributed to their develop¬
ment. The third patient had an infarcted appendix
following prolonged vasopressin infusion and this
would seem to be attributable to vasopressin.
Hepatic ischaemia has not been described before
and in this study vasopressin cannot be conclusively
incriminated since all the patients had livers that had
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decreased during treatment but this change did not
reach statistical significance and a tachycardia return¬
ed upon its cessation. The changes in central venous
pressure were less marked; a transient but statistically
significant rise (p< 0.05) coincided with the decreased
heart rate on starting the infusion.
Urine output
The urine output of individual patients for the 4-hour
period before vasopressin treatment compared with
the 4-h period immediately after, is shown in Table 3.
Although the overall changes fail to reach statistical
significance, they were of clinical significance. All pa¬
tients initially had impaired renal function but five
(patients 1, 2, 3, 9, 10) had a prompt diuresis when va¬
sopressin was initiated. Patient 4 had a diuresis when
started on a vasopressin infusion following bolus
dosage and patient 6 had had a significantly improved
urine output since commencement of an adrenaline
infusion the previous day.
Ischaemia
Myocardial. Dysrhythmias were documented elec-
trocardiographically in three patients during vasopres¬
sin treatment. Patient 2 had an episode of supraven¬
tricular tachycardial patient 8 a period of bradycardia
and patient 9 bradycardia together with ventricular ec¬
topic beats. All these changes disappeared when the
rate of infusion was decreased. In patients 1 and 5 dif¬
fuse myocardial myocytolysis was noted at post¬
mortem examination.
Intestinal. Three patients had evidence of bowel
ischaemia. Patient 1 had pancreatic infarction and pa¬
tient 2 colonic ulceration. Patient 9, after a vasopres¬
sin infusion lasting 124 h, was found to have an infarc-
ted appendix which was removed.
Hepatic. Four patients had some evidence of hepatic
ischaemia. Patient 1 had areas of recent infarction 13
days after vasopressin administration, patient 2 had
centrilobular necrosis, patient 8 had discrete areas of
infarction and patient 5 had ischaemic necrosis.
Gastrointestinal motility
All the patients had an ileus immediately prior to
treatment, nevertheless evacuation of bowel motions
occurred in three patients (patients 1, 9, 10) and the
volume of nasogastric aspirate increased in patients 5
and 7. Patient 1 was in hepatic coma and in an attempt
to improve her conscious level, she had a 4-1 enema
before vasopressin treatment. The enema had been un¬
productive but vasopressin caused a prompt evacua¬
tion of her bowels and a slight improvement in her
conscious level.
Other physiological effects
Temperature changes. The changes in core tempera¬
ture, rectal or axillary, for the 4-h periods before and
after starting vasopressin and before and after its
cessation, are shown in Figure 2. The increase in core
temperature with the start of vasopressin infusion was
statistically highly significant (p< 0.0005). In three pa¬
tients, the core to peripheral temperature difference
was monitored and remained unchanged.
Pulmonary arterial pressures. Pulmonary arterial
pressures were measured in two patients. In one, both
pulmonary artery systolic and diastolic pressures rose
with intermittant administration of vasopressin
returning to baseline levels between doses. In the other
patient pulmonary arterial pressures remained un¬
changed.
Tachyphylaxis. Two of the patients who received pro¬
longed vasopressin infusions appear to have shown
Table 3. Urine output for individual patients for the 4-h period
before vasopressin compared with the 4-h period immediately after
Patient number 4h before 4h after Change (%)
vasopressin vasopressin
1 48 141 194
2 45 105 133
3 43 165 284
4 84 75 - 11
5 0 8
6 214 250 17
7 38 34 -11
8a 26 22 - 15
9 50 101 102
10 164 470 187








4 3 2 1 1 2 3 4 4
,, hours
vasopressin on
3 2 112 3
Vasopressin off
Fig. 2. Core temperature, mean and standard deviation, for 4-h
periods before and after commencement and cessation of vasopres¬
sin infusion
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Table 2. Blood loss during the 4-h period before vasopressin administration compared with the 4-h period immediately after, together with
vasopressin dosage for individual patients in chronological order and the outcome of their bleeding
Patient 4 h before 4 h after Decrease in Vasopressin treatment Bleeding controlled
number vasopressin vasopressin blood loss (%)
1 750 360 52 20 units bolus x 2 Vasopressin alone
2 845 445 47 20 u/h infusion 14 h Vasopressin follow¬
ing laparotomy
3 5459 5865 + 7 10 units bolus x 2 20 units
bolus x 1
Not controlled




5 3500 3040 13 12 —24 u/h infusion 10 h Laparotomy follow¬
ing vasopressin
6 600 500 17 2.5 — 10 u/h infusion 90 h Not controlled
7 1593 966 40 10 u/h infusion 4 h Laparotomy follow¬
ing vasopressin
8a 325 170 48 20 units bolus x 1
1 - 10 u/h infusion 132 h
Not controlled
9 945 730 23 2 —7 u/h infusion 124h Vasopressin follow¬
ing laparotomy
10 165 144 13 5—10u/h infusion 12.5 h Laparotomy follow¬
ing vasopressin
a Figures for 1 h before and after vasopressin, u/h = units/hour
minimal response to vasopressin. Patients 5 and 10
bled following hepatic retransplantation and their
bleeding was eventually controlled surgically. Patients
6 and 9 had intra-abdominal sepsis and haemostasis
was difficult to achieve in spite of prolonged vasopres¬
sin infusions and repeated surgical exploration;
bleeding was eventually controlled by vasopressin in
patient 9.
Mortality
Patients 7 and 10 survived and were discharged from
hospital. The three patients with bleeding uncontroll¬
ed by vasopressin or laparotomy, died of their intra¬
abdominal bleeding within 24 h of cessation of the va¬
sopressin infusion. Patient 2 died of unrelated colonic
bleeding, 18 days after control of his intra-abdominal
bleeding by vasopressin. The other patients died of
multisystem failure 15.2 ±4.1 days (mean±SD) after
receiving vasopressin.
Cardiovascular parameters
Changes in mean arterial pressure, heart rate and cen¬
tral venous pressure for periods before and after com¬
mencement and cessation of vasopressin infusion are
shown in Figure 1. Mean arterial pressure increased
significantly (p< 0.025) with the start of the infusion
but returned to baseline values when the infusion was
stopped. A tachycardia was present in all patients



























3 2 1 ' 1 2 3
Vasopressin off
Fig. 1. Mean arterial pressure, heart rate and central venous pressure
for 3-h periods before and after commencement and cessation of a
vasopressin infusion. Mean and standard deviation for all values are
shown
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tients were receiving artificial ventilation. All were
receiving infusions of fresh frozen plasma and platelet
concentrates as well as calcium supplements but none
had disseminated intravascular coagulopathy.
Arterial pressure and central venous pressure were
measured directly via intra-arterial and central venous
catheters; in addition, a continuous electrocardio¬
gram, core temperature, urine output and nasogastric
drainage were monitored in all patients. Additional
parameters were measured as indicated. Hourly blood
loss was calculated from measurements of external
blood loss. The volume of blood and colloid required
to maintain cardiovascular stability was recorded and
any adverse effects of vasopressin noted. The records
of post-mortem examinations, performed on six of the
patients, were reviewed. Student's paired t-test was
used to compare results where appropriate.
Vasopressin was diluted in 5% Dextrose to form a
solution containing 1 or 2 units/ml and administered
using an accurate syringe driver. The dose ad¬
ministered was similar to that used for the treatment
of oesophageal varices [5, 6] since the detailed phar¬
macokinetics of exogenous vasopressin have not been
evaluated.
Results
The details of the patients and their surgical treatment
before vasopressin was administered are shown in
Table 1. The total duration of bleeding was
32.9±17.3h (mean±SD) with a measured non-
operative blood loss of 10.5 ±4.91 and a blood
transfusion requirement of 18.4 ± 11.21 prior to vaso¬
pressin treatment. In spite of the infusion of clotting
factors and platelets, the prothrombin ratio was
1.5 ±0.3 and the platelet count was 84.7 ±61.7 x
109/ml.
Bleeding
External blood loss was used as an index of bleeding
and the change in the measured loss, to assess
response to vasopressin. Although occult losses are
undetected, this provides an estimate of blood loss
and follows the same trend as the change in transfu¬
sion requirement in individual patients. The estimated
blood loss during the 4-hour period before giving va¬
sopressin compared with the same period after its ad¬
ministration is shown in Table 2, together with vaso¬
pressin dosage for individual patients and the out¬
come of their bleeding.
In all but one of the patients blood loss fell follow¬
ing vasopressin and the overall decrease in blood loss
was statistically significant (p<0.05). Patient 1 had
bleeding that was controlled by vasopressin alone, the
remaining nine patients required additional haemosta¬
tic laparotomy. Four (patients 2, 3, 4, 9) had under¬
gone recent laparotomy for haemostasis before star¬
ting vasopressin and although specific bleeding points
were controlled, massive haemorrhage continued.
Bleeding was controlled by vasopressin in three of the
four, in patient 3 it was uncontrolled. The remaining
patients were treated with vasopressin without prior
laparotomy and all required subsequent laparotomy
for haemostasis. In two of these patients (patients 7,
8), bleeding was reduced preoperatively increasing the
time available for preparation. Four patients had a
Table 1. Details of patients in chronological order who received vasopressin and their surgical management before vasopressin treatment
Patient Age Sex Weight Diagnosis Bleeding source Surgical management
number (years) (kg)
1 14 F 59 Chronic active hepatitis Gastric erosions Liver transplantation








4 60 M 78 Hepatoma Liver Partial hepatectomy,
laparotomy





6 39 M 65 Intra-abdominal sepsis Peritoneum Drainage of abscesses
7 23 M 76 Budd Chiari Artery inferior to liver Liver transplantation
8 38 F 83 Wilsons disease Artery in retroduodenal
lymph node
Liver transplantation
9 50 M 68 Intra-abdominal sepsis Peritoneum and liver Drainage of absces¬
ses, laparotomy
10 28 F 55 Hepatic failure Retroperitoneal area Liver retransplanta-
tion
Intensive Care Med (1988) 14:526-531 IntensiveCare
Medicine
© Springer-Verlag 1988
The physiological effects of vasopressin
when used to control intra-abdominal bleeding
M. P. Shelly, R. Greatorex, R.Y. Calne and G. R. Park
Addenbrooke's Hospital, Cambridge, UK
Received: 15 June 1986; accepted: 30 November 1987
Abstract. Vasopressin was used in ten critically ill pa¬
tients with massive intra-abdominal bleeding
unresponsive to conventional therapy. Vasopressin
controlled bleeding in four patients, three of whom
had continued to bleed following laparotomy for
haemostasis; in two other patients, bleeding was
reduced. All the patients were intensively monitored
throughout the period of the vasopressin treatment;
this enabled other physiological effects of vasopressin
to be documented and reported. Mean arterial
pressure and central venous pressure increased follow¬
ing the administration of vasopressin and there was a
decrease in heart rate. Core body temperature rose sig¬
nificantly. Although all the patients had impaired
renal function before receiving vasopressin, five had a
prompt diuresis following its administration. Eight pa¬
tients died but only three of intra-abdominal bleeding;
two patients survived to leave hospital. Four patients
had post-mortem evidence of ischaemia in the heart,
liver and gastrointestinal tract; vasopressin may have
contributed to the development of this. Vasopressin
may have a place in the management of patients with
life-threatening intra-abdominal haemorrhage but its
use should be confined to those patients in whom con¬
ventional therapy has failed.
Key words: Vasopressin — Abdominal bleeding —
Cardiovascular measurements — Renal failure
Life threatening intra-abdominal bleeding is a rare
event but when it does occur, it provides a challenge
to all involved in its management. Advances in liver
surgery have increased the frequency of major hepatic
surgery and the incidence of intra-abdominal bleeding
following this type of surgery has risen corresponding¬
ly. Since massive intra-abdominal bleeding is an im¬
portant complication in a regional centre for liver
transplantation and major liver surgery, we have been
concerned with its control.
Vasopressin has long been known to reduce portal
pressure [1] and this has led to its use in the control
of bleeding particularly from oesophageal varices.
Direct administration into the superior mesenteric
artery has been used to produce local haemostasis and
minimise systemic effects [2, 3], however, intravenous
administration has the same haemostatic efficacy and
systemic effects [3 — 5] and is considerably simpler. In-
termittant bolus administration of vasopressin reduces
bleeding from oesophageal varices [6, 7] but frequent
short infusions [8] or a continuous infusion [4] may be
more effective.
The ability of vasopressin to reduce pressure in the
splanchnic vascular bed, prompted us to use vasopres¬
sin intravenously in an attempt to control intra-ab¬
dominal bleeding when conventional treatment proved
ineffective.
Patients
All patients following liver transplantation or suffer¬
ing from major intra-abdominal bleeding, are manag¬
ed on the intensive care unit. Ten patients received va¬
sopressin over an 8-year period and the case notes of
these patients were reviewed retrospectively. Initially
vasopressin was used in 3 patients following liver
transplantation to control intra-abdominal haemor¬
rhage when other therapeutic manoeuvers, including
laparotomy, had failed. However, as experience with
the drug grew it was used in patients with other causes
of intra-abdominal bleeding.
All the patients were exsanguinsating from their in¬
tra-abdominal bleeding and all had impaired renal
function from prerenal failure or acute tubular
necrosis; four were requiring haemodialysis. Nine pa-
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Failure of critically ill patients to metabolise midazolam
M. P. SHELLY, L. MENDEL and G. R. PARK
Summary
The pharmacokinetics of midazolam and its metabolite, J-OH midazolam, were studied in six critically
ill patients during and after a continuous intravenous infusion of midazolam. Four patients had an
increased elimination half-life of midazolam; two were associated with a reduction in plasma clearance
with low plasma concentrations of the metabolite, and two with normal metabolite levels and increased
volume of distribution. The two patients with reduced clearance suffered from septic shock and were
studied over a longer period. Their altered clearance was due to a reduced capability to form the 1-0H
metabolite. As their condition improved, plasma concentrations of 1-OH midazolam increased and mida¬
zolam clearance returned towards normal. The impaired ability of critically ill patients with septic shock





Sedation of patients who require intensive care
is necessary to reduce the distress of the patient
and to facilitate treatment. Several agents are
available but all have disadvantages when given
continuously to critically ill patients. Accumula¬
tion of barbiturates may lead to prolonged
sedation after the infusion has been dis¬
continued. Chlormethiazole has been used 1 but
the large fluid volume required may compromise
fluid balance and nutrition. Etomidate and
alphaxalone/alphadalone (Althesin) provide
effective sedation when given by continuous in¬
fusion. but problems with their use have led to
their being abandoned.2-4
Until the introduction of midazolam, benzo¬
diazepines have not been used by continuous
intravenous infusion because of the prolonged
effect of the parent drug and, in some cases, of
its pharmacologically active metabolites.
Midazolam is a water soluble benzodiazepine
with a rapid onset and a short duration of action
in normal subjects.5 It has a short elimination
half-life, a relatively large volume of distribution
and a high plasma clearance.6 Its major meta¬
bolic pathway is hydroxylation and subsequent
conjugation with glucuronic acid before elimina¬
tion in the urine. Midazolam is thought to
undergo biotransformation by the P450 system 7
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and, since it undergoes extensive first pass
metabolism following oral administration, the
liver and gut wall are thought to be important
sites of metabolism although other organs may
also be involved. The 1-hydroxy metabolite of
midazolam is pharmacologically active but has
a shorter elimination half-life than midazolam
itself.8
A prospective study was performed to investi¬
gate the pharmacokinetics ofmidazolam in critic¬
ally ill patients. Prolonged sedation following
continuous intravenous infusion of midazolam
was reported9-11 while this study was being
planned, and the blood sampling protocol was
extended in view of this.
Method
Six consecutive critically ill patients who had not
received benzodiazepines since admission to the
intensive care unit and who required sedation to
facilitate controlled ventilation, received a con¬
tinuous intravenous infusion of midazolam.
Approval for the study was obtained from the
district ethics committee. Informed consent was
obtained from three of the patients themselves
(patients C, D and E) but the remainder were
unable to consent personally and informed con¬
sent for the study was then obtained from their
relatives.
Midazolam hydrochloride was diluted with
5% dextrose to produce a solution that contained
1 mg/ml and administered through a centrally
placed venous catheter. The rate of infusion was
altered by the nursing staff subject to prescribed
limits which were reviewed regularly by medical
staff. No other benzodiazepines were admini¬
stered during the study period.
Blood samples were withdrawn from an in¬
dwelling arterial line into tubes that contained
oxalate anticoagulant, before the infusion was
commenced and one hour after starting the
infusion; thereafter daily blood samples were
taken to ascertain whether steady state had been
reached. Frequent blood samples were taken
following cessation of the infusion, until the
patient was clinically awake (Table I). The blood
was centrifuged and the supernatant plasma
separated and stored at — 20°C for analysis.
Plasma concentrations of midazolam and the
metabolite 1-OH midazolam were estimated by
gas-liquid chromatography with electron cap¬
ture detection.12
Table 1. Times of blood sampling during continuous
intravenous infusion of midazolam.
Before administration of midazolam
One hour after commencement of infusion
Daily sampling at 10:00 hours
On cessation of infusion
Thereafter at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8 hours
Six-hourly until the patient wakes
Pharmacokinetic parameters for midazolam
were determined using standard, model-indepen¬
dent pharmacokinetic methods. It was assumed
that a steady state would be reached if midazo¬
lam was infused continuously at the same rate
for 15 hours or more.
The severity of the patients' illness was assessed
by determination of their APACHE II score13
on admission to the intensive care unit and on
the day of cessation of the midazolam infusion.
The sepsis score14 was also calculated for each
patient on admission and daily thereafter. Note
was made of all other drugs administered to the
patients, particularly other sedative and analgesic
drugs and inotropic agents.
Throughout their period of intensive care, the
conscious level of each patient was recorded
every 2 hours using a sedation scoring system
developed for routine use in this intensive care
unit.15 This system uses six clinically identifiable
end points; fully alert, roused by voice, roused
by pain, unrousable, paralysed, or asleep. The
time taken for the patients to wake following
cessation of the midazolam infusion was noted
from the recorded conscious levels and taken as
the point where the patient became fully alert or
increased their conscious level by at least two
steps. The plasma concentrations of midazolam
and of the metabolite 1-OH midazolam at the
point of awakening were extrapolated from the
graphs of plasma drug and metabolite concen¬
trations against time.
Results
The details of the six patients are shown in Table 2. *
One patient failed to complete the protocol and
a further patient was studied on two occasions.
Patient E received an infusion of midazolam for
16 days to facilitate controlled ventilation. No
samples were taken during the decline phase after
cessation of the infusion but his results are in¬
cluded because of the duration of the infusion.
In patient F, the infusion was discontinued on
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Table 2. Details of the six patients studied.
Age Weight APACHE II Sepsis
Patient (years) Sex (kg) score * score * Diagnosis
A 76 M 78 a 14 2 Prolonged postoperative neuromuscular
b 14 2 blockade
B 68 M 66 a 20 6 Postcardiac arrest
b 17 5
C 54 F 60 a 8 0 Multiple trauma
b 3 3
D 62 M 70 a 16 12 Re-exploration of femoro-popliteal graft
b 17 10
E 60 M 60 a 30 20 Chronic myeloid leukaemia, septic shock
b 32 18
c 26 13
F 76 M 60 a 26 13 Postoperative respiratory failure, septic
b 29 19 shock
c 24 17
* a. On admission; b, on day of cessation of midazolam infusion, except for patient E, day 4 scores; c, patient E,
scores on day 14, patient F, scores on the second occasion when the midazolam infusion was stopped.
Table 3. The mean dose ofmidazolam, the duration of infusion and other sedative, analgesic and vasoactive drugs
administered to each patient.
Mean dose Infusion duration
Patient (mg/hour) (hours) Analgesics Vasoactive agents
A 2.7 10 Morphine
B 6.4 26 Morphine Dopamine
Lignocaine
Digoxin
C 3.4 143 Morphine Dopamine
D 3.8 39 Morphine Dopamine

















the 5th day to assess the patient's conscious level
but was restarted to control agitation. The
infusion was finally stopped 3 days later to
attempt weaning from controlled ventilation.
Blood samples were taken on each occasion the
* infusion was stopped. All the patients except
patients E and F survived to be discharged to the
ward. Patient E died on his 20th day of intensive
care, 5 days after his last dose of midazolam and
patient F died on his 82nd day of intensive care,
75 days after his infusion ended; both died of
multisystem failure. APACHE II and sepsis
scores are shown for patient E on day 4 of his
midazolam infusion, when he suffered from septic
shock, and on day 14, when clinical improve¬
ment was evident. The same scores are shown
for patient F on both days his sedation was dis¬
continued.
In all the patients, the infusion of midazolam
was commenced shortly after their admission to
the intensive care unit. The dose and duration of
the infusions are shown in Table 3, together with
other sedative, analgesic and vasoactive agents
administered. None of the patients received
other benzodiazepines or neuromuscular block¬
ing agents during the study period. Concomit¬
ant drugs administered included antibiotics,
steroids, heparin and diuretics. All patients
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received ranitidine and morphine, which was
administered by intravenous bolus dosage or by
continuous intravenous infusion. Dopamine was
given by continuous intravenous infusion to all
but patient A. Patients A and C had normal renal
function, patients B and D had impaired renal
function whilst patients E and F were in renal
failure. Only patients E and F had impaired liver
function and reduced serum albumin concen¬
trations.
The derived pharmacokinetic parameters are
shown in Table 4, together with the normal
values.16 ■'1 One patient (C) had normal pharma¬
cokinetic parameters and in another (A), the data
were incomplete but appeared normal. The
remaining patients had prolonged elimination
half-lives as a result of reduced clearance of
midazolam. In two cases (patients B and D),
plasma concentrations of 1-OH midazolam were
normal and the increased half-life was due partly
to an increased volume of distribution.
Two patients (E and F) initially had a reduced
clearance of midazolam with increasing plasma
concentration of midazolam during the period of




Patient (litres/kg/hour) (hours) (litres/kg)
Normal
range16,17 0.24-0.71 0.84-5.4 0.86-1.86
A * 2.5 *
B 0.11 13.9 2.23
C 0.42 2.5 1.51
D 0.06 18 Hight
E a 0.04 * *
b 0.49
F a 0.03 21 0.88
b 0.08 7.8 0.98
* No values: patient A, not at steady state when infu¬
sion discontinued; patient E, no samples during decay
from plateau level.
+ Clearance at steady state probably reduced due to
interfering peak in predose sample,
a, Patient E, day 4, patient F, first cessation of mida¬
zolam infusion; b, patient E, day 14. patient F, second
cessation of midazolam infusion.
their infusion and low or absent plasma concen¬
trations of 1-OH midazolam. As their condition








Fig. 1. Plasma midazolam and 1-OH midazolam concentrations for patient E
throughout the period of study. . Plasma midazolam concentration;
plasma 1-OH midazolam concentration.
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Fig. 2. Plasma midazolam and 1-OH midazolam concentrations for patient F during
the study period, including both occasions the midazolam infusion was discontinued.
—, Plasma midazolam concentration; , plasma 1-OH midazolam concentra¬
tion.
decreased and 1-OH midazolam increased,
which indicates that clearance was returning
towards normal. The plasma concentrations of
* midazolam and 1-OH midazolam for patient E
throughout the period of his infusion are shown
in Fig. I. Plasma concentrations of midazolam
increased rapidly after the start of the infusion
and reached a peak on day 4. Plasma concen¬
trations of 1-OH midazolam were low or absent
during this time. On day 5, which coincided with
the patient's first period of haemodialysis, the
plasma concentration of midazolam decreased
but that of 1-OH midazolam increased. Follow¬
ing this, the plasma concentrations ofmidazolam
and 1-OH midazolam decreased to a steady-
state level which was maintained until the infu¬
sion was discontinued. The phase immediately
following discontinuation was not studied in this
patient but, 24 hours after cessation of the
infusion, no midazolam or 1-OH midazolam
were detectable in the plasma.
The plasma concentrations of midazolam and
1-OH midazolam for patient F during his entire
study period are shown in Fig. 2. Plasma con-
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centrations of midazolam again increased rapidly
to high levels by day 4 but, following the first
cessation of the infusion, the levels remained
high. No 1-OH midazolam was detected in the
plasma during this period. After the infusion was
restarted plasma midazolam concentrations
declined slightly until the infusion was finally
stopped on day 8. Following this, the plasma
concentration decreased to therapeutic levels
within 24 hours.
Table 5 shows the time taken for the patients
to wake and the plasma concentrations of
midazolam and 1-OH midazolam at this time.
Table 5. Time taken for patients to wake following
cessation of midazolam infusion, and plasma mida¬
zolam and 1-OH midazolam concentrations at this
time.
Plasma Plasma
Time to midazolam 1-OH midazolam
wake concentration concentration
Patient (hours) (ng/ml) (ng/ml)
A 0 117 25
B 11 365 43
C 2 97 40
D 12 519 32
E * 0 0
F a t 2582 0
b 24 166 20
* Remained unrousable.
t Infusion restarted because of agitation.
a. First cessation, b, second cessation of midazolam
infusion.
Discussion
Few drugs are currently available which will pre¬
dictably produce adequate sedation in patients
who receive intensive care. Midazolam has been
used to induce anaesthesia18 and to produce
sedation19 in healthy patients and its use has
been extended to the critically ill patient in the
intensive care unit. Continuous intravenous
infusion of midazolam produces satisfactory
sedation but prolonged awakening has been
reported in some patients.9-11 A considerable
variation in individual response to midazolam
has been reported previously; the elderly are
particularly sensitive.20 The prolonged sedation
seen in critically ill patients following midazolam
may represent part of a spectrum of response
and may reflect altered hepatic blood flow9 or
impaired metabolic capacity.20 The patients
reported here show three different pharmaco¬
kinetic and pharmacodynamic patterns, which
appear to be related to the severity of the patient's
disease.
The two patients (A and C) with the lowest
APACHE II and sepsis scores had normal
pharmacokinetic parameters. In both these
patients, plasma concentrations of midazolam
and 1 -OH midazolam decreased rapidly and both
woke soon after the infusion was discontinued.
At the time of awakening, plasma concentrations
of midazolam were approximately 100 ng/ml «
and concentrations of 1-OH midazolam were
approximately 30 ng/ml.
All the remaining patients had a low plasma
clearance and a prolonged elimination half-life
of midazolam. Two of these patients (B and D)
had intermediate APACHE II and sepsis scores.
The prolonged elimination ofmidazolam in these
patients, was associated with a large volume of
distribution and normal plasma concentrations
of 1-OH midazolam. These patients remained
sedated for approximately 12 hours after cessa¬
tion of the infusion and were awake, with plasma
concentrations of midazolam normally associ¬
ated with sedation. Plasma concentrations of
1-OH midazolam were again approximately 30
ng/ml. Patients who undergo major surgery and
patients with chronic renal failure have an altered
volume of distribution of midazolam.20 21 This
change has been attributed to reduced protein
binding of the drug, which leads to a higher free
drug fraction.21 A similar mechanism may be
responsible for the large volume of distribution
of midazolam in these patients, both of whom
had impaired renal function. Their concentra¬
tions of serum albumin were normal but its
ability to bind midazolam may have been altered
by disease or other drugs administered concomi¬
tantly.22
The remaining two patients (E and F) both
initially suffered from septic shock and had high
APACHE II and sepsis scores; both patients
received inotropic support. These two patients
initially had a reduced clearance associated with
low or absent plasma concentrations of 1-OH
midazolam. The plasma concentration of *
midazolam in these patients reached high levels
(3000 ng/ml) on the 4th and 5th day of their (
infusions but no adverse haemodynamic or
biochemical effects of these high concentrations
were noted. Both patients subsequently showed
clinical evidence of improvement and their
APACHE II and sepsis scores decreased. This
improvement was associated with the appearance
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of 1-OH midazolam in their plasma and an in¬
crease in midazolam clearance towards normal.
In patient E, this change coincided with his first
period of haemodialysis. This did not initiate
his improvement but is a reflection of it, since
haemodialysis could not be undertaken in the
presence of haemodynamic instability. Further¬
more, similar changes in the plasma concen¬
trations of midazolam and 1-OH midazolam
i were not seen when haemodialysis was repeated.
The high plasma concentrations ofmidazolam
and the absence of metabolite suggest that
impaired metabolism resulted in its cumulation.
A reduction in the metabolism may result from
reduced liver perfusion or an enzyme defect.23
The increase in midazolam clearance as the
patients' condition improved, however, suggests
a reversible impairment rather than an inherited
reduction in midazolam metabolism.20 Because
midazolam has a high hepatic extraction, the rate
of its metabolism is dependent on hepatic blood
flow and any reduction in liver perfusion could
reduce the rate of its metabolism.9 Acute hypo¬
volemia in dogs lowered the clearance of
midazolam, without changes in volume of dis¬
tribution or in protein binding.24 Midazolam
itself has been shown to affect splanchnic blood
flow. Following bolus administration, hepatic
arterial flow decreases and portal venous flow,
after an initial rise, also falls.25 The haemo¬
dynamic stability that follows administration of
midazolam is thought to be due to compensatory
mechanisms which lead to redistribution of blood
within the splanchnic bed; this may also occur in
man.26
Both these patients were sedated for a pro¬
longed period following cessation of the infusion.
Patient E remained unrousable until his death, in
spite of undetectable plasma concentrations of
midazolam and 1-OH midazolam 22 hours fol¬
lowing the infusion; this may have been due to
the prolonged effect of other drugs or to his
severe illness. After the midazolam infusion of
patient F had been discontinued, it was restarted
' because of agitation which occurred in spite of a
high plasma concentration. However, when the
? infusion was discontinued for a second time, he
woke with a plasma concentration of midazolam
within the sedative range and a plasma 1-OH
midazolam concentration of 20 ng/ml. Overall,
there appeared to be no correlation between
plasma midazolam concentration and the time at
which the patient woke following the infusion.
There does, however, appear to be an association
between waking and the plasma concentration
of 1-OH midazolam; patients awoke with levels
between 20 and 40 ng/ml.
Plasma concentrations of 1-OH midazolam are
lower than those of the parent drug and this
represents a wide range. However, it may be that
the action of midazolam is influenced by its
metabolites in the same way as the effects
of morphine appear to depend upon its meta¬
bolites.27,28
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Introduction
Patients who have had major operations,
such as portal-systemic venous shunts for
cirrhosis, entero-hepatic anastomoses for
biliary obstruction, operations for liver
trauma or liver transplantation are usually
admitted to the ICU for postoperative care.
In our hospital they are initially ventilated
artificially for some hours, until blood loss
has been controlled, analgesia established
by appropriate means and consciousness
(which may have been impaired by
encephalopathy) has been recovered.
The ICU stay may be divided into two
phases. The initial phase, covering the first
hours following the procedure, is a period
of stabilisation with effectively a
continuation of the intra-operative
management, with close cardiovascular
and biochemical monitoring. The second
phase is a period of recovery, dominated by
the need for pain relief and resumption of
respiratory function, and characterised by
important metabolic changes associated
with the return of liver function, in a patient
who may previously have been in end-stage
liver failure. The postoperative period is
also marked by the late effects of the
massive blood replacement which is
sometimes needed in patients with
coagulopathy due to liver failure.1 All are
factors which can influence renal, hepatic
and other organ functions.
In this review metabolic and other
changes encountered during the early days
following one such operation, liver
transplantation, when the patient requires
intensive care, are described.
Patients and methods
This paper reviews the postoperative
coursesof 38 patients who underwent liver
transplantation as described by Calne2 at
Addenbrooke's Hospital in Cambridge.
Dr L.angon is from the Centre Hospitalier
Regionaland University ofDijon. I)r
l.indop, Dr Park and Dr Farman work in
the U'Uat Addenhrooke's Hospital.
Cambridge, where these observations were
made.
All of them were assessed preoperatively
according to a standard protocol.3
The preoperative diagnoses are shown in
Table 1. Their distribution is
representative of the entire range of
conditions likely to lead to ICU admission,
with the exception of acute hepatic failure.
Preoperative investigations are shown in
Table 2. The liver score,4 attesting the
severity of liver dysfunction and hence of
operative risk, was calculated.
The anaesthetic and the perioperative
management was as previously described;
during the procedure, 20 patients received
isoflurane in concentrations up to 1.5 per
cent while 18 received up to 0.5 per cent
trichloroethylene. The addition of nitrous
oxide to oxygen depended on the choice of
the anaesthetist. Fentanyl was employed as
required for analgesia and maintenance
relaxation was provided with atracurium or
vecuronium, either as boluses or as an
infusion, or with bolus pancuronium.
At the end of the operation, the patients
were transferred to the intensive care unit.
Weaning from the ventilator was usually
achieved within the first 24 hours,
depending on haemodynamic stability,
satisfactory pulmonary function and the
absence of any important abdominal
bleeding. Children weighing 1(1 kg or less
were usually artificially ventilated for a
period of 2 days. During this phase,
analgesia was provided with intravenous
bolus doses of either morphine or
fentanyl.5 As the patient is being weaned
from the ventilator, bilateral intercostal
blocks are performed for the relief of
parietal pain,'The remaining visceral pain
being treated with as-required intravenous
bolus opioids. Sedation and anxiolysis were
provided by intermittent doses of
midazolam. Tb' ' ation of artificial
ventilation and the need for intravenous
analgesia and sedation were recorded.
Monitoring of hepatic, renal and
hemopoietic function followed the pattern
shown in Table 3. Haemoglobin
concentration was recorded as part of the
blood count, allhough this did not reflect
changes in body production of red cells so
much as the use of blood transfusion or
venesection. Other results, such as urine
output or arterial blood gases, although
monitored throughout the ICU stay, are
Table I, Diagnoses, number ofdeaths and lengths of stay (LOS mean ± SI)) in the ICU in
the 38 patients.
Diagnosis No % Deaths LOS (days)
Primary biliary cirrhosis 9 24 2 3.5 ±1
Metabolic disease 6* 16 1 4.3 ±2.5
Sclerosing cholangitis 5 13 2 9.5 ±7.8
Liver tumour 4 II 1 2.7 ±0.5
Chronic active hepatitis 3 8 (1 5.7 ±3.3
Rctransplantation 3" 8 1 7.5 ±1.5
Cryptogenetic cirrhosis 2 5 (1 5.5 ±2.5
Alcoholic cirrhosis 2 5 0 4.0 ±1
Polycystic disease 2 5 0 7.0 ±2
Others J***
'Wilson'sdisease 2, antitrypsinedeficiency 2, Crigger-Najar'sdisease t, tyrosinosis I.
"Acute rejection2, (48h 20days),chronic rejection 1. "'Biliary atresia I, Budd-Chiarisyndrome I.
Table 2. Patient's preoperative details (mean ±
SD (range))
Mean SD Range
Age (years) 35 16 (3-55)







Platelets (x 1000/ml) 232 175 (45-748)
Albumin (g/l) 26 8 (12-46)




ALT (U l/l) 154 273 (4-1668)
Urea (mmol/l) 9.2 13.3 d-75)
Creatinine (umol/l) 128 134 (15-760)
Table 3. Monitoring of hepatic, renal and
haemopoietic functions following liver
transplantation
Electrolytes* LET** Blood count
On arrival + +
6h +■ +
12 h + + +
24 h + 4- +
Daily f + +
"Sodium, potassium, urea, creatinine, glucose.
*" I .FT. liver function tests: total proteins,
albumin, phosphatase, bilirubin, alkaline
phosphate, alanine amino transferase.
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believed to reflect mainly the quality of
care and so are not reported here. If the
patient was exposed to nitrous oxide,
hydroxycobalamin and folic acid were
given for the first two postoperative days to
reduce the bone marrow toxicity which
follows the employment of this agent for
long procedures.7
Results
The patients' ages ranged from 3 to 55 years
(mean 35, SD 16 years), with liver scores
between 5 and 14 (mean 9.3), indicating a
moderate level of risk. Of the 38 patients, 7
died during their stay in the ICU (6 during
the first week), 5 from major
intra-abdominal bleeding, 1 from viral
infection and 1 from multi-organ failure.
The mean duration of stay in the ICU was 7
days (SD 9 days); seven patients stayed
more than one week. The duration of
artificial ventilation was 37 (SD30) hours,
intravenous analgesia was needed for 67
(SD 51) hours, and sedation for 42 (SD 36)
hours.
Over the first postoperative week,
albumin concentrations were almost
constant, with values a little higher in the 12
and 24 hour samples compared with the
preoperative levels, although always
remaining below the normal range, as
shown in Figure 1.
Following a reduction in the first 24
hours, the bilirubin concentration
remained constant until the third day and
then started to increase, reaching a value
near the preoperative level by the 7th day.
This is shown in Figure 2.
After operation there was a striking
decrease over the first two days in alkaline
phosphatase values, which then remained
almost constant for the remainder of the
week (Fig. 3).
By contrast the ALT (Alanine
aminotransferase) increased during the
first day, reaching a level 5 times greater
than the preoperative value, as shown in
Figure 4, and then decreased over the next
two days, thereafter remaining constant.
Despite a transient increase followed by
a reduction over the first 24 hours, urea
levels tended to increase slightly from the
preoperative values (Fig. 5).
Creatinine levels increased during the
first day following surgery and then fell
again, to reach their preoperative values on
the 3rd day although remaining slightly
above normal (Fig. 6).
The platelet count, shown in Figure 7,
fell until the third day and then rose again
up to the end of the second week.
The white cell count remained
unchanged for the first 3 days, and then
started to increase, reaching a mean value
of 17 200 /ml at the end of the second
postoperative week (Fig. 8).
Discussion
Albumin infusions are given throughout
the early postoperative period to
compensate for losses from the wound via
the drains, so scrum levels reflect mainly
the effectiveness of replacement therapy.
During the course of this period the loss via
the drains decreased, while at the same
time the liver presumably resumed
Figure 1. Changes in serum albumin in the first
week after operation.
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Figure 2. Serum bilirubin levels in the
postoperative period.
nol'l ) I I I I u I I ■
3 3 1 3 i 1
(»VS
Figure 3. Evolution of the serum alkaline
phosphatase after major liver surgery.
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Figure 4. ALT levels rise on the first
postoperative day, and then decay gradually.
1 3 3 ~l 3 i I
I • v s
Figure 5. Changes in blood urea after operation;
the increase over the first few days is due to part to
greater production by the liver.
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Figure 6. Serum creatinine levels rise at first,
presumably reflecting tissue destruction, and then
return to the control level. Note the w ide Standard
Deviation.
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Figure 7. The platelet count falls at first, then
recovers, reaching normal levels within two
weeks.
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Figure 8. The white blood count rises after the
first three days follow ing liver transplantation;
this may reflect immune suppression.
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production of albumin, explaining the
slight increment observed at the end of the
first week.
The trend of bilirubin levels may be
divided into 3 parts; the first immediately
follows transplantation, when the
elimination of the excess bilirubin occurs,
the second is a plateau representing a
balance between production and
elimination and the third, beginning on the
third day, is when production exceeds the
rate of elimination, possibly as a
consequence of haemolysis associated with
massive blood transfusion. Moreover, this
occurs during the period that often sees the
first episode of rejection of the
transplanted liver (commonly from
5 to 14 days after surgery)."
Changes in alkaline phosphatase levels
demonstrate the metabolic activity of the
liver. The steep slope of the first part of the
curve is explained by the catabolism of this
enzyme, which normally has a half-life of
around 40 hours. The slight increase
( AH! O! [ Ill CHIIII A! I Y II I .1
Table 4. Mean values (± SD) of the variables studied over the course of the first week in 38 patients
6h 12 h 24 h 48 h 72 h Day 7
Albumin (g/l) 28.8 29 27.5 24.7 26.5
(4.2) (4.5) (5.4) (5.5) (5.3)
Bilirubin (umol/l) 157 117 118 114 250
(121) (114) (80) (81) (230)
Alk. phosphatase (UI/I) 244 216 166 160 204
(238) (192) (132) (106) (127)
ALT (UI/I) 658 778 579 461 425
(919) (990) (644) (453) (533)
Ureafmmol/I) 13 8.8 11 11.3 12.9 22
(24) (6.2) (12) (13) (13.5) (22)
Creatinine (umol/l) 142 153 163 146 135 130
(106) (91) (110) (97) (100) (117)
White cells (xlOOO/ml) 8.5 10 10.2 9.2 8.2 14.4
(4) (5.5) (4.2) (4.6) (8.2) (14.4)
Platelets (x 1000/ml) 162 146 120 98 104 157
(114) (118) (105) (79) (86) (125)
Haemoglobin (mg/100ml) 12.8 12.9 12.7 12.8 12.5 13.1
(2.6) (3) (2.6) (2.3) (2.1) (1.9)
observed at the end of the first week may
also be related to episodes of rejection
during this period, although there is a
dissociation between the marked increase
in bilirubin and the relative stability of the
alkaline phosphatase. In the case of
transplantation the liver has to recuperate
from a long cold ischaemic period of
preservation, inevitably associated with a
degree of cytolysis, reflected by the
increase in ALT levels during the first
postoperative day. Regeneration of
destroyed hepatocytes seems to begin
within 24 hours of surgery, although on the
7th postoperative day blood levels are still
greater than preoperative values, which
may be due to episodes of rejection.
Renal function is also affected by major
liver operations, but plasma urea and
creatinine levels depend on hepatic as well
as renal function; the slight increment in
these levels seen at the end of the operation
is a consequence of the haemodynamic
perturbation associated with such
procedures. Thereafter the rising urea level
may be an expression of increasing
production by the liver. The dopamine
infusion, given to protect renal function
during and after surgery, is usually stopped
on the second day aftersurgery, which may
contribute to the increase in blood levels by
reducing urea clearance. Changes in
creatinine levels do not parallel those of
urea; here again the rising part of the curve,
from the end of the operation to the end of
the first postoperative day, is possibly
explained by the tissue destruction
occurring during the procedure. This rise is
transient, the levels returning to their
preoperative values within 2 days.
Cyclosporin, usually introduced on the 3rd
postoperative day, seems to have no major
effect on plasma creatinine levels.
Platelet levels are also affected by the
operation, massive blood transfusion
inducing thrombocytopenia.9The presence
of the large wound and internal raw areas
will account for a considerable
consumption, which explains the reduction
in the count seen at the end of the
procedure. The first hours following the
operation may be marked by persistent
intra-abdominal bleeding, necessitating the
continuation of transfusion. No platelet
transfusion is given as long as the count
does not fall below 50000/ml, unless
bleeding continues, so the mean trend is
downwards. When the bleeding ceases the
platelet count increases, reaching normal
levels some two weeks later. Numerous
factors affect the white cell count, including
rejection and infection, which may be an
explanation for the tendency of the curve to
rise.
In conclusion, the results describe the
recovery of liver function in a series of
typical patients after major liver
operations. It is clear that the changes
described are affected by many factors
which depend both on the patients and on
their preoperative diagnoses. Nevertheless
they represent a good model for all patients
receiving intensive care following major
hepatic operations.
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Intercostal nerve blockade for children
M.P. Shelly *t, FFARCS, Research Registrar, G.R. Park, FFARCS, Consultant in Anaesthesia
and Intensive Care, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ.
Summary
A modified technique of intercostal nerve blockade is described which is suitable for use in children. Ten patients
received intercostal nerve blockade on a total of 29 occasions in order to provide analgesia following liver trans¬
plantation and to facilitate weaning from artificial ventilation of the lungs. The opioid requirement ofpatients who
received intercostal nerve blockade was considerably lower than that of those who did not; 56% of the children who
received intercostal nerve blockade required no additional analgesia. One child, the first to receive intercostal nerve
blockade, developed a pneumothorax following the procedure. The technique has proved to be safe in skilled hands. It
is an acceptable method ofpostoperative analgesia in children after liver transplantation andmay be a useful technique
in the management of other paediatric patients.
Key words
Anaesthetic techniques, regional; intercostal.
Anaesthesia; paediatric.
Interest in nerve and regional blockade for children
has been slow to develop. Penile nerve block or caudal
analgesia are often used to supplement anaesthesia and
provide postoperative analgesia for operations such as
circumcision, but other techniques are employed less
frequently. Local analgesic blocks in children have a
number of problems, particularly for the occasional
paediatric anaesthetist.1 These include the practical
difficulties of dealing with small children, their varia¬
tions from the more familiar adult anatomy, the dif¬
ferent equipment or techniques that may be ap¬
propriate and the lack of information regarding the
pharmacokinetics of local anaesthetics in paediatric
patients. The mobility and distress produced by
repeated injections in the awake child are a further
complication.
Intercostal nerve blockade is used widely in adults,
both intra-operatively and for postoperative an¬
algesia;2 it has also been suggested as suitable for the
same indications in children.3 The risk of pneumo¬
thorax is the main disadvantage of intercostal nerve
blockade but its reported incidence in adults varies
widely2 and appears to be operator dependent; no in¬
cidence has been quoted in children.
Intercostal nerve blockade is performed following
liver transplantation in adults, to aid weaning from
artificial ventilation of the lungs. Provision of ade¬
quate analgesia is difficult in this group of patients
since the surgical incision is large: a bilateral subcostal
incision with an upward extension to the xiphisternum.
Analgesia is required both to allow effective physio¬
therapy and to reduce the high incidence of respiratory
complications following liver transplantation. Opioid
analgesics produce sedation and are antitussive. In
addition, the elimination of morphine appears to be
abnormal in patients following liver transplantation4
and this may be further exacerbated by impaired renal
function.5
We have evolved a modification of a standard
method for intercostal nerve blockade in order to pro¬
vide postoperative analgesia for children following
liver transplantation. The technique may also benefit
other children who require thoracic or abdominal sur¬
gery.
* Present position: Senior Registrar, Odstock Hospital, Salisbury, Wilts.
I In receipt of a grant from Napp Laboratories.
Correspondence should be addressed to Dr G.R. Park please.





Fig. 1. Position of the needle relative to the rib when intercos¬
tal nerve blockade is performed by the conventional and the
modified technique.
Methods
Technique of intercostal nerve blockade. The technique
of intercostal nerve blockade is a modification of that
described for adults in the mid-axillary line.6 The local
analgesic used is bupivacaine without adrenaline; 2 mg/
kg are diluted to give a volume of 1 ml for each inter¬
costal space to be blocked. In the smaller child 0.25%
bupivacaine is diluted, if necessary, with 0.9% saline
to give a final concentration of approximately 0.125%,
and in larger children 0.5% bupivacaine is diluted to
give an approximate concentration of 0.375%. A 100-
cm length of low-deadspace manometer tubing is
primed with the solution so that a remote needle tech¬
nique can be used with a second operator to inject the
solution.7
The patient is placed in either the lateral or supine
position and restrained firmly. The skin is cleaned and
the rib palpated in the mid-axillary line. A 25-gauge
needle is introduced perpendicularly through the skin
onto the rib and gently walked down the rib to its
caudad edge. At this point, the needle is angled pos¬
teriorly and advanced slightly medially and posteriorly
so that it is almost parallel to the rib, until the tip of
the needle lies 1-2 mm beneath the edge of the rib.
The bevel of the needle faces cephalad (Fig. 1). A loss
of resistance is frequently experienced and the needle
felt to slide into the subcostal space. The assistant who
holds the syringe is asked to aspirate while the needle
is held firmly in position, with the back of the right
hand supported against the patient and the left hand
palpating the rib or steadying the needle (Fig. 2). If no
blood or air is withdrawn, 1 ml of solution is injected
and the needle removed. It is necessary to block the
intercostal nerves bilaterally at T6-Tu inclusive fol¬
lowing liver transplantation.
Patients. Twenty children under the age of 10 have
undergone liver transplantation at this centre to date.
Fig. 2. Position of the hands and needle during intercostal nerve
blockade in children using the modified technique.
Intercostal nerve blockade was performed in the
immediate postoperative period to facilitate weaning
from controlled ventilation. Not all of the children
received nerve blocks during this period, either because
of the absence of an operator familiar with the tech¬
nique or because of a continuing need for controlled
ventilation. Local analgesia was routinely supple¬
mented by bolus opioid administration as necessary to
relieve visceral pain.
The records of all 20 patients were reviewed to assess
the efficacy of intercostal nerve blockade in this group
and the incidence of any complications. To assess
analgesic efficacy, opioid requirements on the third
postoperative day were converted to morphine equiva¬
lents 8 and expressed as mg morphine/kg for that day.
Intercostal nerve blocks were performed in the inten¬
sive care unit during the first 4 days postoperatively.
However, the third postoperative day was chosen to
assess analgesic requirements because weaning from
artificial ventilation had generally been achieved by
this time and pain from the surgical incision was still
sufficiently severe to impair respiration as well as to
cause distress. At least one erect chest X ray was taken
daily in these children, to enable prompt and accurate
identification of any pneumothorax.
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Results
The 20 children had a total of 21 operations: one
patient underwent retransplantation in the early post¬
operative period. Ten of the children received inter¬
costal nerve blockade on a total of 29 occasions after
11 operations. Ten intercostal nerves were blocked on
each occasion. The other ten children did not receive
nerve blocks; analgesia was provided in these cases by
intravenous opioids.
Analgesic requirements on the third postoperative
day were not determined for seven cases. Two cases
received intercostal nerve blockade as part of their
postoperative analgesic regimen but this was omitted
on the third postoperative day because no skilled
operator was available. The other five patients did not
receive intercostal nerve blockade; two had died by
the third postoperative day and information for the
other three was incomplete and analgesic requirements
could not be assessed for that day. The details of the
14 patients whose analgesic requirements were re¬
viewed, are shown in Table 1. Nine of the patients
Table 1. Details of patients.
Intercostal No
block block
(n = 9) (n = 5)
Mean age, years (range)
Sex, M: F









14.2 (10-22) 12.8 (8-22)
received intercostal nerve blockade and their tracheas
were extubated on or before the third postoperative
day. Of the five patients who did not receive intercostal
nerve blockade, two were extubated on the third post¬
operative day; the other three received controlled
ventilation.
The nine patients who received intercostal nerve
blockade required a mean dose of 0.16 mg/kg mor¬
phine (SD 0.27) on the third postoperative day; the
corresponding dose in those who did not receive the
nerve block was 1.52 mg/kg (SD 0.93). All patients
who did not receive a nerve block, required opioid.
The three patients who still required controlled
ventilation on the third postoperative day had more
severe illness and were sedated with midazolam in
addition to morphine. They received a mean of 1.04
mg/kg morphine on that day; the two patients whose
tracheas were extubated on the third postoperative
day, however, received a mean of 2.25 mg/kg morph¬
ine on that day. Most of the children received inter¬
costal nerve blockade on two or three occasions during
and after weaning from artificial ventilation. The
duration of analgesia on each occasion was approxi¬
mately 12 hours.
The complication rate of the technique was low.
Two of the 20 children developed a unilateral pneumo¬
thorax, but one child had not received intercostal
nerve blockade, while the other had received inter¬
costal nerve blockade 3 days previously and was the
first patient on whom the technique was performed.
The children frequently slept after administration of
the blocks; none had evidence of systemic local
anaesthetic toxicity. Two patients developed sputum
retention after early discharge from the intensive care
unit. Both received intercostal nerve blockade initially
but were subsequently given relatively high doses of
morphine for analgesia and sedation on the ward.
Discussion
Children who undergo liver transplantation are a small
but uniform group. Few other abdominal procedures
are performed in children, that require the same degree
of effective analgesia to relieve severe postoperative
pain over a prolonged period. Intercostal nerve block¬
ade is an established and effective technique for intra¬
operative and postoperative analgesia in adults.2 Use
of the technique has been shown to reduce postoper¬
ative opioid requirements and respiratory impair¬
ment.3 The main disadvantage is the incidence of
pneumothorax and, in children, the smaller anatomical
distances involved may increase this risk. A mid-
axillary approach is used in the technique described
above to reduce the likelihood of pneumothorax.9 The
risk of pleural puncture is further decreased because
the needle enters the intercostal space at an acute
angle, almost parallel to the rib. Thoracic epidural
analgesia is not employed in these patients because of
the bleeding disorders frequently encountered in
patients with liver disease, and the risk of hypotension
due to sympathetic nerve blockade.
Intercostal nerve blockade has a number of advan¬
tages over opioid analgesia following liver transplanta¬
tion. A large surgical incision is present and adequate
analgesia without profound sedation may be difficult
to achieve with opioids. Postoperative respiratory
complications are common in patients following liver
transplantation, and good pain relief with a cooper¬
ative patient and without respiratory depression is
essential for effective physiotherapy. The importance
of these points is illustrated by the two children who
developed sputum retention due to sedation following
opioid analgesia. A postoperative ileus invariably de¬
velops after liver transplantation and recovery of
effective gastrointestinal motility is hastened if the
opioid dose can be reduced. The antidiuretic effect of
morphine may further impair already compromised
renal function in these patients. Adequate renal func¬
tion is important in the elimination ofmorphine2 and,
if impaired, may exacerbate the abnormal elimination
pattern already present in these patients.4 Opioid-
induced nausea and peripheral vasodilatation may also
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cause problems which can be avoided by intercostal
nerve blockade. This study reports only a small
number of patients but the use of intercostal nerve
blockade immediately prior to weaning from artificial
ventilation, and repeated as necessary afterwards,
reduced opioid requirements significantly during this
period.
The complications of intercostal nerve blockade
include pneumothorax, haematoma formation and
local anaesthetic toxicity from inadvertent intravas¬
cular injection. One child who received intercostal nerve
blockade suffered a small unilateral pneumothorax but
that occurred 3 days after his last intercostal blockade.
Since he was the first patient to receive a block, this
may reflect lack of experience of the technique; no
subsequent patient developed this complication.
Pneumothorax is a complication of artificial ventilation
itself, particularly in children, and one other child who
did not receive an intercostal block, also suffered a
unilateral pneumothorax. The pneumothorax in this
patient was associated with barotrauma during con¬
trolled ventilation of noncompliant lungs following the
development of respiratory distress syndrome after
inadvertent administration of cyclosporin into a
central vein.10
All patients had slightly impaired clotting indices at
the time of the blocks but neither bleeding nor haema¬
toma formation proved a problem. Systemic local
anaesthetic toxicity was not observed, although a
maximum bupivacaine dose of 4 mg/kg has been re¬
commended,1 1 but a dose of 2 mg/kg was administered
to these patients because of their impaired liver func¬
tion. Sleep following intercostal nerve blockade was a
consistent feature. This may be due to several factors:
sedation is a side effect of local anaesthetic agents and
may be particularly apparent when relatively large
doses are used or when rapid uptake occurs; satisfac¬
tory analgesia may cause a tired child to sleep; and,
finally, the performance of the blocks or subsequent
physiotherapy may themselves tire the child. Although
sleepy, the children were always reusable and cooper¬
ative. No other complications of the procedure have
been noted and the children appeared to forget quickly
the temporary discomfort of the repeated injections.
The modified technique of intercostal nerve block¬
ade described, has been found to provide effective
postoperative analgesia with a reduction in opioid
requirements.
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HAEMODYNAMIC EFFECTS FOLLOWING SURGICAL
RELEASE OF INCREASED INTRA-ABDOMINAL PRESSURE
§ M. P. SHELLY, A. A. ROBINSON, J. W. HESFORD AND G. R. PARK
a. Although the haemodynamic effects of increased
intra-abdominal pressure have been documented,
the changes which immediately follow decom¬
pression have not. We report the haemodynamic
changes observed on four occasions immediately
before and after the release of abdominal tam¬
ponade resulting from intra-abdominal bleed¬
ing. Measurements made during the release of the
tamponade in the first patient indicated that rapid
blood transfusion at the time of decompression
was inappropriate. Observations were, therefore,
made in a more controlled manner in two further
patients on three subsequent occasions, when
more personnel were available to assist with the




The first patient was a 35-year-old man who
underwent orthotopic liver transplantation for
hepatic failure secondary to sclerosing cholangitis.
, After surgery he continued to bleed from
intra-abdominal sites and required massive blood
transfusion; blood was lost from abdominal drains*
and he developed a tense distended abdomen. His
coagulation screen was slightly abnormal in spite
of the infusion of fresh frozen plasma and platelet
concentrate, but there was no clinical evidence of
a significant coagulation disorder—such as bleed¬
ing from the nose, mouth, pharnyx or the sites of
venous and arterial cannulation.
Eight hours after his liver transplant operation,
laparotomy was undertaken to evacuate intra-
M. P. Shelly,* f.f.a.r.c.s.; A. A. Robinson, m.r.c.p.; J. W.
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The haemodynamic indices of three patients,
who developed abdominal tamponade as a result
of intra-abdominal bleeding following liver trans¬
plantation, were measured on four occasions
as the increased intra-abdominal pressure
was released. Hypotension followed the release
of the tamponade in all patients and was the
result of a decrease in systemic vascular resis¬
tance. This was treated with vasoconstrictors;
the response to various agents was monitored.
Treatment of hypotension following release of
abdominal tamponade by volume replacement
alone may be inappropriate and may lead to
over-transfusion; adrenaline may be the treat¬
ment of choice. Intensive haemodynamic moni¬
toring is advisable.
abdominal clot and to achieve haemostasis.
During the re-exploration, cardiovascular vari¬
ables were measured: heart rate (HR) was taken
from the electrocardiogram, mean arterial pres¬
sure (MAP) was measured via an indwelling radial
artery catheter and mean right atrial pressure
(RAP), mean pulmonary artery pressure (MPAP)
and pulmonary capillary wedge pressure (PCWP)
were measured using a pulmonary artery catheter
(Edwards Laboratories) positioned immediately
before surgery. Cardiac output (CO) was meas¬
ured by a thermodilution technique and values
were calculated for systemic (SVR) and pul¬
monary (PVR) vascular resistances.
On opening the peritoneal cavity, approxi¬
mately 6 litre of blood and clot was removed. No
arterial bleeding points were found to account for
the haemorrhage; there was a general ooze from
many intra-abdominal sites. Intraoperative hypo¬
tension was treated with blood transfusion;
however, since calculation showed the SVR to be
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patient on two occasions (3a and 3b). Morphine
and midazolam, administered for analgesia and
sedation on the Intensive Care Unit were
continued up to the time of surgery at a dose of
3-5 mg h"1 for each agent. A period of stabiliz¬
ation was allowed after the induction of anaes¬
thesia (with fentanyl 50 |ig and ketamine 100 mg).
No neuromuscular blocking agents were admin¬
istered. On account of the results of the intensive
intraoperative monitoring of the first patient,
these patients were monitored using the same
techniques and rapid blood transfusion was
withheld. Peak airway pressures were also noted
and arterial blood was sampled at intervals for
estimation of oxygen and carbon dioxide tensions,
and electrolyte concentrations. In one patient,
end-tidal carbon dioxide concentration (e'<;()2)
was monitored, together with core and peripheral
temperatures using temperature probes in the
nasopharynx and on the foot. Haemodynamic
measurements were made frequently throughout
the perioperative period.
The haemodynamic measurements made before
and after the decompression in patients 2 and 3 are
shown in table II. Heart rate decreased on all
occasions, as did mean arterial pressure; there was
an increase in CO and a sharp decrease in SVR.
Patient 3, during his first laparotomy (3a), was able
Table II. Haemodynamic changes seen before, and after, decompression of abdominal tamponade in patients
2 and 3. HR — Heart rate; MAP = mean arterial pressure; MPAP — mean pulmonary artery pressure;
RAP = right atrial pressure (mean); PCWP = pulmonary capillary wedge pressure; CO = cardiac output;
SVR — systemic vascular resistance; PVR = pulmonary vascular resistance; CT — core temperature;
































(dyn s cm"5) 2 160 93
3a 65 63
3b 108 59
CT (°C) 3b 37.0 36.7
PI pO lb 2S.8 >0.7
C o, 3b 5.6 7.2
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Table 111. Changes in some of the cardiovascular variablesfollowing intra-operative administration ofvarious sympathomimetic agents
in patients 2 and 3. HR = Heart rate; MAP = mean arterial pressure; CO = cardiac output; SVR = systemic vascular resistance.
b = Bolus; i = infusion; *not noted
Before After Before After Before After Before After
methox- methox- ephed- ephed- vaso- vaso- adren- adren-
Patient amine amine rine rine pressin pressin aline aline
Dose 2 10 u. b 0.3 mg
i 4.0 mg h-1
3a 10 mg 15 mg
3b 20 mg 7 u. b 0.3 mg
10 u. i *
HR
(beat min-1) 2 107 120 b 120 b 127
i 127 i 137
3a 109 111 109 133
3b 102 100 126 115 b 100 b 82
111 101 i 110 i 111
MAP
(mm Hg) 2 35 44 b 44 b 53
i 53 i 57
3a 56 58 48 60
3b 44 51 65 87 b 51 b 107
45 67 i 48 i 74
CO
(litre min-1) 2 4.9 3.9 b 3.9 b 4.
i 4.1 i 2.
3a 9.7 11.7 11.4 13.6
3b 10.3 9.9 12.9 11.3 b 9.9 b 10.
10.6 9.7 i 10.9 i 12.
SVR
(dyn s cm-5) 2 376 533 b 533 b 839
i 839 i 1560
3a 338 267 231 282
3b 264 307 285 446 b 307 b 728
294 395 i 300 i 378
to maintain cardiovascular stability better than on
the subsequent occasion; MAP was maintained by
a considerable increase in CO. During decom¬
pression, core temperature decreased slightly
while the temperature on the foot increased by
2 °C. There were marked increases in hydrogen
ion concentration, PaC02 and e'C02, and a smaller
increase in potassium concentration. There was
no consistent change in Pa0a or in ionized calcium
or sodium concentrations.
The responses of HR, MAP, CO and SVR of
patients 2 and 3 to different sympathomimetic
agents are shown in table III. Methoxamine had
no effect on MAP, CO or SVR. However,
ephedrine increased MAP slightly by increasing
CO. Vasopressin increased MAP to a greater
extent and in a more appropriate way by
increasing SVR, but a greater increase in SVR was
seen with the bolus administration of adrenaline.
There was no evidence of an additive effect
between the various agents administered.
DISCUSSION
The immediate haemodynamic changes seen
following the release of increased intra-abdominal
pressure have not been described previously.
Richards and colleagues (1983) described the
haemodynamic changes in three patients before,
and after, the release of abdominal tamponade—
but over a longer time course and not during the
operation. They observed decreases in mean
arterial pressure, central venous pressure and
pulmonary capillary wedge pressure after decom¬
pression, but little alteration in cardiac output or
total peripheral resistance. Other studies on
increased intra-abdominal pressure have been in
patients undergoing laparoscopy (Kelman et al.,
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1972; Lewis et al., 1972). These have produced
less comprehensive, and conflicting, results which
appear to be dependent on the intra-abdominal
pressure (Motew et ah, 1973).
Studies in dogs have described the changes seen
with increasing intra-abdominal pressure (Rich¬
ardson and Trinkle, 1976; Toomasian, 1978;
Kashtan et al., 1981): cardiac output decreased
and total peripheral resistance increased with
increasing intra-abdominal pressure. This effect
was most marked in dogs rendered hypovolaemic.
The reduction in cardiac output was thought to
reflect not only an increased peripheral resistance,
but also myocardial depression and a decrease in
venous return. Alterations in pleural pressure with
increased intra-abdominal pressure were insig¬
nificant and thought not to contribute to the
haemodynamic changes.
The variability in cardiovascular indices ob¬
served in man may be the result of different
degrees of arterial compression, of cardiovascular
instability at the time, and of the concurrent
treatment of this instability. The latter factors
were minimized as far as possible while these
patients were studied. Although intra-abdominal
pressure was not measured, these patients appear
to have had arterial compression as well as venous
occlusion in the splanchnic and lower limb vessels.
The increases in temperature at the foot, and in
Pacc)2, e'C02 and hydrogen ion and potassium
concentrations on decompression are evidence of
re-established distal circulation following arterial
compression. The increase in e'C02 has been noted
previously in similar patients (J. V. Farman,
personal communication).
Before abdominal decompression, MAP was
maintained by blood transfusion; all patients had
a tachycardia and RAP and PCWP were increased.
Patients 1 and 2 had a reduced CO and normal
SVR, but patient 3 had an increased CO, with a
low SVR. All three patients had a low PVR but
high MPAP.
Following abdominal decompression, there was
an immediate increase in CO which was associated
with a decrease in heart rate and an increase in
stroke volume. There was a sharp decrease in
SVR. Since the increase in CO was smaller than
the decrease in SVR, MAP decreased, and since
the main cause of the hypotension was a low SVR,
vasconstrictors were the most appropriate form of
treatment.
Sympathomimetic agents were relatively in¬
effective in increasing SVR. Methoxamine had no
effect and ephedrine, although it increased MAP,
did so by increasing CO, SVR remaining low.
Vasopressin is an endogenous vasoconstrictor
with an important action on the splanchnic
vascular bed. In these patients, it caused an
increase in MAP by increasing SVR. Adrenaline,
which also causes splanchnic vasoconstriction,
increased MAP by increasing SVR when given by
bolus administration. When given by infusion,
adrenaline again increased SVR, and in patient 2
this was sufficient to decrease CO so that MAP did
not increase. Vascular pooling may also occur as
a result of vasodilatation of the splanchnic
circulation and loss of tone of the intestinal smooth
muscles—the latter occurring because of hypoxia
resulting from the increased intra-abdominal
pressure in these patients. The action ofadrenaline
is complex and may depend upon smooth muscle
tone (Weiner, 1985). Intensive monitoring is,
therefore, advisable during its administration,
particularly in this situation.
The haemodynamic changes described fol¬
lowing abdominal decompression are compatible
with the release of a high intra-abdominal pressure
and the re-establishment of splanchnic and lower
limb circulation. The splanchnic venous system is
known to be an important blood reservoir
(Greenaway, 1983) and maximal dilatation of
these vessels would produce a system with a large
capacity. Constriction of the splanchnic vascu¬
lature is mediated by alpha-adrenoceptors
(Corday and Williams, 1960; Hirsch and Rone,
1982). These patients, however, responded poorly
to sympathomimetic agents and required large
doses of endogenous vasoconstrictors with a
specific effect on the splanchnic circulation. This
may be because of the presence of an abnormal
circulation with maximally dilated vessels un¬
responsive to normal doses of sympathomimetic
agents. This, in turn, may be a mechanical
problem, with the vessels splinted open by fibrous
adhesions formed as a result of the patient's
original pathology, or it may be that the
alpha-adrenoceptors are poorly responsive, pos¬
sibly on account of the release of vasoactive
substances or toxins produced during tamponade.
Chernow (1985) has postulated this type of
mechanism based on a theory described by
Berridge and Irvine (1984) and future pharma¬
cological developments in alpha-receptor modu¬
lators may elucidate its importance.
Although all these patients died eventually,
none died with the ventilatory complications, seen
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previously in similar patients, which may have
been the result of overtransfusion. Two further
patients have been managed along the lines
described above. The data on these patients are
incomplete, but both survived to be discharged
from the Intensive Care Unit and, in particular,
neither had pulmonary complications resulting
from fluid overload. The frequent pulmonary
complications previously seen in these patients
may have been the result of inappropriate
treatment of hypotension with excessive blood
transfusion following abdominal decompression.
Although some volume replacement is necessary
during such operations, vasoconstrictors may be
required in addition.
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The prevention of renal impairment in patients undergoing
orthotopic liver grafting by infusion of low dose dopamine
R. J. POLSON, G, R. PARK, M. J. L1NDOP, J. V. FARMAN, R. Y. CALNE
and R. WILLIAMS
Summary
Administration of low dose dopamine (2.0 pg/kglminute) begun before surgery in patients undergoing liver
transplantation decreases the incidence of postoperative renal impairment. Thirty-four consecutive
patients in the Cambridge/King's College Hospital liver transplantation series were studied. Nineteen
patients (21 transplant operations) received prophylactic low dose dopamine throughout the operative
and early postoperative period, while 15 patients (15 transplant operations) received dopamine only
when clinically indicated for incipient renal failure or as an inotropic agent. In the prophylactic
dopamine group, only two transplant operations (9.5%) were complicated by renal impairment, whereas
in the other group, 10 patients (67%) developed renal impairment (p = 0.001); of these, four developed
acute renal failure (27%). Comparison of seven pairs of patients, matched for age, sex, diagnosis,
operative blood loss and operative hypotension (one group receiving dopamine, the other not), revealed
a significantly higher urine output in thefirst 24 hours and creatinine clearance 24-48 hours after surgery
(p < 0.05) in those treated prophylactically. In view of these findings, we would recommend that con¬




Complications', acute renal failure.
Inotropes; dopamine.
Patients undergoing orthotopic liver trans¬
plantation may develop impaired renal function
during the operation or in the early post¬
operative period and occasionally require haemo-
dialysis. This may be due to several interacting
factors, of which major blood loss occurring in
the peri-operative period appears to be the most
important. Haemorrhage results in sympathetic
vasoconstriction, which mainly affects the af¬
ferent glomerular arterioles, with a fall in renal
blood flow and consequent renal ischaemia.
Septicaemia and the use of potentially nephro¬
toxic drugs, such as cephalosporins or amino¬
glycoside antibiotics (especially in combination
with loop diuretics) and the immunosuppressant
cyclosporin A,1 may also be causally implicated.
R.J. Poison, BSc, MRCP. Honorary Registrar in Intensive Care, G.R. Park, BSc, FFARCS, M.J. Lindop,
FFARCS, J.V. Farman, FFARCS, Consultants in Intensive Care, R.Y. Calne, FRS, FRCS, Professor of Surgery,
Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, R. Williams, MD, FRCP, Director and Consultant
Physician, The Liver Unit, King's College Hospital, Denmark Hill, London SE5 9RS.
Correspondence should be addressed to Dr G.R. Park, Department of Anaesthesia, Addenbrooke's Hospital,
Hills Road, Cambridge CB2 2QQ.
ffcBK G-.V.
0003-2409/87/010015 + 05 $03.00/0 © 1987 The Association of Anaesthetists of Gt Britain and Ireland 15
16 R.J. Poison et al.
Dopaminergic stimulation may reverse this sym¬
pathetic vasoconstriction and so help prevent the
renal ischaemia.2 Dopamine hydrochloride in
the dose range 2-5 /rg/kg/minute is a potent
renal dopaminergic agonist and is commonly
used to treat patients with incipient renal
failure,3 so its administration prior to and
during major haemorrhage would seem worthy
of consideration. In this report we describe our
experience with the prophylactic use of an in¬
fusion of dopamine 2 /rg/kg/minute, in patients
having orthotopic liver transplant operations;
the drug was started prior to surgery and con¬
tinued into the postoperative period.
Patients and methods
In an 18-month period, 34 patients were treated
by orthotopic liver transplantation; three of these
patients required retransplantation within the
same period. One patient with primary hyper¬
oxaluria and renal failure, who had a combined
liver and repeat kidney graft operation, was
treated electively with haemodialysis both pre-
and postoperatively and was therefore excluded
from further analysis. All patients received 10%
mannitol 1 g/kg during the procedure and all were
given benzylpenicillin, cefoxitin and tobramycin
during the operation and for 48 hours post¬
operatively. For immunosuppression, pred¬
nisolone and azathioprine were used; oral
cyclosporin A was introduced in the second post¬
operative week in order to avoid the renal and
pulmonary toxicity associated with intravenous
administration immediately after operation.4
Details of the anaesthetic and surgical techniques
have been described previously.5'6
Nineteen patients (21 transplant operations)
received a low dose dopamine infusion of
2 ^g/kg/minute, begun with the induction of
anaesthesia and continued for 48 hours post¬
operatively (group 1), while 15 patients (15
transplant operations) did not (group 2). A
patient who required retransplantation for
chronic rejection 6 months after her first trans¬
plant operation was treated with dopamine
prophylactically only during her second opera¬
tion and so was included in both groups. During
this period there was no formal policy about the
use of prophylactic dopamine; the decision
whether or not to use it was made by the con¬
sultant anaesthetist involved.
The peri-operative details of these two groups
were compared, as was the incidence of renal
impairment defined as oliguria (less than
0.5 ml/kg/hour urine output) in the presence of an
adequate central venous or pulmonary capillary
wedge pressure and a urine/plasma osmolality
ratio of 1.1:1.0 or less,7 or acute renal failure
requiring haemodialysis. In accordance with
conventional management, a dopaminergic dose
of dopamine was begun immediately a patient in
group 2 developed renal impairment.
To determine whether bypass support, which
diminishes venous congestion during the
anhepatic phase of the operation, had a beneficial
effect on renal function, the results for the five
patients in the dopamine-treated group in whom
veno-arterial bypass8 was used and for the six
patients in the untreated group in whom veno-
venous bypass9 was used, were compared with
the remaining patients in their respective groups.
Similarly, as we have previously shown that
younger patients have better survival rates than
older patients after liver transplantation,10 the
renal function of those aged 21 years or under was
compared with that of the older patients within
each treatment group.
Six pairs of patients were matched for age, sex
and diagnosis and as closely as possible for pre¬
operative weight, plasma creatinine concentra¬
tion and intra-operative blood loss and degree of
hypotension. One of each pair was receiving low
dose dopamine. The one patient who required
retransplantation for chronic rejection 6 months
after her first operation was included as the
seventh 'pair'.
Statistical analysis was by the unpaired
Student's t-test, the Mann-Whitney U test and
Fisher's test of exact probability where appro¬
priate.
Results
The two groups of patients were similar with
respect to age, sex, diagnoses, pre-operative
plasma creatinine and operative blood loss
(Table 1). In group 1, only two (9.5%) of the 21
transplant operations were complicated by acute
renal failure. A 13-year-old female who had
compromised renal function before operation,
with a plasma creatinine concentration of
150 ^mol/litre, required haemofiltration from 6
days postoperatively and haemodialysis from 13
days, while a second patient (a 46-year-old male)
required haemofiltration from 2 days and haemo¬
dialysis from 10 days postoperatively.
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Table 1. Renal function in 34 consecutive patients undergoing orthotopic liver trans¬




Number of transplant operations 21 15
Number of patients 19 (7M: 12F) 15 (6M:9F)
Age, years
Mean (SEM) 29.7 (4.3) 34.5 (4.3)
Range 2-58 2-57
Diagnosis
Biliary atresia 3 1
Inborn errors of metabolism 1 1
End stage liver disease:
Primary biliary cirrhosis 5 4
Chronic active hepatitis 3 2
Others 6 3
Malignant liver disease 1 4
Operative blood loss, litres




Mean (SEM) 75.9 (6.6) 79.0 (4.8)
Range 45-150 46-102
Outcome
Renal impairment at 2 weeks 2/21 (9.5%) 10/15 (67%)
Acute renal failure at 2 weeks 2/21 (9.5%) 4/15 (27%)
*One patient who was treated with prophylactic dopamine during her retransplant
operation, but not for her initial operation, is included in both groups.
In contrast, of the 15 patients (15 transplant
operations) in group 2 not electively treated with
dopamine, 10 patients (67%) developed renal
impairment, a statistically significant difference
(p = 0.001). In three cases this occurred during the
operation; one patient subsequently required
haemodialysis from the sixth postoperative day;
six patients required dopamine within the first 24
hours after operation and three of these required
haemodialysis within the first postoperative
week, while the remaining patient started
dopamine during the second postoperative day.
The incidence of renal impairment in patients
in whom bypass support was used was not
significantly different from that in the remaining
patients in their respective groups. Likewise, no
» difference was found when the results within the
two treatment groups were analysed with respect
, to age.
When the results for the paired patients were
compared, it was found that the volume of urine
produced on the first postoperative day and the
creatinine clearance in the period 24-48 hours
after operation were significantly better in those
patients who received prophylactic dopamine
than in those who did not (p<0.05; Table 2).
There was no significant difference between the
pre-operative renal function, the operative blood
loss or the lowest recorded systolic blood pres¬
sure in the two groups.
Discussion
This study suggests that the prophylactic ad¬
ministration of dopamine, begun prior to the
onset of surgery, decreases the incidence of renal
impairment postoperatively in patients under¬
going liver transplantation. Furthermore, al¬
though the numbers are small, renal failure
requiring haemodialysis or continuous arterio¬
venous haemofiltration occurred less often and
much later when prophylactic dopamine was
given. The problems associated with results
obtained from a retrospective study are well
known; however, the dramatic fall in morbidity
and mortality associated with the continuing use
of prophylactic dopamine has been maintained
since the end of the study period and we could not
now ethically consider a prospective study in
these patients. The inclusion in this study of a
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matched pair group overcomes some of the dif¬
ficulties associated with a retrospective study and
tends to reinforce the conclusions drawn from the
findings of the larger unmatched group.
The use of bypass to decompress the portal
circulation and to maintain the systemic blood
pressure and renal perfusion, made no difference
to the frequency with which renal impairment
occurred, contrary to the report by Starzl et al.9
Also, the patients' age did not appear to alter the
incidence of renal impairment, in contrast to its
effect on overall mortality, in which the older
patients did less well.10
The introduction of cyclosporin A has
improved immunosuppression following organ
transplantation.11 However, its use in the early
postoperative period following liver trans¬
plantation is limited by its nephrotoxicity. This
necessitates the use of azathioprine, with the
hazards ofmarrow suppression, and of high dose
steroid therapy, with the disadvantages of an
increased risk of, and difficulty in, the diagnosis
of infection and adverse effects on carbohydrate
metabolism which make parenteral nutrition
difficult. Preliminary studies have shown that
intravenous cyclosporin A results in a marked
decrease in renal blood flow (P.R. Powell-
Jackson, personal communication) and it may
be that simultaneous low dose dopamine in¬
fusion will prevent, or at least lessen, this de¬
crease and thus reduce toxicity, thereby allowing
earlier postoperative use of this agent. Further¬
more, if severe cyclosporin A nephrotoxicity can
be avoided initially, the chances of long-term
kidney damage may be reduced. Recently, a
patient who was treated immediately after opera¬
tion with cyclosporin A, given through a central
venous line, developed severe pulmonary toxi¬
city, but the anticipated nephrotoxicity did not
develop, possibly due to the continued adminis¬
tration of dopamine.
Care is necessary in the extrapolation of
results from liver transplant patients to others,
but it seems appropriate to treat patients
undergoing surgical procedures in which major
haemorrhage occurs (such as ruptured ab¬
dominal aneurysms or following polytrauma)
and who may be at risk of developing acute renal
failure, with a dopamine infusion at a rate of
2 ^ig/kg/minute throughout the operative and
immediate postoperative periods.
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Quality of axillary brachial plexus block
Comparison of success rate using perivascular and nerve stimulator techniques
M. K. TUOMINEN, M. T. PITKANEN, M. K. NUMMINEN and
P. H. ROSENBERG
Summary
A perivascular catheter technique (PVT) and a nerve stimulator technique (NST) for axillary brachial
plexus block were compared in terms of quality: complete, incomplete or failed blocks. In a random¬
ised series, 30 PVT blocks and 30 NST blocks were performed by three staff anaesthetists. In the NST
group, surgical anaesthesia was always achieved, whereas in the PVT group, four blocks required supple¬
mentation with general anaesthesia. In both groups eight patients needed supplementation with additional
conduction blocks of 1-3 peripheral nerves. It is concluded that a nerve stimulator technique may in¬
crease the success rate ofaxillary brachial plexus block to some extent.
Key words
Regional techniques; brachial plexus block.
It is believed that the use of a nerve stimulator
to identify a nerve plexus provides an increase in
both safety and success rate.'~5 The perivascular
technique for axillary brachial blocks,6 as
modified by Selander.1 was used here for some
5 years, after which the method was replaced by
the nerve stimulator technique. In a retrospective
review of our results, surprisingly no difference
was found between the quality of 200 blocks
performed with the two different techniques. It
was therefore decided to compare these two
techniques under controlled conditions in a
prospective study, in order to establish their
efficacy.
Patients and methods
Sixty axillary brachial blocks for elective surgery
were performed by three senior anaesthetists
experienced in regional anaesthesia. In random
order, half of the patients received an axillary
brachial plexus block via the perivascular tech¬
nique with a catheter as described by Selander7
(PVT group). In the remaining patients, blocks
were performed with the aid of a nerve stimu¬
lator in order to identify the axillary nerve
plexus (NST group). No effort was made to
distinguish between the three main nerve trunks.
A Neurostim LA nerve stimulator, type 218
(Hugo Sachs Elektronik KG, FRG)8 and
regional anaesthesia needles (50 mm. 22-G)
with an electro-neurostimulation port (Vygon,
France) were used.
Bupivacaine 0.5%, approximately 3 mg/kg,
was given in a volume of 40 ml to patients
weighing 50-70 kg, 50 ml for those 71-90 kg in
weight and 60 ml for patients weighing over
90 kg. The volume was supplemented with
physiological saline when needed.
Analgesia in defined areas of the ulnar, radial,
median and musculocutaneous nerves was
examined by pin-prick at 10-minute intervals, as
M.K. Tuominen, MD, M.T. Pitkanen, MD. M.K. Numminen, MD, P.H. Rosenberg, MD, Department of
Anaesthesia. Surgical Hospital, Helsinki and University Central Hospital, Kasarmikatu 11-13, 00130 Helsinki,
Finland.
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Pharmacokinetic study of morphine in the
postoperative period following liver
transplantation: a preliminary communication




Patwardhan and his colleagues (1) have shown that morphine does not have a prolonged effect
in patients with severe cirrhosis, and this has led us to usemorphine for postoperative analgesia
in patients following liver transplantation. Small bolus doses and continuous infusion provide
adequate analgesia, but have been associated with problems of prolonged narcosis in the
Intensive Care Unit. These are exemplified by one particular patient, a 45 year old man who
had undergone liver transplantation for malignancy. His early postoperative course was
uneventful, and by the third postoperative day his liver function tests showed that bilirubin,
alkaline phosphatase, SGPT, serum albumin and prothrombin time had stabilized. On the
fourth day, his general condition suddenly deteriorated and he developed acute renal failure
requiring hemofiltration and dialysis. He also required assisted ventilation, and the morphine
infusion originally started for postoperative pain was continued for sedation purposes during
ventilation. Over the next few days his level of consciousness remained depressed in spite of
modest doses ofmorphine (24 mg/day). Despite the absence of miosis, blood was taken for
morphine analysis on the 7th postoperative day. This was analyzed using a radioimmunoassay,
and a plasma concentration of 600 ng/mL was found. Later that day, following dialysis, the
plasma concentration fell to 250 ng/mL. The morphine infusion was continued as the results
of the assay were not available for some time. Plasmamorphine concentrations weremeasured
several more times. These increased steadily over the next 2 days, despite no increase in the
morphine infusion rate, reaching a maximum of 1200 ng/mL on day 9, at which point the
morphine infusion was stopped. Following discontinuation of the infusion, plasmamorphine
levels decreased but even on day 11 a significant plasma concentration (200 ng/mL) remained.
The decreases in plasma morphine levels appeared to be associated with the periods ofdialysis
but not hemofiltration. Our experience with this patient led us to study in more detail the
kinetics ofmorphine following liver transplantation.
Methods
The surgical procedure of liver transplantation basically replaces the diseased liver with
another. As part of the procedure a T-tube is positioned in the common bile duct so that bile
Advances in the Management ofChronic Pain. The International Symposium on Pain Control, edited by P. Band,
J. Stewart, andT. Towson, 1986. Sponsored by the Department ofPharmacology, University of Toronto and Purdue
Frederick Inc. and its International Affiliates. Published by Purdue Frederick Inc., Toronto.
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can drain externally. This operation can be associated with massive blood loss and considerable
acid-base and electrolyte abnormalities. Patients were studied within two hours of their
operation, once hemodynamic stability had been achieved in the ICU. Blood, urine and bile
samples were obtained at regular intervals over the 24 hours after the morphine. Only a 2.5
mg dose ofmorphine, as a single i.v. bolus, was used because of the previous problems we had
encountered. It was injected over a one minute period into a venous line. Specimens were
analyzed for morphine concentration using the radioimmunoassay method described by Moore
and colleagues (2).
Results and Discussion
Five female patients, aged 22-49 years (mean 35 years), weight 36-65 kg (mean 51 kg), have
completed the study. Three patients had a diagnosis of primary biliary cirrhosis, one patient
had fulminant hepatitis A, and one patient underwent retransplantation due to rejection. Table
1 shows the biochemical parameters, and indicates that all the patients had impaired liver
function but normal renal function. The period of time the donor liver was hypoxic (ischemic
time) is also shown.
Table 1
Biochemicalparameters and hepatic ischemia time in five patients undergoing liver
transplantation
Patient Bilirubin SGPT Prothrombin Alkaline Creatinine Ischemic
(2-17 (110-1000 Time Phosphatase (35-125 Time
umol/L) * U/L) (seconds
above
normal)
(30-135 U/L) umol/L) (min.)
AM 98 297 4 91 <100 260
AB 180 1000 5 452 <100 174
JT 268 384 5 150 <100 297
BG 138 99 2 159 <100 279
DW 470 110 4.5 145 <100 359
Mean 230.8 378 4.1 199.4 <100 273.8
*Bracket value refers to the normal range.
The plasma morphine levels for each patient are shown in Figure 1. The normal sharp rise
ofmorphine levels is evident. However, instead of the usual exponential elimination curve, a
double peak pattern was evident in some of the patients. Such a pattern has been observed in
other studies (3,4), and may be the result of enterohepatic recirculation (5) or simply an ar¬
tifact. However, in these patients enterohepatic recirculation is unlikely with the external
drainage ofbile. This second morphine peak, occurring at 4 to 5 hours postoperatively, does
not appear to be associated with any of the clinically apparent events. Urinary morphine and
metabolites follow the same double peak pattern.
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Figure I. Plasma morphine concentrations in 5 patients following single i.v. doses of
morphine administered 1-2 hours following liver transplantation. (Reprintedbypermis¬
sion of The Lancet)
One patient was particularly interesting. This was a woman of49 years who had undergone
liver transplantation for primary biliary cirrhosis. She was studied as per protocol on the first
postoperative day and subsequently had a stormy course, with intercurrent sepsis and develop¬
ment of renal failure requiring dialysis and continuous arteriovenous hemofiltration. During
the first investigation, her hepatic function was impaired but renal function was normal (serum
creatinine was less than 100 umol/L, urea 6.8 mmol/L, and urine output of 2600mL over 24
hours). She was re-studied using the same protocol on the 30th postoperative day, atwhich time
her liver function was improved but renal function was minimal - necessitating dialysis
(creatinine 390 umol/L, urea 73.4 mmol/L and urine output over the 24 hour study period of
100mL). Her plasma morphine levels on the two study days are shown in Figure 2. The dou¬
ble peak is again evident, but on the second day levels were considerably higher despite use
of the same 2.5 mg i.v. dose of morphine (6). Also, there was a peculiar lack ofmorphine
elimination beyond 12 hours post-dose. We are puzzled as to the reasons for this unusual pat¬
tern, but it may support the evidence of others for a greater role of the kidney in morphine
elimination (4). Its importance is clinically obvious, in that patients with renal failure may
behave abnormally when given relatively low doses of morphine, but the extent and exact
mechanism will require further study.
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Day 1
Hours
Figure 2. Plasma morphine concentrations in a liver transplantpatient following single
2.5mg i.v. morphine doses. On Day I the patienthadnormal renal function but impaired
liver function. On Day 30, liver function had improvedbut renal failure requiring dialysis
had occurred. (Reprinted by permission of The Lancet)
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oxygen. Saphenous vein grafting to.the left anterior
descending and right coronary arteries was uneventful,
the patient was cooled during this procedure to
27 C when cardiopulmonary bypass commenced and
rewtirmcd to 37 "C before weaning from the pump.
His progress was complicated 3 days postoperatively
when he developed an exacerbation of upper limb
weakness, the right being more afTected than the left.
This weakness coincided with a lower urinary tract
infection and associated pyrexia of 39 "C. Removal of
his indwelling urethral catheter and antibiotics led to
a resolution of his tcmpcruture. Three weeks post¬
operatively he hud regained his pre-operativc levels or
function.
Deep induced hypothermia led to no exacerbation
of the signs or symptoms of multiple sclerosis. Tran¬
sient postoperative neurological deterioration was
associated with u known aetiology pyrexia.2 Other
possible sources of upper limb weakness such as over
vigorous sternal retraction ' or traumatic cannulation
of the right internal jugular vein4 may be excluded
because of the late onset and relatively short episode




Coronary artery bypass grafting should be offered
to patients with ischaemic heart disease who would
normally warrant it. Some have been excluded in the
past because of concern over the possible consequences
of marked hypothermia and cardiopulmonary bypuss
on their multiple sclerosis. Avoidance or postoperative
temperature elevation should be energetically pursued.
Si Vincent's Hospital, R E. Bf.avis
Fllzroy 3Hf>5, M.J. Daviis
Victoria, Australia
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Cell-saver
l)r Kumar's letter, (Anaesthesia l9Hft; 41: 774 5) was
interesting. The Macmonctic Cell-saver is a type of
autotransfusion blood salvage unit which is not really
suitable for very rapid, massive blood loss. It Is what
I consider to he a slow autotransfusion technique.
Other slow techniques ure the Rcceplal system (Abbott
Laboratories. Queenborough, Kent) and the Solco-
Irans (Cabot Ltd. High Wycombe). These techniques
are useful when the blood loss is slow enough to be
replaced by crystalloid or plasma substitutes. How¬
ever. the Cell-suvcr produces the highest quality sal¬
vaged red cells and one can. of course, also recover
other cellular components. Really large, rapid blood
loss can only be salvugcd and replaced immediately
using the Bent Icy ATS system (Bcntlcy Laboratories,
lll'ord), which uses u roller pump or a similar device'
made up of standard cardiolhoracic unit supplies.
Very large blood loss of several litres/minute can be
/
recovered und immediately replaced with this roller
pump system. It has the disadvantage, as docs the Ccll-
savcr, that it requires technical personnel to run it
safely. It docs, however, have the advantage that since
the blood is salvaged immediately from the wound and
pussed struight back to the patient in a closed loop.
Jehovah's Witness patients often accept this form of
uutotrunsfusion rather thun others which involve some
break in the loop.
Grohy Road Hospital, |. McLellan
Leicester LE3 9QE
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l-ack of haematoiogkal and biochemical consequences following autologous blood transfusion
The use of autologous blood transfusion during sur¬
gical operations is becoming established practice
when major haemorrhage is expected. This technique
is useful when stored blood is difficult to obtain
because of shortage, incompatibility or rapidity
of the bleeding; it may also diminish the risk of
viral cross infection. Various authors have reported
on the efficiency of such methods us the red cell-
washing1 (Cell-saver. Ilaemonclies, Natick. MA.
USA), whole blood recycling systems2 (the Sorenson
reccplal device. Sorenson Research Corporation, Salt
Luke City, Utuh, USA) und the uulolrunsfusion
system1 (Bcntley Laboratories. Irvine, CA,
USA).
We have been using an automatic system (Haemon-
etics Cell-saver) during liver transplantation which,
following the collection of blood from the operative
field, heparinises it. then separates the red blood cells
by centril'ugution. washes and resuspends them in
saline with u huematocril of 60%.'
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There is controversy in the literature over the exist¬
ence3 or not4 of a coagulopathy due to heparin which
is re-infused with activated clotting factors. Any
abnormalities that do exist should be particularly
apparent in patients following liver transplantation
In whom impaired liver function limits the body's
ability to inactivate heparin and activated clotting
factors. Liver function is impaired during liver
transplantation, at the beginning when the recipient's
own liver is being skeletonised, during the anhepatic
phase and for several days after re-implantation of the
donor liver when recovery from the ischaemic damage
sustained when the liver was extracorporeal, occurs.
Haemorrhage can occur intra-operatively during all of
these phases, due to adhesions following previous
surgery or division of anastomotic vessels. Bleeding is
exacerbated by the portal hypertension and coagulo¬
pathy. In addition, the infusion of large amounts of
washed red cells' suspended in 0.9% saline may lead to
biochemical abnormalities such as hypernatraemia and
hypokalemia.
The intra-operatlve biochemical and haematological
changes of cell-saving systems' and liver trans¬
plantation" have been described separately, but little
attention has been given to postoperative elTects.
Blood loss and administration details of 20 patients
are shown In Table I,
Immediately on admission to the Intensive care unit
after liver transplantation routine investigations are per-
formed on arterial blood (Table 2). The patients had all
received a similar amount of stored (citrate, phos¬
phate, dextrose and adenine) blood intra-operatively.
Ten of these patients had received. In addition, between
0.67 and 4.3 litres of cell-saved red blood cells. No
statistically significant differences were found between
Table I. Blood lost and administration details In ten patients
who received banked blood only and ten patients who received
banked blood and cell-saved blood.
Table 2. Investigations performed on the two patient
Investigation
Cell-saved Non cell-saved
group mean group mean
value (SD) value (SDl
Cell-saved Non cell-saved
group mean group mean
value (SD) value (SD)
(Hires) (litres)
Total blood lots 7.4(4.09), 4.5(1.77)
Tolat transfusion
(hanked -I- cell-saved) 7.** (3.08) 6.25 (1.32)
Banked blood 6.23 (2.63) 6.25 (1.32)
Cell-saved red blood cells 1.65 (range
0.67-4.3) Nil
Biochemical
Hydrogen ion (mmol/lllre) 36.4(5 95) 34.2(4.911
Base excess (mmol/litre) 2.7 (4.79) 2.3 (5.09)
Potassium ion (mmol/litre) 3.2 (0.48) 5.0 (0.52)
Sodium ion (mmol/lilre) 136 (3.59) 137 (4.07)
Glucose (mmol/litre) 20.7 (9.86) 14.7(7.22)
Urea (mmol/litre)
^ 9.8 (7.06) 6.0(3.641
Haematologlcal
Haemoglobin (g/dlltre) 13.8(1.59) 13.4(2.2*1
Platelets ( * 10 -•/litre) 116 (54.49) 181 (85.431
Prothrombin time ratios • 1.47 (0.19) 1.37 (0.15)
Partial thromboplastin time
ratios* 1.45 (0.50), 1.15(00*3
Thrombin time ratios* l.24(O.I5r 1.12(0.14)
* Patient/control.
any haematological or biochemical variables between
the two groups (Student's f-test).
The use of a red cell washing and re-Infusion system
of this type appears not to cause significant haemato¬
logical or biochemical disturbances in patients follow
ing liver transplantation. It is therefore unlikely to
cause significant changes In other groups of patients
Department of Anaesthesia, L. MZNftft
Addenhrnoke's Hospital, M. F. Ssorts
Hills Road, O R. P*a*
Cambridge CB2 2QQ
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Safety hazard with cylinder yoke on a Boyle's machine
The following incident occurred recently and could
have led to injury. A BOC International Mk 2 anaes¬
thetic machine was in use, working from cylinders.
One of the oxygen cylinders, having nearly emptied,
was changed for a fresh one. This was offered up to
the yoke, the retaining bar was swung into place and
the winged screw tightened in the usual way.
The cylinder valve was opened to check the pressurr
of the contents whereupon there was a sudden escapr
of gas at high pressure from between the valve am'
PftCK « e .
us>.my -
\v
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PHARMACOKINETICS OF MORPHINE IN TWO CHILDREN
BEFORE AND AFTER LIVER TRANSPLANTATION
M. P. SHELLY, E. P. CORY AND G. R. PARK
Morphine is metabolized by the liver (Stanski,
Greenblatt and Lowenstein, 1978) and the
metabolites excreted by the kidney. Recent
advances in the estimation of morphine have,
however, led to the emphasis being placed on the
importance of its elimination by the kidney
(McQuay and Moore, 1984a; Moore, Sear and
Baldwin, 1984). Renal failure has long been
known to prolong the action of morphine, and
although this aspect has now been investigated
further (Aitkenhead et al., 1984; Ball et ah, 1985;
Shelly and Park, 1985), the cause of the prolonged
action remains obscure. In particular, the role of
morphine metabolites has yet to be clarified.
Morphine has a number of active metabolites,
including morphine-6-glucuronide (Shimomura
et ah, 1971) and normorphine (Lasagna and
De Kornfield, 1958; Johannesson and Milthers,
1962); the 3-glucuronide is thought to be inactive
when administered parenterally (Sasajima, 1970;
Shimomura et ah, 1971). Initially, this was a pilot
study to investigate the role of biliary excretion in
the elimination of morphine, but we wish to
report two patients who appear to illustrate the
importance of the kidney in the elimination of
morphine or its metabolites.
PATIENTS AND METHODS
Approval was obtained from the district Ethics
Committee and informed consent was obtained
from the parents of two children about to undergo
orthotopic liver transplantation. Preoperative
details are summarized in table I. Both children
had end-stage liver failure unresponsive to other
M. P. Shelly; G. R. Park; Addenbrooke's Hospital, Hills
Road, Cambridge, CB2 2QQ. E. P. Cory, Bioanalytical




Plasma morphine, morphine-3-glucuronide and
morphine-6-glucuronide concentrations were
measured (HPLC) in two children immediately
before orthotopic liver transplantation and in the
postoperative period. Both of the patients had
end-stage hepatic failure, but one also had
impaired renal function before operation and was
oliguric during and after surgery. Both patients
metabolized morphine rapidly, but in the patient
with renal failure, the metabolites appeared to
accumulate. Morphine has active metabolic
products and the accumulation of these in
patients with impaired renal function may lead to
a clinically observable prolongation of its effect.
medical and surgical treatment. One had congeni¬
tal biliary atresia, the other cholestatic jaundice
following neonatal hepatitis; both had secondary
biliary cirrhosis. Renal function in both patients
was thought to be normal in the preoperative
period although, in retrospect, patient 2 had
unrecognized renal impairment at this time: her
Table I. Details of two children before liver transplantation
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Patient 2
Time after dose (min)
Fig. 1. Plasma morphine, morphine-3-glucuronide and morphine-6-glucuronide concentrations in
patient 1 and patient 2 during the 60 min immediately before the start of surgery, and at 24 h after the
administration of the morphine.
plasma urea concentration was increased although
her plasma creatinine concentration was within
normal limits.
Anaesthesia was introduced with thiopentone;
alcuronium was given to facilitate tracheal intuba¬
tion and controlled ventilation. Anaesthesia was
maintained with halothane and nitrous oxide in
oxygen. Following the induction of anaesthesia,
but before surgery, a blood sample (baseline) was
taken and morphine 1 mg kg _1 was administered
i.v. as part of the anaesthetic regimen. Further
blood samples were taken at 5, 10, 15, 20, 30, 40,
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50, 60 min after the administration of the mor¬
phine while venous access was secured and moni¬
toring commenced—but before the start of major
surgery. Blood removed for sampling was replaced
by blood to maintain fluid balance. Further blood
samples were taken from each child after surgery.
Plasma morphine, morphine-3-glucuronide
(M-3-G) and morphine-6-glucuronide (M-6-G)
concentrations were measured by high pressure
liquid chromatography (HPLC). The standards
usedweremorphine (EvansMedical Ltd, Beacons-
field) and M-3-G (Sigma Chemical Corporation);
M-6-G was synthesized using a modification of
the technique described by Yoshimura, Oguri and
Tsukamoto (1968) and obtained through Napp
Research Centre, Cambridge. Samples were
prepared in control plasma for calibration, quality
control and validation. Calibration curves were
constructed for all three compounds.
Solid phase Bond Elut C18 cartridges (Jones
Chromatography, Llanbradach, Glamorgan) were
used to extract morphine and the two metabolites
from plasma. Subsequent quantification was by
HPLC using ultraviolet absorption at 210 nm to
estimate M-3-G concentrations and electrochemi¬
cal detection at +0.9 V (v. silver-silver chloride)
to measuremorphine and M-6-G. The lower limit
of detection for M-3-G by ultraviolet absorption
was 10 ng ml-1 and for morphine and M-6-G by
electrochemical detection was 1.5ngml_1. Rec¬
overy from plasma for all three compounds was
greater than 90%.
Pharmacokinetic parameters were determined
using ESTRIP (Brown and Manno, 1978) to
estimate terminal slopes. Clearance was calculated
as dose (D) divided by the area under the curve
(AUC) where AUC was estimated from the data
points by the linear or logarithmic trapezoidal
method and extrapolated to infinity. Volume of
distribution at steady state was calculated as
D.AUMC/AUC2 where AUMC is the area under
the first moment curve, again extrapolated to
infinity.
Clinical and biochemical indices of each pat¬
ient's conscious level, and liver and renal function,
as well as their opioid requirement, were recorded
before and after surgery.
RESULTS
The plasma concentrations of morphine, M-3-G
and M-6-G for both patients are shown in figure
1. During the first 1 h after the induction of
anaesthesia, but before the start of major surgery,
the plasma concentration of morphine increased
initially to high values and then decreased rapidly
in both patients. The pharmacokinetic para¬
meters of morphine were: in patient 1, half-life
0.4 h, volume of distribution at steady state
4.4 litre kg"1 and clearance 93 ml min"1 kg"1; in
patient 2, half-life 0.52 h, volume of distribution
at steady state 3.4 litre kg_1 and clearance
68 ml min"1 kg"1.
The plasma concentration of M-3-G increased
in both patients, but more steeply and to higher
values in patient 2. The concentration of M-3-G
then decreased in patient 1, whereas it was main¬
tained in patient 2. Plasma M-6-G concentration
increased to a peak at approximately 15 min in
patient 1 and was maintained at this value subse¬
quently. In patient 2, however, the concentration
ofM-6-G increased gradually for the first 15 min,
but continued to increase thereafter such that at
the end of the 1 h the value was higher than that
of the morphine base.
Patient 1, 24 h after his original dose of
morphine, had no detectable morphine,M-3-G or
M-6-G present in his plasma. Patient 2, 24 h after
her original dose of morphine, had no detectable
morphine base, but the concentrations ofM-3-G
and M-6-G were unchanged from concentrations
measured at 60 min.
Intraoperative details for both patients are
shown in table II. The duration of surgery and the
blood loss were similar in both patients and both
received a large blood transfusion. Patient 2,
however, was anuric throughout the operation,
whereas patient 1 had an adequate urine output.
The patients' postoperative urine outputs,
conscious levels and opioid requirements are
shown in figure 2. Patient 1 maintained a urine
output of approximately 1 ml kg"1 h"1. He re¬
quired the regular administration of fentanyl, in
spite of which he remained difficult to sedate and
further morphine was required 26 h after the
initial dose to allow satisfactory control of
ventilation. Patient 2 continued to have an
Table II. Operative details
Patient 1 Patient 2
Duration of surgery (h) 5 5.5
Blood loss (ml kg-') 79 80
Transfusion requirement 61 100
(ml kg"1)
Urine output (ml kg"1) 6.0 0
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Fig. 2. Postoperative urine output, conscious level and opioid requirement in both patients.
inadequate urine output. In addition, although
she received no further opioid, she continued to
be unresponsive to painful stimuli and had
pin-point pupils throughout this period.
Both patients started to produce bile promptly
after surgery and continued to do so, indicating
reasonable recovery of liver function.
Patient 2 eventually responded to diuretic
therapy and had a large diuresis. One hour after
the start of her diuresis, she became responsive to
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stimuli and her pupils enlarged slightly. Six hours
later she required further opioid.
DISCUSSION
Although the liver has long been thought of as the
site ofmorphine metabolism (Stanski et al., 1978),
recently, patients with cirrhosis have been shown
to eliminate morphine normally (Patwardhan
et ah, 1981). It has also been suggested that
morphine is metabolized in patients with hepatic
failure (Hug et ah, 1979), but no details were
provided of the assay method used to estimate the
concentrations of morphine in that study. Extra-
hepatic sites of morphine metabolism, such as the
kidney (McQuay and Moore, 1984b) and the
gastrointestinal tract (Park, 1985) have been
postulated.
Both the patients described had liver failure
during the preoperative period, yet both metabol¬
ized morphine rapidly; morphine concentrations
decreased and the concentrations of M-3-G and
M-6-G increased. Although neither patient was
capable of producing bile at this time, the
concentrations of morphine decreased. This may
refute the importance of the biliary excretion of
morphine.
The clearance of morphine in these children
was greater than that previously reported in
children (Dahlstrom et al., 1979). This may reflect
the different methods used to estimate the plasma
morphine concentration, or it may result from the
relatively short sampling period available in our
study before surgery was undertaken with the
consequent haemodynamic instability.
The main differences between the two children
were their renal function, and their plasma M-3-G
and M-6-G concentrations. Patient 1 had normal
renal function and had eliminated all detectable
morphine, M-3-G and M-6-G by 24 h after the
administration of the initial dose. Patient 2 had
impaired renal function and a poor urine output.
Morphine base was no longer detectable at 24 h,
but high concentrations of M-3-G and M-6-G
were present in spite of a large intraoperative
blood transfusion to replace an operative blood
loss approximating to her circulating blood
volume. This accumulation ofmorphine metabol¬
ites would appear to indicate that an adequate
urine output is important for their elimination.
The clinical evidence of recovery in patient 2
when her diuresis started adds support to this
hypothesis.
M-3-G is thought to be inactive parenterally,
but M-6-G is known to be a powerful analgesic
(Shimomura et al., 1971); however, its other
actions are unknown. Patient 2 was unresponsive
to pain and had pin-point pupils in association
with the increased concentrations of M-6-G and
this may indicate other opioid-like properties,
particularly sedation. This assay method used was
calibrated for only M-3-G and M-6-G. Other
metabolites which may be active (e.g. normor-
phine) were not measured.
CONCLUSION
The two patients described illustrate that mor¬
phine can be metabolized rapidly, even in the
presence of severe liver failure. Impairment of
renal function with a low urine output in one of
the patients was associated with accumulation
ofmorphine-3-glucuronide and morphine-6-glu-
curonide and with prolonged narcosis. Morphine
has active metabolic products and it may be these
that produce the clinically observed prolonged
action of morphine in patients with renal failure.
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Severe hypercakaewifa 4m to a parathyroid-type homoae-accretlng tamos* of the llrer treated
by hepatic trampiantarion
We read with interest the paper by Dr Sealey {Anaes¬
thesia 1985; 40; 170-7), and especially about the
problems she encountered postoperatively. We have not
been presented with a patient who has pre-operative
hypercalcaemia, but it is interesting that several of our
patients have suffered from late postoperative hyper¬
calcaemia despite the use of prednisolone for immuno¬
suppression. We have not yet explained this phen¬
omenon, or seen it reported in the literature.
We have had similar difficulties in patients after liver
transplantation, namely, hypoxaemia consequent on
basal consolidation, difficulty in the provision of
adequate analgesia and renal failure following heavy
blood loss and cross clamping of the inferior vena cava.
Recent changes in our management of these patients
have alleviated some of these problems. Routine use of
intermittent positive pressure breathing (IPPB) has
markedly reduced postoperative basal collapse and sub¬
sequent consolidation. For the first 48 hours following
cxtubation of the trachea, IPPB is administered from
a Bird Mark 7 or Servo 900C ventilator, via a close
fitting facemask, four times a day, along with intensive
physiotherapy. Adequate analgesia is essential during
this period but whilst the infusion of opiates is ef¬
ficacious,1'' we have teen considerable prolongation of,
and sensitivity to, the effects of opiates in this group of
patients. Our early pharmacokinetic studies suggest
that, following liver transplantation, the metabolism or
excretion of morphine occurs in a manner not pre¬
viously reported. We therefore discontinue opiate in¬
fusions well in advance ofweaning from ventilation and
provide analgesia by intercostal nerve blockade, unless
clotting is grossly deranged. Renal impairment (with a
urine output less than 0.5 ml/kg/hour, a high right atrial
or pulmonary capillary wedge pressure and a urine/
plasma osmolality ratio < I. I) which previously oc¬
curred in 67% of our patients has been dramatically
reduced to 10% by the prophylactic use ofdopamine. A
dopaminergic agonist dose (2 mcg/kg/minute) is used,
starting prior to surgery and continuing for 48 hours
afterwards (R. Poulson, O.R. Park, M.J. Lindop el al.
unpublished).
Addenhrooke's Hospital, O R. Park
Hills Road, M.J. Lindop
Cambridge CB2 2QQ J.V. Farman
M.P. Shelley
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A reply
Dr Park and colleagues have raised a number of inter¬
esting points in the postoperative care of liver trans¬
plant patients.
Postoperative hypercalcaemia. Serum calcium levels
are measured throughout operation in our patients and
calcium chloride is given to maintain normal ionised
levels. The need to give calcium falls sharply when the
new liver is in place, is perfused and is metabolising
citrate. In a series of 10 patients, which included the
patient with preoperative hypercalcaemia, mean post¬
operative serum calcium levels were total calcium, 3.32
mmol/litre (range, 2.29 4.%) and ionised calcium 1.44
mmol/litre range, 1.14-1.76). One patient and three
patients respectively had normal levels. The duration of
raised ionised calcium was a mean of 21 hours. This
excluded those normal levels, and the 1.76 mmol/l
result—that of the patient with pre-operative hyper¬
calcaemia—which took 99 hours to return to normal
Late serum calcium levels in our patients have been
unremarkable.
Analgesia and sedation. Patients are ventilated on an
intermittent mandatory ventilation (IMV) mode, on
return from theatre to avoid the use of muscle relaxants
which make It very difficult to assess the effect of anal¬
gesic and sedative drugs, until they have warmed up
from intraoperative hypothermia, are haemodynaml-
cally stable and arterial blood gas analysis and urine
output are satisfactory. Hence it is important to explain
to the patient what is going to happen in the intensive
care unit and all are visited pre-operatively by the anaes¬
thetist, the physiotherapist, and intensive care sister.
It was not possible to explain fully to the hyper-
calcaemic patient reported on. what to expect in
intensive care since the time course of his whole illness
was very brief. This made management more difficult.
Analgesia is managed throughout the postoperative
period (on an ofT the ventilator) by an infusion of
opiate, usually papaveretum. The dose Is limited to that
required to keep the patient comfortable not to allow
accumulation or untoward sedation: normal or less
than normal amounts of opiate are required. No other
sedatives are allowed, apart from a small dose of a
benzodiazepine at night time, if necessary for sleep. We
would be most interested to know the results of the
Cambridge pharmacokinetic study but must stress that
we find opiate infusion quite satisfactory if it is man¬
aged in the above manner and would be quite unhappy
to use bilateral—for a bilateral subcostal incision—
intercostal blockade.
Respiratory therapy. Physiotherapy in our patients is
intense but does not routinely include intermittent
positive pressure breathing. There are a number of
factors which interfere with postoperative respiratory
function: a large abdominal wound, abdominal disten-
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The svnthesis and identification of this important metabolite will
facilitate investigation of the specificity of antisera used in
immunoassays, and thus confirm or refute the accuracy of current
assavs. In addition, since morphine-6-glucuronide may have
analgesic activity greater than that of morphine itself,10"1 it may-
prove to be a useful therapeutic agent in its own right.
ICRF Department of MeJica! Oncotocv.
St Bartholomew's and Hacknr. Hospitals.
London FC1. .
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RENAL FAILURE AND USE OF MORPHINE IN
INTENSIVE CARE
Sir,—\X'e were interested in Dr Ball and her colleagues'
comments (April 6. p 784) on the influence of renal failure on
morphine clearance. \X'e have described a patient with renal failure
after orthotopic liver transplantation who was given a morphine
infusion for postoperative analgesia and whose plasma morphine
levels were very high.1 This prompted us to study in more detail the
pharmacokinetics of morphine in patients undergoing liver
transplantation (and we hope to report on this later). Patients are
investigated immediately postoperatively as soon as cardiovascular
stability has been attained, usually within 2 h of returning to the
intensive care unit. At this time their renal function is not impaired.
Various doses ofmorphine are administered and plasma levels- are
monitored for 24 h.
One patient, a 49-year-old woman with primary biliary cirrhosis,
was studied in the immediate postoperative period, after a 2 - 5 mg
dose of morphine. Renai failure subsequently developed and she
was studied again one month later with the same dose. During the
first investigation renal function was normal (serum creatinine
below lOO^mol 1. urea 6 - 8 mmol/1, urine output 2600 ml in the 24 h
period). On the second occasion her renal failure was controlled by
arteriovenous haemofiltration and dialysis (creatinine 390 qmoL l.
urea 73-4 mmol 1, 24 h urine output 100 ml).
Plasma morphine levels are shown in the figure. During the first
study a peak 16-8 ng ml was reached after 4 h and morphine levels
returned to normal within 12 h. However, on the second occasion
the peak was 32- 2 ng ml after 6 h, and morphine levels were above
20 ng ml throughout the study.
The first study was done when the patient had good renal function
but impaired liver function after an ischaemic period of 297 mm.
During the second study she was in renal failure but her liver
function, apart from a raised bilirubin, was essentially unchanged.
Although the pattern of results was similar on both occasions,
during the second study the peak plasma level was almost double
that of the earlier one and the half-life was much longer. The
day 1
da^ 30
2 - t 8 10 :: it 16 16 20 22 2-
Time ( h r s)
Plasma morphine levels in patient after liver transplantation.
Day 1 = immediate postoperative study. Day 30= patient in rena! failure.
difference in peaks may represent a different volume ofdistribution,
though the sustained high plasma morphine levels on the second
occasion cannot be explained in this way. These results support Ball
and colleagues' view that a renal mechanism for the clearance of
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Sir.—Dr Kinlen and colleagues (Feb 2, p 263) have suggested that
the 50-fold increased incidence of stomach cancer in patients with
common variable immunodeficiency(CVID) may be related to their
high frequency of achlorhydria. However, they also point out that,
since the excess of gastric cancer in patients with pernicious
anaemia without immunodeficiency is less than 10-fold, other
factors m3y contribute to the pathogenesis of gastric cancer in
patients with CYID. such as an earlier onset of the atrophic gastritis
or bacterial colonisation of the stomach in combination with the
immune impairment.
We think that achlorhydria may not be crucial in the pathogenesis
of stomach cancer in patients with CYID. Like others we have
found that only about half of the patients with CVID are
achlorhydric and even fewer have pernicious anaemia. Therefore
patients with CVID and pernicious anaemia would have at least a
10-fo!d greater risk of gastric cancer than would patients with
pernicious anaemia without immune impairment. This difference
suggests that achlorhydria is not essentia! in the development of
stomach cancer in patients with CVID. The finding that only halfof
the patients with CYID and stomach cancer are achlorhydric is also
at variance with an important role for achlorhydria in the
pathogenesis of gastric cancer in such patients."'5
Tagungsberichte
in charge. There is adequate consultant sessional alloca¬
tion for the purpose of running intensive care units but
at the present time this sessional allocation is unknown.
The patient is cared for jointly by the consultant who
admits the patient, and the consultant in administrative
charge of the unit. There is no approved training scheme
for junior medical staff from any speciality for intensive
therapy medicine. Anaesthetic trainees, however, can be
expected to be exposed to intensive therapy during their
General Professional Training. This, however, is a train¬
ing requirement for all anaesthetists and takes no ac¬
count of those few trainees who would like to undertake
consultant sessional responsibility for intensive therapy
units. These clearly need further training at Higher Pro¬
fessional Training level.
A recent very welcome development has been the
establishment of the Intcr-Faculty/Collcgiate Liaison
Group in Intensive Therapy. This was established on
the recommendation of the President of the Royal Col¬
lege of Surgeons of England and the Royal Society of
Physicians of England and the Dean of the Faculty of
Anaesthetists. The remit of this group was to identify
suitable posts at senior registrar (HPT) level in anaesthe¬
sia, medicine and surgery where one for one exchanges
could be arranged to facilitate higher training in all as¬
pects of intensive therapy. Candidates must have satis¬
fied the requirements for accreditation in general (inter¬
nal) medicine of the JCHMT; in anaesthesia of the
JCHTA or in the appropriate surgical speciality of
JCHST.
My personal hope is that the recommendations of
the Inter-Faculty Collegiate Liaison Group will prove
acceptable and additional funding found centrally for
implementation of new rational training programmes
open to trainees for all specialities.
Intcnsivmcdi/.in: Organisation und Ausbildung -
dcutsche Aspckte
W. Dick (Institut fiir Anacsthesiotogic, Johannes Gutenbcrg-
Universitiil, Mainz)
Die Intensivmedizin in der Rundesrepublik Deutschland
ist heute ein medi/inischcr Itercich, dcr von zahlrcichcn
Disziplincn als intcgralcr Bestandtcil ihrcs Fachgebietes
angcschcn wird. Aus den opcrativcn und konscrvativcn
Wachslationen der vergangencn Jahre haben sich inzwi-
schen Einhcitcn der Intensiviiberwachung, Einheiten der
sogenannten fachspczifischcn Intensivbehandlung und
schlieBlich Einheitcn der interdisziplinaren konservati-
ven oder operativen Intcnsivthcrapic cntwickclt. Die
Einrichtungcn dcr Intcnsiviiherwachung sowic dcr fnch-
spcz.illschcn Intensivbchandlung stchen in dcr Rcgcl
untcr Lcitung des jcwciligen Fachvertreters, zumindest
die operativen inlcrdisziplintiren Intensivtherapieeinhei-
len unter der Leilung des Anaesthesisten.
Nicht nur die grol.tcn Kliniken leiden heute unter
einem Mangel an intensivmcdizinischen Betten. Wurde
urspriinglich von einem Gesamtbettenbedarf fur den
konscrvativcn Bcreieh von 10% und fur den operativen
Bereich von 10% ausgegangen, so wird derzeit aus Ko-
stengriinden versucht, den Bestandtcil der Intensivthera-
piebettcn einzufricren odcr gar drastisch zu reduzieren.
Sogenannte Intermediiireinheiten, die zur Entlastung der
Intcnsivbchandlungsstalionen fiihren kbnntcn durch sol-




vcrlcgbar sind, abcr audi nicht mchr dcr Inlcnsivbc-
handlung bediirfen, cxisticrcn nicht.
Seit Jahrcn bestcht cine qualifizierlc und program-
micrtc Wcitcrbildung des Pflcgcpcrsonals. das in intcn-
sivmedizinischen Einheitcn tlitig ist. Es handelt sich um
die Wciterbildung zur Fachschwestcr/Fachpfleger fitr
Anaesthesic und Intensivmedizin, fur inncre Medi/in
und Intensivmedizin sowie fur Padialric und Intensivme¬
dizin. Ein vcrglcichbar obligatorisches Weitcrbildungs-
programm, das cincn glciclunaUigcn Standard audi itn
arztlichen Bereich derjenigen Fachdisziplinen sichern
wiirde, die intensivmedizinischc Versorgungsaufgaben
haben, existiert derzeit nicht.
Viclmchr bleibt es den Fachgcscllschaftcn bzw. den
Arztckammern iibcrlassen, den Mindestinhall der Wei-
terbildung in den cinzclnen Fachgebieten lestzulegcn
und dabci auch den intensivmcdizinischen Bereich ange-
messen zu beriicksichtigen. Eine entsprechcnde Quali-
tatsverbesscrung im iirzllichen Bereich in Anlclinung an
den Pflegebereich erscheinl dringend gcbolen.
Einc Entwicklung. dieeincn cigenstandigen Facharzt
fiir Intensivmedizin oder eine eigenslandige Fachschwe-
ster/Fachpnegcr I'iir Intcnsivmcdizin zum Ziele liatle,
wird von den originiiren Fachgebieten mil inlensivmedi-
zinischcn Versorgungsaufgabcn nicht fur erstrcbcnswcrt
gehalten.
The Transplant Patient
G.K. Dark (Department of Anaesthetics, Addenbrooke's Hospi¬
tal Cambridge)
Cambridge is a unique centre in Great Britain with an
active organ transplantation programme in two hospi¬
tals: Addenbrooke's Hospital (kidney, pancreas, cornea
and liver) ami Papworth Hospital (heart and heart/lung).
Intensive care may be appropriate after any organ has
been transplanted, but is essential following liver, heart
and heart/lung. Not only arc these long, complicated
operations, but transplantation is only undertaken when
end-stage organ failure has occurred resulting in a poor
pre-operativc state. The techniques and expertise devel¬
oped to deal with the problems posed by the constant
flow of such critically ill patients is of benefit to other
patients needing intensive care.
Post-operative care following liver transplantation is
challenging and may involve every aspect of intensive
care. The early problems arc a continuation of those
encountered during the operation and include hypother¬
mia, massive blood loss and rapid changes of plasma
potassium and glucose |t, 21- Problems occurring later
include continued bleeding, renal failure, hypoxaemia,
sepsis, rejection and nutrition. Some of these problems
have been solved. Non-surgical abdominal bleeding has
been controlled by the infusion of vasopressin when con¬
ventional blood component therapy has failed. The inci¬
dence of renal failure has been dramatically reduced by
the administration of low-dose dopamine starling pre¬
operative^ and continuing for 4X h. Ilypoxaemia can
result from several causes, including collapse ol the lung
bases. This has been prevented by the routine use ol
intermittent positive pressure breathing following extu-
bation of the trachea.
Following transplantation, in particular that of the
heart or liver, patients appear to be unusually sensitive
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to narcotics [3], which may necessitate the use of re¬
gional anaesthesia.
References: 1. Carmichacl FJ,. Lindop MJ, Farman JV (1985)
Anaesthesia for hepatic transplantation: cardiovascular and
metabolic alterations and their management. Ancsth Analg
64:106. 2. Lindop M.I, l arman .IV, Smith MF (1983) Anaes¬
thesia assessment and intraoperative management in liver trans¬
plantation. Calnc RY (cd) Ciranc and Stralton, London, p 121.
- 3. Shelly MP, Park OR (1984) A pharmacokinetic study of
intravenous morphine sulphate in patients who have undergone
liver transplantation. Second International Symposium on Pain
Control. Department ob Pharmacology. University of Toronto,
Canada.
Therapie nach schwcrcn Traumen
K. Peter (Institut fur Anacsthcsiologic der Ludwig-Maximi-
lians-Univcrsitat Miinchen)
Das posttraumatische kardiozirkulatorische Versagen
(hamorrhagisch-hypovolamischer Schock) wird definiert
als akutcs MiRvcrhaltnis zwischen Sauerstoffangebot
ttnd -bedarf des Organismus, was zu Storungen der
Funktion von Zcllc unci Zellmembran, schlieRlich zum
Zclltod fiihrt. Ausgeldst wird dies durch cine schockbe-
dingte, hypovoliimischc Verminderung des Hcrzzeitvolu-
mens, was durch eine sympathico-adrenerge Rcaktion
kompensiert werden soil. Diesc Reaktion ist durch Rc-
zeptoren im Herz- ttnd GcfaBsystem vermittclt und wird
gegebenenfalls durch llypoxie, Hyperkapnie ttnd Azi-
dosc vcrstiirkt. Die Stimulation adrenerger Alpha- und
Bcta-Rezeptoren fiihrt zu schockspezifischen Veriindc-
rungen dcr Perfusion der Mikrozirkulation und Ictzllich
z.u ciner Umvcrteilung des verminderten Herzzeitvolu-
mens zugunstcn vitalcr Organe (Herz und Gehirn).
Obergeordnetcs Zicl dcr Therapie schwerstlraumati-
sierter Patienten ist die Wiederherstellung bzw. Sicher-
stellung der wichtigsten Organfunktionen. Speziell be-
deutet dies die Aufhebung dcr Pcrfusionsstorungen der
Endstrombahn. Nur so kttnn eine normale Durchstro-
mung und Sauerstoffversorgung allcr Organe gesichert
wcrden. Die zuniichst funktionelle Minderung dcr Funk¬
tion von Zellc und Zcllmembran kann normalisiert, und
ein Organversagcn (Schocklungen, -niere, -leber) vcrhin-
dcrt werden. Im Detail muG der pulmonale Gasaus-
tausch gesichert werden - durch friihzeitige Intubation
und Bcatmung das vcrmindcrtc Blutvolumcn normali¬
siert werden - durch Infusion kolloidalcr/krislalloidcr
Lbsungcn und die Saucrstofftransportkapazitat des
Blutcs muB angchobcn werden ~ Transfusion von Liry-
throzyten - Kontraktilitatsmindcrung und Vasokon-
striktion sollten durch positiv-inotrope Substanzcn und
Vasodilatatoren therapiert werden.
Ncuestc Untcrstichungscrgcbnissc zcigen, daB im
traumatischcn Schock dem Vcrlust von Funktioncn dcr
makro- und mikrovasculiiren GefiiBendothclicn einc
wichtige pathophysiologische Bedeutung zukommt.
Lange Zeit gait das vasculare Endothel als eine weitge-
hend reaktionslose, tapctenartige Auskleidung des Ge-
faGsystems. In den letzten Jahren erwiesen sich Endo-
thclzcllcn als hoch stoffwechsclaktive Strukturen, denen
wichtige Bedeutung zukommt. 1. Barricrc-Funktionen,
also die Abgrenzung des intra- und extravascularen Rau-
mes, 2. Mitbeteiligung bei der C02-Abgabe der Lunge,
3. Lokale und systemische Regulation des GefaGwider-
standes, 4. Bildung eincr antithrombogenen GefaBobcr-
flache.
Bcsondere Bedeutung kommt im traumatischcn
Schock der Storung der physiologischen Regulation des
lokalcn GcfaBwidcrstandcs zu.
Vasodilaticrendc Wirkungen dcr vasoaktiven StolTc
werden in regional untcrschicdlicher Weise durch
einc Mediatorsubstanz. des GcfaRcndothels vcrmittelt.
Dies kann nur die inlaktc Endothclzclle Icistcn.
Funktionsverlust des Endothcls macht dahcr vasodi-
latatorische Einfliissc unwirksam. Daraus resulticrt einc
weitcre, lokale Behindertmg der Orgiinperfttsion. Dies
hilt im Gcsamtablauf des traumatischcn Schocks einc
wichtige Bedeutung, ist itber derzeit Iherapcutisch noch
nicht direkt zu beeinflussen.
Maschinelle Unterstiitzung der Atmung
K. Fcilke (Institut fiir Aniisthcsiologie der Univcrsitiit Diissct-
dorf)
Wiihrend der letzten 15 Jahrc haben sich die Prinzipien
der maschinellen Unterstiitztung dcr Atmung wie Iblgt
gciindert: 1. durch positiven endcxspiratorischcn Druck
(PEEP) und kontinuicrlich positiven Atcmwegsdruck
(CPAP) und 2. durch die Mdglichkeit. dal.I maschinell
bcatmctc Patientcn glcichzeitig auch sponlan atmcn
kbnnen, entwedcr mil llille cines konlinuicrlichcn oiler
eines Flow-of-Demand vom Beatmungsgcriit. Historisch
gesehen cntwickelte sich dies atts dcr Kombination von
Bcalmungsgcralcn, mil denen inlermitticrcndc Uhcr-
druckbeatmung mit PIF.P mbglich war, und kontinuier-
licbcn Flow-CPAP-Svstcmcn. die an cin vorhandcncs
Vcntil, das dem Paticnten die spontane Inspirtition er-
laubtc, angeschlosscn wurden. Diese ncuen Mbglichkci-
ten haben zit Iblgcndem aktucllcn Konzcpt der IJntcr-
stiitzung dcr Atmung gefiihrt:
Voile Untcrstiilzung dcr Atmung:
CMV = kontrollicrtc mnschincllc Beatmung ohnc oiler mil
Parlicllc Unlerstiilzung der Almung: I'LLP oiler CI'AP
IMV = intcrmitticrcndc maschincllc/
mandalorischc Bcatmung
Weiterhin hat sich auch der EntwohnungsprozcB durch
die Einfiihrung von IMV gciinderl. Anstiitt den Patien¬
tcn von kontrolliertcr aufSpontanatmung dirckt iibcrzu-
ftihren, besteht jclz.t die Mdglichkeil, (lurch schrittweise
Rcduzierung der maschinellen Beatmungsfrec|uenz bis
attfWertc von 2-0/min ilen Paticnten zu entwdlinen, ent-
sprcchend seiner eigenen Fiihigkeil, eine zufrieilensiel-
lende lungenmechanische und Blutgasfunklion aufrecht-
zuerhalten. Mil dem IMV-Konzept sinil eine Reihe von
Vorteilcn verbunden, wie z.B. eine verminderte NotWen-
digkeil ztir Vcrabreichttng sedttliver Medikamente und
giinstige Attswirkung auf Kreislattf und Nicrcnlunklion.
Auf der andcrcn Seitc ist der Patient unter IMV-Bedin-
gungen stets dem Risiko einer inadaqualen maschinellen
Unterstutzung der Atmung ausgesctzt. Wciterhin gibt
es technische Probleme mit IMV und CPAP. Konti-
nuierliche Flow-Systcme erlaubcn keinc Mcssung der
Bcatmungs- und Atcmvolumina, ttnd cinige dcr Dc-
mand-Flow-Systeme erfordern unerwi'inscht holie und
mbglicherweisc gefiihrliche inspiratorisehc Anstrengun-
gen des Patienten. um den inspiralorsichen Flow auszu-
losen.
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advocated a skin excision margin one inch from
the edge of the primary tumour with resection
of an additional two inches of fat and deep
fascia beneath the undermined skin edges; he
also advocated resection of some muscle.
Dr Rampen's review is inaccurate in several other
particulars. Day et al did not indicate that micro¬
scopic satellites were absent around lesions less
than 1 mm thick—rather they wrote that no satel¬
lites were detected around 168 lesions of 0-75 mm
or less thick; for 151 patients with 0-76-1-50 mm
thick lesions 7 151 4-6",. were found to have
satellites.3 Furthermore, Elder et al indicated that
they found no local recurrences in their patients
(which they defined as reappearances of biopsy-
proved melanoma within or contiguous to the
definitive excision scar).4
Dr Rampen's analysis5 of the WHO study6
concluded that a 9-4°,, rate for local recurrence after
excision of stage I melanomas with tumour free
excision margins of 2 cm or less was unacceptably
high. We have recently found in a minimum 10
year follow up study of stage I melanomas treated
with conventional wide excision margins (most
5 cm or greater) that the rate of local tumour
recurrence was 26 258 (10°o).7 only should
patients treated for melanoma be followed up for
prolonged periods to determine the accurate rate of
local tumour recurrence, but the relative propor¬
tions of thin and thick tumours should be detailed
as well as the surgical excision margins.* Despite
wide resection margins thick tumours are likely to
be associated with an increased rate of local tumour
recurrence, which will reflect simply the continuing
growth of what were initially microscopic satellites
outwith the margins of the resection—however
wide they may have been.
The work of Day et aP did indicate a 63°n
incidence of histologically proved microsatel-
lites in the tissues surrounding melanomas
greater than 4 mm thick, but they did not
relate the position of these micrometastases to
the margins of the primary tumour. We
require to know the position of satellite lesions
as well as their incidence in conventional wide
margin excision specimens if we are to set out
rationally recommendations on margins of
excision for stage I malignant melanoma of the
skin. A prospective randomised trial of varying
excision margins related to primary tumour
thickness and observed incidence of both
micrometastases in adjacent tissue and eventual
rate of local tumour recurrence over prolonged
follow up is long overdue.
Richard W Griffiths
Department of Plastic and
Jaw Surgery,
Frenchay Hospital,
Bristol BS16 1 LE
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Sir,—Dr FHJ Rampen does less than justice
to Ackermann and Scheiner1 in his leading
article on what constitutes adequate excision
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of malignant melanoma. The American
authors' argument runs as follows.
Local satellite metastases indicate that more
widespread metastasis has already taken place.
Excision of these local satellite metastases
would therefore not eradicate the tumour and
would be expected to have no effect on survival.
Surgical intervention can thus either
eradicate lesions which have not metastasised
(these tend to be "thinner") or at least allow
histological assessment of prognostic features
which may suggest that metastasis is likely to
have already taken place and that surgery is
already too late (these lesions tend to be
"thicker"). In either case a wide margin of
excision is unnecessary.
Adequate control of local disease by surgery
may be important for cosmetic or psychological
reasons where a cure cannot be achieved. For
the same reasons it is important to avoid
subjecting the patient to unnecessarily mutilat¬
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Medical problems with breath testing
of drunk drivers
Sir,—I was sorry to see the BMJ joining the
Daily Express in publishing yet another letter
(29 September, p 831) designed to cast doubts
on the reliability of breath alcohol testing. The
story it tells has already been repeated in the
Sunday Times and carries a ring of authority as
a result of having appeared in your columns.
Like Dr Peter Duffus and Dr James A Dunbar,
I occasionally receive such letters from hopeful
solicitors, but this is one of the least convincing
that I have read. In the first place, Dr Duffus
and Dr Dunbar ignore one of the basic maxims
in the business: "What the subject says he has
drunk is not evidence."
The subject, on the other hand, seems to
have been well briefed in the art of evading
conviction. Taking a stiff whisky after an
accident and before the police arrive is a well
known ploy for confusing the issue and is
illegal in many countries. Refusing a con¬
firmatory blood test is another—rather new—
ploy. Blood test results cannot be argued with,
while breath tests as a result of the press
campaign against them are only too easy to
dispute.
The consultant gastroenterology whose
report got the subject off the hook was no
doubt an expert in his discipline, but this was
not breath alcohol. If stomach contents had
reached the subject's mouth the breath concen¬
tration would have been much higher than
50 ug 100 ml because even diluted whisky has
an alcohol concentration about a hundred
times that of blood. The mouth concentration
would fall rapidly so that the second sample
would have given a much lower reading. The
close agreement between the two readings is
strong evidence that they were both recording
true breath alcohol.
The Home Office is about to publish the
results ofan enormous blood/breath correlation
studv, and I have little doubt that these will be
similar to those of its previous study which
showed that not one out of 620 subjects would
have been wrongly convicted on a breath test.1
Wfevca. E
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I hope, however, that the Home Office will
continue the policy which I have always
advocated, of allowing a blood test to anyone
who wants it, and will not allow those who
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*,* A correction to the letter from Dr Duffus
and Dr Dunbar is published on p 1080.—Ed,
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Children may still be harmed by a stay
in hospital
Sir,—I must take issue with Minerva over a
vital omission from her abstract (29 September,
p 838) of Shannon's paper about children in
hospital and subsequent behaviour problems.'
Minerva concludes that "admission to hospital
need not be seen as a risk to a child's later
development," whereas the New Zealand
group take pains to emphasise that their work
was done "in an enlightened paediatric
setting . . . where there is unlimited parental
visiting and facilities for mothers to stay."
Figures from the recent Mitchell report on
children in hospital in Scotland2 show that of
nearly 90 000 children discharged from
Scottish hospitals in 1980 only 53°0 were
from designated children's hospitals or
departments. This leaves 47°n being nursed
in adult wards, where the state of paediatric
enlightenment can be very far from ideal. As
Mitchell comments, "a deplorable state of
affairs."
The Mitchell report's other concern is with
the size of paediatric units, advocating
increased centralisation of resources into units
of at least 50 beds. While our association
participated in the preparation of the report
and endorses its recommendations, we have
two main fears about the way it might be
implemented. Firstly, closure of local paediatric
units may result in yet more children being
admitted to adult wards. Secondly, insufficient
emphasis may be placed on the problems of
parents having to travel to more distant
paediatric units and on Mitchell's recommend¬
ation that "parents must receive assistance to
maintain the closest possible links with their
children as of right."
Christine Kelt
Vict-Chairman
National Association for the
Welfare of Children in
Hospital (Scotland),
Edinburgh
1 Shannon FT, Ferguson DM, Dimond ME. Early
hospital admissions and subsequent behaviour
problems in 6 year olds. Arch Dis Child 1984,59
815-9.
2 Working Group of the National Medical Consultative
Committee. Scottish Home and Health Department
Scottish Health Service Planning Council. Children
in hospital: arrangements for inpatient care. Edin¬
burgh: HMSO, 1984.
Morphine toxicity with dilated pupils
Sir,—Dr Michael Nielsen and Dr John Henry
(15 September, p 681) refer to using naloxone
for the diagnosis and treatment of comatose
patients with small pupils. While in the
acutely poisoned patient pinpoint pupils and
depressed consciousness and respiration are
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almost diagnostic of an opiate overdose, this
may not always be the case. Two patients
recently treated in this intensive care unit
have had widely dilated pupils following a
dose of narcotic sufficient to depress their
consciousness and respiration.
The first patient had undergone liver
transplantation and received a morphine
infusion for postoperative pain relief and to
facilitate artificial ventilation. On the ninth
day after a stormy postoperative course (which
included renal failure) concern was expressed
over his conscious state. He had received
225 mg of morphine in this period and was
still requiring artificial ventilation. His pupils
were noted to be large. Despite this a sample
of blood was taken for plasma morphine assay
(measured by radioimmunoassay'), and he was
given several small doses of naloxone with
improvement in his conscious level.
The second patient, who had a history of
chronic renal failure, was admitted to the unit
six days after a road traffic accident. He had
received 510 mg of dihydrocodeine for pain
relief during this six day period. He was
unconscious and was intubated without the
use of any drugs; respiratory depression was
present, and his arterial carbon dioxide
pressure was raised (711 kPa (53 mm Hg).
His pupils were noted to be dilated. Blood
was taken for plasma morphine assay and
analysed by the same method. He responded
to 0-3 mg naloxone with an increase in
conscious level and respiration (arterial carbon
dioxide pressure falling to 4 84 kPa (36 mm
Hg)) and was subsequently maintained on a
naloxone infusion.
In both patients the plasma morphine
concentrations were very high (1185 ng'ml
in the first, 3963 ng/ml in the second), con¬
firming the clinical impression of narcotic
toxicity in the absence of small pupils. Renal
failure may have contributed to the problems
seen in both patients,2 3 and we hope to report
them both in greater detail when further






1 Moore RA, Baldwin D, Allen MC, Watson PJQ,
Bullingham RES, McQuay JH. Sensitive and
specific morphine radioimmunoassay with iodine
label: pharmacokinetics of morphine in man after
intravenous administration. Ann Clin Biochem
(in press).
2 Aitkenhead AR, Vater M, Achola K, Cooper CMS,
Smith G. Pharmacokinetics of single-dose IV
morphine in normal volunteers and patients with
end stage renal failure. Br J Anaesth 1984;56:S13.
3 Barnes NJ, Goodwin FJ. Dihydrocodeine narcosis in
renal failure. Br Med J 1983 ;286:438-9.
Apheresis procedures in polycythaemia
Sir,—Dr Terry Hamblin discusses the use of
apheresis in treating various disorders (29
September, p 779), but omits consideration
of the removal of red cells using a cell separator
(erythrapheresis).
The technique has been used for some time
for rapid red cell exchange in patients with
sickle cell disease.1 We have shown that in
patients with primary polycythaemia and
polycythaemia secondary to chronic hypoxic
lung disease a single separation can reduce
packed cell volume and blood viscosity to
normal.4 This avoids the inconvenience of
multiple venesections and considerably reduces
visits to hospital. The other main advantage of
erythrapheresis over other methods is safety;
the red cells removed are replaced with an
equal volume of iso-osmotic replacement fluid.
This minimises any thrombocytosis or sudden
changes in cardiac output.
While the advantages of such a rapid and
effective technique in primary polycythaemia
are self apparent (reducing exposure to
radioactive phosphorus or cytotoxic agents)
we have also shown that isovolaemic haemo-
dilution has advantages in patients with
chronic hypoxic lung disease complicated by
secondary polycythaemia. After erythrapheresis
in this group we have shown appreciable
symptomatic improvement and increases in
exercise tolerance and mental alertness with
no complications related to the separations.3
Dr Hamblin emphasises the susceptibility of
apheresis procedures to placebo effects. In a
study comparing the effects of erythrapheresis
with a sham apheresis procedure we found
that this technique had no significant placebo
effect with respect to changes in exercise
tolerance.'
It is not feasible for every patient with
polycythaemia secondary to lung disease to
undergo erythrapheresis, and we do not
recommend purchase of an expensive machine
for this alone. We think, however, that those
patients with severe polycythaemia in whom
venesection would be required over a prolonged
period and in whom any adverse haemo-
dynamic disturbance is undesirable would
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Time to push aside the diagnosis of
infantile colic
Sir,—The short report on infantile colic and
parental smoking (15 September, p 660)
prompts me to raise a more fundamental
question—is there such a thing as infantile
colic ?
If one takes that term literally then I
personally doubt it very much. There are
some babies who cry incessantly for no
apparent reason. Whether or not the origin of
this is parental anxiety and insecurity, a
vicious circle is created between the latter and
the baby's crying. But I am often impressed
that if the baby is removed from the vicious
circle by admission to a paediatric ward the
screaming or colic ceases. Affected infants do
often later have a "difficult" temperament be
it inherent or secondary to the environmental
problem.'
With emotions so charged it is hardly
surprising that standard remedies should be
thought to be effective. No studies yet show a
statistically significant improvement with
infants treated with dicyclomine, and any
claimed efficacy is probably due to its sedative
rather than its antispasmodic action.
What harm can be done by using the label
of colic when faced with a screaming baby ?
Firstly, some babies with such potentially fatal
illnesses as meningitis are initially labelled as
having colic. Secondly, the standard remedy
dicyclomine has side effects which may
occasionally be life threatening.2 Thirdly,
wrong advice is often given regarding cows'
milk protein sensitivities, etc.
I thus feel that much would be gained if the
diagnosis of colic was pushed aside to fester
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Diazepam tolerance
Sir,—Dr P J Cook and others (11 August,
p 351) give some results that differ from our
findings with diazepam and the midazolam.
Like them we found great variability in
response to both drugs.' 2 Diazepam is slow
acting, which causes problems with inter¬
mittent injections—particularly when they are
given at one minute intervals. The onset time
with midazolam varies indirectly with age,3
and on clinical grounds we believe this applies
to diazepam. The important point is that
older patients not only require less drug but
are sedated more quickly than the young, who
are often very resistant.
When giving a fixed weight related dose of
midazolam we found a good positive correla¬
tion between rapidity of response and the
percentage of unbound midazolam in plasma.'
Furthermore, in one large series of patients a
direct relation was found between plasma
albumin concentrations and rapidity of onset,
thus emphasising the importance of plasma
binding.5 The conclusions that Dr Cook and
others draw from their figure 3 in relation to
plasma binding are unjustified as the younger
patients required more drug. It would have
been more meaningful to give the free drug
as a percentage of the total plasma diazepam.
One important omission is the name of the
diazepam preparation used—since the soya
bean oil emulsion formulation (Diazemuls) has
a bioavailability up to 20°o less than the
standard organic solvent preparation (Valium).6
If these were given at random the findings are
meaningless. The possible influence of cime-
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